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Abstract	  
	  
Pulmonary	  hypertension	  (PH)	  is	  a	  rare	  but	  disabling	  disorder,	  characterised	  by	  raised	  
pulmonary	   artery	   pressure	   leading	   to	   right	   ventricular	   heart	   failure,	   progressive	  
disability	   and	   death.	   Chronic	   thromboembolic	   pulmonary	   hypertension	   (CTEPH),	   a	  
distinct	  category	  of	  PH,	  is	  a	  condition	  in	  which	  the	  initiating	  event	  is	  either	  overt	  or	  
occult	  pulmonary	  embolism	  (PE).	  It	  is	  believed	  that	  the	  persistence	  of	  thrombus	  is	  a	  
prerequisite	   for	   the	   development	   of	   PH	   following	   PE.	   It	   was	   hypothesised	   that	  
defective	   fibrinolysis	   on	   the	   surface	   of	   the	   pulmonary	   endothelium	   causes	  
progression	  from	  PE	  to	  CTEPH.	  
Thrombin	   generation	   and	   fibrinolysis	  were	   assayed	   in	   parallel	   on	   endothelial	   cells	  
using	   exogenous	   tissue	   factor	   or	   TNF-­‐α	   stimulation.	   Thrombin	   generation	   was	  
measured	   using	   a	   modified	   calibrated	   automated	   thrombogram	   assay	   (CAT).	  
Fibrinolysis	  was	  measured	  using	  a	  turbidometric	  assay.	  Assays	  were	  established	  first	  
on	   human	   umbilical	   vein	   endothelial	   cells	   (HUVECs).	   The	   study	   of	   patient’s	  
endothelium	   is	   complicated	   by	   the	   difficulty	   in	   accessing	   tissue.	   Using	   a	   recently	  
developed	  technique,	  blood	  outgrowth	  endothelial	  cells	  (BOECs)	  were	  isolated	  from	  
the	   mononuclear	   fraction	   of	   peripheral	   blood	   from	   patients	   with	   CTEPH	   and	  
controls.	  Discrete	   colonies	  of	  BOECs	  appeared	  between	  days	  7-­‐21	   in	   culture.	  Cells	  
were	  passaged	  to	  obtain	  confluent	  BOEC	  monolayers	  with	  characteristic	  endothelial	  
cobblestone	   morphology.	   Endothelial	   identity	   was	   confirmed	   using	  
immunofluorescence	   with	   a	   range	   of	   endothelial	   markers	   including	   VWF	   and	   VE-­‐
Cadherin.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
BOECs	  were	  successfully	  isolated	  from	  patients	  with	  CTEPH	  and	  healthy	  controls	  in	  
order	   to	  evaluate	   thrombin	  generation	  and	   fibrinolysis	  using	   the	  assays	  developed	  
on	   HUVECs.	   No	   difference	   in	   thrombin	   generation	   was	   observed	   but	   surprisingly	  
shorter	  clot	  lysis	  times	  were	  shown	  on	  BOECs	  from	  CTEPH	  patients	  as	  compared	  to	  
controls.	  	  In	  order	  to	  determine	  the	  cause	  of	  the	  paradoxical	  increase	  in	  fibrinolysis,	  
mRNA	  expression	  of	  a	  panel	  of	  candidate	  genes	  was	  performed	  using	  RT-­‐PCR	  array	  
analysis.	  
	  
Differences	   in	   gene	   expression	   were	   seen	   between	   CTEPH	   and	   healthy	   control	  
BOECs.	   Statistically	   significant	   results	   included	   an	   increase	   in	   fibroblast	   growth	  
factor	  2	  and	  fibronectin	  expression	  with	  a	  decrease	  in	  VEGF	  receptor	  2	  expression.	  
Other	   genes	   implicated	   in	   the	   pathogenesis	   of	   PH	   and	   CTEPH	   for	   example	  
endothelin	   receptor	   A,	   matrix	   metalloproteinase	   2	   and	   9	   also	   showed	   altered	  
expression	   and	   therefore	   further	   studies	   with	   larger	   numbers	   are	   required	   to	  
confirm	  these	  findings.	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1 Introduction	  
The	  circulatory	  system	  is	  an	  organ	  system	  that	  is	  vital	  in	  the	  distribution	  of	  nutrients,	  
oxygen,	   carbon	   dioxide,	   hormones	   and	   blood	   cells	   around	   the	   body.	   It	   also	  
maintains	  homeostasis	  by	  stabilizing	  body	  temperature	  and	  pH.	  
The	   cardiovascular	   system	   in	   humans	   is	   a	   closed	   system,	   meaning	   blood	   never	  
leaves	  the	  network	  of	  blood	  vessels	   (arteries,	  veins	  and	  capillaries).	  There	  are	  two	  
main	   circulation	   systems	   in	   humans:	   the	   pulmonary	   circulation,	   in	   which	   oxygen	  
depleted	   blood	   is	   pumped	   away	   from	   the	   heart	   via	   the	   pulmonary	   artery	   to	   the	  
lungs,	   oxygenated	   and	   returned	   to	   the	   heart	   via	   the	   pulmonary	   vein	   and	   the	  
systemic	  circulation	  in	  which	  oxygenated	  blood	  is	  transported	  away	  from	  the	  heart	  
around	  the	  body.	  
1.1 Normal	  Haemostasis	  
Under	  normal	  conditions,	  circulating	  blood	  is	  maintained	  as	  a	  fluid	  by	  physiological	  
anticoagulants	   acting	   at	   the	   surface	   of	   endothelial	   cells	   and	   by	   the	   lack	   of	  
procoagulant	   stimuli.	   If	   there	   is	   injury	   to	   the	   blood	   vessel	   there	   are	   5	   tightly	  
regulated	  phases	  of	   response	   that	   act	   to	  prevent	   excessive	  blood	   loss	   and	  enable	  
vessel	   repair.	   These	   are	   vascular	   spasm,	   primary	   haemostasis	   (platelet	   plug	  
formation),	  secondary	  haemostasis	  (blood	  coagulation),	  fibrinolysis	  and	  remodelling	  
and	   repair	   of	   the	   injury	   site.	  Normal	   haemostasis	   results	   in	   rapid	  occlusion	  of	   the	  
damaged	  vessel	  preventing	  bleeding	  and	   infiltration	  of	  pathogens	   in	   to	   the	  blood.	  
Fibrinolysis	   is	   the	   final	   phase	   of	   haemostasis	   in	   which	   the	   clot	   is	   remodelled	   and	  
dissolved	   as	   the	   vessel	   is	   repaired.	   This	   is	   vital	   for	   maintaining	   vessel	   patency.	  
Normal	  haemostasis	  is	  regulated	  by	  blood	  vessels,	  platelets	  and	  coagulation	  factors	  
through	  positive	  and	  negative	  feedback	  mechanisms.	  	  
1.1.1 Primary	  haemostasis	  
After	   immediate	   vascular	   spasm,	   primary	   haemostasis	   is	   the	   initial	   response	   to	  
vessel	  injury.	  The	  endothelial	  cell	  (EC)	  layer	  is	  damaged	  exposing	  the	  sub	  endothelial	  
extracellular	   matrix	   (ECM)	   to	   the	   blood	   stream.	   This	   results	   in	   loss	   of	   the	  
anticoagulant	   endothelial	   surface	   and	   exposure	   to	   molecules	   such	   as	   collagen,	  
fibronectin,	  thrombospondin	  and	  laminin.	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At	   lower	   shear	   rates,	   for	   example	   in	   the	   venous	   circulation,	   platelets	   interact	  
directly	  with	   collagen	   through	   glycoproteins	   (GP)-­‐Ia/IIa	   and	  VI.	   However	   at	   higher	  
shear	   rates,	   such	   as	   in	   arterioles,	   adhesion	   of	   platelets	   is	   dependent	   on	   von	  
Willebrand	   Factor	   (VWF)	   and	   its	   receptor,	   the	   GPIb-­‐IX-­‐V	   complex.	   VWF	   is	   a	   large	  
multimeric	  glycoprotein	  that	  is	  secreted	  by	  the	  endothelium	  and	  activated	  platelets	  
[1].	  
When	   collagen	   is	   exposed,	  VWF	  binds	   and	   shear	   stress	   induces	   unravelling	   of	   the	  
globular	   form	   to	   expose	   the	   A1	   domain	   [2].	   Circulating	   platelets	   bind	   to	   VWF	  
through	  the	  receptor	  complex	  GPIb-­‐IX-­‐V.	  This	  interaction	  functions	  under	  high	  shear	  
but	  has	  a	  “fast	  off”	  as	  well	  as	  “fast	  on”	  association.	  Nonetheless,	  it	  initiates	  platelet	  
activation	   and	   reduces	   platelet	   velocity	   via	   repeated	   binding	   interactions.	   The	  
platelet	   integrins	   are	   stimulated	   to	   adopt	   their	   active	   configuration	   and	   at	   lower	  
velocity	   can	   form	   stable	   and	   immobilising	   interactions	   with	   VWF	   and	   collagen.	  	  	  	  
Binding	  of	  collagen	  and	  VWF	   induces	   intracellular	  signalling	  that	  causes	  adherence	  
aggregation	  and	  activation	  of	  platelets	  [3].	  Platelet	  binding	  to	  collagen	  (or	  the	  action	  
of	  thrombin)	  leads	  to	  activation	  of	  platelet	  prostaglandin	  synthesis,	  which	  results	  in	  
the	   production	   of	   thromboxane	   A2.	   Thromboxane	   A2	   lowers	   platelet	   cyclic	  
adenosine	   monophosphate	   (cAMP)	   levels	   and	   initiates	   the	   degranulation	   of	  
platelets.	   Platelets	   contain	   2	   types	   of	   granules;	  α-­‐granules	  which	   contain	   platelet	  
derived	  growth	  factor,	  thrombospondin,	  fibrinogen,	  VWF,	  factor	  V,	  PF-­‐4	  (a	  heparin	  
antagonist)	   and	   dense	   granules	   which	   contain	   adenosine	   triphosphate	   (ATP),	  
adenosine	   diphosphate	   (ADP),	   5-­‐hydroxytryptamine	   (5-­‐HT)	   and	   calcium.	  
Thromboxane	  A2	  is	  also	  a	  powerful	  vasoconstrictor.	  Released	  ADP	  and	  thromboxane	  
A2	  cause	  additional	  platelets	  to	  aggregate	  at	  the	  site	  of	  vascular	  injury	  and	  to	  adhere	  
to	   each	   other,	   causing	   further	   platelet	   activation	   and	   release	   of	   more	   ADP	   and	  
thromboxane	  A2	   in	  a	  positive	   feedback	   loop.	  Activated	  platelets	   release	  additional	  
VWF	   resulting	   in	   another	   positive	   feedback	   loop	   that	   leads	   to	   the	   formation	   of	   a	  
primary	  platelet	  plug	  [4].	  During	  activation,	  negatively	  charged	  phospholipids,	  such	  
as	  phosphatidylserine,	  are	  exposed	  by	  the	  action	  of	  scramblase	  which	  allows	  loss	  of	  
the	  resting	  phospholipid	  asymmetry	  [5].	  This	  serves	  as	  a	  surface	  for	  activation	  and	  
assembly	  of	  coagulation	  factors.	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1.1.2 Secondary	  haemostasis	  
Secondary	  haemostasis	   involves	  the	  activation	  of	  the	  coagulation	  cascade,	  a	  series	  
of	   reactions	   that	   ultimately	   results	   in	   thrombin	   production	   that	   leads	   to	   the	  
formation	  of	  an	  insoluble	  fibrin	  clot.	  Although	  described	  as	  a	  cascade,	  it	  is	  actually	  a	  
complex	   network	   of	   interactions	   with	   positive	   and	   negative	   feedback	   loops.	   The	  
cascade	   can	   be	   initiated	   through	   two	   different	   pathways,	   the	   contact	   activation	  
pathway	  (intrinsic)	  and	  the	  tissue	  factor	  (TF)	  pathway.	  	  The	  physiological	  significance	  
of	  the	  contact	  activation	  pathway	  is	  not	  clear.	  	  
1.1.2.1 Initiation	  of	  coagulation	  
TF	   is	   a	   transmembrane	   protein	   expressed	   on	   the	   surface	   of	   cells	   at	   extravascular	  
sites.	   Following	   vessel	   damage,	   TF	   is	   exposed	   to	   the	   blood.	  Most	   clotting	   factors	  
circulate	   as	   inactive	   zymogens,	   however	   a	   small	   amount	   (approximately	   1%)	   of	  
factor	   VII	   (FVII)	   circulates	   in	   its	   active	   form,	   FVIIa	   [6].	   FVIIa	   binds	   to	   TF	   forming	   a	  
complex	   that	  activates	  FIX	  and	  FX	   (Figure	  1.1).	   In	   the	  absence	  of	   its	  cofactor,	  FVa,	  
FXa	  converts	  a	  small	  amount	  of	  prothrombin	  (FII)	  into	  thrombin.	  
	  	  
	  
Figure	  1.1	  Initiation	  of	  the	  coagulation	  cascade	  
Circulating	  FVIIa	  binds	  to	  TF	  exposed	  after	  vessel	   injury.	  The	  TF/FVIIa	  complex	  activates	  FX	  
and	  FIX.	  FXa	  generates	  trace	  amounts	  of	  thrombin.	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1.1.2.2 Feedback	  activation	  	  
The	  small	  amount	  of	  thrombin	  generated	  during	  the	  initiation	  phase	  is	  sufficient	  to	  
activate	  FVIII	  and	  FV	  [7],	  the	  cofactors	  for	  FIXa	  and	  FXa	  respectively	  (Figure	  1.2).	  The	  
FIXa/FVIIIa	  complex	  (or	  intrinsic	  tenase)	  activates	  a	  large	  amount	  of	  FXa.	  	  This	  leads	  
to	  an	  amplification	  of	  FXa	  production	  that	  bypasses	  the	  need	  for	  TF/FVIIa,	  which	  is	  
important	  because	  tissue	  factor	  pathway	  inhibitor	  (TFPI)	  inhibits	  TF/VIIa	  as	  soon	  as	  
any	   FXa	   is	   formed,	   forming	   a	   quaternary	   FXa-­‐TF-­‐FVIIa-­‐TFPI	   complex.	   The	   FXa/FVa	  
complex	  (prothrombinase	  complex)	  then	  converts	  prothrombin	  into	  thrombin	  up	  to	  
278,000	  times	  more	  efficiently	  than	  FXa	  alone	  [8,	  9].	  
It	   has	   been	   proposed	   that	   once	   the	   platelet	   plug	   has	   started	   to	   cover	   the	   sub-­‐
endothelial	   cells,	   secondary	   haemostasis	   is	   allowed	   to	   continue	   by	   circulating	  
microparticles	   containing	   TF,	   or	   alternatively	   spliced	   soluble	   TF,	   adhering	   to	   the	  
surface	   of	   activated	   platelets	   [10,	   11].	   Assembly	   of	   intrinsic	   tenase	   and	  
prothrombinase	  on	  negatively	  charged	  phospholipids,	  such	  as	  on	  activated	  platelets,	  
results	   in	  accelerated	   formation	  of	  FXa	  and	  thrombin.	  After	   feedback	  activation	  of	  
coagulation	   has	   taken	   place,	   sufficient	   thrombin	   is	   generated	   for	   the	   efficient	  
conversion	  of	  fibrinogen	   into	  fibrin	  (Figure	  1.2).	  Thrombin	  has	  a	  central	  role	   in	  the	  
regulation	   of	   haemostasis.	   It	   acts	   as	   both	   a	   procoagulant	   enzyme,	   generating	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Figure	  1.2	  Propagation	  of	  the	  clotting	  cascade	  
Thrombin	  generated	  during	  the	  initiation	  phase	  activates	  FV	  and	  FVIII,	  cofactors	  for	  FXa	  and	  
FIXa.	  This	  leads	  to	  a	  massive	  generation	  of	  thrombin	  that	  converts	  fibrinogen	  to	  fibrin.	  	  	  
1.1.2.3 Regulation	  of	  coagulation	  	  
There	  is	  tight	  regulation	  of	  the	  procoagulant	  pathways	  by	  three	  major	  pathways:	  the	  
TFPI,	  protein	  C	  and	  the	  antithrombin	   (AT)	  pathways	   [13].	  All	   three	  target	  different	  
components	  of	  the	  coagulation	  cascade	  (Figure	  1.3).	  
TFPI,	   a	   Kunitz	   type	   serine	   protease	   inhibitor,	   inhibits	   the	   extrinsic	   coagulation	  
pathway	   by	   inhibiting	   TF/FVIIa	   and	   FXa	   as	   noted	   above.	   It	   targets	   the	   initiation	  
phase	  of	  coagulation	  [14].	  
The	  Protein	  C	  pathway	  targets	  the	  propagation	  phase	  by	  inactivating	  FVa	  and	  FVIIIa.	  
Protein	   C	   bound	   to	   the	   endothelial	   protein	   C	   receptor	   (EPCR)	   is	   activated	   by	  
thrombin	   complexed	   to	   thrombomodulin	   (TM).	   The	   TM	   is	   found	   on	   surrounding	  
intact	  endothelial	  cells	  which	  enables	  activated	  protein	  C	  (APC)	  to	  act	  at	  the	  edge	  of	  
the	  plug	  formation	  [15].	  The	  anticoagulant	  activity	  of	  APC	  is	  enhanced	  by	  protein	  S	  
(PS).	  
AT,	   a	   serine	   protease	   inhibitor	   circulates	   in	   plasma.	   It	   inhibits	   multiple	   serine	  
proteases	  in	  the	  coagulation	  pathway	  (thrombin,	  FXa,	  FIXa	  and	  FVIIa).	  It	  inactivates	  
thrombin	  and	  the	  other	  serine	  proteases	  by	  binding	  irreversibly	  to	  the	  active	  serine	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site	  (through	  an	  arginine	  residue)	  to	  form	  a	  stable	  1:1	  complex	  so	  the	  active	  site	  is	  
not	  accessible	  to	  their	  usual	  substrate	  [16].	  Initially	  the	  serine	  at	  the	  active	  centre	  of	  
the	  protease	  cleaves	  a	  peptide	  bond	  in	  the	  “bait	  loop”	  near	  the	  C	  terminus	  of	  AT.	  A	  
major	   conformational	   change	   in	   the	   serpin	   then	   occurs,	   with	   the	   protease	   still	  
attached	  to	  the	  loop.	  The	  inactivated	  enzyme-­‐serpin	  complex	  is	  then	  cleared	  rapidly	  
from	  the	  circulation	  by	  the	  liver.	  The	  activity	  of	  AT	  is	  greatly	  enhanced	  by	  its	  binding	  
to	  heparan	  sulphate	  on	  intact	  endothelial	  cells.	  A	  conformational	  change	  (release	  of	  
the	   “bait	   loop”	   from	  partial	   insertion	   in	   the	  β-­‐sheet	   core	   of	   the	  molecule)	   occurs	  
when	  AT	  binds	  to	  heparan	  sulphate	  (via	  a	  lysine	  residue)	  that	  increases	  the	  rate	  of	  
thrombin	   (as	  well	   as	   FXa,	   FIXa	  and	  FVIIa)	   inactivation	  by	  over	  2000	   fold	   to	  almost	  
instantaneous	   [17].	   AT	   is	   important	   as	   it	   ensures	   the	   inhibition	   of	   free	   serine	  
proteases	  that	  escape	  the	  proximity	  of	  the	  platelet	  plug,	  ensuring	  localisation	  of	  the	  
haemostatic	  response	  [18].	  
	  
Figure	  1.3	  Regulation	  of	  the	  coagulation	  cascade	  
The	  coagulation	  cascade	   is	   tightly	  regulated	  by	  three	  main	  pathways,	  TFP,	  APC	  and	  AT.	  PS	  
acts	   as	   a	   cofactor	   for	   TFPI	   and	  APC.	   PS/TFPI	   inhibits	   TF/FVIIa	   and	   FXa.	   PS/APC	   inactivates	  
FVa	  and	  FVIIIa.	  AT	   inhibits	  multiple	  serine	  proteases	  but	   for	  simplicity	   in	   the	  diagram	  only	  
inhibition	  of	  thrombin	  (FIIa)	  is	  shown.	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1.1.2.4 Clot	  formation	  
In	   very	   simple	   terms,	   a	   clot	   is	   formed	   by	   the	   action	   of	   thrombin	   on	   fibrinogen.	  
Fibrinogen	  is	  a	  340kDa	  molecule	  produced	  by	  the	  liver.	  It	  is	  an	  elongated	  structure	  
about	  45nm	  long	  which	  consists	  of	  two	  outer	  D	  domains,	  connected	  by	  a	  coiled–coil	  
segment	   to	   a	   central	   E	   domain.	   Each	   molecule	   has	   two	   symmetrical	   halves	  
containing	  a	  set	  of	  three	  polypeptide	  chains	  Aα, Bβ and	  γ, joined	  in	  the	  E	  domain	  by	  
five	   disulphide	   bridges.	   	   In	   addition	   to	   the	   D	   and	   E	   domains	   there	   are	   two	   αC	  
domains	  at	  the	  carboxyl	  terminal	  region	  of	  the	  Aα	  chain.	  	  Two	  types	  of	  γ	  chains	  are	  
present,	   the	   major	   γ	   chain	   and	   the	   minor	   or	   γ’.	   The	   γ’	   arises	   from	   alternative	  
processing	   of	   the	   primary	  mRNA	   transcript	   and	   results	   in	   a	   unique	   20	   amino	   acid	  
sequence.	  γ’	  chains	  account	  for	  about	  8%	  of	  the	  total	  fibrinogen	  γ	  chains	  and	  15%	  of	  
plasma	  fibrinogen	  molecules,	  mostly	  in	  the	  heterodimeric	  form	  [19].	  
Fibrin	   is	   formed	   after	   thrombin	   cleavage	   of	   the	  N	   terminal	   fibrinopeptide	  A	   (FPA)	  
and	  fibrinopeptide	  B	  (FPB).	  Cleavage	  of	  FPA	  from	  fibrinogen	  Aα-­‐chains	  exposes	  the	  
polymerisation	   site	   EA.	  Double	   stranded	  protofibrils	   are	   formed	  when	  EA	   combines	  
with	  the	  constitutively	  complementary	  site	  Da	  in	  the	  D-­‐domain	  of	  the	  neighbouring	  
molecule,	   resulting	   in	   a	   staggered	   end	   to	   middle	   overlapping	   structure.	   These	  
aggregate	   laterally	   to	   form	   fibres	   and	   then	   branching	   occurs	   creating	   the	   3D	  
network	  [19,	  20].	  Two	  types	  of	  branching	  may	  occur.	  The	  first	  type,	  tetramolecular	  
or	   bilateral	   branch	   point,	   occurs	   when	   a	   pair	   of	   double	   stranded	   fibrils	   converge	  
laterally.	  The	  second	  type,	  the	  trimolecular	  or	  equilateral	  branch	  point,	  occurs	  at	  the	  
junction	   of	   3	   double	   stranded	   fibrils	   of	   equal	   width.	   This	   second	   type	   is	   more	  
common	  when	  fibrinopeptide	  cleavage	  is	  slow,	  i.e.	  at	  low	  thrombin	  concentrations,	  
and	   results	   in	   a	   more	   branched	   network,	   which	   is	   important	   in	   determining	   the	  
ultimate	  structure	  of	  the	  clot.	  
Release	   of	   FPB	   from	   Bβ polypeptide	   chains	   is	   slower	   than	   FPA	   but	   exposes	   an	  
independent	  polymerisation	  site	  EB.	   It	  also	  results	   in	  the	  availability	  of	  αC	  domains	  
for	  interaction	  with	  other	  αC	  domains,	  which	  promotes	  lateral	  fibril	  association	  with	  
αC	  binding	  to	  αC	  on	  neighbouring	  fibrin	  molecules.	  	  
	  
	  
	   20	  
1.1.2.4.1 Factor	  XIII	  
Factor	  XIII	  (FXIII)	  circulates	  as	  a	  A2B2	  tetramer	  bound	  by	  its	  B	  subunits	  to	  the	  γ’	  chain	  
of	   fibrinogen.	   It	   develops	   enzymatic	   activity	   at	   physiological	   calcium	   levels	   in	   the	  
presence	   of	   fibrin	   which	   facilitates	   the	   activating	   cleavage	   of	   the	   A	   subunits	   by	  
thrombin.	  The	  A	  subunits	  then	  dissociate	  from	  fibrin	  and	  the	  B	  subunit	  and	  bind	  to	  
the	   Aα	   chain	   of	   fibrin.	   	   FXIII	   active	   form	   catalyses	   the	   formation	   of	   γ	   dimers	   by	  
introducing	   lysine	   covalent	  bonds	  between	   the	   lysine	   (γ406)	  of	  one	   chain	   and	   the	  
glutamine	   (γ398/399)	   of	   another.	   The	   Da:EA	   interaction	   facilitates	   the	   antiparallel	  
alignment	   of	   γ	   chain	   pairs,	   which	   accelerates	   the	   cross-­‐	   linking	   rate.	   These	   cross-­‐
links	  are	  important	  in	  strengthening	  the	  clot	  [21].	  
Factor	  XIII	  can	  also	  incorporate	  α2-­‐antiplasmin	  into	  the	  clot,	  at	  Aα303,	  which	  makes	  
the	  clots	  more	  resistant	  to	  fibrinolysis	  [22].	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1.1.3 Fibrinolysis	  
Fibrinolysis,	   the	   process	   that	   breaks	   down	   a	   thrombus,	   is	   dependent	   on	   the	  
plasminogen	   activator	   family	   of	   proteins,	   which	   regulate	   the	   conversion	   of	  
plasminogen	   into	   its	   active	   form	   plasmin,	   a	   fibrinolytic	   protease	   (Figure	   1.4).	  
Plasminogen	  is	  produced	  in	  the	  liver	  and	  circulates	  in	  the	  plasma.	  There	  are	  2	  major	  
plasminogen	  activators,	  tissue	  type	  (tPA)	  and	  urokinase	  type	  (uPA)	  [23].	  	  
tPA	   is	   thought	   to	  be	   important	   in	   fibrinolysis	   in	   the	  circulation	  because	   it	  binds	   to	  
fibrin.	  uPA	  is	  assumed	  to	  act	  primarily	  in	  the	  context	  of	  cell	  surfaces,	  once	  bound	  to	  
its	  receptor	  uPAR,	  initiating	  lysis	  of	  fibrin	  at	  extravascular	  sites.	  However	  it	  has	  been	  
shown	  that	  uPA	  can	   in	   fact	  mediate	   lysis	  within	   the	  pulmonary	  microvascular	   tree	  





Figure	  1.4	  Fibrinolysis	  
Plasminogen	   is	   activated	   by	   tissue-­‐type	   plasminogen	   activator	   (tPA)	   or	   urokinase-­‐type	  
plasminogen	  activator	  (uPA).	  Plasmin	  cleaves	  fibrin	  into	  soluble	  fibrin	  degradation	  products.	  
PAI-­‐1	   inhibits	   tPA	   and	   uPA.	   Plasmin	   is	   inhibited	   by	   α2antiplasmin	   (α2ap)	   and	   α2	  
macroglobulin	   (α2m).	   TAFI,	   activated	   by	   FIIa	   (thrombin),	   inhibits	   fibrinolysis	   by	  modifying	  
the	  fibrin	  substrate.	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1.1.3.1 tPA	  pathway	  
There	  is	  a	  high	  affinity	  plasminogen	  binding	  site	  on	  fibrinogen	  that	  is	  located	  in	  the	  
distal	  part	  of	  each	  Cα	  domain,	  however	  there	  is	  little	  or	  no	  stimulatory	  effect	  in	  the	  
presence	   of	   fibrinogen.	   It	   is	   only	   when	   fibrinogen	   is	   converted	   to	   fibrin	   that	   tPA	  
mediated	  plasminogen	  activation	  is	  greatly	  accelerated	  by	  the	  exposure	  of	  tPA	  and	  
plasminogen	  binding	  sites	  [25-­‐27].	  	  	  
2	   phases	   are	   seen	   in	   tPA	  mediated	   lysis.	   In	   the	   first	   slow	   phase,	   single	   chain	   tPA	  
activates	   plasminogen	   on	   the	   intact	   fibrin	   surface.	   In	   the	   second	   phase,	   fibrin	   is	  
partially	  degraded	  by	  plasmin	  exposing	  additional	  binding	  sites	  (lysine	  residues,	  Lys)	  
for	  plasminogen	  and	  tPA.	  The	  cryptic	  character	  of	  the	  binding	  sites	  on	  fibrinogen	  is	  
important	  as	   it	  restricts	  the	  formation	  of	  plasmin	  and	  therefore	  fibrinolytic	  activity	  
to	  the	  location	  where	  it	  is	  required.	  
In	  the	  first	  phase,	  kinetic	  studies	  have	  shown	  that	  there	   is	  binding	  of	  the	  activator	  
(tPA)	  to	  fibrin	  with	  subsequent	  binding	  of	  the	  plasminogen	  molecule.	  Studies	  have	  
localised	  a	  set	  of	  low	  affinity	  tPA	  and	  plasminogen	  binding	  sites	  in	  each	  D	  region	  of	  
fibrin(ogen)	   Aα	   148-­‐160	   (can	   bind	   tPA	   and	   plasminogen)	   and	   γ312-­‐324	   (tPA	   only)	  
[28].	  
Activation	  of	  plasminogen	  occurs	  through	  tPA	  binding	  to	  fibrin	  followed	  by	  binding	  
of	   a	  plasminogen	  molecule	   to	   fibrin	   to	   form	  a	   ternary	   complex.	   tPA	  binding	   is	   Lys	  
independent	   (probably	   through	   its	   finger-­‐like	   domain)	   whereas	   the	   binding	   of	  
Plasminogen	   is	   Lys-­‐dependent,	   suggesting	   binding	   occurs	   through	   its	   kringle	  
domain.	   Crystal	   structures	   have	   shown	   that	   the	   binding	   sites	   for	   tPA	   and	  
plasminogen	   are	   located	   close	   to	   each	   other	   (about	   45Å)	   which	   facilitates	   the	  
activation	  [28].	  	  
Plasmin	   is	   thus	   generated	   and	   cleaves	   fibrin	   at	   specific	   sites	   yielding	   identifiable	  
fragments	  (initiation	  phase)	  and	  exposes	  C	  terminal	  lysines.	  This	  leads	  to	  the	  second	  
phase	  in	  which	  plasminogen	  binds	  to	  the	  C	  terminal	  lysines	  leading	  to	  up	  to	  a	  30	  fold	  
increase	  in	  accumulation	  of	  plasminogen.	  The	  partially	  degraded	  fibrin	  also	  acts	  as	  a	  
cofactor	   in	   the	   plasmin	   mediated	   conversion	   of	   Glu-­‐plasminogen	   to	   Lys-­‐
plasminogen,	  which	   is	  a	  better	  substrate	   for	   tPA	   [26,	  29].	  All	   this	   results	   in	  a	   local	  
burst	  of	  plasmin	  generation	  (propagation	  phase).	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Plasmin,	  generated	  in	  both	  the	  first	  and	  second	  phase,	  also	  converts	  tPA	  to	  a	  two-­‐
chain	  form	  by	  hydrolysis,	  which	  is	  more	  active	  than	  the	  single	  chain	  form,	  resulting	  
in	   further	  positive	   feedback.	  Plasmin	  also	  binds	   to	   the	  C	   terminal	   lysines	  on	   fibrin,	  
which	  protects	  it	  from	  inactivation	  by	  α2-­‐antiplasmin.	  	  
	  
Cells,	  including	  ECs,	  play	  an	  important	  role	  in	  fibrinolysis.	  They	  contain	  plasminogen-­‐	  
and	   plasminogen	   activator-­‐receptors.	   Studies	   have	   shown	   that	   vascular	   cells	   have	  
the	   capacity	   to	   regulate	   fibrinolysis	   through	  modulation	   of	   plasminogen	   receptor	  
expression	  [30].	  Annexin	  A2	  (ANXA2),	  an	  anionic	  phospholipid	  binding	  protein,	  was	  
identified	  by	  Hajjar	  et	  al	  [31]	   in	  1994	  as	  a	  co	  receptor	  for	  plasminogen	  and	  tPA	  on	  
ECs.	  Thrombin	  has	  been	  shown	  to	  increase	  ANXA2	  on	  the	  surface	  of	  HUVECs	  which	  
correlated	   with	   increased	   plasminogen	   binding	   and	   tPA	   mediated	   plasmin	  
generation	  [32].	  More	  recent	  studies	  have	  shown	  that	  ANXA2	  exists	  as	  2	  molecules	  
of	   ANXA2	   bound	   together	   by	   a	   dimer	   of	   protein	   S100A10,	   in	   a	   complex	  
heterotetramer	   [33].	   ANXA2	   contains	   phospholipid	   binding	   sites	   that	   anchor	  
S100A10	   to	   the	   cell	   surface	   membrane.	   Studies	   have	   shown	   that	   the	   ANXA2	  
functions	  to	  stabilise	  S100A10	  levels	  and	  to	  localise	  it	  to	  the	  cell	  surface.	  	  It	  has	  now	  
been	   shown	   that	   it	   is	   the	   S100A10	   which	   binds	   tPA	   and	   plasminogen	   via	   its	   c-­‐
terminal	   lysine	   residue	   [34].	   	   Co-­‐localisation	  with	   the	   urokinase-­‐type	   plasminogen	  
activator	  and	  receptor	  complex	  [35,	  36]	  has	  been	  shown	  and	  this	  results	  in	  rapid	  and	  
localised	   plasmin	   generation	   at	   the	   endothelial	   cell	   surface.	   Other	   plasminogen	  
receptors	   have	   also	   been	   discovered	   [37]	   but	   further	   research	   is	   needed	   to	   fully	  
understand	  the	  exact	  roles	  of	  all	  the	  different	  receptors.	  
1.1.3.2 Urokinase	  pathway	  
Single	  chain	  uPA	  (scuPA)	  does	  not	  activate	  plasminogen	  in	  the	  absence	  of	  fibrin.	  In	  
the	  presence	  of	  a	  fibrin	  clot,	  scuPA	  induces	  fibrin	  specific	  clot	  lysis.	  It	  is	  an	  ineffective	  
activator	   of	   plasminogen	   bound	   to	   intact	   fibrin	   but	   has	   a	   higher	   activity	   towards	  
plasminogen	   bound	   to	   newly	   generated	   C	   terminal	   lysine	   residues	   on	   partially	  
degraded	  fibrin	  [38].	  	  Plasmin	  is	  able	  to	  convert	  scuPA	  to	  the	  more	  active	  two	  chain	  
uPA	   (tcuPA).	   Cell	   associated	   plasmin	   is	   protected	   from	   rapid	   inhibition	   by	   α2-­‐
antiplasmin.	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Binding	  of	  scuPA	  to	  uPAR	  on	  the	  cell	  surface	  results	  in	  a	  strongly	  enhanced	  plasmin	  
generation.	   uPAR	   is	   a	   GPI-­‐anchored	   protein	   that	   binds	   with	   high	   affinity	   and	  
activates	   uPA.	   uPAR	   is	  moderately	   expressed	   in	  many	   tissues	   including	   the	   lungs,	  
kidneys,	   spleen	   blood	   vessels,	   uterus,	   bladder,	   heart	   and	   liver.	   Stronger	   uPAR	  
expression	  is	  observed	  in	  areas	  of	  tissue	  remodelling	  with	  macrophages,	  neutrophils	  
and	  endothelial	  cells	  as	  the	  predominant	  uPAR	  expressing	  cell	  types.	  Haemopoietic	  
progenitor	  cells	  also	  express	  uPAR.	  
The	  uPA/uPAR	  system	  also	  has	  many	  biological	  activities	   that	  occur	   independently	  
of	   the	   protease	   activity,	   which	   are	   related	   to	   the	   regulation	   of	   the	   interactions	  
between	  the	  cells	  and	  the	  surrounding	  extracellular	  matrix.	  uPAR	  has	  been	  found	  to	  
be	  overexpressed	  in	  a	  wide	  variety	  of	  human	  cancers,	   inflammation	  and	  infections	  
[39].	   Although	   a	   very	   interesting	   area	   this	   is	   beyond	   the	   scope	   of	   my	   research	  
project	  and	  I	  will	  therefore	  not	  discuss	  it	  in	  any	  more	  detail.	  	  
1.1.3.3 Regulation	  of	  fibrinolysis	  
1.1.3.3.1 	  Overview	  
The	   process	   of	   fibrinolysis	   is	   modulated	   by	   both	   positive	   and	   negative	   feedback	  
mechanisms.	   Inhibition	  of	   fibrinolysis	  may	  occur	  at	   two	   levels:	  Plasmin	   is	   inhibited	  
by	   α2-­‐antiplasmin	   and	   plasminogen	   activators	   tPA	   and	   uPA	   are	   inhibited	   by	  
plasminogen	   activator	   inhibitors	   (PAI)	   1	   and	   2.	   Plasminogen	   activation	   is	   also	  
inhibited	  by	   thrombin	  activated	   fibrinolysis	   inhibitor	   (TAFI),	  which,	   after	  activation	  
by	   thrombin	   (TAFIa)	   inhibits	   fibrinolysis	   by	   removing	   the	   lysine	   binding	   sites	   for	  
plasminogen	   and	   to	   a	   lesser	   extent	   tPA	   on	   fibrin.	   TAFIa	   also	   inhibits	   fibrinolysis	  
initiated	  by	  urokinase	  [40],	  at	  the	  level	  of	  plasminogen	  binding	  and	  activation.	  
1.1.3.3.2 Thrombin	  activated	  fibrinolysis	  inhibitor	  
TAFI,	  a	  carboxypeptidase,	  removes	  C	  terminal	  lysines	  from	  the	  surface	  of	  the	  fibrin	  
clots.	   It	   has	   no	   endogenous	   inhibitors,	   but	   activity	   is	   regulated	   by	   temperature	  
dependent	   instability	  with	  a	  half-­‐life	  of	  8	  to	  15	  minutes	  at	  37°C.	   Elevated	   levels	  of	  
TAFI/TAFIa	   have	  been	  demonstrated	   in	   venous	   and	   arterial	   diseases.	   By	   removing	  
the	  C	  terminal	  lysine	  residues	  from	  partly	  degraded	  fibrin,	  TAFIa	  abrogates	  the	  fibrin	  
cofactor	  function	  of	  fibrin	  for	  plasminogen	  activation.	  This	  prevents	  the	  progression	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of	  fibrinolysis	   into	  the	  propagation	  phase	  and	  results	  in	  a	  dramatic	  decrease	  in	  the	  
fibrinolytic	  efficiency	  of	  tPA.	  
TAFIa	   acts	   in	   a	   threshold	   dependent	   manner.	   If	   TAFIa	   is	   present	   above	   a	   certain	  
threshold	   fibrinolysis	   cannot	   progress	   beyond	   the	   initial	   phase.	   If,	   however,	   TAFIa	  
levels	  drop,	  the	  rate	  of	  fibrinolysis	  accelerates	  through	  an	  exponential	  increase	  in	  C-­‐
terminal	   lysine	   residues.	   The	   threshold	   is	   influenced	  by	   the	  plasmin	   concentration	  
and	  therefore	  also	  by	  tPA	  and	  α2-­‐antiplasmin	  concentrations	  [41,	  42].	  
Thrombin	   is	   a	   weak	   activator	   of	   TAFI,	   however	   in	   complex	   with	   thrombomodulin	  
(TM)	   the	   efficiency	   of	   activation	   is	   increased	   1250	   fold	   [43].	   TAFI	   activation	   is	  
sensitive	  to	  the	  dynamics	  of	  coagulation	  activation:	  	  at	  low	  thrombin	  concentrations	  
it	  requires	  the	  presence	  of	  TM	  whereas	  when	  higher	  concentrations	  of	  thrombin	  are	  
generated	  via	  the	  intrinsic	  pathway	  of	  coagulation,	  TAFI	  activation	  is	  independent	  of	  
TM.	  Thus	  in	  the	  presence	  of	  TM,	  the	  activation	  of	  TAFI	  is	  independent	  of	  thrombin	  
generation	  and	  in	  in	  vitro	  experiments,	  the	  addition	  of	  thrombomodulin	  corrects	  the	  
early	  lysis	  of	  clots	  in	  factor	  X,	  IX,	  VIII	  and	  XI	  deficient	  plasma	  [43,	  44].	  	  
TAFI	   can	  also	  be	  activated	  by	  plasmin.	   The	  efficiency	  of	   activation	   is	   enhanced	  by	  
glycosaminoglycans	   such	   as	   heparin	   [45].	   It	   has	   been	   postulated	   that	  
thrombin/thrombomodulin	   is	  the	  major	  physiological	  activator,	  since	  the	  efficiency	  
is	  ten	  fold	  higher	  than	  plasmin/heparin	  [46].	  More	  recent	  studies	  have	  also	  shown	  
that	  plasmin	  plays	  an	  important	  role	  in	  vitro	  in	  clot	  lysis	  assays	  [47,	  48]	  as	  well	  as	  in	  
vivo	  in	  a	  thromboembolism	  model	  [47].	  
Recent	   data	   has	   shown	   that	   TAFI	   also	   has	   a	   role	   in	   inflammation	   as	   several	  
proinflammatory	   mediators	   have	   been	   shown	   to	   be	   substrates	   e.g.	   bradykinin,	  
complement	  factors	  C3a	  and	  C5a.	  I	  will	  not	  discuss	  these	  as	  this	  is	  beyond	  the	  scope	  
of	  this	  research	  project.	  
1.1.3.3.3 PAI-­‐1	  
PAI-­‐1	   is	   the	   primary	   inhibitor	   of	   both	   tPA	   and	   uPA.	   It	   is	   present	   at	   low	  
concentrations	   in	   normal	   plasma,	   but	   higher	   levels	   may	   be	   seen	   in	   many	   clinical	  
conditions	   e.g.	   after	   major	   surgery	   or	   myocardial	   infarction	   [49].	   It	   is	   mainly	  
synthesised	   in	   endothelial	   cells,	   but	   is	   also	   secreted	   by	  monocytes,	   macrophages	  
hepatocytes	  and	  platelets.	  PAI-­‐1	  reacts	  with	  single	  and	  two	  chain	  tPA	  but	  only	  two	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chain	   uPA.	   It	   inhibits	   its	   targets	   by	   formation	   of	   a	   1:1	   stoichiometric	   reversible	  
complex,	   followed	  by	   covalent	  binding	  between	   the	  active	   site	   serine	   residue	  and	  
the	  carboxyl	  group	  of	  the	  P1	  residue	  at	  the	  reactive	  site	  (bait	  region)	  of	  the	  serpin.	  
Importantly	  if	  it	  does	  not	  bind	  to	  tPA	  or	  uPA,	  it	  is	  spontaneously	  converted	  into	  an	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1.1.4 Factors	  influencing	  clot	  formation	  	  
The	  ability	  of	  a	  clot	  to	  resist	  mechanical	  stress	  and	  fibrinolytic	  processes	  is	  important	  
to	  clot	  stability.	  The	  mechanical	  properties	  of	  fibrin	  are	  important,	  as	  it	  must	  be	  able	  
to	   form	   a	   plug	   to	   stop	   bleeding	   and	   withstand	   shear	   stress.	   The	   viscoelastic	  
properties	   will	   determine	   whether	   the	   clot	   can	   deform,	   rupture	   or	   embolise	   and	  
may	   determine	   response	   to	   treatment.	   Previous	   experiments	   have	   shown	   that	   at	  
least	   three	   factors	   are	   vital	   in	   regulating	   the	   mechanical	   behaviour	   of	   clots:	  
fibrinogen	   concentration	   and	   structure,	   fibrin	   network	   architecture	   and	   FXIIIa	  
induced	  fibrin	  cross	  linking	  [50].	  
1.1.4.1 Fibrinogen	  concentration	  and	  structure	  
Fibrinogen	  circulates	  in	  human	  plasma	  at	  concentrations	  of	  2-­‐4g/L.	  Elevated	  plasma	  
fibrinogen	   levels	  have	  been	  shown	  to	  be	  associated	  with	  cardiovascular	  disease	   in	  
epidemiological	   studies	   [51],	   however,	   it	   is	   not	   clear	  whether	   these	   are	   causal	   or	  
secondary.	   In	  a	   recent	   study	  using	  a	  mouse	  model,	   raising	   fibrinogen	   levels	   led	   to	  
increased	  thrombus	  fibrin	  content,	  promoted	  faster	  fibrin	  formation	  and	  increased	  
fibrin	  network	  density	  and	  stability	  [52].	  Increased	  resistance	  to	  thrombus	  lysis	  was	  
also	  seen.	  This	  suggests	  that	  hyperfibrinogenaemia	  may	  have	  a	  causal	  role	  in	  acute	  
thrombosis.	  	  
Qualitative	  abnormalities	   in	   fibrinogens	  have	  also	  been	   shown	   to	  affect	   fibrin	   clot	  
structure	  and	  stability.	  	  In	  the	  hereditary	  dysfibrinogenaemia	  Dusart,	  (Chapel	  Hill	  III,	  
Paris)	  in	  which	  there	  is	  substitution	  of	  arginine	  to	  cysteine	  at	  residue	  554	   in	  the	  Aα	  
chain,	  clots	  with	  thin	  fibres,	  increased	  branching,	  decreased	  porosity	  and	  increased	  
resistance	  to	   lysis	  have	  been	  seen	   in	  vitro.	  This	  mutation	  has	  been	  associated	  with	  
thrombosis	  in	  unrelated	  kindreds	  [53-­‐55].	  	  
Post	  translational	  modification	  of	  circulating	  fibrinogen	  e.g.	  oxidation	  and	  glycation	  
have	  also	  been	  proposed	  to	  modulate	  the	  fibrin	  quality	  in	  prothrombotic	  states	  [56].	  
Fibrinogen	   purified	   from	   subjects	   with	   poorly	   controlled	   type	   2	   diabetes	   mellitus	  
formed	   fibrin	   clots	   with	   decreased	   pore	   size,	   increased	   fibre	   density	   and	   branch	  
points	  with	   reduced	   susceptibility	   to	   clot	   lysis	   [57].	   These	   subjects	   had	   decreased	  
plasminogen	  and	  tPA	  binding	  to	  the	  fibrin	  with	  less	  plasmin	  generated	  compared	  to	  
controls	  [58].	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In	   recombinant	   fibrinogen	   that	   lacks	   the	   Cα	   domain,	   in	   vitro	   studies	   have	   shown	  
that	  the	  clot	  is	  less	  stiff	  and	  more	  susceptible	  to	  fibrinolysis	  [59]	  .	  	  	  
1.1.4.2 Fibrin	  network	  architecture	  
The	  branching	  of	  fibrin	  fibres	  is	  important,	  as	  it	  is	  this	  feature	  that	  makes	  the	  clots	  
into	  a	  stable	  network.	  The	  distance	  between	  branch	  points	  and	  the	  total	  number	  of	  
branch	   points	   can	   vary	   depending	   on	   the	   structure	   of	   the	   fibrinogen	   and	   the	  
conditions	   in	   which	   polymerisation	   occurs	   [60].	   Protofibrils	   aggregate	   laterally	   to	  
form	  fibres	  and	  may	  diverge	  to	  produce	  a	  branching	  point.	   It	  has	  been	  shown	  that	  
conditions	  that	  favour	  lateral	  aggregation	  tend	  to	  produce	  clots	  made	  of	  thick	  fibres,	  
whereas	   conditions	   that	   inhibit	   lateral	   aggregation	   tend	   to	   give	   clots	   consisting	  of	  
thin	  fibres	  with	  many	  branch	  points	  [61].	  	  
The	  conditions	  present	  during	  the	  conversion	  of	  fibrinogen	  to	  fibrin	  determine	  the	  
structure	   including	   fibre	   thickness,	   branching	   and	   network	   density.	   Experimental	  
data	   have	   shown	   that	   pH,	   calcium	   concentration,	   polyphosphate,	   fibrinogen,	  
fibrin(ogen)	  binding	  proteins	  and	  thrombin	  can	  all	  affect	  the	  network	  architecture.	  
Low	  thrombin	  concentrations	  produce	  coarse,	  unbranched	  networks	  of	  thick	  fibres,	  
high	  concentrations	  produce	  highly	  branched	  dense	  networks	  of	  thin	  fibres	  [62,	  63].	  
In	   FVIII	   and	   IX	  deficiency	  a	   reduced	   rate	  and	  peak	  of	   thrombin	  generation	   is	   seen	  
that	   results	   in	   deficiencies	   in	   fibrin	   production	   and	   formation	   of	   a	   coarse	   fibrin	  
network	   containing	   thick	   fibres	   [64,	   65].	   Fibrin	   formation	   occurs	   early	   in	   the	  
thrombin	   generation	   process	   and	   the	   fibrin	   network	   structure	   and	   stability	   are	  
dependent	  on	  TF	  activity	   [66].	   Increased	   thrombin	  generation	   indirectly	   reinforces	  
clot	  stability	  via	  activation	  of	  TAFI	  thus	  protecting	  the	  clot	  from	  premature	  lysis	  [67].	  
Platelets	   and	   endothelial	   cells	   may	   also	   modulate	   fibrin	   network	   formation	   as	  
discussed	  in	  1.1.5.2.	  Furthermore,	  direct	  interactions	  between	  cell	  receptors	  and	  the	  
network,	   pro	   and	   anti	   coagulant	   activities	   of	   the	   cells	   themselves	   and	   substances	  
released	  from	  cells	  locally	  may	  all	  play	  a	  role.	  Several	  receptors	  have	  been	  shown	  to	  
bind	   fibrin(ogen),	   including	   vascular	   endothelial	   (VE)	   cadherin	   and	   inter-­‐cellular	  
adhesion	  molecule	   1	   (ICAM-­‐1).	   Integrin	   αvβ3	   on	   endothelial	   cells	   and	   αIIbβ3	   on	  
platelets	  have	  been	   shown	   to	  modulate	   fibrin	  network	   structure	  and	   stability	   [68,	  
69].	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Flow	   profoundly	   influences	   fibrin	   network	   structure.	   Fibrin	   formation	   studied	   in	  
systems	  modelling	  both	  venous	  and	  arterial	  shear	  shows	  orientation	  of	  fibrin	  fibres	  
along	   flow	   vectors	   [70].	   Campbell	   et	   al	   [71]	   studied	   clot	   structure	   at	   even	   lower	  
shear,	   similar	   to	   that	   expected	   during	   extravasation	   of	   blood	   into	   extravascular	  
tissue.	  They	  found	  a	  prominent	  network	  of	  thick	  fibres,	  as	  well	  as	  fibre	  aggregates	  in	  
which	   multiple	   individual	   fibres	   coalesced	   into	   bundles.	   A	   minor	   network	   of	   thin	  
fibres	  connected	  individual	  thick	  fibres.	  	  
1.1.4.3 FXIIIa	  cross	  linking	  
Factor	   XIIIa	   has	   an	   important	   role	   in	   increasing	   clots	   firmness	  by	   increasing	   cross-­‐
links	   between	   adjacent	   fibrin	   chains	   (γ-­‐chain	   dimers	   and	   α-­‐chain	   polymers	   are	  
produced)	  [21].	  A	  common	  polymorphism	  in	  FXIII	  is	  the	  G	  >	  T	  nucleotide	  substitution	  
in	  exon	  2	  of	  the	  FXIII	  A-­‐subunit	  gene.	  This	  results	  in	  the	  replacement	  of	  valine	  by	  a	  
lysine	  residue	  at	  a	  site	  close	  to	  the	  thrombin	  activation	  site	  	  (V34L).	  The	  population	  
prevalence	   has	   been	   estimated	   at	   48%	   in	   the	   Caucasians	   population	   (41%	  
heterozygous,	   7%	   homozygous)	   [72]	   with	   lower	   prevalence	   rates	   of	   32-­‐36%	  
demonstrated	  in	  patients	  with	  MI	  or	  Stroke	  patients	  [73].	  Fibrinogen	  concentration	  
has	   been	   shown	   to	   determine	   the	   modulatory	   effect	   of	   V34L	   on	   clot	   structure:	  
higher	  fibrinogen	  concentrations	  have	  been	  shown	  to	  be	  associated	  with	  decreased	  
clot	   permeability	   resulting	   in	   tighter	   clot	   structure	   in	   the	   presence	   of	   factor	   XIII	  
34Val	   alleles	   compared	   with	   those	   in	   the	   presence	   of	   34Leu	   alleles	   [74].	   The	  
importance	   of	   fibrinogen	   and	   FXIII	   interactions	   is	   also	   shown	   by	   the	  α-­‐fibrinogen	  
Thr312Ala	   polymorphism.	   This	   variant	   has	   been	   shown	   to	   influence	   clot	   structure	  
through	   increased	   factor	   XIII	   cross-­‐linking.	   An	   association	   between	   venous	  
thromboembolism	  and	  this	  polymorphism	  has	  been	  found	  in	  the	  studies	  of	  patients	  
with	  VTE	  [75-­‐77].	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1.1.5 Factors	  influencing	  fibrinolysis	  
To	   understand	   the	   relationship	   between	   clot	   structure	   and	   the	   rate	   of	   lysis,	   the	  
physical	  process	  of	  digestion	  should	  be	  considered.	  For	  example	  digestion	  of	  fibrin	  
fibres	  from	  the	  surface	  inward,	  results	  in	  differences	  in	  lysis	  rate	  between	  thick	  and	  
thin	   fibres.	   Following	   thrombolysis,	   with	   externally	   applied	   lytic	   agents,	   a	   distinct	  
lysis	   front	   is	   seen	   [78]	   resulting	   in	   occurrence	   of	   binding	   and	   proteolytic	   events	  
within	  a	  narrow	  zone.	   In	  vivo,	   clotting	  and	   fibrinolysis	  are	   initiated	  simultaneously	  
and	  although	  no	  lysis	  front	  is	  seen,	  the	  physical	  process	  is	  similar	  with	  in	  that	  there	  
is	  lateral	  transection	  and	  faster	  cleavage	  of	  thinner	  fibres.	  
1.1.5.1 Fibrin	  structure	  
Fibrin	   structure	  has	  been	  shown	  to	  directly	  affect	   the	   rate	  of	   fibrinolysis.	  Previous	  
turbidometric	  studies	   in	  which	   lysis	  was	   initiated	  with	   tPA	  and	  plasminogen	   in	   the	  
presence	  of	  varying	  amounts	  of	  thrombin	  to	  modulate	  fibre	  size	  has	  shown	  a	  direct	  
correlation	  between	  the	  size	  of	  fibres,	  as	  assessed	  by	  maximal	  turbidity	  and	  the	  rate	  
of	  lysis	  [62].	  	  However,	  this	  effect	  was	  abrogated	  when	  the	  curves	  were	  normalised	  
for	  the	  maximum	  turbidity	  [62].	  Further	  work	  using	  cross-­‐linked	  fibrin	  labelled	  with	  
colloidal	   gold	   particles	   and	   confocal	  microscopy	   showed	   that	   fibrinolysis	   proceeds	  
by	   transverse	   cutting	  of	   fibres,	   rather	   than	  progressive	   cleavage	  uniformly	  around	  
the	   fibre.	  Plasma	   fibrin	  clots	  with	  a	  dense	  network	  of	   thinner	   fibres	  dissolved	  at	  a	  
slower	  rate	  than	  those	  with	  coarse	  fibrin	  structure.	   	  However	   individual	  thin	  fibres	  
were	  cleaved	  at	  a	  faster	  rate	  than	  thick	  ones.	  The	  tPA	  binding	  front	  was	  broader	  in	  
coarse	   fibrinogen	   clots	   and	  moved	  more	   rapidly	   in	   fine	   plasma	   fibrin	   clots,	  which	  
may	  partly	  account	  for	  the	  difference	  in	  lysis	  rates	  [79].	  
1.1.5.2 Cellular	  contribution	  
Platelets	   have	   an	   important	   effect	   on	   clot	   structure	   and	   therefore	   fibrinolysis.	  
Platelet	   rich	   clots	   are	   heterogeneous	   with	   platelet	   poor	   areas	   consisting	   of	   a	  
network	  of	  randomly	  orientated	  branching	  fibres,	  alternating	  with	  platelet	  rich	  areas	  
in	  which	  bent	  and	  retracted	  fibres	  are	  organised	  with	  some	  orientation	  with	  fibres	  
aligned	   radially	   with	   respect	   to	   the	   platelet	   aggregate.	   Higher	   numbers	   of	   fibrin	  
fibres	   are	   present	   in	   platelet	   rich	   areas	   with	   fibres	   adjacent	   to	   the	   platelet	  
aggregates	  being	   shown	   to	  be	   thinner	   and	  denser	   than	   those	   in	   the	  platelet	  poor	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areas.	   Collet	   et	   al	   showed	   that	   the	   fibrinolysis	   resistance	   of	   platelet	   rich	   clots	   is	  
related	  to	  a	  reduction	  in	  tPA	  binding	  rate	  and	  the	  lysis	  speed	  of	  the	  platelet	  rich	  area	  
compared	   to	   platelet	   poor	   area	   [80].	   The	   lysis	   front	  was	   linear	   until	   it	   came	   into	  
contact	   with	   a	   platelet-­‐fibrin	   aggregate	   when	   it	   became	   curved	   so	   the	   aggregate	  
was	   progressively	   surrounded	   by	   completely	   lysed	   area.	   Addition	   of	   the	  GPIIb/IIIa	  
inhibitor,	   abciximab	   resulted	   in	   similar	   binding	   rates	   and	   lysis	   fronts	   between	  
platelet	  rich	  and	  platelet	  poor	  areas	  [80].	  
Kunitada	   et	   al	   showed	   that	   the	  difference	   in	   lysis	   rates	   between	  platelet	   rich	   and	  
platelet	  poor	  clot	  was	  not	  due	  to	  PAI-­‐1	  release	  by	  the	  platelets,	  rather	  the	  decreased	  
binding	   of	   rtPA	   as	   a	   consequence	   of	   clot	   retraction	   and	   decreased	   access	   to	  
fibrinolytic	   proteins	   [81].	   Pre-­‐treatment	   with	   cytochalasin	   D,	   which	   inhibits	   clot	  
retraction,	   abolished	   the	   platelet	   induced	   inhibition	   of	   lysis	   and	   tPA	   binding	   by	  
platelets.	  This	  suggests	  that	  platelets’	  main	  role	  is	  to	  make	  a	  denser	  fibrin	  network	  
by	  pulling	  the	  fibres	  together	  via	  their	  binding	  to	  IIb/IIIa.	  
Local	   fibrinolytic	   activity	  may	  be	  enhanced	  by	   cellular	  expression	  of	  uPA,	  UPAR	  or	  
tPA	  and	  decreased	  by	  cellular	  release	  of	  plasminogen	  activator	  inhibitor[82]	  and/or	  
TAFI	  [83].	  In	  vitro	  studies	  have	  shown	  that	  the	  ability	  of	  TF	  bearing	  vascular	  cells	  to	  
initiate	  fibrin	  production	  correlates	  with	  their	  endogenous	  procoagulant	  activity	  [66,	  
84,	   85].	   Highly	   procoagulant	   cells	   e.g.	   fibroblasts	   and	   smooth	  muscle	   cells	   (SMC)	  
support	   the	   formation	   of	   dense	   fibrin	   networks,	   whereas	   intravascular	   cells	  
(unstimulated	   endothelial	   cells)	   produce	   coarse	   networks	   that	   are	   susceptible	   to	  
fibrinolysis.	   Pro	   inflammatory	   mediators	   e.g.	   Tumour	   Necrosis	   Factor-­‐α (TNFα)	  
induce	   a	   procoagulant	   phenotype	   in	   endothelial	   cells	   through	   increased	   TF	   and	  
decreased	  TM	  expression	  in	  a	  time	  and	  dose	  dependant	  manner.	  TNF-­‐α	  stimulated	  
endothelial	   cells	   have	  been	   shown	   in	   vitro	   to	   promote	   formation	  of	   a	   denser	   and	  
more	  stable	  fibrin	  network	  compared	  to	  unstimulated	  cells	  [66].	  
TM	  has	  an	   important	   role	   in	  altering	   the	   rate	  of	   fibrinolysis.	   There	   is	   considerable	  
heterogeneity	   in	   the	   expression	   of	   TM	   on	   endothelial	   cells	   and	   this	   will	   have	   an	  
effect	   on	   TAFI	   activation.	   The	   heterogeneity	   is	   dependent	   on	   the	   extracellular	  
environment,	  the	  component	  of	  the	  extracellular	  matrix	  and	  the	  surface	  area	  of	  the	  
vessel	   in	  contact	  with	  blood.	  TM	  concentration	  can	  be	  as	   low	  as	  1nM	  in	  the	  larger	  
arteries	   and	   as	   high	   as	   100nM	   in	   capillary	   beds	   [15,	   86].	   This	   implies	   that	   TAFI	   is	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more	  readily	  activated	  in	  small	  vessels	  but	  we	  must	  also	  take	  into	  consideration	  the	  
additional	  cofactors	  in	  protein	  C	  generation	  and	  function	  e.g.	  endothelial	  protein	  C	  
receptor	   as	  well	   as	   other	  modulators	   of	   TM	   availability,	   such	   as	   platelet	   factor	   4,	  
protein	  C	  inhibitor,	  and	  protein	  S.	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1.2 The	  Normal	  Endothelium	  
Blood	  vessels	  are	  composed	  of	  an	  intimal	   layer	  consisting	  of	  endothelial	  cells	  (ECs)	  
and	   subendothelial	   basement	   membrane,	   a	   medial	   layer	   consisting	   of	   smooth	  
muscle	   cells	   and	   their	   extracellular	   matrix	   and	   the	   adventitial	   layer	   consisting	   of	  
fibroblasts	   and	   their	   extracellular	   matrix.	   All	   three	   layers	   demonstrate	   properties	  
important	   to	   haemostasis.	   The	   medial	   and	   adventitial	   layers	   provide	   mechanical	  
strength	   and	   enable	   blood	   vessels	   to	   constrict	   or	   dilate,	  while	   the	   subendothelial	  
basement	  membrane	  contains	  many	  adhesive	  proteins	  that	  provide	  binding	  sites	  for	  
platelets	  and	  leukocytes.	  	  
A	  single	   layer	  of	  ECs,	   the	  endothelium,	   forms	  the	   inner	   lining	  of	  blood	  vessels	  and	  
provides	  a	  physical	  barrier	  between	  tissues	  and	  blood.	  However,	  the	  endothelium	  is	  
not	   just	   an	   inert	   membrane	   but	   an	   organ	   which	   regulates	   synthetic,	   metabolic,	  
immunologic	  and	  secretory	  functions	  [87].	  
ECs	   are	   able	   to	   respond	   and	   adapt	   according	   to	   the	   nature	   of	   their	   environment	  
[88].	   These	   responses	   include	   acute	   release	   of	   endothelial	   products,	   immediate	  
response	   to	   hypoxia	   by	   activation	   of	   hypoxia	   inducible	   factors	   HIF-­‐1	   and	   HIF-­‐2,	  
induction	   of	   new	  endothelial	   receptors	   and	   secreted	   proteins	   and	   participation	   in	  
immunological	   reactions.	   The	   acute	   response	   involves	   receptor	   mediated	   cell	  
signalling,	  an	  influx	  of	  calcium	  ions	  and	  induction	  of	  phosphorylation.	  This	  activates	  
enzymes	   that	   generate	   nitric	   oxide,	   prostacyclin/prostaglandin	   E2	   and	   in	   certain	  
circumstances	   endothelin-­‐1.	   There	   is	   also	   recruitment	   of	   vesicles	   with	   preformed	  
proteins	  to	  the	  plasma	  membrane.	  The	  Weibel	  Palade	  bodies	  (WPBs)	  are	  a	  specific	  
storage	  organelle	  within	   ECs	   that	   release	   von	  Willebrand	   factor	   (VWF),	   P	   selectin,	  
angiopoietin	   2	   and	   many	   other	   inflammatory	   and	   angiogenic	   mediators	   listed	   in	  
Table	  1.1.	  Release	  of	  tPA	  also	  occurs:	  there	  is	  some	  controversy	  as	  to	  whether	  this	  is	  
from	  WPBs	  or	  from	  separate	  vesicles	  [89,	  90].	  The	  contents	  of	  WPBs	  are	  released	  in	  
response	   to	   a	   large	   number	   of	   agonists	   including	   thrombin,	   histamine,	   serotonin	  
and	  vasopressin.	  These	  agonists	  can	  be	  divided	   into	   two	  groups,	   those	   that	  act	  by	  
increasing	   intracellular	   calcium	   levels	   and	   those	   that	   act	   by	   raising	   intracellular	  
cAMP	   levels.	   Thrombin,	   acting	   via	   the	   protease	   activated	   receptor	   1	   (PAR-­‐1)	  
elevates	  the	  intracellular	  calcium	  resulting	  in	  a	  rapid,	  local	  response	  with	  exocytosis	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of	   most	   of	   the	   WPBs	   present	   in	   the	   cell	   [91].	   ECs	   response	   to	   TNF-­‐α	   is	   via	   the	  
classical	  NFκB	  pathway.	  This	  induces	  a	  range	  of	  genes	  required	  for	  the	  inflammatory	  
response	  including	  vascular	  cell	  adhesion	  molecule	  (VCAM)-­‐1,	  intercellular	  adhesion	  
molecule	  (ICAM)-­‐1	  and	  in	  culture	  tissue	  factor	  (TF)	  [92],	  PAI-­‐1	  and	  uPA.	  	  
	  
Table	  1.1	  Content	  of	  Weibel	  Palade	  bodies	  
Protein	   Function	  
VWF	   Haemostasis,	  angiogenesis	  




Endothelin	   Vasoconstriction	  
Endothelin	  converting	  enzyme	   Vasoconstriction	  




Angiopoietin-­‐2	   Inflammation,	  vascular	  homeostasis	  
Osteoprotegerin	   Vascular	  homeostasis	  
CD63/lamp3	   Cell	  adhesion/migration	  
α1,3-­‐fucosyltransferase	  VI	   Membrane	  glycosylation	  	  
	  
There	  is	  significant	  heterogeneity	  between	  endothelial	  cells	  in	  different	  sites	  in	  the	  
vascular	  tree,	  which	  are	  understood	  to	  result	  in	  site-­‐specific	  variation	  in	  haemostasis	  
[86].	   This	   explains	   why	   changes	   within	   the	   production	   of	   coagulation	   proteins	   or	  
increased	   activation	   of	   cells	   e.g.	   platelets	   or	   monocytes,	   affect	   the	   haemostatic	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1.2.1 Endothelial	  progenitor	  cells	  
Endothelial	   progenitor	   cells	   (EPCs)	   circulate	   in	   the	   blood	   stream,	   are	   able	   to	  
proliferate	  at	  a	  clonal	  level	  and	  can	  differentiate	  into	  mature	  endothelial	  cells.	  EPCs	  
are	   thought	   to	   be	   derived	   from	   bone	  marrow,	   however	   recent	   research	   suggests	  
they	   may	   also	   derive	   from	   other	   sources	   including	   blood	   vessels	   [94]	   and	  
parenchymatous	  organs	  [95].	  	  	  
Until	   1997,	   new	   vessel	   formation	   in	   adults	  was	   thought	   to	   occur	   via	   a	   process	   of	  
endothelial	   sprouting	   from	  pre-­‐existing	  vessels,	  with	  vasculogenesis	  only	  occurring	  
in	  the	  fetus.	  In	  1997	  Asahara	  et	  al	  described	  the	  isolation	  of	  putative	  EPCs	  [96].	  Since	  
that	   time	   there	   has	   been	   much	   interest	   in	   EPCs,	   in	   particular	   in	   relation	   to	  
cardiovascular	   disease.	   However	   despite	   extensive	   work	   in	   this	   area	   a	   lack	   of	  
consensus	  remains	  with	  regards	  the	  terminology	  of	  these	  cells	  [97-­‐99].	  Different	  cell	  
types	  may	  be	  grown	  from	  blood,	  all	  of	  which	  display	  different	  characteristics,	  yet	  all	  
have	   been	   called	   EPCs.	   To	   understand	   these	   differences	   in	   more	   detail	   the	  
methodologies	  used	   to	   identify	   the	  EPCs	  must	  be	  considered.	  There	  are	   two	  main	  
methods	  to	  study	  EPCs:	  flow	  cytometry	  of	  fresh	  samples	  and	  cell	  culture.	  I	  will	  look	  
at	  both	  methods,	  but	  concentrate	  on	  cell	  culture,	  as	  this	  was	  the	  method	  used	  in	  my	  
research.	  
1.2.1.1 Cell	  culture	  
A	   variety	   of	   protocols	   have	   been	   used	   for	   the	   isolation	   of	   EPCs	   since	   the	   original	  
description	   by	   Asahara	   et	   al	   [96]	   in	   which	   cells	   were	   preselected	   on	   the	   basis	   of	  
expression	   of	   key	   EPC	   markers	   prior	   to	   culture.	   A	   minor	   subpopulation	   that	   was	  
CD34+,	   KDR+	   cells	   were	   isolated	   as	   early	   as	   three	   days	   after	   plating	   on	   human	  
fibronectin	  in	  an	  endothelial	  medium.	  The	  cells	  showed	  typical	  functional	  properties	  
of	  endothelial	  cells	  with	  the	  uptake	  of	  ac-­‐LDL,	  and	  expression	  of	  other	  endothelial	  
lineage	  markers	  e.g.	  CD31	  and	  KDR	  [96].	  Following	  transplantation	  into	  animals	  the	  
cells	   were	   recruited	   to	   sites	   of	   ischaemia	   where	   they	   were	   shown	   to	   promote	  
vasculogenesis	  [96].	  They	  called	  these	  cells	  endothelial	  progenitor	  cells	  (EPCs).	  
This	   method	   was	   subsequently	   modified	   to	   include	   growth	   of	   cells	   from	  
unfractionated	   mononuclear	   cells	   [100].	   Hill	   et	   al,	   in	   the	   seminal	   paper	   of	   this	  
method,	  described	  typical	  clusters	  appearing	  five	  to	  seven	  days	   in	  culture	  after	  re-­‐
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plating	   the	  non-­‐attached	   cells	  onto	   fibronectin.	  The	   typical	  cluster	  had	  round	  cells	  
centrally	  with	  spindle	  shaped	  cells	  sprouting	  at	  the	  periphery	  [101].	  These	  cells	  were	  
termed	   colony	   forming	   units-­‐endothelial	   cells	   (CFU-­‐EC).	   A	   correlation	   was	   seen	  
between	   the	   numbers	   of	   CFU-­‐EC	   and	   the	   cumulative	   index	   of	   cardiovascular	   risk	  
factors.	   This	   led	   to	   the	   development	   of	   a	   patented	   kit	   for	   this	  method	   (Endocult	  
Liquid	  Medium	  Kit™	  Stem	  Cells	  Technologies	  Inc).	  	  
Some	   groups	   have	   shown	   that	   these	   CFU-­‐EC	   express	   CD45	   (the	   pan	   leukocyte	  
antigen),	   CD14	   and	   CD115	   (monocyte/macrophage	   markers)	   and	   it	   is	   therefore	  
thought	   that	   these	   cells	   actually	   represent	   the	   extreme	   plasticity	   of	   the	  
monocyte/macrophage	  lineage	  [102]	  responding	  to	  the	  culture	  conditions.	  
The	  use	  of	  longer	  incubation	  times	  and	  the	  omission	  of	  re-­‐plating	  the	  non-­‐adherent	  
cells	   led	   to	   the	  demonstration	  of	   two	  phenotypically	  distinct	   forms:	  early	  and	   late	  
EPCs.	  A	  summary	  of	  cell	  culture	  methods	  is	  shown	  in	  Figure	  1.5.	  
Early	  EPCs	  appear	  as	  early	  as	  day	  three	  in	  culture.	  They	  display	  limited	  proliferative	  
capacity	   and	  disappear	   after	   about	   two	  weeks	   in	   culture.	   These	   cells	  may	   also	  be	  
termed	  circulating	  angiogenic	  cells	  (CAC)	  [98].	  CACs	  remain	  following	  removal	  of	  the	  
non-­‐adherent	  cells;	  although	  CACs	  do	  not	  show	  colony	  formation,	  they	  are	  able	  to	  
promote	   neovascularisation	   in	   animal	   models	   [103].	   Vasa	   et	   al	   showed	   CAC	  
concentration	  to	  be	  decreased	  in	  association	  with	  increasing	  number	  of	  risk	  factors	  
for	   coronary	   artery	   disease	   [104].	   Smoking	   was	   the	   most	   significant	   risk	   factor	  
shown	   to	   affect	   the	   numbers	   of	   CACs.	   Rehman	   et	   al	   showed	   that	   CAC	   numbers	  
increased	  immediately	  after	  exercise	  [105].	  	  
Late	   EPCs	   appear	   after	   7	   to	   21	   days,	   displaying	  morphology	   typical	   of	   endothelial	  
cells,	  forming	  a	  confluent	  cobblestone	  layer	  and	  have	  a	  high	  proliferative	  potential.	  
In	   2004,	   Ingram	   et	   al	   used	   this	  method	   of	   isolation	   to	   grow	   cells	   from	  peripheral	  
blood,	   which	   appeared	   following	   at	   least	   ten	   days	   in	   culture	   [102].	   These	   were	  
termed	   endothelial	   colony	   forming	   cells	   (ECFC).	   These	   cells	   were	   shown	   to	   have	  
extensive	   proliferative	   potential	   (with	   more	   than	   100	   population	   doublings)	   and	  
self-­‐renewal	  capacity	  and	  were	  able	  to	  form	  capillary	  like	  structures	  in	  vitro.	  ECFCs	  
expressed	   VWF,	   VE-­‐cadherin	   (CD144),	   VEGF-­‐R,	   and	   CD34,	   but	   did	   not	   express	  
CD45/115	   (monocyte	   lineage)	   consistent	   with	   a	   true	   endothelial	   lineage.	   Studies	  
have	   shown	   that	   a	   hierarchy	   of	   EPCs	   (based	   on	   clonogenic	   and	   proliferative	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potential)	   reside	   throughout	   the	   vascular	   endothelium	   and	   are	   a	   reservoir	   for	  
mobilising	   circulating	   ECFC	   [106].	   Tura	   et	   al	   have	   shown	   that	   late	   outgrowth	  
endothelial	   cells	   isolated	   from	   the	   peripheral	   blood	   display	   similar	   properties	   to	  
mature	   endothelial	   cells	   (HUVECs)	   in	   terms	   of	   morphology,	   surface	   antigen	  
expression,	   immunohistochemistry,	   rtPCR	   gene	   expression	   analysis,	   proliferation	  
and	  functional	  assessment,	  with	  de	  novo	  vessel	  formation	  in	  a	  sponge	  model	  [107].	  
They	  concluded	  that	  these	  cells	  are	  not	  derived	  from	  the	  bone	  marrow,	  but	  did	  not	  
suggest	  an	  alternative	  origin.	  	  
Guven	  et	  al	  showed	  higher	  numbers	  of	  late	  EPC	  colonies	  as	  well	  as	  CAC	  in	  patients	  
with	  significant	  coronary	  artery	  disease	  compared	  to	  healthy	  controls,	  in	  contrast	  to	  
studies	  using	  alternative	  methods	  of	  EPC	  isolation	  (flow	  or	  CFU-­‐EC)	  [108].	  	  
	  
Figure	  1.5	  Summary	  of	  EPC	  isolation	  by	  cell	  culture	  
Cell	   culture	   of	   EPCs	   from	   peripheral	   blood	   mononuclear	   cells.	   Colony	   forming	   units	   –	  
endothelial	   cells	   (CFU-­‐EC)	   are	   derived	   from	   the	   non-­‐adherent	   cells,	   appear	   early	   and	   are	  
predominantly	   haemopoietic	   cell	   lineage.	   Circulating	   angiogenic	   cell	   (CAC),	   also	   known	   as	  
early	  EPCs	  have	   limited	  proliferative	  capacity.	  Endothelial	  colony	  forming	  units	   (ECFC)	  also	  
known	   as	   late	   outgrowth	   endothelial	   cells	   or	   blood	   outgrowth	   endothelial	   cells	   (BOECs)	  
have	   endothelial	   markers,	   are	   highly	   proliferative	   and	   show	   neovascularisation	   in	   animal	  
models.	  (UEA-­‐1	  Ulex	  eupoaeus	  agglutinin-­‐1).	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1.2.1.2 Flow	  cytometry	  
Flow-­‐cytometric	  identification	  of	  EPCs	  has	  two	  main	  limitations:	  	  the	  precise	  antigen	  
phenotype	  of	  EPCs	  is	  not	  known	  and	  EPCs	  are	  very	  rare	  in	  the	  peripheral	  circulation.	  
There	  may	  therefore	  be	  overlap	  with	  other	  cell	  lineages	  and	  the	  use	  of	  only	  two	  or	  
three	  antigens	  to	  identify	  the	  population	  definitively	  is	  challenging.	  
	  
Early	  studies	  used	  CD34	  as	  a	  marker	  of	  immaturity/stem	  cell	  lineage	  and	  KDR/Flk-­‐1	  
(which	  represents	  the	  VEGF	  receptor	  2)	  as	  an	  endothelial	  marker.	  This	  was	  because	  
CD34	  and	  KDR	  have	  overlapping	  expression	  on	  stem	  cells	  and	  endothelial	  cells	  and	  
could	  therefore	  represent	  putative	  EPCs.	  This	  was	  also	  consistent	  with	  the	  original	  
description	   from	  Asahara	  et	  al.	  However	  some	  mature	  endothelial	   cells	  within	   the	  
microvasculature	   also	   express	  CD34.	  Other	   groups	  have	   tried	  using	  other	  markers	  
such	   as	   CD133	   as	   well	   as	   other	   endothelial	   markers	   such	   as	   CD31	   (PECAM-­‐1)	   or	  
VWF.	   CD133	   is	   another	   marker	   of	   immaturity	   and	   has	   never	   been	   found	   to	   be	  
expressed	   on	   mature	   endothelial	   cells,	   so	   it	   may	   correspond	   better	   to	   EPCs	   but	  
CD133+	  KDR+	  cells	  are	  more	   immature	  and	   therefore	  even	   rarer	   in	   the	  peripheral	  
blood.	   CD34+KDR+	   is	   the	   only	   putative	   cell	   phenotype	   to	   be	   shown	   to	   be	   an	  
independent	   predictor	   of	   cardiovascular	   outcome.	  Werner	   et	   al	   [109]	   showed	   an	  
inverse	   correlation	   between	   cell	   numbers	   and	   outcome.	   Some	   studies	   have	  
demonstrated	  that	  these	  cells	  behave	  like	  EPCs	  in	  vivo	  [110],	  whereas	  other	  groups	  
suggest	   these	   represent	   distinct	   haematopoietic	   progenitors	   that	   do	   not	  
differentiate	  into	  endothelial	  cells.	  	  
	  
It	   is	   therefore	   evident	   that	   the	   EPC	   population	   includes	   a	   broad	   spectrum	   of	  
endothelial	  progenitors	  with	  different	  phenotypic	  features	  and	  biological	  profiles.	  It	  
is	  therefore	  important	  when	  looking	  at	  studies	  within	  this	  field	  to	  examine	  both	  the	  
method	  used	  to	  identify	  the	  cells	  (flow	  or	  culture)	  and	  the	  method	  of	  culture	  used	  to	  
ensure	  that	  any	  comparisons	  are	  with	  the	  same	  cells.	  
	  A	   descriptive	   term	   for	   the	   endothelial	   cells	   grown	   in	   culture	   is	   blood	   outgrowth	  
endothelial	   cells	   (BOECs).	   In	   this	   project,	   the	   cells	   grown	   will	   be	   referred	   to	   as	  
BOECs,	  corresponding	  to	  the	  late	  EPCs	  or	  endothelial	  colony	  forming	  cells	  (ECFCs).	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1.3 Abnormal	  Haemostasis	  
Imbalances	   in	   haemostasis	   can	   occur	   and	   this	   may	   lead	   to	   excessive	   bleeding	   or	  
thrombus	  formation.	  	  Examples	  of	  coagulation	  defects	  that	  cause	  excessive	  bleeding	  
include	   haemophilia	   A	   (FVIII	   deficiency),	   haemophilia	   B	   (FIX	   deficiency)	   and	   Von	  
Willebrand	   Disease	   (VWF	   deficiency).	   	   Thrombosis,	   the	   formation	   of	   a	   blood	   clot	  
inside	   a	   vessel	   in	   the	   absence	   of	   a	   bleeding	   precipitant,	   is	   thought	   in	   classical	  
teaching	  to	  be	  caused	  by	  abnormalities	  in	  the	  composition	  of	  the	  blood,	  the	  quality	  
of	   the	  vessel	  wall	  or	   the	  nature	  of	   the	  blood	   flow.	  This	   is	   referred	   to	  as	  Virchow’s	  
triad.	  As	  venous	  thromboembolism	  is	  known	  to	  be	  a	  risk	  factor	  in	  the	  development	  
of	  chronic	  thromboembolic	  pulmonary	  hypertension	  (CTEPH),	  this	  will	  be	  considered	  
in	  more	  detail.	  
1.3.1 Venous	  thromboembolism	  
Venous	   thromboembolism,	   which	   includes	   both	   deep	   vein	   thrombosis	   (DVT)	   and	  
pulmonary	   embolism	   (PE),	   is	   a	  major	   cause	   of	  morbidity	   and	  mortality:	   PE	   is	   the	  
third	  most	   common	  cause	  of	  death	   from	  cardiovascular	  disease	  after	  heart	   attack	  
and	   stroke	   [111].	   The	   annual	   incidence	   of	   venous	   thromboembolism	   has	   been	  
reported	  to	  be	  approximately	  two	  to	  three	  per	  1000	  people	  and	  rises	  steeply	  with	  
age	   [112,	   113].	   Case	  mortality	   rates	   vary	   depending	   on	   the	   study	   population	   but	  
rates	  of	  between	  1	  and	  17%	  have	  been	  reported	  [114,	  115].	  	  Important	  sequelae	  of	  
VTE	   are	   post	   thrombotic	   syndrome	   and	   chronic	   thromboembolic	   pulmonary	  
hypertension	  (CTEPH).	  CTEPH	  will	  be	  discussed	  in	  more	  detail	  in	  section	  1.5.	  
1.3.1.1 Deep	  Vein	  Thrombosis	  
Under	   normal	   conditions,	   the	   veins	   of	   the	   lower	   limb	   contain	   a	   high	   number	   of	  
valves.	  These	  consist	  of	  a	  connective	  tissue	  core	  covered	  by	  endothelium.	  The	  ECs	  
lining	   the	   valve	   leaflets	   are	   usually	   at	   a	   higher	   density	   and	   not	   orientated	   in	   the	  
direction	  of	  blood	  flow	  [116].	   	  Venous	  thrombosis	   in	  the	   lower	   limb	  usually	  occurs	  
within	   the	   valve	   pockets.	   Several	   features	  make	   this	   area	   vulnerable	   to	   thrombus	  
formation:	   reduced	  flow	  and	  shear	  stress	  during	  the	  valve	  cycle	   [117],	   the	  relative	  
hypoxia	  of	  blood	   in	   the	  cusps	   (70%	  of	  mainstream	   flow)	   [118]	  and	  a	   tendency	   for	  
leukocytes	  and	  platelets	  to	  become	  trapped	  in	  the	  valve	  pocket	  [119].	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Although	  tissue	  factor	   is	  understood	  to	  be	  the	  principal	   initiator	  of	  clot	   formation,	  
examination	  of	  the	  human	  veins	  in	  thrombosis	  rarely	  shows	  damage	  to	  the	  venous	  
endothelium.	   This	   suggests	   that	   the	   pathway	   to	   clot	   formation	   in	   pathological	  
thrombosis	   is	   distinct	   from	   the	   response	   to	   injury	   [120].	   It	   may	   be	   that	  
microparticles	  bearing	  TF	  play	  a	  role	  in	  thrombus	  formation	  [121].	  Studies	  have	  also	  
suggested	   that	   stasis,	   hypoxia	   and	   inflammation	   may	   each	   lead	   to	   endothelial	  
activation	  and	  an	  increased	  risk	  of	  thrombosis	  [122].	  Current	  evidence	  suggests	  that	  
stasis	  alone	   is	   insufficient	   to	  cause	  venous	   thrombosis	   [123]	  and	  therefore	  venous	  
thrombosis	  is	  usually	  due	  to	  a	  combination	  of	  factors	  including	  altered	  anticoagulant	  
or	   procoagulant	   proteins	   in	   the	   blood,	   stasis,	   hypoxia,	   inflammation,	   activation	   of	  
immunity	  and	  activation	  of	  platelets	  [124].	  (See	  Table	  1.1	  for	  inherited	  and	  acquired	  
risk	  factor	  for	  venous	  thromboembolism).	  
1.3.1.2 Pulmonary	  Embolism	  
PE	   is	   a	   blockage	   of	   the	   pulmonary	   artery	   or	   one	   of	   its	   branches,	   usually	   by	   a	  
thrombus.	  Air,	  fat	  and	  amniotic	  fluid	  emboli	  also	  account	  for	  a	  very	  small	  percentage	  
of	  cases.	  It	  was	  Virchow	  in	  the	  19th	  century	  who	  first	  recognised	  that	  blood	  clots	  in	  
the	  pulmonary	  artery	  originate	  as	  venous	  thrombi,	  and	  hence	  gave	  them	  the	  name	  
embolia.	  Historical	  studies	  have	  shown	  that	  without	  treatment	  approximately	  20%	  
of	   calf	   vein	   DVT	   will	   extend	   to	   popliteal	   and	   femoral	   veins	   (proximal	   DVT)	   and	  
without	   treatment	  approximately	  half	  of	  patients	  with	  a	  proximal	  DVT	  develop	  PE	  
[125].	  Obstruction	  of	   the	  blood	   flow	  within	   the	  pulmonary	   vasculature	  may	   cause	  
pain,	   difficulty	   breathing	   and	   palpitation	   as	   well	   as	   low	   blood	   pressure,	   right	  
ventricle	  dysfunction	  and	  sudden	  death.	  Risk	  factors	  for	  PE	  are	  broadly	  the	  same	  as	  
for	  DVT	  and	  are	  shown	  in	  Table	  1.2.	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Table	  1.2	  Risk	  factors	  for	  venous	  thromboembolism	  
Acquired	  
	  
Inherited	   Other	  or	  uncertain	  
Major	  surgery/orthopaedic	  surgery	   Antithrombin	  
deficiency	  
High	  FVIII	  
Immobility	   Protein	  C	  deficiency	   High	  FIX	  
Oestrogen	  related:	  
Combined	  oral	  contraceptive,	  hormone	  
replacement	  therapy,	  tamoxifen	  
Protein	  S	  deficiency	   High	  FXI	  
Pregnancy	  and	  post	  partum	   Factor	  V	  Leiden	   High	  fibrinogen	  
Cancer	  including	  MPN,	  APML	   Prothrombin	  
G20210A	  
High	  TAFI	  
Indwelling	  venous	  device	   Dysfibrinogenaemia	   Low	  TFPI	  
Antiphospholipid	  syndrome	   FXIII	  34	  val	   Hyper-­‐
homocysteinaemia	  
Inflammatory	  states	  






e.g.	  Paroxysmal	  Nocturnal	  Haemoglobinuria,	  
Thrombotic	  Thrombocytopenic	  Purpura,	  
Sickle	  cell	  disease	  	  
Blood	  group	  non-­‐O	   	  
Intravenous	  drug	  abuse	   	   	  
Increasing	  age	   	   	  
Obesity	   	   	  
Dehydration	   	   	  
Hypertension	   	   	  
Smoking	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1.4 Pulmonary	  Hypertension	  
1.4.1 Classification	  
Pulmonary	  hypertension	  (PH)	  is	  a	  rare	  but	  disabling	  disorder	  estimated	  to	  affect	  up	  
to	  100	  million	  people	  worldwide	  [126].	  It	  is	  defined	  by	  an	  elevated	  mean	  pulmonary	  
artery	   pressure	   greater	   than	   25mmHg.	   It	   is	   a	   complex	   disorder	   characterised	   by	  
increased	   pulmonary	   vascular	   resistance,	   causing	   an	   increase	   in	   pulmonary	   artery	  
pressure	  leading	  to	  right	  ventricular	  heart	  failure,	  progressive	  disability	  and	  death.	  
The	  current	  clinical	  classification	  of	  PH	  was	  agreed	  at	  the	  4th	  World	  Symposium	  on	  
Pulmonary	   Hypertension	   in	   Dana	   Point	   in	   2008	   [126].	   It	   subdivides	   PH	   into	   five	  
categories.	  
	  
• Group	  1	  Pulmonary	  arterial	  hypertension	  
§ Group	  1.1	  Idiopathic	  pulmonary	  arterial	  hypertension	  (IPAH)	  
§ Group	  1.2	  Heritable	  pulmonary	  arterial	  hypertension	  
§ Group	  1.3	  Drug	  induced	  and	  toxin	  induced	  forms	  of	  pulmonary	  arterial	  
hypertension	  
§ Group	  1.4	  Pulmonary	  arterial	  hypertension	  associated	  with	   identified	  diseases	  
e.g.	   Connective	   tissue	   disease,	   HIV,	   portal	   hypertension,	   Schistosomiasis	   and	  
chronic	  haemolytic	  anaemia	  
§ Group	  1.5	  Persistent	  pulmonary	  hypertension	  of	  the	  newborn	  
• Group	  1’	  Pulmonary	  veno-­‐occlusive	  disease	  and/or	  pulmonary	  capillary	  
haemangiomatosis	  
• Group	  2	  Pulmonary	  hypertension	  due	  to	  left	  heart	  disease	  (pulmonary	  venous	  
hypertension)	  
• Group	  3	  Pulmonary	  hypertension	  due	  to	  interstitial	  lung	  diseases	  and/or	  hypoxia	  
• Group	  4	  Chronic	  Thromboembolic	  Pulmonary	  Hypertension	  (CTEPH)	  
• Group	  5	  Pulmonary	  hypertension	  with	  unclear	  multifactorial	  mechanisms	  
	  
Studies	  in	  the	  1980s	  revealed	  an	  untreated	  survival	  of	  two	  to	  three	  years	  [127]	  and	  
although	   this	   is	   now	   significantly	   improved	   there	   remains	   a	   need	   to	   improve	  
understanding	  of	  the	  mechanisms	  underlying	  its	  aetiology	  and	  progression	  in	  order	  
to	  develop	  more	  targeted	  therapies.	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1.4.2 Pathogenesis	  
Although	   distinct	   differences	   in	   pathogenesis	   exist	   between	   the	   types	   of	   PH,	  
especially	   in	   disease	   initiation,	   there	   are	   a	   number	   of	   common	   features:	   all	   are	  
characterised	   by	   excessive	   pulmonary	   vasoconstriction	   and	   abnormal	   vascular	  
remodelling.	   The	   processes	   may	   affect	   all	   vessel	   layers	   with	   medial	   hypertrophy,	  
concentric	   intimal	   lesions	   and	   thickened	   adventitia.	   The	   characteristic	   plexiform	  
lesion	   is	   a	   glomeruloid	   structure	   forming	   channels	   in	   branches	   of	   the	   pulmonary	  
artery.	   The	   lesion	   is	   considered	   to	   be	   an	   abnormal	   growth	   of	   modified	   smooth	  
muscle	  and	  endothelial	  cells	  [128,	  129].	  Interestingly	  the	  endothelial	  cells	  within	  the	  
plexiform	  lesion	  in	  IPAH	  have	  been	  shown	  to	  be	  monoclonal	  [130].	  
In	  recent	  years	  there	  have	  been	  many	  developments	  including	  improved	  insight	  into	  
the	  genetic	  basis	  of	  heritable	  PH,	  as	  well	  as	  discoveries	  showing	  the	  role	  of	  excessive	  
vascular	   cell	   growth,	   inflammation,	   vasoconstriction	   and	   thrombosis	   in	   the	  
pathogenesis	   of	   the	   disease	   [131].	   	   The	   current	   understanding	   of	   the	   general	  
concepts	  in	  pathogenesis	  in	  PH	  will	  be	  considered.	  	  
1.4.2.1 Pulmonary	  vasoconstriction	  	  
The	  pulmonary	   vascular	   endothelium	   contains	   prostaglandin	   (PG)	   I2	  synthase.	   This	  
acts	   on	   PGH2	   to	   generate	   Prostacyclin,	   PGI2,	   which	   acts	   to	   relax	   smooth	   muscle	  
cells,	  and	  inhibit	  platelet	  aggregation	  via	  the	  stimulation	  of	  cAMP	  production	  [132].	  
PGH2	   is	  also	  a	  substrate	   for	   thromboxane	  synthase	  which	  generates	   thromboxane	  
A2	   that	   stimulates	   vasoconstriction	   and	   platelet	   aggregation	   via	   thromboxane/PG	  
receptors.	   In	   PH	   prostacyclin	   levels	   have	   been	   shown	   to	   be	   reduced	   and	  
thromboxane	   levels	   increased	   [133].	   This	   finding	   led	   to	   the	   successful	   use	   of	  
prostacyclin	  as	  treatment	  in	  PH.	  
Nitric	  oxide	   is	   synthesised	   in	   the	  endothelium	  by	  endothelial	  NO	  synthase	   (eNOS).	  
The	  end	  effect	  of	  NO	  on	  pulmonary	  smooth	  muscle	  cells	  is	  vasodilation	  mediated	  via	  
cyclic	  GMP	   [134].	   	   Reduced	  NO	  bioavailability	   is	   a	   feature	  of	   all	   forms	  of	   PH.	   This	  
may	   be	   due	   to	   oxidative	   stress	   [135],	   reduced	   NO	   synthase	   expression	   [136]	   or	  
inhibition	  of	  NO	  synthesis	   [137].	   	   Increased	   levels	  of	  asymmetric	  dimethyl	  arginine	  
(ADMA),	  an	  endogenous	  competitive	  inhibitor	  of	  NOS,	  have	  been	  found	  in	  patients	  
with	   IPAH,	  CTEPH	  and	  PH	  related	  to	  sickle	  cell	  disease	  and	  systemic	  sclerosis	   [137,	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138].	   In	  CTEPH	  patients	  a	   correlation	  between	  ADMA	   levels	  and	  survival	  has	  been	  
shown.	   The	   resulting	   reduction	   in	   NO	   lowers	   tissue	   cGMP	   levels.	   Inhibition	   of	  
phosphodiesterase	   (PDE)	   type	   5,	  which	   degrades	   cGMP,	   has	   been	   found	   to	   be	   an	  
effective	  therapy	  in	  certain	  types	  of	  PH.	  
Endothelin-­‐1	   (ET-­‐1)	   is	   a	   vasoconstrictor	   synthesised	   by	   many	   cells	   including	  
pulmonary	   endothelial	   cells	   and	  pulmonary	   smooth	  muscle	   cells.	   It	   signals	   via	   ETA	  
and	  ETB	  receptors	  on	  pulmonary	  smooth	  muscle	  cells	  [139].	  ET-­‐1	  levels	  are	  increased	  
in	   patients	   with	   IPAH	   and	   CTEPH	   [140,	   141].	   Therapy	   with	   ET-­‐1	   inhibitors	   is	   an	  
important	  part	  of	  the	  medical	  management	  of	  PH.	  
Other	   vasoactive	   mediators	   that	   have	   been	   suggested	   to	   play	   a	   role	   are	   5-­‐	  
hydroxytryptamine	  (5-­‐HT)	  and	  K+	  and	  Ca2+	  channel	  abnormalities.	  	  
1.4.2.2 Cell	  proliferation	  and	  pulmonary	  vascular	  remodelling	  
The	  characteristic	  plexiform	  lesion	  seen	  in	  PH	  shows	  endothelial	  cell	  proliferation	  as	  
well	   as	   medial	   hypertrophy	   with	   increased	   pulmonary	   smooth	   muscle	   cells,	  
proliferation	   and	   fibrosis	   of	   the	   intima	   and	   adventitial	   thickening.	  Many	   different	  
factors	  have	  been	  implicated	  in	  causing	  the	  proliferation	  and	  remodelling.	  
Some	   vasoconstrictors	   may	   also	   exert	   proliferative	   effects.	   Endothelin	   stimulates	  
smooth	  muscle	  cell	  proliferation	  and	  5HT	  also	  causes	  smooth	  muscle	  proliferation.	  
Many	   growth	   factors	   have	   been	   implicated	   in	   vascular	   remodelling.	   These	   are	  
thought	   to	   act	   as	   chemo	   attractants	   and	   mitogens	   for	   vascular	   cells,	   including	  
endothelial	   cells,	   fibroblasts	   and	   smooth	   muscle	   cells.	   	   Their	   effects	   also	   include	  
activation	  of	  cell	  surface	  tyrosine	  kinase	  receptors,	  intracellular	  signalling	  leading	  to	  
cell	   proliferation,	   migration	   and	   resistance	   to	   apoptosis.	   The	   factors	   implicated	  
include	   vascular	   endothelial	   growth	   factor	   (VEGF),	   basic	   fibroblast	   growth	   factor	  
(bFGF),	   platelet	   derived	   growth	   factor,	   matrix	   metalloproteases	   and	   transcription	  
factors.	  
VEGF	   and	   its	   receptor	   VEGF-­‐R2	   have	   been	   shown	   to	   be	   expressed	   in	   plexiform	  
lesions	   in	   IPAH.	   However,	   its	   exact	   role	   in	   the	   pathogenesis	   of	   PH	   is	   debated,	   as	  
there	  are	  conflicting	  studies	  in	  animal	  models	  [142,	  143].	  
Basic	  fibroblast	  growth	  factor	  (bFGF)	  is	  ubiquitously	  expressed	  and	  increased	  plasma	  
(and	  urine)	  bFGF	  levels	  have	  been	  observed	  in	  patients	  with	  PH	  [144].	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Other	   factors	   which	   may	   have	   a	   role	   in	   abnormal	   proliferation	   and	   remodelling	  
include	   platelet	   derived	   growth	   factor	   [145],	   TGF-­‐β	   (including	   BMPR2	   see	   section	  
1.4.2.5)	  [146],	  transcription	  factors	  (e.g.	  Notch3)	  [147]and	  matrix	  metalloproteases	  
[148].	  
With	  structural	  remodelling	  seen	  in	  IPAH	  as	  well	  as	  CTEPH	  and	  to	  a	  lesser	  extent	  in	  
PH	   associated	  with	   hypoxia,	   cell	   as	   well	   as	   intimal	   and	   adventitial	   proliferation	   is	  
central	   to	   the	   pathogenesis	   of	   PH.	   Further	   studies	   are	   required	   to	   identify	   all	   the	  
factors	  involved	  in	  remodelling	  and	  how	  they	  interact.	  	  	  
1.4.2.3 	  Endothelial	  repair	  and	  angiogenesis	  	  
Endothelial	  cell	  dysfunction	  is	  thought	  to	  be	  crucial	  in	  the	  pathogenesis	  of	  PH	  [149].	  
In	  1994	  Tuder	  et	  al	   reported	   that	  plexiform	   lesions	  might	   result	   from	  deregulated	  
growth	  of	   endothelial	   cells,	  with	  perivascular	   inflammatory	   cells	   influencing	   lesion	  
development	   [150].	   VEGF	   was	   also	   demonstrated	   to	   be	   present	   in	   the	   plexiform	  
lesion	  and	  this	  led	  to	  the	  consideration	  that	  disordered	  angiogenesis	  may	  also	  play	  a	  
role	  in	  PH.	  
Animal	   studies	  using	  bone	  marrow	  transplantation	  have	  shown	   that	  bone	  marrow	  
progenitor	   cells	   are	   recruited	   during	   pulmonary	   vascular	   remodelling	   [151,	   152].	  
EPCs	  circulate	   in	   the	  peripheral	  blood	  and	  have	  been	  shown	  to	  be	   involved	   in	   the	  
maintenance	   of	   endothelial	   integrity,	   function	   and	   repair	   [153]	   as	   well	   as	  
participating	   in	   vasculogenesis	   and	  angiogenesis	   in	   vascular	  beds	   [154].	   EPCs	  have	  
been	   shown	   to	   be	   reduced	   in	   patients	   with	   Eisenmenger	   syndrome	   [155]	   and	   in	  
IPAH	   [156].	  However	  other	   studies	  have	   found	   increased	  EPCs	   in	   IPAH	   [157,	   158],	  
which	   is	   thought	   to	   reflect	   an	   unsuccessful	   effort	   to	   repair	   damage	   to	   pulmonary	  
endothelium.	  
The	   interest	   in	   the	  endothelium	  has	   led	   to	  various	   research	  groups	   looking	  at	  ECs	  
isolated	  from	  tissue	  at	  lung	  transplant	  or	  pulmonary	  endarterectomy	  or	  EPCs.	  Masri	  
et	  al	  cultured	  pulmonary	  artery	  endothelial	  cells	  from	  healthy	  controls	  and	  patients	  
with	   IPAH	   [159].	   They	   found	   that	   ECs	   derived	   from	   IPAH	   lungs	   were	  
hyperproliferative	   and	   anti-­‐apoptotic.	   This	   was	   dependent	   on	   the	   STAT3	   signal	  
transduction	  pathway,	  which	  is	  known	  to	  be	  critical	  for	  cell	  growth	  stimulation	  and	  
anti-­‐apoptotic	  effects	  [160].	  Quarck	  et	  al	  isolated	  pulmonary	  artery	  endothelial	  cells	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(PAECs)	  and	  smooth	  muscle	  cells	  from	  patients	  with	  CTEPH	  and	  again	  found	  that	  the	  
cells	  showed	  enhanced	  proliferation	  and	  migratory	  capacity	  in	  vitro	  [161].	  	  
Circulating	   endothelial	   cells	   (CECs),	   identified	   by	   flow	   cytometry	   or	   immunobead	  
techniques,	   are	   a	   novel	   marker	   of	   endothelial	   damage	   and	   have	   been	   shown	   to	  
correlate	  with	  VWF	   and	   tPA	   levels	   [162].	   Smadja	   et	   al	   studied	   CECs	   in	   pulmonary	  
hypertension	   in	   patients	   with	   IPAH	   and	   CTEPH	   compared	   to	   controls	   [163].	  
Interestingly	   they	   found	   no	   difference	   in	   progenitor	   counts	   (using	   cell	   culture)	  
between	  the	  groups	  but	  did	  find	  significantly	  increased	  CEC	  numbers	  (immunobead	  
and	   flow	   cytometry	   technique)	   in	   IPAH	  but	   not	   in	   CTEPH	   [163].	   In	   this	   study	   they	  
took	  both	  peripheral	   and	  pulmonary	   artery	  blood	  and	   found	   the	  peripheral	   blood	  
gave	  identical	  results,	  suggesting	  that	  the	  peripheral	  blood	  is	  a	  reliable	  proxy	  for	  the	  
central	  compartment.	  Pilot	  studies	  of	   intravenous	   infusions	  of	  cultured	  EPCs	  (from	  
autologous	  mononuclear	  cells)	   in	  IPAH	  have	  been	  shown	  to	  augment	  the	  6-­‐minute	  
walk	  distance	  and	   improve	  pulmonary	   vascular	  haemodynamics	   at	   12	  weeks	  after	  
the	  infusion	  [164,	  165].	  
1.4.2.4 Immune	  responses	  and	  inflammatory	  cells	  
The	  role	  of	  the	  immune	  response	  in	  PH	  is	  not	  fully	  understood.	  Increased	  cytokine	  
and	   chemokine	   levels	   have	   been	   detected	   in	   the	   blood	   of	   patients	   with	   PH.	  
Monocyte	  chemo	  attractant	  protein	  1	  was	  found	  to	  be	  increased	  in	  CTEPH	  patients	  
and	   correlated	   with	   pulmonary	   vascular	   resistance	   [166].	   Inflammation	   has	   been	  
implicated	  as	  a	  trigger	   factor	   for	  PAH	  as	  well	  as	  contributing	  to	  the	  progression	  of	  
the	  disease	   [167].	  Macrophages,	  monocytes,	   lymphocytes	   (T	  and	  B),	   and	  dendritic	  
cells	   are	   found	   in	   plexiform	   lesions	   [150].	   Further	   research	   is	   required	   to	   fully	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1.4.2.5 Genetics	  
Over	  recent	  years	  there	  has	  been	  an	  increase	  in	  the	  understanding	  of	  idiopathic	  PH,	  
particularly	  in	  relation	  to	  the	  genetics	  of	  PH.	  	  Germline	  mutations	  have	  been	  shown	  
in	   the	   bone	   morphogenic	   protein	   receptor	   2	   (BMPR	   2)	   in	   approximately	   80%	   of	  
familial	  cases	  [168,	  169]	  as	  well	  as	  between	  11%	  and	  40%	  of	  idiopathic	  cases	  with	  no	  
known	  family	  history	  of	  disease	  [146,	  170].	  Segregation	  studies	  have	  demonstrated	  
an	   autosomal	   dominant	   pattern	   of	   inheritance	   with	   reduced	   penetrance.	   This	  
reduced	  penetrance	  suggests	  that	  a	  “second	  hit”	  may	  be	  required	  in	  addition	  to	  the	  
mutation	   to	   cause	   clinical	   disease	   with	   inflammatory	   insults	   [171]	   and	   increased	  
activity	   of	   serotonin	   [172]	   suggested	   as	   possible	   candidates	   based	   on	   studies	   in	  
heterozygous	   BMPR2	   knockout	   mice.	   BMPR	   2,	   a	   type	   II	   receptor	   in	   the	   TGF-­‐β	  
superfamily,	  is	  a	  constitutively	  active	  serine-­‐threonine	  receptor	  kinase.	  Although	  its	  
mechanism	   of	   action	   is	   not	   fully	   understood,	   upregulation	   of	   proproliferative	  
pathways	   involving	   p38	   mitogen	   activated	   protein	   kinase	   [173]	   and	   reduced	  
activation	   of	   transcription	   factor	   Smad	   1	   [174]	   have	   been	   suggested	   by	   in	   vitro	  
studies.	  Mutations	   in	   ALK-­‐1	   have	   also	   been	   identified	   in	   patients	   with	   severe	   PH	  
[175].	   BMP9	   has	   been	   identified	   as	   a	   ligand	   for	   a	   receptor	   complex	   comprising	  
BMPR	  2	   and	  ALK-­‐1,	  which	  may	  provide	   information	   into	   the	   link	  between	  PH	  and	  
hereditary	  haemorrhagic	  telangiectasia	  (HHT)	  [176].	  	  
1.4.2.6 Thrombosis	  
Thrombosis	   in	   relation	   to	   CTEPH	   will	   be	   further	   discussed	   in	   the	   next	   section,	  
however	  the	  association	  between	  thrombosis	  and	  PH	  is	  not	  limited	  to	  CTEPH	  [177].	  
Evidence	   from	  autopsy	  studies	   indicates	   that	   recurrent	   thrombosis	   in	  situ	  plays	  an	  
important	  role	  in	  remodelling	  of	  the	  pulmonary	  vasculature	  in	  all	  forms	  of	  PH	  [178,	  
179].	   Similarly,	   not	   all	   patients	   with	   CTEPH	   have	   had	   an	   overt	   thromboembolic	  
event.	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1.5 Chronic	  Thromboembolic	  Pulmonary	  Hypertension	  	  
Chronic	   thromboembolic	  pulmonary	  hypertension	   (CTEPH)	   is	  a	  distinct	  category	  of	  
PH,	   in	   which	   there	   is	   obstruction	   of	   the	   predominantly	   major	   pulmonary	   vessels	  
(central	  or	  proximal)	  by	  organised	  blood	  clot(s).	  Recent	  data	  derived	  from	  registries	  
suggest	   that	   CTEPH	   occurs	   at	   an	   incidence	   of	   3-­‐30	   per	   million	   in	   the	   general	  
population.	   A	   recent	   survey	   in	   the	   UK	   found	   469	   patients	   newly	   diagnosed	   with	  
CTEPH	  in	  a	  five	  year	  period	  [180].	  It	  is	  felt	  that	  the	  initiating	  event	  is	  overt	  or	  occult	  
thrombosis.	  	  
1.5.1 Definition	  
CTEPH	   should	   only	   be	   diagnosed	   after	   a	   minimum	   of	   three	   months	   of	   effective	  
anticoagulation.	   It	   is	   defined	   by	   the	   following	   observations:	   a	   mean	   pulmonary	  
arterial	  pressure	  greater	  than	  25mmHg	  with	  a	  pulmonary	  capillary	  wedge	  pressure	  
less	   than	   (or	   equal	   to)	   15mmHg	   and	   at	   least	   one	   (segmental)	   perfusion	   defect	  
detected	  by	  lung	  scanning,	  CTPA	  or	  pulmonary	  angiography.	  
1.5.2 Risk	  factors	  
CTEPH	  is	  considered	  to	  be	  a	  venous	  thromboembolic	  disorder,	  however	  the	  classical	  
venous	  thromboembolic	  risk	  profile	  (described	  in	  1.3.1)	  is	  not	  seen.	  	  Known	  VTE	  risk	  
factors	  and	  the	  evidence	  for	  their	  role	  in	  CTEPH	  will	  be	  discussed	  below.	  
1.5.2.1 Previous	  venous	  thromboembolism	  
CTEPH	   is	   known	   to	   be	   a	   long-­‐term	   complication	   of	   symptomatic	   pulmonary	  
embolism	  (PE)	  with	  a	  cumulative	  incidence	  of	  0.1-­‐9.1%	  within	  two	  years	  of	  the	  event	  
[181-­‐191].	  This	  wide	  variation	  in	  incidence	  is	  felt	  to	  be	  due	  to	  the	  diagnostic	  criteria	  
and	  methods	  used	  to	  diagnose	  PH	  in	  the	  studies.	  Interestingly	  a	  significant	  number	  
of	   cases	   (20-­‐40%)	   of	   patients	  with	   CTEPH	  have	   no	   documented	   evidence	   of	   overt	  
venous	  thromboembolism	  [192,	  193].	  In	  the	  recent	  European	  CTEPH	  Registry	  74.8%	  
of	   CTEPH	   patients	   had	   documented	   previous	   PE,	   while	   56.1%	   had	   previous	   deep	  
venous	   thrombosis	   [194].	   	   In	   one	   prospective	   cohort	   study	   multivariate	   analysis	  
showed	  younger	  age,	  previous	  PE,	   idiopathic	  clinical	  presentation	  of	  PE	  and	   larger	  
perfusion	  defects	  at	  the	  time	  of	  PE	  were	  associated	  with	  an	  increased	  risk	  of	  CTEPH	  
[183].	   In	   one	   study	   of	   PE	   in	   which	   serial	   lung	   perfusion	   scans	   were	   performed,	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massive	  obstruction	  (defined	  as	  greater	  than	  50%)	  was	  a	  risk	  factor	  for	  mortality	  in	  
the	   first	   few	   days,	   but	   not	   subsequently	   [191].	   In	   this	   study	   1%	   of	   the	   study	  
population	  subsequently	  developed	  CTEPH.	  While	  most	  patients	  showed	  complete	  
resolution	  of	  the	  defects	  at	  one	  year,	  large	  persistent	  perfusion	  defects	  in	  sequential	  
lung	   scans	   were	   seen	   in	   patients	   who	   developed	   CTEPH	   [191].	   This	   suggests	   a	  
relationship	  between	   failure	   to	   resolve	   the	   thrombus	  and	   the	  development	  of	  PH,	  
but	  as	  the	  numbers	  were	  small	  (4	  from	  320	  patients)	  further	  studies	  are	  required	  to	  
confirm	  this.	  This	  is	  discussed	  further	  below	  in	  1.5.3.1	  
1.5.2.2 Plasma	  factors	  
The	  presence	  of	  most	  hereditary	  thrombophilic	  defects	  e.g.	  protein	  C,	  protein	  S	  or	  
antithrombin	   deficiencies,	   the	   G20210A	   prothrombin	   gene	   mutation	   and	  
hyperhomocysteinaemia	   have	  not	   been	   shown	   to	   be	   associated	  with	   CTEPH	   [195,	  
196].	  Although	  the	  factor	  V	  Leiden	  polymorphism	  (R506Q)	  has	  previously	  not	  been	  
shown	  to	  be	  associated	  with	  CTEPH	  [197],	  a	  recent	  retrospective	  study	  	  has	  shown	  
heterozygosity	   for	   R506Q	   to	   be	   more	   frequent	   in	   CTEPH	   than	   in	   other	   PH	   (29%	  
versus	  7.8%;	  p=0.001)[195].	  	  
Pulmonary	  arterial	  endothelial	  cells	  are	  unusual	  in	  synthesising	  significant	  amounts	  
of	  Factor	  VIII	  (FVIII)	  as	  well	  as	  von	  Willebrand	  factor	  (VWF)	  [198-­‐200].	  It	  is	  therefore	  
interesting	  that	  Bonderman	  et	  al	   in	  a	  study	  of	  122	  patients	  with	  CTEPH	  found	  that	  
elevated	   levels	  of	  FVIII	  and	  VWF	  were	  significantly	  more	  common	   in	  patients	  with	  
CTEPH	   than	   those	  with	   idiopathic	  PH,	  which	  were	   in	   turn	   significantly	  higher	   than	  
controls	  (FVIII	  >230iu/dl	  41%	  CTEPH,	  22%	  IPAH,	  5%	  control)	  [201].	  Interestingly	  FVIII	  
levels	  were	   found	   to	   fall	   following	   treatment	  with	  prostanoids	  but	  not	  pulmonary	  
endarterectomy	  [202]	  .	  This	  suggests	  that	  the	  elevation	  is	  not	  due	  to	  PH	  per	  se	  and	  
may	  reflect	  an	  underlying	  prothrombotic	  (or	  vasculopathic)	  process.	  	  
Lupus	  anticoagulant	  (LAC)	  and	  antiphospholipid	  antibodies	  have	  been	  shown	  to	  be	  
associated	   with	   both	   VTE	   and	   CTEPH	   [195,	   197,	   203,	   204].	   A	   comparison	   of	  
idiopathic	  PH	  and	  CTPEH	  patients	  demonstrated	  high	  APA	  titres	  to	  be	  more	  common	  
in	  CTEPH	  patient	   (10%	  vs.	  1%)	   [197].	  Furthermore,	   in	  CTEPH	  patients	  positive	  APA	  
titres	  were	  shown	  to	  be	  associated	  with	  the	  presence	  of	  LAC,	  whereas	  in	  idiopathic	  
PH	  either	  the	  LAC	  or	  the	  APA	  was	  positive	  not	  both	  [197].	  A	  possible	  explanation	  for	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these	   observations	   is	   that	   the	   LAC	   may	   produce	   a	   prothombotic	   state	   in	   CTEPH	  
patients	  [205,	  206],	  whereas	  in	  other	  causes	  of	  PAH	  the	  presence	  of	  LAC	  may	  reflect	  
associated	  immunological	  and	  inflammatory	  mechanisms.	  
1.5.2.3 Associated	  medical	  conditions	  
Various	  medical	  conditions	  have	  been	  associated	  with	  a	  higher	  incidence	  and	  worse	  
prognosis	   in	   CTEPH.	   These	   include	   splenectomy,	   ventriculoatrial	   (VA)	   shunt	   for	  
hydrocephalus	  therapy,	  inflammatory	  bowel	  disease	  and	  chronic	  osteomyelitis	  [204,	  
207].	  In	  a	  recent	  retrospective	  study,	  data	  from	  687	  CTEPH	  patients	  was	  compared	  
to	   non-­‐thromboembolic	   cohorts	   and	   thyroid	   replacement	   therapy	   and	   history	   of	  
malignancy	  emerged	  as	  novel	  risk	  factors	  [204].	  	  
1.5.3 CTEPH	  pathophysiology	  
The	  pathogenesis	  of	  CTEPH	  is	  not	  fully	  understood	  but	  appears	  to	  be	  a	  dual	  vascular	  
disorder	   with	  major	   vessel	   vascular	   remodelling	   of	   thrombus	   resolution	   involving	  
endothelial	   cells,	   smooth	   muscle	   cells	   and	   fibroblasts,	   resulting	   in	   arterial	  
obstruction	  and	  a	  small	  vessel	  arteriopathy,	  which	  is	  indistinguishable	  from	  classical	  
pulmonary	  arterial	  hypertension	  [192,	  208].	  
It	   is	   speculated	   that	   after	   PE,	   failed	   thrombus	   resolution	   and	   a	   lack	   of	   thrombus	  
angiogenesis	  leads	  to	  development	  of	  fibrotic	  occlusions	  which	  leads	  to	  a	  misguided	  
vascular	   remodelling	   process	   and	   the	   development	   of	   pulmonary	   hypertension.	  
Infection,	   immune	   processes,	   malignancy,	   genetics	   and	   other	   factors	   may	  modify	  
these	  processes.	  	  
1.5.3.1 	  Thrombus	  resolution	  
The	   process	   of	   thrombus	   resolution	   is	   complex	   and	   involves	   degradation	   and	  
organisation	   of	   the	   thrombus	   and	   adaptive	   remodelling	   of	   the	   vessel	  wall.	   This	   is	  
very	   similar	   to	   granulation	   tissue	   formation	   in	   wound	   healing	   and	   leukocyte	  
recruitment	  and	  angiogenesis	  play	  important	  roles.	  	  
In	   CTEPH,	   material	   from	   PEA	   has	   shown	   partial	   recanalisation	   of	   the	   pulmonary	  
arteries,	  with	  endothelialised	  blood	  vessels	   in	   the	  distal	  areas	   inside	   the	  clot	   [209,	  
210]	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It	  is	  believed	  that	  the	  persistence	  of	  thrombus	  is	  a	  prerequisite	  for	  the	  development	  
of	  PH	  following	  PE.	  Serial	  perfusion	  scans	  suggest	  that	  15-­‐25%	  of	  patients	  have	  only	  
partial	   resolution	  of	   the	  thrombus	  even	  several	  months	  after	   their	  PE	   [211].	  Given	  
that	  only	  20%	  of	  the	  luminal	  diameter	  may	  be	  necessary	  for	  restoration	  of	  flow,	  the	  
proportion	  with	  only	  partial	  resolution	  of	  thrombus	  is	  likely	  to	  be	  much	  higher	  [212].	  
Interestingly,	   these	   data	   are	   in	   keeping	  with	   analogous	   studies	   of	  DVT	   in	  which	   a	  
high	   proportion	   (up	   to	   70%)	   of	   patients	   do	   not	   completely	   recanalise	   and	   where	  
presence	  of	  residual	  thrombus	  may	  be	  a	  predictor	  for	  recurrence	  [213,	  214].	  Failure	  
to	   lyse	   and	   recanalise	   thrombi	   is	   thought	   to	   create	   abnormal	   flow	   and	   trigger	  
abnormal	  vascular	  remodelling.	  Indeed	  in	  a	  dog	  model,	  blocking	  of	  fibrinolysis	  with	  
tranexamic	  acid	  resulted	  in	  PH	  following	  experimentally	  induced	  PE	  [215].	  
Incomplete	  or	  abnormal	  thrombus	  resolution	  may	  arise	  for	  many	  reasons.	  It	  may	  be	  
due	  to	  factors	  affecting	  the	  clot	  formation	  and	  fibrinolysis	  e.g.	  thrombin	  generation,	  
the	  fibrinogen,	  or	  fibrinolytic	  pathways	  (See	  section	  1.5.3.3),	  abnormal	  inflammation	  
or	  deficient	  angiogenesis.	  
1.5.3.1.1 Inflammation/Infection	  
Neutrophils	   and	  monocytes	   are	   recruited	   into	   organising	   thrombi	   and	   it	   is	   known	  
that	   thrombus	   resolution	   is	   severely	   impaired	   when	   recruitment	   of	  monocytes	   is	  
reduced	   [216].	   Monocytes	   express	   and	   secrete	   chemo	   attractants	   e.g.	   monocyte	  
chemotactic	  protein	  (MCP)-­‐1,	  growth	  factors	  e.g.	  vascular	  endothelial	  growth	  factor	  
(VEGF),	   basic	   fibroblast	   growth	   factor	   (bFGF)	   and	   proteases	   e.g.	   urokinase	   type	  
plasminogen	  activator	  and	  matrix	  metalloproteinases	  [217].	  
Increased	  pulmonary	  vascular	  resistance	  has	  been	  correlated	  with	  increased	  MCP-­‐1	  
(a	   CCL2	   chemokine)	   levels.	   MCP-­‐1	   also	   activates	   monocytes	   to	   release	   further	  
growth	   factors	   and	   proteases.	   VEGF	   and	   bFGF	   are	   thought	   to	   be	   important	   in	  
angiogenesis	  within	  a	  thrombus	  (see	  section	  1.5.3.1.2).	  Urokinase	  type	  plasminogen	  
activator	  (uPA)	  is	  an	  important	  activator	  of	  plasminogen.	  It	  is	  thought	  to	  have	  a	  role	  
in	   venous	   thrombus	   resolution	   as	   well	   as	   other	   important	   roles	   as	   a	   protease	   in	  
tissues.	   Matrix	   metalloproteinases	   (MMPs)	   are	   a	   family	   of	   zinc	   containing	  
proenzymes	   that	   have	   a	   role	   in	   connective	   tissue	   breakdown	   and	   matrix	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remodelling.	   MMP	   2	   and	   9	   are	   thought	   to	   be	   the	   most	   important	   for	   thrombus	  
breakdown.	  	  
The	   overall	   importance	   of	   inflammation	   is	   indicated	   by	   the	   increased	   levels	   of	   C-­‐
reactive	  protein	  (CRP)	  [206],	  MCP-­‐1	  [166]	  and	  TNF-­‐α	   [218]	  in	  plasma	  and	  thrombus	  	  
from	  patients	  with	  CTEPH.	  
Wynants	  et	  al	  studied	  the	  effects	  of	  CRP	  on	  pulmonary	  vascular	  cells	  in	  CTEPH.	  They	  
found	   that	   smooth	   muscle	   cells	   extracted	   from	   PEA	   material	   showed	   a	   250%	  
increase	   in	   proliferation	  when	   exposed	   to	   CRP	   [219].	   LOX-­‐1,	   the	   receptor	   for	   CRP	  
was	   found	   to	   be	   increased	   on	   cells	   from	   CTEPH.	   The	   endothelial	   cells	   from	   the	  
material	   showed	   increased	   secretion	   of	   ET-­‐1	   (129%)	   and	   VWF	   (694%)	   as	   well	   as	  
increased	  adhesion	  capacity	  (37%)	  mediated	  through	  ICAM-­‐1.	  Interestingly	  CRP	  had	  
no	   effect	   on	   cells	   from	   non-­‐thromboembolic	   PH	   patients.	   This	   suggests	   that	   CRP	  
(and	  therefore	  inflammation	  or	  infection)	  may	  contribute	  to	  the	  persistence	  of	  fibro-­‐
thrombotic	  material	  obstructing	  the	  pulmonary	  arteries	  in	  CTEPH.	  
Further	   evidence	   for	   a	   role	   of	   infection	   in	   the	   pathogenesis	   of	   CTEPH	   is	   the	  
association	  between	  Staphylococcal	   infection	  (e.g.	   infected	  VA	  shunts,	  pacemakers	  
and	   Port-­‐A-­‐Caths)	   and	   CTEPH.	   Data	   from	   the	   French	   group	   reported	   17	   cases	   of	  
CTEPH	   associated	   with	   Port-­‐A-­‐Caths	   of	   whom	   30%	   were	   culture	   positive	   for	  
Staphylococcus	  epidermidis	  [220].	  Bonderman	  et	  al	  showed	  that	  Staphylococcal	  DNA	  
was	  detected	  in	  6	  out	  of	  7	  thrombi	  from	  VA	  shunt	  carriers	  (from	  PEA	  material)	  [221].	  
This	  was	  studied	  further	  using	  a	  mouse	  model	  that	  showed	  staphylococcal	  infection	  
delayed	   thrombus	   resolution	   and	   caused	   up-­‐regulation	   of	   TGF-­‐β (which	   is	  
profibrotic)	  and	  connective	  tissue	  growth	  factor.	  	  
These	  findings	  all	  suggest	  a	  role	  for	  infection	  and	  inflammation	  in	  the	  pathogenesis	  
of	  CTEPH	  possibly	  by	  contributing	  to	  the	  persistence	  of	  obstructing	  material	   in	  the	  
pulmonary	  arteries	  or	  by	  altering	  vascular	  remodelling	  with	  increased	  fibrosis.	  
1.5.3.1.2 Deficient	  angiogenesis	  
Within	  the	  pulmonary	  arteries,	  angiogenesis	  is	  dependent	  on	  the	  vasa	  vasorum	  from	  
the	   systemic	   bronchial	   arteries.	   After	   occlusion	   these	   vessels	   spread	   into	   the	  
pulmonary	   arteries	   and	   pre-­‐existing	   collaterals	   are	   opened	   preventing	   pulmonary	  
infarction	  (in	  many	  cases)	  [222].	  In	  CTEPH	  the	  number	  of	  pulmonary	  adventitial	  vasa	  
	   53	  
vasorum	  has	  been	  shown	  to	  be	   increased	  and	  the	  core	  of	  the	  non-­‐resolving	  clot	   is	  
recanalised	   by	   neovascular	   endothelised	   structure	   originating	   from	   the	   vasa	  
vasorum	  [166,	  222].	  
In	   the	   early	   phase	   of	   thrombus	   resolution,	   thrombi	   contract	   and	   retract	   from	   the	  
vein	  wall.	  This	  results	  in	  the	  formation	  of	  cell-­‐lined	  pockets	  between	  the	  thrombus	  
and	   the	   intima	   of	   the	   vein	   wall.	   The	   appearance	   of	   these	   vascular	   channels	   is	  
associated	   with	   the	   expression	   of	   VEGF	   and	   bFGF,	   which	   are	   thought	   to	   drive	  
neovascularisation	   [223,	   224].	   Some	  animal	   studies	   have	  demonstrated	   that	  VEGF	  
administration	  enhances	  thrombus	  resolution	  [225],	  but	  other	  experimental	  models	  
have	  not	  shown	  this	  [226].	  Stimulation	  of	  hypoxia	  inducible	  factor	  1a	  in	  the	  vein	  wall	  
leads	   to	   increased	   angiogenic	   drive	   and	   promotes	   recanalisation	   and	   thrombus	  
resolution	  [227].	  
Zabini	  et	  al	  found	  an	  increase	  in	  certain	  angiostatic	  factors	  (PF4,	  IP-­‐10,	  collagen	  type	  
1)	   and	   their	   receptors	   in	   CTEPH	   PEA	  material	   [228].	   They	   also	   showed	   that	   these	  
factors	   could	   alter	   calcium	   handling	   in	   normal	   pulmonary	   endothelial	   cells	   and	  
therefore	  this	  may	  contribute	  to	  endothelial	  dysfunction	  [228].	  
1.5.3.2 Vascular	  remodelling	  
The	   vascular	   lesions	   observed	   in	   CTEPH	   comprise	   distal	   extension	   of	  
muscularisation,	   concentric	   laminar	   intimal	   fibroelastosis	   and	   eccentric	   intimal	  
fibrosis,	  medial	  hypertrophy	  and	  occasional	  plexiform	  lesions.	  	  
The	   cells	   isolated	   from	   tissue	   obtained	   at	   PEA	   have	   shown	   diverse	  morphological	  
phenotypes.	   In	  2009	  Yao	  et	  al	   reported	  the	   identification	  of	  a	  putative	  endothelial	  
progenitor	  cell	  in	  the	  endarterectomised	  tissue	  of	  patients	  with	  CTEPH.	  These	  were	  
CD34+,	   CD133+	   Flk-­‐1+	   and	   they	  postulated	   that	   these	   cells	  might	   be	   important	   in	  
intimal	  remodelling	  [209].	  Collagen	  secreting	  cells	  in	  the	  proximal	  vascular	  wall	  were	  
also	   detected	   which	   may	   contribute	   to	   a	   microenvironment	   that	   leads	   to	  
dysfunctional	   endothelial	   cells.	   Sakao	   et	   al	   suggested	   that	   the	   microenvironment	  
created	  by	  the	  unresolved	  clot	  stimulates	  myofibroblast-­‐like	  cells	  to	  induce	  changes	  
in	  ECs	  [229].	  This	  leads	  to	  dysfunctional	  ECs	  (disruption	  of	  mitochondrial	  reticulum,	  
inactivation	  of	  autophagy,	  alteration	  of	  SOD-­‐2	  and	  decreased	  production	  of	  reactive	  
oxygen	   species),	   which	   may	   contribute	   to	   the	   progression	   of	   CTEPH	   [229].	   Cells	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isolated	  and	  cultured	  from	  the	  proximal	  pulmonary	  artery	  during	  PEA	  from	  patients	  
with	   CTEPH	   showed	   enhanced	   proliferation	   and	  migratory	   capacity	   in	   vitro	   [161].	  
Firth	   et	   al	   showed	   augmentation	   of	   pulmonary	   artery	   smooth	   muscle	   cell	  
proliferation	   in	   response	   to	   chronic	   fibrin	   exposure	   [230].	   This	   suggests	   that	  
unresolved	  clot	  containing	  fibrin	  might	  alter	  the	  vascular	  remodelling	  process.	  
Recent	  data	  suggests	  the	  incidence	  of	  small	  vessel	  disease,	  as	  seen	  in	  other	  forms	  of	  
PH,	   may	   be	   greater	   in	   CTEPH	   patients	   with	   associated	   medical	   conditions	   [207].	  
However	   it	   is	  not	  clear	   if	   there	   is	  any	  relationship	  between	  the	  time	  a	  patient	  has	  
pulmonary	   hypertension	   before	   the	   diagnosis	   of	   CTEPH	   and	   the	   degree	   of	   small	  
vessel	  disease	  observed	  [231].	  
1.5.3.3 Impaired	  fibrinolysis	  
Inadequate	   fibrinolysis	  may	   arise	   for	   a	   number	   of	   reasons.	   Firstly,	   the	   higher	   and	  
more	  rapid	  the	  thrombin	  burst	  associated	  with	  the	  thrombus	  formation,	  the	  denser	  
and	  more	  lysis	  resistant	  the	  clot	  will	  be	  [232].	  High	  concentrations	  of	  thrombin	  also	  
activate	   TAFI	   which	   will	   retard	   thrombus	   degradation.	   The	   normal	   function	   of	  
endothelial	  cells	  is	  to	  suppress	  thrombin	  generation	  and	  fibrin	  formation	  in	  order	  to	  
maintain	   vessel	   patency.	   Studies	   by	   Campbell	   et	   al	   [66]	   have	   shown	   that	   when	  
stimulated	  by	   inflammatory	  cytokines,	  prothrombotic	  activity	   is	   induced	  on	  the	  EC	  
with	  production	  of	  an	  abnormally	  dense	   fibrin	  network	  that	  resisted	  fibrinolysis.	  A	  
further	  study	  by	  Jerome	  et	  al	  [69]	  using	  HUVECs	  showed	  that	  the	  fibrin	  adjacent	  to	  
the	  cell	  surface	  was	  more	  resistant	  to	   lysis	  than	  clot	   further	  away.	  They	  suggested	  
this	  was	  the	  result	  of	  fibrin	  binding	  to	  integrin	  αvβ3 	  on	  the	  EC	  surface.	  
Secondly	  the	  fibrin(ogen)	  itself	  may	  be	  lysis	  resistant	  as	  a	  result	  of	  genetic	  variation	  
or	  due	  to	  posttranslational	  modification	  such	  as	  excess	  sialylation	  [233].	  Morris	  et	  al	  
prepared	  fibrinogen	  from	  ten	  patients	  with	  CTEPH	  and	  formed	  clots	   in	  vitro	   [234].	  
The	  CTEPH	  fibrin	  was	  cleaved	  significantly	  (although	  only	  slightly)	  slower	  by	  plasmin	  
than	   normal	   controls.	   The	   basis	   for	   the	   resistance	   was	   not	   studied	   but	   they	  
suggested	   that	   failure	   to	   cleave	   the	   beta	   chain	   N	   terminus	   may	   potentiate	   its	  
angiogenic	   and	   signalling	   activity;	   thus	   providing	   a	  mechanism	  whereby	   defective	  
lysis	   could	   lead	   to	   vascular	   remodelling.	   Subsequently,	   the	   fibrinogen	   from	   33	  
patients	   with	   CTEPH	   was	   studied	   by	   liquid	   chromatography	   mass	   spectrometry	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analysis.	   Abnormal	   peaks	   were	   then	   targeted	   by	   genomic	   DNA	   sequencing.	   Five	  
variants	   were	   found,	   with	   one	   variant	   found	   in	   three	   unrelated	   patients.	   All	   the	  
variants	  showed	  abnormalities	   in	  fibrin	  polymer	  structure	  and	  impaired	  lysis	  [235].	  
In	   a	   study	   by	   Suntharalingam	   et	   al	   the	   prevalence	   of	   eight	   functionally	   relevant	  
haemostatic	  polymorphisms	  was	  studied	   in	  214	  UK	  patients	  with	  CTEPH	  compared	  
to	   normal	   controls,	   including	   the	   fibrinogen	   Aα	   T312A	   polymorphism	   [236].	   A	  
significant	   increase	   in	   the	   frequency	   of	   the	  Ala312	   allele	  was	   found	   in	   those	  with	  
CTEPH.	  The	  312A	  results	  in	  altered	  α−α	  chain	  cross-­‐linkage	  and	  has	  been	  associated	  
with	   increased	   resistance	   to	   thrombolysis	   and	   embolisation.	   It	   has	   also	   been	  
associated	   with	   increased	   post	   stroke	   mortality	   in	   patients	   with	   atrial	   fibrillation	  
(AF).	  	  
Thirdly,	   the	   fibrinolytic	   system	   may	   be	   defective.	   Studies	   so	   far	   on	   the	   plasma	  
components	   of	   the	   fibrinolysis	   system	   in	   PH	   have	   shown	   inconclusive	   results.	   In	  
assessing	   the	   fibrinolytic	   profiles	   of	   patients	   with	   PH,	   Welsh	   et	   al	   [237]	   found	  
prolonged	   Euglobulin	   clot	   lysis	   times	   and	   elevated	   levels	   of	   PAI-­‐1	   in	   patients	  with	  
primary	   pulmonary	   hypertension.	   Olman	   et	   al	   [238]	   found	   higher	   tPA	   and	   PAI-­‐1	  
antigen	   levels	   in	  patients	  with	  CTEPH	  but	  no	  difference	   in	  enzymatic	  activities	  was	  
detected	   between	   groups.	   In	   a	   study	   looking	   at	   the	   fibrinolytic	   capacity	   of	   ECs	  
extracted	  from	  patients	  with	  PH	  or	  CTEPH	  undergoing	  endarterectomy	  no	  difference	  
was	   found	   between	   controls	   or	   types	   of	   pulmonary	   hypertension.	   However	   this	  
study	  was	   limited	   to	  measurement	   of	   tPA	   and	   PAI-­‐1	   antigen	   released	   from	   EC	   in	  
response	   to	   thrombin	   [239].	   More	   recent	   evidence	   demonstrates	   that	   the	  
contribution	   of	   EC	   to	   fibrinolysis	   is	   much	   more	   extensive	   and	   complex	   than	  
considered	  in	  these	  early	  studies.	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1.6 Hypothesis	  and	  Aims	  
1.6.1 Hypothesis	  
Defective	   fibrinolysis	   on	   the	   surface	   of	   the	   pulmonary	   endothelium	   determines	  
progression	  from	  PE	  to	  CTEPH	  and	  may	  represent	  a	  promising	  target	  for	  therapy	  at	  
an	  early	  stage	  to	  prevent	  progression.	  	  
1.6.2 Aims	  
The	   objective	  was	   to	   determine	   the	   efficiency	   of	   fibrinolysis	   and	   in	   particular	   the	  
contribution	  of	  the	  endothelium	  to	  fibrinolysis	   in	  patients	  with	  CTEPH.	   	  To	  achieve	  
this,	   assays	   to	   measure	   thrombin	   generation,	   clot	   formation	   and	   lysis	   were	  
established	   in	  plasma	  and	  then	  on	  endothelial	  cells	  using	  HUVECs.	   	  The	  study	  of	  a	  
patient’s	  endothelium	  is	  complicated	  by	  the	  difficulty	  in	  accessing	  tissue	  for	  analysis.	  
A	   further	  aim	  was	   therefore	   to	  use	  a	   recently	  developed	  technique	  to	  grow	  blood	  
outgrowth	   endothelial	   cells	   (also	   called	   endothelial	   colony	   forming	   cells)	   from	  
peripheral	   blood	   [102],	   obtained	   from	   healthy	   controls	   and	   patients	   with	   CTEPH	  
attending	  the	  pulmonary	  hypertension	  service	  at	  Imperial	  College.	  The	  results	  of	  cell	  
characteristics	  as	  well	  as	  the	  functional	  assays	  would	  be	  compared	  between	  healthy	  
controls	  and	  CTEPH	  patients.	  Cells	  from	  a	  parallel	  study	  of	  patients	  with	  IPAH	  would	  
be	  made	  available	  as	  an	  additional	  control	  group.	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2 Methods	  
	  
2.1 	  Preparation	  of	  platelet	  poor	  plasma	  pool	  
20	  ml	  of	  blood	  was	  collected	  from	  16	  healthy	  volunteers;	  each	  sample	  was	  collected	  
into	   10mM	   sodium	   citrate	   anticoagulant	   (final	   concentration)	   and	   18µg	   of	   corn	  
trypsin	   inhibitor	   (Haematologic	   Technologies	   Inc,	   USA)	   per	   ml	   of	   blood	   (approx.	  
40µg	  per	  ml	  plasma).	  Platelet	  poor	  plasma	  (PPP)	  was	  prepared	  by	  centrifuging	  the	  
blood	   at	   3500	   g	   for	   15	  minutes,	   then	   the	   plasma	   supernatant	   at	   11,000	   g	   for	   10	  
minutes.	  The	  PPP	  samples	  were	  pooled	  and	  aliquoted	  into	  1ml	  and	  3ml	  vials,	  which	  
were	  stored	  at	  -­‐80°C.	  
	  
The	   pooled	   plasma	   was	   tested	   in	   the	   clinical	   haematology	   laboratory	   at	  
Hammersmith	   Hospital,	   Imperial	   College	   Healthcare	   NHS	   trust	   to	   ensure	   normal	  
coagulation	   parameters.	   Prothrombin	   time	   (PT),	   activated	   partial	   thromboplastin	  
time	  (APTT)	  and	  fibrinogen	  (Clauss	  technique)	  were	  measured.	  
The	  PPP	  normal	  plasma	  showed	  PT	  11.2	   sec	   (N.R	  9.6-­‐11.6s),	  APTT	  32	   sec	   (N.R	  24-­‐
32s),	  fibrinogen	  2.5g/L	  (N.R	  2-­‐4g/L).	  	  
2.2 	  Human	  umbilical	  vein	  endothelial	  cells	  (HUVECs)	  	  
2.2.1 	  HUVEC	  extraction	  
Umbilical	  cords	  were	  collected	  from	  women	  with	  a	  normal	  pregnancy	  under	  going	  
an	   elective	   caesarean	   section	   following	   obtainment	   of	   informed	   consent	   (Ethics	  
approval:	  Hammersmith	  Hospital	  NHS	  Trusts	  Research	  Ethics	  Committee	  registration	  
2002/6283).	  
	  
Using	  a	  method	  first	  described	  by	  Jaffe	  et	  al	  [240]	  human	  umbilical	  vein	  endothelial	  
cells	  were	   extracted	   using	   collagenase.	   The	   cords	  were	   stored	   in	  Hank’s	   Balanced	  
Salt	  Solution	  (HBSS)	  (GIBCO®HBSS,	  Life	  Technologies,	  UK)	  with	  100µg/ml	  gentamicin	  
(GIBCO,	  Life	  Technologies,	  UK)	  at	  4°C	  until	  ready	  for	  use,	  usually	  a	  maximum	  of	  24	  
hours.	   The	   cord	  was	   cleaned	  with	  ethanol	   and	  both	  ends	   cut	  with	  a	   sterile	  blade.	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The	   umbilical	   vein	  was	   identified	   and	   a	   3-­‐way	   tap	  was	   inserted	   at	   both	   ends	   and	  
secured	   in	   place	  with	   surgical	   thread.	   Following	   flushing	   of	   the	   vein	  with	  HBSS	   to	  
remove	   blood	   or	   clots,	   the	   cord	   was	   incubated	   with	   0.5mg/mL	   Collagenase-­‐A	  
(Roche,	   UK)	   in	   20ml	   HBSS	   with	   calcium	   and	   magnesium	   (GIBCO®HBSS,	   Life	  
Technologies,	   UK)	   for	   10	   minutes	   at	   37°C	   and	   5%	   CO2.	   The	   cell	   suspension	   was	  
removed	   and	   centrifuged	   at	   room	   temperature	   for	   8	   minutes	   at	   300	   g.	   The	   cell	  
pellet	  was	   resuspended	   in	   5	  ml	   EGM-­‐2	  media	   (EBM-­‐2	   basal	  media	   supplemented	  
with	   EGM-­‐2	   bullet	   kit:	   hEGF,	   Hydrocortisone,	   GA-­‐1000	   (gentamicin	   and	  
Amphotericin	  B),	  VEGF,	  hFGF-­‐B,	  R3-­‐IGF-­‐1,	  Ascorbic	  Acid,	  Heparin	  and	  FBS.	  Final	  FBS	  
concentration	   2%.	   Lonza,	   USA)	   and	   seeded	   into	   a	   T25	   flask	   precoated	   with	   1%	  
gelatine	   solution.	   Flasks	   were	   coated	   for	   a	  minimum	   of	   30	  minutes	   at	   37°C	   with	  
gelatine	   and	   excess	   gelatine	   removed	   prior	   to	   the	   addition	   of	   cells.	   Cells	   were	  
cultured	  at	  37°C,	  5%	  CO2.	  The	  media	  was	  changed	  24	  hours	  later	  to	  remove	  floating	  
red	  blood	  cells.	  
2.2.2 Passage	  of	  cells	  
Once	  cells	  reached	  90	  -­‐	  95%	  confluence	  they	  were	  passaged	  as	  follows:	  	  cells	  were	  
washed	   twice	   with	   HBSS	   (without	   calcium	   and	   magnesium)	   and	   incubated	   with	  
0.5ml	  trypsin-­‐EDTA	  (Gibco,	  Life	  Technologies,	  UK)	  for	  2	  minutes	  at	  37°C	  and	  5%	  CO2	  
to	  detach	   the	  cells.	   The	   trypsin	  was	  neutralised	  with	  EGM-­‐2	  media	  and	  cells	  were	  
seeded	  onto	  a	  gelatine	  coated	  T75	  flask.	  Media	  (10ml	  for	  a	  T75	  flask)	  was	  changed	  
on	  alternate	  days.	  Further	  passages	  were	  carried	  out	  using	  the	  same	  method	  once	  
cells	  reached	  confluence,	  usually	  every	  3-­‐4	  days.	  
	  
For	   experiments	   requiring	   pooled	   HUVECs,	   3	   cords	   were	   pooled	   at	   passage	   1.	   In	  
brief	  3	  T25	  flasks	  were	  trypsinised	  as	  described	  above.	  The	  cells	  in	  suspension	  were	  
combined	  and	  then	  seeded	  to	  2	  T75	  flask,	  precoated	  with	  gelatine.	  Cells	  were	  then	  
passaged	   once	   they	   had	   reached	   confluence	   as	   described	   above.	   All	   experiments	  
were	  carried	  out	  on	  cells	  at	  passage	  3	  to	  6.	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2.2.3 Cryopreservation	  of	  cells	  
HUVECs	  were	  cryopreserved	  in	  liquid	  nitrogen.	  Once	  cells	  had	  reached	  confluence	  in	  
a	   T75	   flask	   they	   were	   washed	   with	   HBSS	   and	   trypsinised	   with	   1ml	   trypsin.	   The	  
trypsin	  was	  neutralised	  with	  EGM-­‐2	  media	  and	  the	  cells	  were	  centrifuged	  at	  306	  g	  
for	  8	  minutes.	  The	  supernatant	  was	  discarded	  and	  cells	  were	  resuspended	  in	  1ml	  of	  
FBS	  with	  10%	  dimethyl	  sulfoxide	  (DMSO).	  The	  cells	  in	  cryovials	  were	  stored	  in	  a	  cryo	  
freezing	   container	   (Nalgene®Mr	   Frosty,	   Sigma-­‐Aldrich,	   UK)	   at	   -­‐80°C	   before	   being	  
transferred	  into	  liquid	  nitrogen.	  	  
	  
To	  recover	  cryopreserved	  cells,	  vials	  were	  transferred	  from	  the	  liquid	  nitrogen	  on	  ice	  
and	  then	  thawed	  at	  37°C.	  Cells	  were	  seeded	  into	  a	  T75	  flask	  with	  15ml	  EGM-­‐2	  media	  
and	  the	  media	  changed	  the	  next	  day.	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2.3 Blood	  outgrowth	  endothelial	  cells	  (BOECs)	  
The	   study	   of	   a	   patient’s	   endothelium	   is	   complicated	   by	   the	   difficulty	   in	   accessing	  
tissue	   for	  analysis.	  Using	  a	   recently	  developed	  technique	   [102]	  BOECs	  were	  grown	  
from	  the	  mononuclear	  fraction	  of	  peripheral	  blood.	  
2.3.1 Preparation	  of	  mononuclear	  cell	  layer	  
Blood	  was	   collected	   from	  healthy	   controls	   and	   patients	  with	   CTEPH	  or	   IPAH	   after	  
gaining	   informed	   consent.	   (Ethics	   approval:	   Charing	   Cross	   Research	   Ethics	  
Committee;	   Investigation	   of	   circulating	   protein	   and	   cell	   biomarkers	   in	   pulmonary	  
hypertension,	  registration	  number:	  09/H0711/4).	  
	  
48ml	   of	   blood	  was	   collected	   into	   6	   BD	  Vacutainer®	   CPTTM	   cell	   preparation	   tubes	  
with	   0.1M	   sodium	   heparin	   (Becton,	   Dickinson	   and	   Company	   (BD),	   UK).	   The	   tubes	  
were	  inverted	  to	  mix	  the	  anticoagulant	  additive	  with	  the	  blood.	  Tubes	  were	  stored	  
upright	   at	   room	   temperature	   and	   processed	   within	   one	   hour	   of	   collection.	   BD	  
Vacutainer®	  CPTTM	   tubes	  have	  been	  designed	  to	  combine	  a	  blood	  collection	  tube	  
and	   a	   system	   for	   separation	   of	  mononuclear	   cells.	   They	   contain	   a	   cell	   separation	  
media	   composed	   of	   a	   thixotropic	   polyester	   gel	   and	   FICOLLTM	   HypaqueTM	   solution	  
(Polysaccharide/Sodium	   Diatrizoate).	   The	   separation	   occurs	   during	   centrifugation.	  
The	  gel	  portion	  of	  the	  medium	  moves	  to	  form	  a	  barrier	  separating	  the	  mononuclear	  
cells	  and	  plasma	  from	  the	  denser	  blood	  components.	  
	  
Immediately	   prior	   to	   centrifugation	   tubes	   were	   inverted	   8-­‐10	   times	   to	   remix	   the	  
blood	   sample.	   Tubes	   were	   centrifuged	   at	   room	   temperature	   (18-­‐25°C)	   in	   a	  
horizontal	   rotor	   (swing	  out	  head)	   for	  30	  minutes	  at	  1600	  g.	   The	  mononuclear	   cell	  
layer	  and	  platelets	  appears	  as	  a	  whitish	  layer	  just	  under	  the	  plasma	  layer,	  with	  the	  
red	   cells	   trapped	   below	   the	   polyester	   gel.	   	   The	   tubes	   were	   remixed	   immediately	  
after	  centrifugation,	  to	  resuspend	  the	  cells	  into	  the	  plasma,	  by	  gently	  inverting	  the	  
tubes	  8-­‐10	  times.	  The	  contents	  of	  the	  tube	  above	  the	  gel	  (plasma,	  mononuclear	  cell	  
layer	  and	  platelets)	  were	  then	  removed	  using	  a	  Pasteur	  pipette	  and	  added	  to	  8mls	  
of	   Phosphate	   Buffered	   Saline	   (Gibco®PBS,	   Life	   Technologies,	   USA)	   with	   10%	   FBS	  
(HyClone,	   Thermoscientific,	   USA).	   The	   plasma	   containing	   suspended	  mononuclear	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cells	   was	   then	   centrifuged	   at	   520	   g	   for	   10	   minutes	   at	   room	   temperature.	   The	  
supernatant	  was	  aspirated	  and	  discarded.	  The	  pellet	  was	  resuspended	  in	  10ml	  PBS	  
with	  10%	  FBS	   and	   centrifuged	  at	   520	   g	   for	   10	  minutes	   at	   room	   temperature.	   The	  
supernatant	  was	  aspirated	  and	  discarded	  and	   the	  pellet	   resuspended	   in	  10ml	  PBS	  
with	  10%	  FBS.	  	  10µl	  of	  cell	  suspension	  was	  diluted	  1	  in	  10	  in	  PBS.	  30µl	  of	  the	  diluted	  
sample	  was	  added	  to	  an	  equal	  volume	  of	  trypan	  blue.	  The	  viable	  cells	  were	  counted	  
on	  a	  haemocytometer	  and	  the	  total	  number	  of	  mononuclear	  cells	  in	  the	  sample	  was	  
calculated.	   The	   remaining	   cell	   suspension	   was	   centrifuged	   again	   at	   520	   g	   for	   10	  
minutes	   and	   the	   supernatant	   was	   aspirated.	   The	   cell	   pellet	   was	   resuspended	   in	  
EGM-­‐2	  (EBM-­‐2	  supplemented	  with	  10%	  FBS	  (Hyclone)	  and	  aliquots	  from	  the	  EGM-­‐2	  
bullet	  kit).	  From	  now	  on	  this	  will	  be	  referred	  to	  as	  cEGM-­‐10%.	  
	  
2.3.2 Preparation	  of	  Type	  1	  Collagen	  
Glacial	  acetic	  acid	  (Fisher	  Scientific,	  UK)	  was	  diluted	  in	  50ml	  of	  sterile	  distilled	  water	  
to	  a	  final	  concentration	  of	  0.02N.	  50µg/ml	  (final	  concentration)	  of	  rat	  tail	  collagen	  I	  
(BD	  Biosciences,	  UK)	  was	  added	  to	  the	  dilute	  acetic	  acid	  solution.	  The	  solution	  was	  
filtered	  through	  a	  0.22µm	  syringe	  filter	  and	  then	  stored	  at	  4°C	  for	  up	  to	  one	  month.	  
Plates	   or	   flasks	  were	   coated	  with	   collagen	   and	   incubated	   for	   at	   least	   one	  hour	   at	  
37°C,	  5%	  CO2.	  The	  excess	  collagen	  was	  removed	  and	  the	  plate	  or	  flask	  was	  washed	  
twice	  with	  PBS	  prior	  to	  seeding	  with	  cells.	  
	  
2.3.3 Culture	  and	  passage	  of	  BOECs	  
Cells	  were	  seeded	  at	  a	  density	  of	  3-­‐5	  x107	  mononuclear	  cells	  per	  well	  on	  to	  type	  1	  
rat	  tail	  collagen	  coated	  plates	  in	  4ml	  cEGM-­‐10%	  for	  each	  well	  of	  a	  6	  well	  plate.	  Cells	  
were	  cultured	  at	  37°C,	  5%	  CO2.	  After	  24	  hours	  the	  media	  was	  removed	  from	  the	  well	  
at	  a	  rate	  of	  1ml	  per	  5	  seconds.	  2ml	  of	  warm	  cEGM-­‐10%	  was	  added	  slowly	  to	  the	  well	  
and	   then	   removed	   to	  wash	   the	   cells.	   4ml	   cEGM-­‐10%	  was	   added	   to	   the	  well.	   The	  
media	   was	   changed	   daily	   for	   the	   first	   7	   days	   by	   removing	   and	   adding	   the	  media	  
slowly	  using	  a	  pipette.	  From	  day	  8	  the	  media	  was	  changed	  on	  alternate	  days.	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Discrete	   colonies	   of	   BOECs	   appeared	   between	   day	   7	   and	   21	   of	   culture.	   Once	   a	  
colony	  appeared	  this	  was	  marked	  and	  the	  date	  of	  appearance	  recorded.	  Cells	  were	  
passaged	   to	   obtain	   confluent	   BOEC	   monolayers	   with	   characteristic	   cobblestone	  
morphology.	   The	   decision	   to	   passage	   the	   colonies	   depended	   on	   the	   speed	   of	  
growth,	  the	  size	  of	  the	  colony	  as	  well	  as	  the	  size	  of	  the	  cells	  within	  the	  colonies.	  The	  
first	  passage	  was	  usually	  7-­‐10	  days	  after	  the	  first	  appearance	  of	  the	  colony.	  	  
	  
For	   the	   first	   passage,	   cells	   were	   washed	   twice	   with	   HBSS	   (without	   calcium	   and	  
magnesium)	   and	   incubated	   with	   300µl	   trypsin/EDTA	   for	   1-­‐2	  minutes	   at	   37°C,	   5%	  
CO2.	   150µl	   trypsin/EDTA	  was	   pipetted	   up	   and	   down	   over	   the	   area	   of	   the	   cells	   to	  
ensure	   detachment	   of	   cells.	   700µl	   of	   cEGM-­‐10%	  was	   added	   to	   neutralise	   trypsin.	  
Cells	  colonies	  were	  combined	  and	  passaged	  to	  either	  one	  well	  of	  a	  6	  well	  plate	  or	  a	  
T25	  flask	  according	  to	  numbers	  and	  size.	  When	  adequate	  levels	  of	  confluence	  were	  
achieved,	   cells	   were	   passaged	   as	   follows:	   cells	   were	   washed	   twice	   with	   HBSS	  
(without	   calcium	   and	  magnesium),	   incubated	  with	   trypsin-­‐EDTA	   (300µl	   for	   6	   well	  
plate,	   500µl	   for	   T75	   and	   1ml	   for	   T75)	   for	   2	   minutes	   at	   37°C,	   the	   trypsin	   was	  
neutralised	  with	  cEGM-­‐10%	  and	  cells	  were	  seeded	  to	  collagen	  coated	  flasks	  (using	  a	  
maximum	  split	  ratio	  of	  1	  in	  3).	  Experiments	  were	  carried	  out	  at	  passages	  4	  to	  7.	  	  
2.3.4 	  Cryopreservation	  of	  BOEC	  
BOECs	  were	  cryopreserved	  in	  liquid	  nitrogen.	  Once	  cells	  had	  reached	  confluence	  in	  a	  
T75	   flask	   they	   were	   washed	   with	   HBSS	   (without	   calcium	   and	   magnesium)	   and	  
trypsinised	  with	  1ml	  trypsin.	  The	  trypsin	  was	  neutralised	  with	  cEGM-­‐10%	  media	  and	  
the	  cells	  were	  centrifuged	  at	  306g	  for	  8	  minutes.	  The	  supernatant	  was	  discarded	  and	  
cells	   were	   resuspended	   in	   one	   ml	   of	   FBS	   (Hyclone)	   with	   10%	   dimethyl	   sulfoxide	  
(DMSO).	  The	  cells	  in	  cryovials	  were	  stored	  in	  a	  cryo	  freezing	  container	  (Nalgene)	  at	  -­‐
80°C	  before	  being	  transferred	  into	  liquid	  nitrogen.	  	  
To	  recover	  cryopreserved	  cells,	  vials	  were	  transferred	  from	  the	  liquid	  nitrogen	  on	  ice	  
and	  then	  thawed	  at	  37°C.	  Cells	  were	  seeded	  into	  a	  T75	  flask	  with	  15mls	  cEGM-­‐10%	  
media	  and	  the	  media	  changed	  the	  next	  day.	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2.3.5 Preparation	  of	  cell	  lysates	  
For	  all	  RNA	  and	  protein	  lysates,	  endothelial	  cells	  were	  seeded	  at	  100,000	  cells	  in	  3ml	  
media	  (EGM-­‐2	  or	  cEGM-­‐10%)	  per	  well	  in	  a	  6	  well	  plate	  and	  incubated	  for	  48	  hours	  at	  
37°C,	  5%	  CO2.	  For	  supernatant	  collection,	  endothelial	  cells	  were	  seeded	  at	  100,000	  
cells	   in	  2ml	  media	   (EGM-­‐2	  or	   cEGM-­‐10%)	  and	   incubated	   for	  48	  hours	  at	  37°C,	  5%	  
CO2.	   For	   analysis	   of	   all	   BOEC	   samples	   one	   well	   was	   used	   for	   RNA,	   two	   wells	   for	  
protein	  and	  one	  well	  for	  supernatant.	  
2.3.5.1 RNA	  
The	   cells	   were	   harvested	  with	   350µl	   of	   RLT	   buffer	   (Qiagen,	   UK)	   containing	   1%	   2-­‐
Mercaptoethanol	  per	  well	  of	  a	  6	  well	  plate.	  The	  lysate	  was	  collected	  and	  stored	  at	  	  -­‐
80°C	  until	  required.	  	  
2.3.5.2 Protein	  
The	   cells	  were	  washed	   twice	  with	  1ml	  of	   ice	   cold	  PBS,	   then	  harvested	  with	  100µl	  
lysis	   buffer	   (0.5%	   triton	   X-­‐100,	   20mM	   Tris-­‐HCl	   (pH	   7.5),	   150mM	   NaCl	   in	   water,	  
0.5mM	   Phenolmethylsulfonyl	   fluoride	   (PMSF),	   10mM	   Sodium	   Fluoride	   (NAF),	  
protease	   inhibitor	   cocktail	   1:100	   (Sigma	   Aldrich,	   UK)	   and	   Sodium	   orthovanadate	  
(Sigma	  Aldrich,	  UK)).	   	  The	   lysate	  was	  placed	  in	  on	   ice	  and	  vortexed	  periodically	  for	  
15	  minutes	  to	  allow	  lysis	  of	  the	  cells.	  The	  tubes	  were	  centrifuged	  at	  21912	  g	  for	  15	  
minutes	  at	  4°C.	  The	  supernatant	  was	  removed	  and	  stored	  at	  -­‐80°C	  until	  required.	  
2.3.5.3	  Collection	  of	  supernatant	  
The	  conditioned	  media	  was	  collected	  and	  spun	  at	  21912	  g	  at	  4°C	  for	  5	  minutes	  to	  
remove	  cell	  debris.	  The	  supernatant	  was	  stored	  at	  -­‐80°C	  until	  required.	  A	  cell	  count	  
was	  performed	  on	   the	   remaining	   cells.	   In	  brief	   200µl	   of	   trypsin	  was	   added	   to	   the	  
well,	   incubated	   for	  1-­‐2	  minutes	  and	   then	  neutralised	  with	  300µl	  media	   (EGM-­‐2	  or	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2.4 Calibrated	  Automated	  Thrombogram	  (CAT)	  assay	  
2.4.1 Overview	  of	  CAT	  assay	  
The	  CAT	  enables	  measurement	  of	   thrombin	  generation	   in	   real	   time.	   It	   is	  a	  plasma	  
based	  assay	  in	  which	  tissue	  factor	  (TF),	  CaCl2	  and	  phospholipids	  initiate	  coagulation	  
and	   the	   amount	   of	   thrombin	   generated	   is	   measured	   through	   the	   cleavage	   of	   a	  
fluorogenic	  substrate	  over	  time	  and	  quantified	  by	  reference	  to	  a	  standard	  calibrator.	  
Phospholipids	  are	  added	  to	  provide	  a	  surface	  on	  which	  coagulation	  can	  occur	  once	  
triggered	  by	  TF	  [241].	  	  
The	   advantage	   of	   using	   a	   fluorogenic	   substrate	   and	   the	   measurement	   of	  
fluorescence	   is	   that	   it	   is	   not	   heavily	   influenced	   by	   turbidity	   and	   therefore	   the	  
appearance	   of	   a	   clot	   will	   not	   impair	   the	   signal.	   This	   allows	   the	   use	   of	   plasma	  
containing	   fibrinogen	   as	   well	   as	   platelets,	   although	   PPP	   was	   used	   for	   the	  
experiments	  in	  this	  research	  project.	  	  
One	   important	   consideration	  when	  measuring	   fluorescence	   is	   that	   the	   amount	   of	  
signal	  is	  dependent	  on	  many	  variables	  including	  the	  age	  of	  the	  filters	  and	  the	  lamp,	  
the	  colour	  and	  material	  of	  the	  96	  well	  plate	  and	  the	  colour	  of	  the	  plasma.	  The	  CAT	  
assay	  was	  developed	  to	  include	  a	  thrombin	  calibrator	  to	  correct	  for	  this.	  
Two	  other	  variables	  are	  also	  corrected	  for	  with	  the	  use	  of	  the	  thrombin	  calibrator,	  
the	  inner	  filter	  effect	  and	  substrate	  depletion.	   If	  a	  range	  of	  concentrations	  of	  AMC	  
(the	  fluorphore	   in	  the	  substrate)	   is	  added	  to	  plasma,	  the	  relationship	  between	  the	  
amount	  of	   signal	  and	   the	  concentration	  of	  AMC	   is	  non-­‐linear.	  This	   is	   the	  so	  called	  
‘inner	   filter	   effect’.	   It	   results	   in	   the	   measured	   Fluorescent	   units	   (FU)	   per	   minute	  
being	  non-­‐proportional	  to	  the	  amount	  of	  thrombin	  resulting	   in	  underestimation	  of	  
high	  thrombin	  concentrations.	  Underestimated	  thrombin	  concentrations	  can	  further	  
result	   from	  consumption	  of	   the	   substrate	   that	  occurs,	  with	   around	  30-­‐40%	  of	   the	  
substrate	  being	  consumed.	  This	  decreases	  the	  velocity	  of	  substrate	  conversion	  per	  
concentration	  of	  thrombin.	  
The	  Thrombinoscope	   software	   (Stago	  UK,	   Ltd)	  used	   to	  analyse	   the	  data	  allows	   for	  
these	   variables	   by	   measuring	   a	   thrombin	   calibrator	   as	   a	   reference.	   The	   molar	  
concentration	  of	  thrombin	  is	  calculated	  and	  corrections	  are	  made	  for	  the	  activity	  of	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α2macroglobulin-­‐thrombin	   complex,	   as	   well	   as	   the	   inner	   filter	   effect	   and	   the	  
substrate	  consumption.	  	  
Thrombin	  generation	  is	  described	  and	  quantified	  by	  three	  main	  parameters:	  1.	  Lag	  
time,	   (this	   approximates	   the	   clotting	   time),	   2.	   Peak	   height	   (the	   maximum	  
concentration	  of	   thrombin	   reached)	   and	  3.	   Endogenous	   Thrombin	  Potential	   (ETP),	  
(the	  total	  amount	  of	  thrombin	  generated	  over	  time)	  which	  corresponds	  to	  the	  area	  
under	  the	  curve,	  shown	  in	  Figure	  2.1.	  The	  rate	  of	  thrombin	  generation	  can	  also	  be	  
calculated	  from	  these	  parameters.	  Analysis	  of	  the	  data	  was	  performed	  using	  Graph	  
pad	  prism	  (Graph	  Pad	  Software	  Inc,	  version	  6).	  For	  plasma	  and	  HUVEC	  results,	  data	  
were	   analysed	   using	   the	   student	   t-­‐test.	   For	   BOECs	   the	  Mann	  Whitney	  U	   test	  was	  




Figure	  2.1	  Thrombin	  generation	  
The	   thrombin	   generation	   curve	   showing	   lag	   time,	   peak	   height	   and	   ETP	   (area	   under	   the	  
curve).	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2.4.2 Preparation	  of	  phospholipid	  vesicles	  
Negatively	   charged	   phospholipids	   are	   required	   for	   coagulation	   to	   occur.	   The	  
physiological	   source	   is	   activated	   platelets,	   although	   other	   cells	   may	   also	   expose	  
phospholipids	   such	   as	   phosphatidylserine.	   In	   in	   vitro	   assays	   phospholipid	   vesicles	  
may	  replace	  activated	  platelets.	  
Synthetic	   phospholipids	   from	   Avanti	   Polar	   Lipids	   Inc.	   (USA)	   were	   used	   in	   all	  
experiments.	   1,2-­‐Dioleoyl-­‐sn-­‐glycero-­‐3-­‐phosphocholine	   (DOPC),	   1,2-­‐Dioleoyl-­‐sn-­‐
glycero	   phosphoethanolamine	   (DOPE),	   1,2-­‐Dioleoyl-­‐sn-­‐glycero-­‐3-­‐Phospho-­‐L-­‐Serine	  
(DOPS)	  in	  a	  ratio	  20:60:20	  were	  used.	  	  	  	  	  	  
Appropriate	  amounts	  of	  the	  three	  phospholipid	  variants	   in	  chloroform	  were	  mixed	  
and	   the	   chloroform	  evaporated	  under	   a	   nitrogen	   stream.	   The	  phospholipids	  were	  
resuspended	   in	   20mM	   HEPES	   (4-­‐(2-­‐hydroxethyl)-­‐1-­‐piperazineethanesulfonic	   acid)	  
(Sigma	   Aldrich,	   UK),	   140mM	   NaCl,	   pH	   7.4.	   Unilamellar	   vesicles	   were	   obtained	   by	  
extruding	   the	   phospholipid	  mixture	   19	   times	   through	   a	   polycarbonate	  membrane	  
with	  pore	  size	  0.1µm.	  
2.4.3 	  CAT	  assay	  in	  plasma	  
80µl	   of	   PPP	   was	   incubated	   with	   4µM	   phospholipid	   vesicles	   (DOPS/DOPC/DOPE	  
20:60:20),	  1-­‐5	  pM	  TF	  (Dade	  Innovin,	  Siemens,	  Germany)	   in	  a	  final	  volume	  of	  100µl	  
(all	   concentrations	   final).	   The	  plate	  was	   incubated	   for	  10	  minutes	  at	  37°C	  prior	   to	  
initiating	  the	  assay.	  Thrombin	  generation	  was	  initiated	  by	  automatic	  dispensation	  of	  
20µl	   of	   2.5mM	   Z-­‐GlyArg-­‐AMC-­‐HCI	   (Bachem,	   USA),	   2.5%	   DMSO,	   20mM	  HEPES	   (pH	  
7.35),	  60mg/ml	  BSA	  (Sigma	  Aldrich,	  UK),	  100mM	  CaCl2	  into	  each	  well.	  The	  reaction	  
was	  performed	  at	  37°C	  and	  measurements	  were	  performed	  with	  an	  excitation	  and	  
emission	  wavelength	  of	  390nm	  and	  460nm,	  respectively.	  Thrombin	  generation	  was	  
assessed	   using	   a	   Fluoroscan	   Ascent	   FL	   Plate	   reader	   (Thermo	   Scientific,	   UK)	   in	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2.4.4 CAT	  assay	  on	  unstimulated	  cells	  
The	  CAT	  assay	  was	  adapted	  to	  study	  thrombin	  generation	  on	  a	  cell	  monolayer.	  Cells	  
were	  grown	  to	  confluence	   in	  a	  T75	   flask,	  washed	  and	   trypsinised.	  The	   trypsin	  was	  
neutralised	   with	   EGM-­‐2	  media.	   Cells	   were	   counted	   using	   a	   haemocytometer	   and	  
seeded	  at	  30,000	  per	  well	  in	  a	  96	  well	  plate	  (Nunc,	  Thermo	  Scientific,	  UK)	  in	  100µl	  of	  
media.	  Cells	  were	  incubated	  overnight	  at	  37°C,	  5%	  CO2.	  The	  media	  was	  removed	  and	  
thrombin	  generation	  was	  measured	  as	  described	  (2.4.3)	  with	  the	  addition	  of	  platelet	  
poor	  plasma	  with	  TF	  and	  phospholipid.	  
2.4.5 CAT	  assay	  on	  stimulated	  cells	  
To	   further	   assess	   the	   cells’	   contribution	   to	   thrombin	   generation,	   the	  method	  was	  
adapted	   to	   study	   stimulated	   cells.	   TNF-­‐α	   is	   known	   to	   cause	   expression	   of	   TF	   on	  
cultured	   endothelial	   cells	   [92].	   Cells	   were	   grown	   to	   confluence	   in	   a	   T75	   flask,	  
washed	   and	   trypsinised.	   EGM-­‐2	  media	  was	   added	   and	   cells	  were	   counted	  using	   a	  
haemocytometer.	   A	   seeding	   density	   of	   30,000	   cells	   per	  well	  was	   used.	   Cells	  were	  
incubated	   overnight	   at	   37°C	   5%	   CO2.	   The	   media	   was	   removed	   and	   cells	   were	  
stimulated	  with	   0.01-­‐2nM	  TNF-­‐α	   (Sigma	  Aldrich,	  UK)	   in	   EGM-­‐2	   for	   4-­‐6	  hours.	   The	  
media	  was	  removed	  and	  100µl	  mix	  containing	  80µl	  plasma	  and	  4µM	  phospholipids	  
was	  added	  to	  each	  well.	  Thrombin	  generation	  was	  initiated	  as	  previously	  described	  
in	  2.4.3.	  
	  
To	  ensure	  that	  the	  results	  seen	  were	  due	  to	  TF	  expression,	  cells	  in	  some	  wells	  were	  
incubated	   with	   25µg/ml	   monoclonal	   anti-­‐TF	   antibody	   (Enzyme	   Research	  
Laboratories,	  UK;	  previously	  shown	  to	  be	  an	   inhibitory	  antibody	   in	  our	   laboratory)	  
for	  1	  hour	  after	  stimulation	  with	  TNF-­‐α.	  The	  CAT	  assay	  was	  performed	  as	  described	  
above.	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2.5 Clot	  Lysis	  assay	  
2.5.1 Overview	  of	  clot	  lysis	  assay	  
A	  turbidimetric	  assay	  was	  used	  to	  assess	  clot	   lysis.	  This	   is	  a	  plasma	  based	  assay	   in	  
which	  TF,	  CaCl2	  and	  phospholipids	  initiate	  clot	  formation	  and	  the	  addition	  of	  tissue	  
plasminogen	  activator	   (tPA)	   results	   in	  clot	   lysis	  as	  described	  by	  Lisman	  et	  al	   [242].	  
Changes	   in	  turbidity	  are	  measured	  over	  time	  from	  clot	  formation,	  during	  which	  an	  
increase	  in	  turbidity	  is	  seen,	  to	  clot	  lysis	  when	  the	  turbidity	  decreases.	  Clot	  lysis	  time	  
is	  measured	   from	  the	  midpoint	  of	   the	   increase	   in	   turbidity	   to	   the	  midpoint	  of	   the	  
decrease	   in	  turbidity,	  shown	  in	  Figure	  2.2.	  This	  measurement	   is	  widely	  used	   in	  the	  
literature	   for	   the	  description	  of	   lysis.	   Analysis	   of	   the	  data	  was	   performed	   in	   excel	  
and	  graph	  pad	  prism	  (version	  6).	  For	  plasma	  and	  HUVEC	  results,	  data	  were	  analysed	  
using	  the	  student	  t-­‐test.	  For	  BOECs	  the	  Mann	  Whitney	  U	  test	  was	  used.	  Correlation	  
of	  data	  was	  analysed	  using	  the	  Spearman	  correlation.	  	  	  	  
	  	  
Figure	  2.2	  Lysis	  curve	  and	  lysis	  time	  
Change	  in	  absorbance	  at	  405nm	  is	  measured	  over	  time.	  Clot	  lysis	  time	  is	  measured	  form	  the	  
midpoint	  of	  the	  increase	  in	  turbidity	  to	  the	  midpoint	  of	  the	  decrease	  in	  turbidity.	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2.5.2 Clot	  Lysis	  assay	  in	  plasma	  
50µl	  PPP	  was	  incubated	  with	  8µM	  phospholipid	  vesicles,	  0.5-­‐5pM	  TF,	  50-­‐250ng/ml	  
tPA	   (Technoclone,	  Austria)	   in	  a	   final	   volume	  of	  90µl	   (all	   concentrations	   final).	  Clot	  
formation	   and	   lysis	   was	   initiated	   by	   automatic	   dispensation	   of	   10	   µl	   CaCl2	   (final	  
concentration	   20mM).	   The	   reaction	   was	   performed	   at	   37°C	   and	   absorbance	   at	  
405nm	  was	  measured	  over	  time.	  The	  lysis	  assay	  was	  performed	  on	  FLUOstar	  Omega	  
plate	  reader	  (BMG	  Labtech,	  UK).	  
2.5.3 Lysis	  assay	  on	  unstimulated	  cells	  
The	  assay	  was	  adapted	  to	  study	  clot	  lysis	  on	  a	  cell	  monolayer.	  Cells	  were	  grown	  and	  
seeded	  as	  described	  in	  2.4.4.	  The	  media	  was	  removed	  and	  clot	  lysis	  was	  measured	  
as	   described	   for	   plasma	   (2.5.2)	  with	   the	   addition	   of	   plasma,	   TF,	   phospholipid	   and	  
tPA.	  
2.5.4 Lysis	  on	  stimulated	  cells	  
To	   study	   the	   intrinsic	   function	   of	   the	   cells	   in	   clot	   lysis,	   the	   method	   was	   further	  
adapted	  to	  measure	  lysis	  on	  TNF-­‐α	  stimulated	  cells.	  Cells	  were	  grown	  and	  seeded	  as	  
described	   in	  2.4.4.	   The	  media	  was	   removed	  and	  cells	  were	   stimulated	  with	  TNF-­‐α	  
(0.01-­‐2nM)	   in	   EGM-­‐2	   for	   4-­‐6	   hours.	   The	   media	   was	   removed	   and	   90µl	   mix	  
containing	  50µl	   plasma,	  8µM	  phospholipids	  and	  150ng/ml	   tPA	  was	  added	   to	  each	  
well.	  Clot	  lysis	  was	  initiated	  as	  previously	  described	  in	  2.5.2.	  
	  
To	  ensure	  that	   the	  results	  seen	  were	  due	  to	  TNF-­‐α	   induced	  TF	  expression,	  cells	   in	  
some	  wells	   were	   incubated	   with	   25µg/ml	   anti-­‐TF	   antibody	   (see	   2.4.5)	   for	   1	   hour	  
after	   stimulation	  with	  TNF-­‐α	   and	   then	   the	   lysis	  assay	  was	  performed	  as	  described	  
above.	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2.6 Immunofluorescence	  
Immunofluorescence	   was	   used	   to	   confirm	   the	   endothelial	   lineage	   of	   the	   BOECs	  
grown	  from	  controls	  and	  patients	  by	  staining	  for	  a	  range	  of	  endothelial	  markers	  as	  
described	  below.	  
2.6.1 Preparation	  of	  paraformaldehyde	  stock	  solution	  
4.8g	   paraformaldehyde	   (PFA,	   Sigma	   Aldrich,	   UK)	   was	   added	   to	   2ml	   10%	   PBS	   and	  
16ml	  distilled	  water.	  In	  a	  fume	  cupboard,	  the	  solution	  was	  heated	  to	  65°C	  and	  10M	  
NaOH	  was	  added	  drop	  wise	  until	   the	   solution	  cleared.	  The	  solution	  was	  cooled	   to	  
room	   temperature	   and	   then	   filtered	   through	   Whatman	   No1	   paper	   to	   remove	  
insoluble	  material.	  This	  was	  aliquoted	  and	  frozen	  at	  -­‐20°C.	  
2.6.2 	  Preparation	  and	  fixing	  of	  cells	  
Glass	   coverslips	   (13mm)	  were	   placed	   in	   a	   24	  well	   plate,	  washed	   and	   coated	  with	  
gelatine	  (for	  HUVECs)	  or	  type	  1	  collagen	  (for	  BOECs).	  Endothelial	  cells	  were	  seeded	  
at	  a	  density	  of	  100,000	  cells	  per	  coverslip	  in	  500µl	  media	  (EGM-­‐2	  for	  HUVECs,	  cEGM-­‐
10%	   for	   BOECs)	   and	   incubated	   at	   37°C,	   5%	   CO2	   overnight.	   PFA	   stock	   (24%)	   was	  
thawed	  at	  65°C.	  It	  was	  diluted	  to	  3%	  with	  HBSS	  (with	  calcium	  and	  magnesium).	  The	  
cells	  were	  washed	  twice	  with	  warm	  HBSS	  (with	  calcium	  and	  magnesium).	  250µl	  of	  
3%	  PFA	  was	  added	  to	  each	  coverslip	  and	  cells	  were	  fixed	  in	  the	  dark	  for	  20	  minutes.	  
The	   cells	  were	   then	  washed	   twice	  with	   PBS	   (one	  ml	   per	  well)	   and	   any	   remaining	  
formaldehyde	  quenched	  with	   1ml	   of	   50mM	  NH4Cl	   in	   PBS	   for	   10	  minutes	   at	   room	  
temperature.	  Coverslips	  were	  stored	  at	  4°C	  until	  required.	  	  
2.6.3 Staining	  of	  cells	  
Coverslips	  were	  washed	  twice	  with	  PBS	  (one	  ml	  per	  well).	   	  250µl	  of	  0.4%	  TX100	  in	  
PBS	   was	   incubated	   with	   each	   coverslip	   in	   a	   24	   well	   plate	   for	   4	   minutes	   to	  
permeabilise	   the	   cells.	   The	   cells	  were	  washed	   twice	  with	   PBS	   and	   then	   incubated	  
with	  3%	  BSA/PBS	  for	  10	  minutes	  (250ml	  per	  well).	  The	  cells	  were	  incubated	  with	  the	  
primary	  antibody	   (Table	  2.1),	  diluted	   in	  3%	  BSA/PBS,	   for	  one	  hour	   in	  a	  humidified	  
box,	   followed	   by	   three	   washes	   with	   3%	   BSA/PBS.	   The	   secondary	   antibody	   and	  
nuclear	  stain	  (To-­‐Pro3),	  diluted	  in	  3%	  BSA/PBS,	  were	  added	  to	  the	  cells,	  followed	  by	  
a	  one	  hour	  incubation	  in	  a	  humidified	  box.	  The	  cells	  were	  washed	  three	  times	  with	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3%	  BSA/PBS,	  three	  times	  with	  PBS	  and	  twice	  with	  distilled	  water.	  The	  coverslip	  with	  
the	  stained	  cells	  was	  mounted	  on	  a	  glass	  slide	  using	  Vectashield	  and	  the	  edge	  was	  
sealed	   with	   nail	   varnish.	   Images	   were	   captured	   using	   an	   LSM510	  META	   confocal	  
microscope	   (Carl	   Zeiss)	   using	   a	   63x	   objective	   lens	   and	   running	   Version	   3.2	   of	   the	  
LSM	  acquisition	  software.	  	  
Table	  2.1	  Antibodies	  used	  in	  Immunofluorescence	  
Antibody	   Dilution	   Species	   Company	  
VWF	  (polyclonal)	   1	  in	  1000	   Rabbit	   DAKO	  
VE-­‐Cadherin	  (CD	  144)	  
(clone	  55-­‐7H1)	  
1in	  100	   Mouse	   BD	  Biosciences	  
Anti-­‐rabbit	  	  
Alexafluora	  488	  	  
1	  in	  1000	   Goat	   Invitrogen	  
Anti-­‐mouse	  
Alexafluora	  555	  
1	  in	  1000	   Goat	   Invitrogen	  
To-­‐pro	  3	  (nuclear	  stain)	   1	  in	  1000	   N/A	   Invitrogen	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2.7 	  Senescence	  
Cellular	   senescence,	   first	  described	  by	  Hayflick	   [243],	   is	   the	  process	  where	  normal	  
diploid	  cells	  cease	  to	  divide.	  It	  was	  first	  described	  in	  vitro	  but	  more	  recent	  evidence	  
shows	  that	  it	  occurs	   in	  vivo.	   It	   is	  a	  stress	  and	  damage	  response	  that	  locks	  cells	  in	  a	  
permanent	   form	   of	   growth	   arrest.	   Endothelial	   cell	   senescence	   results	   in	   a	  
phenotype	  which	  is	  pro-­‐inflammatory,	  pro-­‐atherosclerotic	  and	  prothrombotic	  [244].	  
Senescent	   cells	   have	   a	   classical	   appearance	   in	   culture	   growing	   larger	   and	   flatter.	  
Senescent	   cells	   have	   been	   shown	   to	   have	   increased	   expression	   of	   senescence-­‐
associated	   β-­‐galactosidase	   (SA-­‐β-­‐Gal)[245].	   Using	   a	   senescence	   detection	   kit	  
(Biovision,	  USA)	  SA-­‐β-­‐Gal	  was	  detected	  histochemically	  in	  cultured	  endothelial	  cells.	  
Endothelial	  cells	  were	  seeded	  at	  80,000	  cells	  per	  well	  in	  a	  24	  well	  plate	  (pre	  coated	  
with	   gelatine	   for	  HUVEC	  or	   type	   1	   collagen	   for	   BOEC)	   and	   incubated	   overnight	   at	  
37°C,	  5%	  CO2.	  Cells	  were	  washed	  with	  PBS	  and	  fixed	  using	  a	  fixative	  solution	  (250µl	  
per	  well)	  for	  15	  minutes	  at	  room	  temperature.	  The	  staining	  solution	  was	  prepared:	  
470µl	   staining	  solution,	  5µl	   staining	  supplement	  and	  25µl	  20mg/ml	  X-­‐gal	   in	  DMSO	  
per	  well.	  The	   fixative	  solution	  was	  removed	  and	  the	  cells	  were	  washed	  twice	  with	  
PBS.	   500µl	   of	   staining	   solution	   mix	   was	   added	   to	   each	   well	   and	   the	   plate	   was	  
covered	   and	   incubated	  overnight	   at	   37°C.	   The	   staining	   solution	  was	   removed	   and	  
300µl	  of	  70%	  glycerol	  was	  added.	  The	  plates	  were	  stored	  at	  4°C	  until	  analysis.	  The	  
wells	   were	   observed	   under	   the	   microscope	   for	   the	   development	   of	   blue	   colour	  
which	  denotes	  β−Gal	  activity	  and	  hence	  senescence.	  Photos	  were	  taken	  at	  10x-­‐20x	  
magnification	  and	  the	  number	  of	  blue	  cells	  and	  non-­‐blue	  cells	  were	  counted	  using	  
Image	   J	   software	   (Image	   J	  1.46	  with	  cell	   counter	  plugin,	  NIH,	  USA).	  A	  minimum	  of	  
500	  cells	  were	  counted	  for	  each	  sample.	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2.8 	  PCR	  arrays	  
Using	   the	   human	   endothelial	   cell	   biology	   array	   (Qiagen)	   the	   RNA	   from	   control,	  
CTEPH	   and	   IPAH	   BOEC	   was	   screened	   for	   the	   expression	   of	   84	   genes	   related	   to	  
endothelial	  cell	  biology	  (see	  Appendix	  1	  for	  full	  list	  of	  genes).	  
2.8.1 Purification	  of	  RNA	  
RNA	  was	  collected	  as	  described	  in	  2.3.5.1.	  RNA	  purification	  was	  performed	  using	  the	  
RNeasy®	  Mini	   Kit	   (Qiagen,	  UK)	   as	   per	   the	  manufacturer’s	   instructions.	   The	   lysate	  
was	   homogenised	   by	   passing	   it	   through	   a	   blunt	   21-­‐gauge	   needle	   5	   times.	   One	  
volume	  of	  70%	  ethanol	  was	  added	  to	  the	  sample	  and	  then	  transferred	  to	  an	  RNeasy	  
Mini	  spin	  column.	  This	  was	  centrifuged	  at	  8000	  g	  for	  15	  seconds.	  The	  flow-­‐through	  
was	   discarded.	   350µl	   RW1	   buffer	   was	   added	   to	   the	   column,	   centrifuged	   for	   15	  
seconds	  at	  8000	  g	  and	  the	  flow	  through	  discarded.	  On	  column	  DNase	  digestion	  was	  
carried	  out	  as	  per	  the	  manufacturer’s	  instructions.	  	  10µl	  DNase	  I	  was	  added	  to	  70µl	  
RDD	   buffer	   and	   mixed.	   80µl	   DNase	   incubation	   mix	   was	   added	   to	   the	   column	  
membrane	  and	   incubated	  at	   room	  temperature	   for	  15	  minutes.	  350µl	  RW1	  buffer	  
was	   added	   to	   the	   column,	   centrifuged	   for	   15	   seconds	   at	   8000	   g	   and	   the	   flow-­‐
through	   discarded.	   500µl	   RPE	   buffer	   was	   added	   to	   the	   column	   and	   spun	   for	   15	  
seconds,	   and	   the	   flow-­‐through	   discarded.	   500µl	   RPE	   buffer	   was	   added	   to	   the	  
column	  and	  centrifuged	  for	  2	  minutes	  at	  8000	  g	  and	  the	  follow	  through	  discarded.	  
The	  column	  was	  placed	  into	  a	  new	  2ml	  collection	  tube	  and	  centrifuged	  for	  1	  minute	  
to	  dry	   the	  membrane.	  The	  column	  was	  placed	   in	  a	  new	  1.5ml	  collection	   tube	  and	  
30µl	   RNase-­‐free	   water	   was	   added	   directly	   to	   the	   spin	   column	   membrane	   and	  
centrifuged	   for	   one	   minute	   to	   elute	   the	   RNA.	   The	   RNA	   was	   quantified	   using	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2.8.2 cDNA	  synthesis	  
cDNA	   was	   prepared	   using	   the	   RT2First	   Strand	   Kit	   (Qiagen,	   UK)	   following	   the	  
manufacturer’s	   instructions.	   The	   genomic	   DNA	   elimination	   mix	   was	   prepared	   as	  
follows:	   500µg	   of	   RNA	  was	   added	   to	   2µl	   of	   Buffer	   GE	   and	  made	   up	   to	   10µl	   with	  
RNase-­‐free	  water.	  The	  mix	  was	  incubated	  for	  5	  minutes	  at	  42°C	  using	  the	  Veriti	  96	  
well	   Thermal	   cycler	   (Applied	   Biosystems)	   and	   then	   placed	   on	   ice	   for	   at	   least	   1	  
minute.	  	  The	  reverse	  transcription	  mix	  was	  prepared.	  For	  one	  reaction	  4µl	  5x	  Buffer	  
BC3,	  1µl	  Control	  P2,	   2µl	  RE3	  Reverse	  Transcriptase	  and	  3µl	  RNase-­‐free	  water	  was	  
made.	   10µl	   reverse	   transcription	   mix	   was	   added	   to	   the	   tube	   containing	   10µl	  
genomic	  DNA	  elimination	  mix	  and	  mixed	  gently	  by	  pipetting.	  The	  mix	  was	  incubated	  
for	   15	   minutes	   at	   42°C	   to	   generate	   cDNA	   and	   then	   the	   reaction	   was	   stopped	  
immediately	  by	  incubating	  at	  95°C	  for	  5	  minutes.	  91µl	  RNase-­‐free	  water	  was	  added	  
to	  each	   reaction	  and	  mixed.	  The	   reactions	  were	  placed	  on	   ice	  prior	   to	  proceeding	  
with	  real	  time	  PCR.	  
2.8.3 Real	  time	  PCR	  for	  Profiler	  PCR	  Arrays	  
Real	  time	  PCR	  works	  via	  the	  generation	  of	  a	  fluorescent	  signal	  that	  is	  measured	  after	  
each	  cycle	  to	  detect	  the	  replication	  of	  the	  PCR	  product.	  The	  readout	  is	  given	  as	  the	  
number	  of	  cycles	  required	  for	   the	   fluorescent	  signal	   to	  surpass	  the	  threshold	   level	  
(CT	  value).	  A	  threshold	  is	  set	  because	  background	  fluorescence	  may	  be	  present	  due	  
to	   free	   dye,	   non-­‐specific	   cleavage	   and	   sample	   autofluorescence.	   This	   is	  
automatically	   set	   by	   the	   PCR	   machine.	   The	   fewer	   cycles	   required	   to	   surpass	   the	  
threshold,	  the	  greater	  the	  mRNA	  originally	  present	  in	  the	  sample.	  Measurement	  of	  
the	  signal	  from	  constitutively	  expressed	  housekeeping	  genes	  allows	  normalisation	  of	  
results.	  Representative	  RT-­‐PCR	  curves	  are	  shown	  in	  Figure	  2.3.	  
	  
The	  RT	  2Profiler™PCR	  arrays	   (SABiosciences,	  Qiagen)	  uses	   the	   SYBR	  Green	  method	  
for	  real-­‐time	  PCR	  analysis.	  SYBR	  Green	  preferentially	  binds	  to	  double	  stranded	  (ds)	  
DNA	  producing	  a	  strong	  fluorescence	  signal,	  with	  the	  signal	  intensity	  proportional	  to	  
the	  amount	  of	  ds	  DNA.	  The	  primers	  used	  in	  each	  of	  the	  wells	  have	  been	  specifically	  
designed	   for	   use	   in	   the	   SYBR	   Green	   system	   and	   are	   designed	   to	   produce	   an	  
amplicon	   size	   of	   100	   to	   250bp.	   The	   DNA	   melting	   temperature	   is	   specific	   to	   the	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amplified	   fragment,	   which	   allows	   for	   checking	   of	   each	   well	   with	   a	   melt	   curve	   to	  
ensure	  synthesis	  of	  a	  single	  product.	  
	  
	  
Figure	  2.3	  An	  example	  of	  the	  amplification	  curves	  	  
Each	  amplified	  product	  produces	  a	  curve	  with	  baseline,	   log-­‐linear	  and	  plateau	  phases.	  The	  
line	  at	  200	  RFU	   is	   the	   threshold.	  The	  CT	   value	   for	  each	  well	   is	   the	  exact	  number	  of	   cycles	  
required	  for	  the	  fluorescent	  signal	  to	  cross	  the	  threshold.	  	  
	  
	  
The	   PCR	   component	   mix	   was	   prepared	   as	   per	   the	   manufacturer’s	   instructions	  
(Qiagen).	   1350µl	   2x	   RT2	   SYBR	   Green	  Mastermix,	   102	  ml	   cDNA	   synthesis	   reaction,	  
1248ml	  RNase-­‐free	  water	  were	  mixed	  and	  then	  placed	  in	  a	  loading	  reservoir.	  25µl	  of	  
the	  PCR	  component	  mix	  was	  added	  to	  each	  well	  of	  the	  RT2	  Profiler	  PCR	  array	  plate	  
using	  an	  8-­‐channel	  pipettor.	  The	  PCR	  array	  plate	  was	  tightly	  sealed	  using	  the	  optical	  
thin	  wall	  8	  cap	  strips	  provided.	  The	  plate	  was	  centrifuged	   for	  1	  minute	  at	  300g	   to	  
remove	  bubbles.	  The	  BioRad	  CFX96	  real	  time	  cycler	  was	  used	  for	  the	  experiments.	  
Cycling	  parameters	  are	  shown	  in	  table	  2.2.	  	  
Table	  2.2	  Cycling	  conditions	  for	  PCR	  array	  on	  Bio-­‐Rad	  CFX96	  
Cycles	   Duration	   Temperature	  °C	   	  
1	   10	  min	   95	   Hot	  Start	  DNA	  Taq	  polymerase	  activated	  
40	   15	  sec	   95	   	  
	   60	  sec	   60	   Fluorescence	  data	  collection	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A	   dissociation	   (melting)	   curve	   analysis	   was	   performed	   on	   all	   samples	   to	   verify	  
synthesis	  of	  a	  single	  product.	  An	  example	  curve	   is	  shown	  in	  figure	  2.4.	  The	  default	  
melting	  curve	  programme	  (95°C	  for	  10	  minutes,	  65°C	  for	  5	  minutes	  (optics	  off),	  65°C	  




Figure	  2.4	  An	  example	  of	  the	  melt	  peak	  
Melting	  curve	  analysis	  is	  performed	  on	  each	  well.	  A	  single	  peak	  verified	  synthesis	  of	  a	  single	  
product.	  	  
	  
The	  CT	  values	  for	  all	  the	  wells	  were	  exported	  to	  an	  excel	  spread	  sheet,	  after	  ensuring	  
that	   the	   threshold	   values	   are	   the	   same	  across	   all	   arrays	   run	   in	   the	   same	  analysis.	  
Each	  plate	  contains	  5	  housekeeping	  genes,	  Actin	  beta	  (ACTB),	  Beta-­‐2-­‐microglobulin	  
(B2M),	   Glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase	   (GAPDH),	   ribosomal	   protein	  
large,	   P0	   (RPLP0)	   and	   Hypoxanthine	   phosphoribosyltranfesrase	   1	   (HPRT1).	   Data	  
were	  normalised	  to	  the	  housekeeping	  gene	  (or	  genes).	  There	   is	  also	  genomic	  DNA	  
contamination	   control	   as	   well	   as	   positive	   PCR	   control	   and	   reverse	   transcription	  
controls.	  Data	  were	  analysed	  using	  the	  SABiosciences	  PCR	  Array	  data	  analysis	  web-­‐
based	   software,	   which	   automatically	   performs	   all	   ΔΔCT	   based	   fold-­‐change	  
calculations	  from	  the	  uploaded	  raw	  threshold	  cycle	  data.	  The	  normalised	  change	  in	  
expression	  level	  (quantity	  of	  mRNA)	  is	  expressed	  as	  Δ CT	  ,	  which	  is	  the	  difference	  in	  
CT	   values	   between	   the	   gene	   and	   the	   housekeeping	   control.	   The	   difference	   in	  
normalised	  values	  (ΔΔCT)	  for	  a	  given	  gene	  between	  test	  and	  control	  is	  then	  obtained	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and	  the	  ‘fold-­‐change’	  calculated	  (2-­‐ΔΔCT)	  by	  considering	  that	  each	  cycle	  will	  double	  
the	   amount	   of	   product.	   This	   method	   is	   widely	   used	   but	   does	   make	   assumptions	  
including	   the	   fact	   that	   the	  primer	  efficiencies	  are	  similar	   (which	  the	  company	  says	  
they	  are)	  and	  that	  each	  cycle	  will	  double	  the	  amount	  of	  product.	  	  
	   78	  
3 Development	  of	   thrombin	  generation	  and	  clot	   lysis	  
assays	  in	  plasma	  and	  on	  HUVECs	  
The	   results	   of	   this	   thesis	   will	   be	   divided	   into	   3	   chapters.	   The	   first	   chapter	   will	  
describe	   the	  establishment	  and	  optimisation	  of	   the	   two	   functional	  assays,	   the	  CAT	  
assay	  and	   the	   lysis	   assay.	   The	  assays	  were	  established	   in	  plasma	   first	   and	   then	  on	  
HUVECs.	   The	   next	   chapter	   will	   discuss	   the	   results	   of	   the	   assays	   on	   BOECs	   from	  
healthy	   controls	  and	  CTEPH	  patients.	   The	   final	   results	   chapter	  will	   look	  at	   the	  PCR	  
array	  results.	  
3.1 CAT	  assay	  in	  plasma	  
To	  establish	   the	  CAT	  assay,	   thrombin	   generation	  was	  performed	   in	  pooled	  normal	  
plasma	  that	  had	  previously	  been	  collected	  and	  stored	  at	  -­‐80°C	  by	  colleagues	  in	  the	  
laboratory.	   This	   had	   been	   centrifuged	   once	   at	   1200g.	   The	   addition	   of	   increasing	  
tissue	  factor	  (TF)	  concentrations	  showed	  a	  dose	  response	  with	   increasing	  peak	  and	  
ETP	  parameters	  and	  decreasing	   lag	  time.	  However,	  some	  thrombin	  generation	  was	  
still	  shown	  in	  the	  absence	  of	  TF.	  The	  mean	  peak	  concentration	  of	  this	  unstimulated	  
rise	   in	   thrombin	   was	   51nM,	   with	   a	   lag	   time	   of	   approximately	   10	  minutes.	   This	   is	  
shown	  in	  Figure	  3.1.	  	  
	  
Figure	  3.1	  Thrombin	  generation	  in	  normal	  pooled	  plasma	  
CAT	  assay	  in	  single	  spun	  normal	  pooled	  plasma	  supplemented	  with	  4µM	  phospholipids	  and	  
CaCl2	  initiated	  by	  TF	  (0-­‐5pM).	  Thrombin	  activity	  is	  measured	  by	  the	  cleavage	  of	  a	  fluorogenic	  
substrate	  (Z-­‐Gly-­‐Gly-­‐Arg-­‐AMC.HCL)	  in	  real	  time.	  A	  peak	  is	  seen	  without	  the	  addition	  of	  TF.	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Many	   factors	   have	   been	   shown	   to	   affect/influence	   CAT	   assay	   results	   [246,	   247].	  
Firstly,	  the	  presence	  of	  endogenous	  TF	  can	  be	  minimised	  by	  including	  an	  additional	  
centrifugation	  step	  in	  the	  preparation	  of	  plasma.	  The	  plasma	  was	  therefore	  spun	  at	  
12000g	  for	  10	  minutes	  and	  a	  pellet	  was	  seen.	  Repeat	  CAT	  assays	  on	  the	  plasma	  after	  
the	  additional	  spin	  showed	  a	  decrease	   in	  peak	  and	  ETP	  (Figure	  3.2)	  with	  both	  1pm	  















Figure	  3.2	  Thrombin	  generation	  in	  normal	  pooled	  plasma	  after	  second	  spin	  
CAT	  assay	  in	  single	  spun	  normal	  pooled	  plasma	  supplemented	  with	  4µM	  phospholipids	  and	  
CaCl2	  initiated	  by	  TF	  (0-­‐5pM).	  Thrombin	  activity	  is	  measured	  by	  the	  cleavage	  of	  a	  fluorogenic	  
substrate	  (Z-­‐Gly-­‐Gly-­‐Arg-­‐AMC.HCL)	  in	  real	  time.	  The	  decrease	  in	  peak	  can	  be	  seen	  after	  the	  
plasma	  is	  spun	  for	  a	  second	  time	  at	  12000g.	  Data	  given	  as	  mean	  (n=3).	  
	  
A	  new	  plasma	  pool	  was	  therefore	  collected	  and	  used	   in	  all	  subsequent	  assays.	  The	  
plasma	   pool	   was	   collected	   as	   described	   in	   2.1.	   The	   blood	   was	   collected	   into	   CTI	  
(18µg/ml	   blood,	   equivalent	   to	   40µg/ml	   plasma)	   and	   double	   spun	   to	   minimise	  
thrombin	   generation	   in	   the	   absence	  of	   TF.	   CTI	   inhibits	   the	   contact	   factor	   pathway	  
activation	  which	  has	  been	  shown	  to	  be	  important	  at	  lower	  TF	  concentrations	  [248].	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Secondly	  the	  CAT	  assay	  has	  been	  shown	  to	  be	  sensitive	  to	  the	  effects	  of	  temperature	  
[249].	  De	  Smedt	  et	   al	   suggested	  preheating	   the	  plate	   for	  10	  minutes	   at	  37°C	  on	  a	  
plate	   heater	   to	   ensure	   adequate	   temperature	   equilibration.	   This	   reduces	   the	  
likelihood	   of	   over-­‐estimation	   of	   the	   ETP	   and	   peak	   parameters	   that	   is	   thought	   to	  
result	  from	  decreased	  thrombin	  inactivation	  compared	  to	  prothrombin	  conversion	  at	  
lower	  temperatures	  [250].	  The	  CAT	  assay	  was	  therefore	  performed	  with	  and	  without	  
preheating	   to	   see	   if	   this	   effect	   was	   observed	   using	   our	   plasma	   and	   our	  machine.	  
Figure	  3.3	  shows	  the	  decrease	  in	  peak	  and	  ETP	  seen	  with	  preheating.	  This	  effect	  was	  
also	  seen	  at	  1pM	  TF.	  Recently	  updated	  software	  for	  the	  CAT	  assay	  now	  includes	  an	  
automated	  10	  minute	  incubation	  step	  at	  37°C	  (Stago	  version	  5).	  	  
	  	  
Figure	  3.3	  Thrombin	  generation	  and	  the	  effect	  of	  pre-­‐warming	  
CAT	   assay	   on	   normal	   pooled	   plasma	   supplemented	  with	   4µM	  phospholipids.	   The	   samples	  
were	  pre-­‐warmed	  for	  10	  minutes	  on	  a	  plate	  heater	  at	  37°C	  or	  not.	  The	  decrease	  in	  peak	  can	  
be	  seen	  after	  pre-­‐heating.	  Data	  given	  as	  mean	  (n=3).	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The	   standard	   conditions	  were	   therefore	   established	  with	   the	  double	   spun	  plasma,	  
preheating	   for	   10	  minutes	   on	   a	   plate	  warmer	   and	   using	   1	   and	   5pM	   TF.	  Mean	   lag	  
time,	  peak	  and	  ETP	  for	  the	  PPP	  as	  well	  as	  inter	  and	  intra	  assay	  variability	  are	  shown	  
in	  Table	  3.1.	  	  	  
Table	  3.1	  Results	  of	  CAT	  assay	  using	  standard	  conditions,	  in	  pooled	  normal	  plasma,	  
double	  spun	  and	  collected	  into	  CTI.	  	  	  
	   1pM	  TF	   5pM	  TF	  
Lag	  time	  (mins)	   	   	  
Mean	  
CV	  (Intra)	  %	  







Peak	  (thrombin	  nM)	   	   	  
Mean	  
CV	  (Intra)	  %	  







ETP	  (thrombin	  nM	  min-­‐1)	   	   	  
Mean	  
CV	  (Intra)	  %	  








Data	  is	  from	  n=4	  experiments,	  with	  each	  experiment	  in	  triplicate	  wells.	  CV	  =	  co-­‐efficient	  of	  
variation,	  intra-­‐assay	  and	  inter-­‐assay	  calculated	  using	  Graph	  pad	  prism.	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3.2 CAT	  assay	  on	  unstimulated	  HUVECs	  	  
The	   CAT	   assay	  was	   originally	   developed	   for	   use	  with	   plasma	   samples,	   however	   in	  
vivo	   thrombin	   generation	   during	   thrombosis	   occurs	   on	   or	   near	   the	   endothelial	  
surface.	   	   The	   CAT	   assay	   was	   therefore	   adapted	   to	   use	   HUVECs	   as	   a	   more	  
physiological	  surface	  on	  which	  the	  reactions	  could	  occur.	  The	  same	  PPP,	  as	  used	  in	  
the	  plasma	  experiments,	  was	  used	  in	  all	  experiments.	  After	   incubation	  overnight	   in	  
EBM-­‐2,	   the	   cells	   were	   checked	   for	   confluence	   and	   then	   the	   CAT	   assay	   was	  
performed.	  	  
The	  results	  using	  HUVECs	  were	  found	  to	  be	  more	  variable	  than	  in	  plasma	  alone.	  To	  
improve	  the	  reproducibility,	  cells	  were	  seeded	  at	  a	  standard	  density	  of	  30,000	  cells	  
per	  well	   in	  100µl	   of	  media.	   This	  was	   to	  ensure	   that	   there	  were	   similar	   confluence	  
levels	   in	   the	  wells	   throughout	  all	   the	  experiments.	  Some	  cells	  did	  grow	  faster	   than	  
others	   and	   this	   was	   noted	   if	   results	   were	   outside	   expected.	   To	   further	   improve	  
reproducibility	  cells	  were	  incubated	  for	  a	  minimum	  of	  18	  hours	  in	  the	  96	  well	  plates	  
prior	  to	  performing	  the	  assays.	  
It	  is	  known	  that	  following	  multiple	  passages	  HUVECs	  become	  senescent,	  resulting	  in	  
changes	  in	  their	  gene	  and	  protein	  expression	  in	  the	  cells.	  To	  reduce	  variability	  due	  to	  
passage	  number	  experiments	  were	  carried	  out	  between	  passages	  (P)	  4	  and	  6.	  	  
One	   of	   the	   possible	   reasons	   for	   the	   variability	  was	   differences	   between	   individual	  
umbilical	  cords	  used	   for	   the	  collection	  of	  HUVECs.	  To	  try	   to	  eliminate	  some	  of	   this	  
variability,	   three	   cords	   were	   pooled	   at	   P1	   and	   experiments	   were	   carried	   out	   on	  
pooled	  HUVECs	  at	  P3	  or	  4.	  This	  improved	  the	  variability	  but	  was	  still	  more	  marked,	  
especially	  at	  lower	  TF	  concentrations,	  than	  in	  plasma	  alone.	  
Figure	   3.4	   shows	   the	   typical	   curves	   obtained	   for	   thrombin	   generation	   on	  
unstimulated	  HUVECs.	  The	  lag	  time,	  peak	  and	  ETP	  on	  unstimulated	  HUVECs	  using	  the	  
optimised	   conditions	   demonstrated	   a	   similar	   dose	   response	   to	   plasma	   alone.	  	  
Increasing	  TF	  concentration	  causes	  a	  reduction	  in	  lag	  time	  and	  higher	  peak	  thrombin	  
and	   ETP.	   Comparison	   between	   the	   peak	   thrombin	   generated	   on	  HUVECs	  with	   the	  
results	  obtained	  in	  plasma	  alone	  showed	  no	  difference	  (Figure	  3.4	  E).	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Figure	  3.4	  Thrombin	  generation	  results	  on	  unstimulated	  HUVECs	  
HUVECs	  were	  seeded	  at	  30,000	  cells	  in	  a	  96	  well	  plate	  over	  night.	  The	  media	  was	  removed	  
and	  PPP	  supplemented	  with	  4µM	  phospholipids,	  CaCl2	  and	  TF	  (0-­‐5pM)	  was	  added.	  Thrombin	  
activity	   was	   measured	   by	   the	   cleavage	   of	   a	   fluorogenic	   substrate	   in	   real	   time.	   Typical	  
thrombin	  generation	  curves	  are	  shown	  in	  A.	  A	  dose	  response	  is	  seen	  with	  increasing	  peak	  (B)	  
and	   ETP	   (C)	   with	   increasing	   TF	   concentrations.	   The	   lag	   time	   (D)	   shows	   a	   corresponding	  
decrease.	  A	   comparison	  of	  peak	   thrombin	  generation	   in	  plasma	  and	  on	  HUVECs	   shows	  no	  
difference	  (E).	  Data	  is	  given	  as	  mean	  ±	  SD	  (n=	  4)	  for	  B,C	  and	  D.	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The	  variation	   in	  HUVEC	  experiments	   is	   illustrated	  by	   the	   inter-­‐assay	   coefficients	  of	  
variation	  as	   shown	   in	  Table	  3.2,	  with	  more	  marked	  variation	  observed	  at	   lower	  TF	  
concentrations.	   Intra-­‐assay	   variation	  was	   less	   than	   13%	   for	   all	   parameters	   at	   both	  
concentrations	  of	  TF.	  
	  
Table	   3.2	   Inter-­‐assay	   coefficients	   of	   variation	   of	   thrombin	   generation	   on	  
unstimulated	  HUVECs	  
	   0	  TF	   1pm	  TF	   5pM	  TF	  
Lag	  time	  (mins)	   	   	   	  
Mean	   NA	   6.93	   2.3	  
CV	  (inter)	  %	   NA	   25.26	   8.54	  
Peak	  (thrombin	  nM)	   	   	   	  
Mean	   2.35	   46.62	   244.1	  
CV	  (Inter)	  %	   4.43	   15.63	   5.24	  
ETP	  (thrombin	  nM	  min-­‐1)	   	   	   	  
Mean	   NA	   610	   1209	  
CV	  (inter)	  %	   NA	   24.56	   4.36	  	  
Results	  from	  CAT	  experiments	  using	  pooled	  HUVECS	  (n=3).	  NA	  =	  not	  available.	  	  	  
Previous	  studies	  on	  unstimulated	  HUVECs	  have	  shown	  a	  very	  low	  peak	  of	  thrombin	  
occurring	  after	  a	  long	  lag	  time	  on	  unstimulated	  HUVECs	  [66],	  suggesting	  a	  very	  small	  
amount	  of	   TF	   is	   present	  on	   the	   surface	  of	   unstimulated	   cultured	  endothelial	   cells.	  
However,	  no	  thrombin	  generation	  was	  seen	  in	  the	  experiments	  unless	  TF	  was	  added	  
to	   the	   experiment.	   This	   is	   in	   keeping	   with	   the	   anticoagulant	   function	   of	   normal	  
unstimulated	  endothelial	  cells.	  	  	  
3.3 	  CAT	  assay	  on	  TNF-­‐α 	  stimulated	  HUVECs	  	  
TNF-­‐α stimulation	  has	  been	  shown	  to	  cause	  expression	  of	  TF	  on	  endothelial	  cells	   in	  
vitro	   [92,	   251].	   Using	   TNF-­‐α	   stimulation,	   the	   cultured	   HUVECS	   were	   induced	   to	  
express	  TF,	  which	  then	  triggered	  thrombin	  generation	  after	  recalcification.	  Thrombin	  
generation	  was	   then	  monitored	  using	   the	  same	  technique	  as	   for	   the	  standard	  CAT	  
assay.	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Initially	   cells	   obtained	   from	   single	   cords	  were	   used,	   however	   there	  was	   significant	  
variation	   in	   response	   to	   TNF-­‐α, with	  no	  demonstrable	   response	   in	   some.	   Thus	  
pooled	  HUVECs	  were	  used	  as	  previously,	  and	  the	  assay	  was	  optimised	  in	  relation	  to	  
the	  TNF-­‐α  concentration	  and	  incubation	  time,	  to	  ensure	  sufficient	  TF	  expression	  on	  
the	  cells	  to	  result	  in	  detectable	  thrombin	  generation.	  Stimulation	  of	  the	  cells	  for	  less	  
than	  4	  hours	  frequently	  resulted	  in	  minimal	  or	  no	  thrombin	  generation.	  
A	  series	  of	  experiments	  were	  then	  performed	  with	  longer	  incubation	  times	  up	  to	  24	  
hours.	  An	  increased	  rate	  of	  cell	  death	  was	  found	  at	  24	  hours,	  by	  which	  time	  the	  cells	  
had	  been	  in	  the	  96	  well	  plates	  for	  approximately	  48	  hours.	  In	  those	  wells	  that	  did	  not	  
show	   increased	   cell	   death	   (i.e.	   viable	   cells)	   no	   further	   increase	   in	   thrombin	  
generation	  was	  observed	  after	  5	  hours.	  The	  increased	  cell	  death	  may	  have	  been	  due	  
to	  the	  effects	  of	  the	  TNF-­‐α	  but	  may	  also	  have	  been	  a	  result	  of	  the	  cells	  being	  very	  
confluent	  with	  only	  a	  small	  amount	  of	  media	  in	  the	  wells.	  
In	  conclusion,	  the	  optimal	  incubation	  time	  was	  shown	  to	  be	  between	  4	  and	  6	  hours;	  
all	   cells	   were	   subsequently	   incubated	   for	   5	   hours	   to	   allow	   for	   other	   assays	   to	   be	  
performed	   in	   a	   timely	   manner.	   The	   results	   obtained	   using	   the	   optimised	   assay	  
conditions	   are	   shown	   in	   Figure	   3.5	   in	   which	   a	   dose	   response	   can	   be	   seen	   with	  
increasing	  TNF-­‐α	   concentrations	   resulting	   in	  a	   shortened	   lag	   time	  and	  higher	  peak	  
thrombin	   and	   ETP.	   Interestingly,	   a	   plateau	  was	   seen	   in	   all	   3	   parameters	   once	   the	  
TNF-­‐α	   concentration	   reached	   0.5nM.	   This	   might	   suggest	   that	   in	   the	   5-­‐hour	  
incubation	  period	  the	  HUVECs	  are	  only	  able	  to	  produce	  a	  finite	  amount	  of	  TF	  to	  drive	  
thrombin	  generation.	  It	  is	  also	  possible	  that	  the	  TNF-­‐α	  has	  an	  effect	  on	  other	  factors	  
e.g.	  thrombomodulin,	  which	  alter	  thrombin	  generation.	  A	  small	  thrombin	  peak	  with	  
long	  lag	  time	  was	  seen	  in	  some	  experiments	  even	  on	  unstimulated	  cells,	  in	  contrast	  
to	  the	  results	  when	  optimising	  the	  assay	  with	  exogenous	  TF.	  A	  possible	  reason	  is	  that	  
the	   cells	   are	   in	   the	   96	   plates	   for	   longer	   (up	   to	   6	   hours)	   which	   may	   allow	   some	  
activation	  to	  take	  place	  even	  in	  the	  absence	  of	  TNF-­‐α.	  
The	  intra	  and	  inter-­‐assay	  coefficients	  of	  variation	  were	  higher	  with	  stimulated	  cells.	  
Inter-­‐assay	  CVs	  ranged	  between	  7	  and	  28%	  on	  stimulated	  HUVECs.	  Interestingly	  the	  
CVs	  on	  unstimulated	  HUVECs	  were	   the	   largest,	  up	   to	  80%,	  which	  probably	   reflects	  
the	  heterogeneity	  of	  these	  cells.	  




Figure	  3.5	  Thrombin	  generation	  on	  TNF-­‐α 	  stimulated	  HUVECs	  
HUVECs	  were	   seeded	   at	   30,000	   cells	   per	  well	   in	   a	   96	  well	   plate	   and	   incubated	   overnight.	  
Cells	  were	  stimulated	  with	  TNF-­‐α (0-­‐1.0nM)	   for	  5	  hours.	  Thrombin	  generation	   triggered	  by	  
the	   induced	   TF	   was	   assayed	   with	   the	   addition	   of	   PPP	   supplemented	   with	   4µM	  
phospholipids.	  
Typical	   thrombin	   generation	   curves	   are	   shown	   in	   A.	   Peak	   (B)	   and	   ETP	   (C)	   show	   a	   dose	  
response	  with	  increasing	  TNF-­‐α.	  The	  lag	  time	  (D)	  shows	  a	  corresponding	  dose	  response	  with	  
shorter	   lag	   time	  with	   increasing	   TNF-­‐α. A	   plateau	   was	   reached	   at	   0.5nM	   TNF-­‐α,	   which	   is	  
evident	  on	  the	  thrombin	  generation	  curves	  and	  in	  all	  3	  parameters.	  Data	  is	  given	  as	  mean	  ±	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To	  confirm	  that	  the	  thrombin	  generation	  seen	  was	  a	  consequence	  of	  TF	  expression	  
on	   the	   HUVECs,	   an	   inhibitory	   anti-­‐TF	   antibody	   (previously	   used	   in	   our	   laboratory,	  
MabTFE,	   Enzyme	   Research	   Laboratories,	   UK)	  was	   incubated	  with	   the	   cells	   for	   one	  
hour	   after	   the	   initial	   stimulation	   with	   TNF-­‐α.	   The	   addition	   of	   anti-­‐TF	   antibody	  
resulted	  in	  near	  complete	  abolition	  of	  thrombin	  generation	  (Figure	  3.6).	  	  
	  	  
	  
Figure	  3.6	  Thrombin	  generation	  on	  TNF-­‐α 	  stimulated	  HUVECs	  with	  the	  addition	  of	  
anti-­‐TF	  antibody	  
HUVECs	  were	   seeded	   at	   30,000	   cells	   per	  well	   in	   a	   96	  well	   plate	   and	   incubated	   overnight.	  
Cells	  were	  stimulated	  with	  1.0nM	  TNF-­‐α	   for	  5	  hours	  and	  then	  incubated	  for	  one	  hour	  with	  
25µg/ml	  monoclonal	   anti-­‐TF	   antibody	   (inhibitory,	   ERL).	   Thrombin	   generation	  was	   assayed	  
with	  the	  addition	  of	  PPP	  supplemented	  with	  phospholipids.	  The	  addition	  of	  anti-­‐TF	  antibody	  
abolished	  thrombin	  generation.	  Data	  shown	  as	  mean	  (n=3).	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These	   preliminary	   experiments	   established	   that	   the	   CAT	   assay	   could	   be	   used	  with	  
endothelial	   cells	   to	   assess	   thrombin	   generation	   with	   both	   unstimulated	   and	  
stimulated	   cells	   and	   that	   TNF-­‐α	   induced	   sufficient	   TF	   to	   promote	   comparable	  
amounts	  of	  thrombin	  generation.	  	  
There	  was	  very	  little	  difference	  in	  thrombin	  generation	  between	  plasma	  and	  HUVECs	  
and	  plasma	  alone,	  following	  addition	  of	  exogenous	  TF,	  suggesting	  that	  the	  cells	  did	  
not	  influence	  the	  thrombin	  generation	  in	  this	  assay.	  When	  TF	  was	  expressed	  by	  the	  
cells	  after	  TNF−α	  stimulation,	  TF	  a	  lower	  peak	  thrombin	  was	  seen	  (Figure	  3.7),	  with	  a	  
plateau	  reached	  at	  0.5nM	  TNF-­‐α.	  
	  
	  
Figure	   3.7	   Comparison	   of	   peak	   thrombin	   generation	   between	   plasma,	  
unstimulated	  and	  stimulated	  HUVECs	  
The	  mean	  peak	  thrombin	  generated	  is	  shown	  for	  plasma,	  unstimulated	  HUVECs	  (both	  with	  
5pM	   TF),	   and	   TNF-­‐α	   stimulated	   HUVECs.	   No	   difference	   is	   seen	   between	   plasma	   and	  
unstimulated	  HUVECs.	  Peak	  thrombin	  was	  lower	  on	  TNF-­‐α	  stimulated	  HUVECs	  than	  plasma	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3.4 Lysis	  assay	  in	  plasma	  	  
The	  turbidimetric	  assay	  to	  assess	  fibrinolysis	  in	  plasma	  has	  been	  well	  described	  [40,	  
242,	  252-­‐254].	  To	  set	  up	  this	  assay	  within	  the	  laboratory,	  the	  literature	  was	  reviewed	  
for	  optimum	  conditions.	  The	  TF	  concentration	  used	  to	  promote	  clot	  formation	  was	  
similar	  to	  that	  used	  in	  the	  CAT	  assay	  so	  this	  was	  used	  as	  the	  starting	  point.	  However	  
within	   the	   literature	   the	   use	   of	   a	   wide	   range	   of	   tPA	   concentrations	   had	   been	  
described	  [40,	  242,	  255].	  	  
To	  establish	  the	  optimal	   tPA	  concentration	  a	  series	  of	  assays	  were	  performed	  with	  
varying	   tPA	   and	   TF	   concentrations	   to	   ensure	   that	   the	   lysis	   occurred	   in	   a	   timely	  
manner	  as	  well	  as	  being	  sensitive	  to	  different	  concentrations	  of	  TF.	  Figure	  3.8	  shows	  
lysis	  curves	  obtained	  using	  1pm	  and	  5pM	  TF	  and	  50-­‐200	  ng/ml	  tPA.	  The	  results	  show	  
shorter	  lysis	  times	  at	  higher	  tPA	  concentrations	  and	  longer	  lysis	  times	  with	  higher	  TF	  
concentrations.	  Furthermore	  at	  all	  tPA	  concentrations,	  the	  peak	  absorbance	  at	  1pM	  
TF	  is	  higher	  than	  for	  5pM.	  	  This	  difference	  arises	  because	  at	  lower	  TF	  concentrations	  
there	   is	   a	   less	   thrombin	   generation,	   and	   this	   has	   an	   effect	   on	   the	   fibrin	   fibres	  
formed.	   At	   lower	   thrombin	   concentrations,	   fibres	   are	   thicker	   (higher	   mass/length	  
ratio)	   and	   therefore	   the	   absorbance	   is	   higher,	  whereas	   at	   higher	   TF	   the	   fibres	   are	  
thinner	  and	  so	  the	  absorbance	   is	  not	  as	  high.	  This	  was	  shown	  by	  Gabriel	  et	  al	  who	  
showed	   that	   fibrin	   structure	   was	   altered	   by	   changing	   the	   ratio	   of	   thrombin	   to	  
fibrinogen	  [62].	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Figure	  3.8	  Lysis	  curves	  and	  lysis	  time	  in	  normal	  pooled	  plasma	  
Plasma	   (50µl),	   phospholipid	   (8µM),	   TF	   (1pM	   or	   5pM)	   and	   HEPES	   buffer	   were	  mixed	  with	  
increasing	   concentrations	   of	   tPA	   (50-­‐200ng/ml)	   and	   the	   reaction	   was	   initiated	   by	   the	  
addition	  of	  CaCL2	  (20mM).	  Absorbance	  at	  405nm	  was	  measured	  at	  2	  minute	  intervals.	  Lysis	  
time	  is	  calculated	  from	  the	  mid-­‐point	  of	  the	  clear	  to	  maximum	  turbid	  transition	  to	  the	  mid-­‐
point	  of	  the	  maximum	  turbid	  to	  clear	  transition.	  A	  and	  B	  show	  the	  lysis	  curves	  at	  1pM	  and	  
5pM	   TF,	   respectively.	   C	   and	   D	   show	   the	   calculated	   lysis	   times	   at	   1pM	   and	   5pM	   TF,	  
respectively.	  A	  dose	  response	  can	  be	  seen	  with	  increasing	  tPA	  concentrations	  resulting	  in	  a	  
shorter	  lysis	  time.	  Figure	  A	  and	  B	  shows	  the	  mean	  (n=3),	  and	  C	  and	  D	  show	  the	  mean	  ±	  SD	  
(n=3).	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On	   comparison	   of	   the	   lysis	   times	   at	   both	   TF	   concentrations	   at	   varying	   tPA	   (Figure	  
3.9),	   it	  can	  be	  seen	  that	  at	   low	  concentrations	  of	  tPA	  the	  test	  was	   less	  sensitive	  to	  
changes	  in	  TF	  concentration	  and	  at	  high	  levels	  of	  tPA	  the	  clots	  were	  lysed	  too	  quickly	  
and	  were	  less	  sensitive	  to	  TF	  concentrations	  (no	  statistical	  difference	  between	  lysis	  
time	  using	  200ng/ml	  tPA	  at	  1	  or	  5pM	  TF).	  	  
The	   addition	   of	   phospholipid	   is	   essential	   as	   a	   negatively	   charged	   surface	   for	   the	  
coagulation	   cascade	   to	   assemble	   on	   and	   generate	   a	   clot.	   Initially	   the	   experiments	  
were	   carried	   out	   using	   4µM	   phospholipid	   (the	   same	   concentration	   as	   in	   the	   CAT	  
assay),	  but	  due	  to	  problems	  with	  reproducibility,	  the	  different	  conditions	  in	  the	  assay	  
were	   reviewed	   and	   the	   PL	   concentration	   was	   varied.	   By	   increasing	   the	   PL	  
concentration	  to	  8µM	  the	  results	  showed	  less	  variation.	  Based	  on	  these	  experiments	  
the	  optimal	  concentration	  of	  tPA	  was	  150ng/ml	  with	  8µM	  phospholipid.	  	  	  
	  
	  
Figure	   3.9	   Comparison	   of	   lysis	   times	   at	   1pm	   and	   5pM	   TF	   with	   varying	   tPA	  
concentrations	  
Plasma	  (50µl),	  phospholipid	  8µM,	  1	  or	  5pM	  TF	  and	  HEPES	  buffer	  were	  mixed	  with	  increasing	  
concentrations	  of	  tPA	  (50-­‐200ng/ml)	  and	  the	  reaction	  was	  initiated	  by	  the	  addition	  of	  CaCl2	  
(20mM).	   Absorbance	   at	   405nm	   was	   measured	   at	   2	   minute	   intervals.	   Lysis	   time	   was	  
calculated.	  At	  150ng/ml	  p=0.001.	  Data	  given	  as	  mean	  ±	  SD	  (n=3).	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Figure	  3.10	  shows	  the	  lysis	  curves	  using	  the	  optimised	  conditions	  with	  150ng/ml	  tPA.	  
There	   is	  a	  flat	   line	  when	  no	  TF	   is	  added	  and	  a	  dose	  response	  can	  be	  seen	  with	  the	  
increasing	  TF	  concentration.	  	  
	  	  	  
Figure	  3.10	  Representative	  lysis	  curves	  using	  optimised	  conditions	  
Plasma	   (50µl),	   phospholipid	   (8µM),	   150ng/ml	   tPA	   and	   HEPES	   buffer	   are	   mixed	   with	  
increasing	   concentrations	   of	   TF.	   The	   reaction	   is	   initiated	   by	   the	   addition	   of	   CaCl2.	  
Absorbance	  was	  measured	  at	  405nm	  at	  2	  minutes	  intervals.	  Data	  shown	  is	  as	  mean	  (n=3).	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3.5 Lysis	  assay	  on	  unstimulated	  HUVECs	  	  
The	   lysis	   assay	   was	   next	   adapted	   for	   use	   on	   HUVECs.	   The	   cells	   were	   grown	   to	  
confluence	  in	  96	  well	  plates	  as	  in	  the	  thrombin	  generation	  assay	  and	  then	  the	  assay	  
was	  performed	  using	  the	  cells	  as	  a	  more	  physiological	  surface	  on	  which	   lysis	  might	  
occur	  in	  the	  pulmonary	  vasculature.	  	  
To	  ensure	  that	  the	  conditions	  used	  in	  the	  plasma	  assay	  were	  also	  the	  best	  conditions	  
on	  HUVECs,	  the	  assay	  was	  performed	  using	  varying	  concentrations	  of	  tPA.	  Again	  no	  
statistically	   significant	   difference	   was	   seen	   between	   1	   and	   5pM	   TF	   at	   lower	  
concentrations	   of	   tPA:	   at	   tPA	   concentrations	   of	   150ng/ml	   and	   200ng/ml	   the	  
difference	  was	  statistically	  significant.	  
To	   investigate	  whether	  plasma	  and	  cell	  derived	  tPA	  would	  be	  sufficient	   to	   lyse	   the	  
clot	  the	  assay	  system	  was	  also	  tested	  without	  the	  addition	  of	  exogenous	  tPA.	  When	  
left	   for	   the	   standard	   time	   of	   3	   hours	   no	   clot	   lysis	  was	   seen.	   If	   left	   overnight	  with	  
absorbance	   measured	   every	   10	   minutes	   a	   slow	   decrease	   in	   the	   absorbance	  
beginning	  after	  approximately	  2-­‐3	  hours	  was	  seen,	  but	  complete	  lysis	  was	  not	  seen	  
until	  at	  least	  12	  hours.	  	  Although	  it	  would	  have	  been	  interesting	  to	  use	  the	  system’s	  
endogenous	   tPA	   as	   the	   source	   of	   lysis	   because	   this	   may	   represent	   a	   more	  
physiological	   model,	   and	   differences	   may	   have	   been	   seen	   between	   patients	   and	  
controls,	   there	   were	   several	   issues	   that	  made	   it	   impractical.	   The	   small	   volume	   of	  
plasma	  in	  each	  well	  meant	  that	  after	  10	  hours	  there	  was	  significant	  evaporation	  of	  
the	  plasma,	  which	  might	  have	  affected	  the	  results.	  If	  left	  for	  more	  than	  15	  hours,	  the	  
plasma	  had	  completely	  evaporated	  from	  some	  wells	  and	  therefore	  the	  absorbance	  
measurements	  were	  incorrect.	  Also	  in	  many	  of	  the	  wells	  the	  reading	  did	  not	  return	  
to	  baseline	  so	  it	  was	  not	  possible	  to	  say	  if	  the	  clot	  had	  lysed	  or	  if	  some	  other	  process	  
had	  altered	  the	  absorbance.	  Therefore	  addition	  of	  150ng/ml	  tPA	  was	  chosen	  as	  the	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Figure	   3.11	   shows	   an	   example	   of	   the	   lysis	   curves	   obtained	   using	   unstimulated	  
HUVECs	  with	  the	  optimised	  conditions.	  	  
	  	  
Figure	  3.11	  Lysis	  curves	  with	  varying	  TF	  on	  unstimulated	  HUVECs	  
HUVECs	  were	   seeded	   at	   30,000	   cells	   per	  well	   in	   a	   96	  well	   plate	   and	   incubated	   overnight.	  
Plasma	   (50µl),	   phospholipid	   (8µM),	   tPA	   (150ng/ml)	   and	   HEPES	   buffer	   were	   mixed	   with	  
increasing	   concentrations	   of	   TF	   and	   the	   reaction	   was	   initiated	   by	   the	   addition	   of	   CaCL2	  
(20mM).	  Absorbance	  at	  405nm	  measured	  at	  2	  minute	  intervals.	  	  Data	  shown	  as	  mean	  (n=3).	  	  	  
In	  contrast	  to	  the	  results	  obtained	  in	  plasma	  alone,	  a	  change	  in	  absorbance	  was	  seen	  
even	  without	   the	  addition	  of	  exogenous	  TF.	  This	  did	  not	  always	  occur,	  but	   if	   it	  did	  
then	   the	   peak	   absorbance	   always	   occurred	   much	   later	   than	   after	   exogenous	   TF	  
addition;	   at	   around	   40-­‐60	  minutes	   rather	   than	   in	   the	   first	   5-­‐10	  minutes.	  On	   some	  
occasions	   no	   distinct	   peak	  was	   seen	   but	   the	   absorbance	   increased	   gradually	   over	  
time.	  The	  explanation	  for	  this	  phenomenon	  was	  not	  investigated	  further;	  however	  it	  
may	  be	  related	  to	   low	  concentrations	  of	  activated	  factors	  present	   in	  plasma	  or	  the	  
small	   amount	  of	   thrombin	  generation	  observed	   in	   the	   incubated	  but	  unstimulated	  
cells	  in	  the	  TNF-­‐α	  experiments	  described	  above	  (section	  3.3).	  As	  no	  response	  is	  seen	  
in	  plasma	  without	  the	  addition	  of	  TF,	   it	   is	   likely	  to	  be	  the	  cells	  that	  are	  causing	  this	  
phenomenon.	  Other	  studies	  have	  previously	  shown	  that	  TF	  may	  be	  expressed	  at	  low	  
levels	  even	  on	  unstimulated	  cells	  in	  culture	  [66].	  This	  small	  amount	  of	  thrombin	  may	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therefore	  be	  enough	   to	   cause	   clot	   formation	  and	  give	   rise	   to	   the	   turbidity	   change	  
observed	  in	  the	  lysis	  experiments.	  	  
3.5.1 Comparison	  of	  lysis	  between	  plasma	  and	  unstimulated	  HUVECs	  
The	   lysis	   curves	   in	  plasma	  and	  on	  unstimulated	  HUVECs	  are	   shown	   in	   Figure	  3.12.	  
The	   shapes	   of	   the	   curves	   are	   comparable	   at	   both	   1pM	   and	   5pM	   TF,	   however	   the	  
peak	   absorbance	   is	   lower	   at	   both	   TF	   concentrations	  on	   the	  unstimulated	  HUVECs.	  
The	  calculated	  lysis	  time	  was	  significantly	  longer	  on	  unstimulated	  HUVECs	  compared	  
to	  plasma	  alone	  at	  the	  same	  TF	  concentrations.	  The	  difference	  was	  most	  marked	  at	  




Figure	  3.12	  Comparison	  of	  lysis	  in	  PPP	  and	  on	  unstimulated	  HUVECs	  
The	   lysis	   curves	   in	   plasma	   and	   on	   unstimulated	   HUVECs	   (A).	   On	   HUVECs	   a	   lower	   peak	  
absorbance	  is	  seen	  at	  both	  1pM	  and	  5pM	  TF	  compared	  to	  plasma.	  Lysis	  time	  (B)	  in	  plasma	  is	  
significantly	   shorter	   compared	   to	   lysis	   time	   on	   unstimulated	   HUVECs.	   This	   difference	   is	  
greater	   at	  1pM	  TF	   (****	  p=<0.0001)	   than	  5pM	  TF	   (*	  p=0.0310).	   Plasma	   (mean	  ±	   SD	  n=	  3)	  
unstimulated	  pooled	  HUVECs	  (mean	  ±	  SD	  n=	  4).	  	  	  	  
One	   explanation	   for	   the	   prolongation	   of	   lysis	   times	   on	  HUVECs	   is	   the	   presence	   of	  
thrombomodulin.	   Studies	   have	   shown	   that	   soluble	   thrombomodulin	   prolongs	   the	  
lysis	  time	  in	  a	  purified	  plasma	  system	  in	  the	  presence	  of	  TAFI	  [83,	  256].	  Mosnier	  et	  al	  
showed	  that	  activation	  of	  TAFI	  on	  endothelial	  cells	  was	  thrombomodulin	  dependent	  
and	   that	   activation	   of	   TAFI	   did	   not	   occur	   if	   thrombomodulin	   was	   inhibited	   [83].	  
Interestingly	  they	  showed	  seeding	  density	  to	  be	  important	  for	  this	  effect	  to	  be	  seen.	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When	   seeded	   at	   very	   high	   density,	   with	   resultant	   higher	   concentrations	   of	  
thrombomodulin,	   a	   reduction	   in	   TAFI	   activation	   occurred	   due	   to	   activation	   of	   the	  
protein	   C	   pathway.	   Bajzar	   et	   al	   further	   studied	   lysis	   on	   unstimulated	  HUVECs	   and	  
found	   that	   cultured	  HUVECs	  were	  able	   to	   inhibit	   fibrinolysis	   through	  a	  mechanism	  
that	  was	  dependent	  on	  both	  TAFI	  and	  thrombomodulin	  [256].	  	  It	  has	  previously	  been	  
shown	   that	   release	   of	   PAI-­‐1	   from	   cultured	   endothelial	   cells	  may	   also	   prolong	   lysis	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3.6 Lysis	  assay	  on	  TNF-­‐α 	  stimulated	  HUVECs	  	  
As	   described	   for	   the	   CAT	   assay,	   the	   effect	   of	   TNF-­‐α stimulation	   on	   HUVECS	   was	  
examined	   in	   the	   lysis	   assay.	  Having	  optimised	   the	  TNF-­‐α	   concentration	   in	   the	  CAT	  
assay	   and	   knowing	   that	   there	   was	   sufficient	   TF	   expression	   to	   result	   in	   thrombin	  
generation,	   the	  same	  TNF-­‐α	   concentration	   (0.1	  –	  1	  nM)	  was	  used	  to	  stimulate	   the	  
cells	   in	   the	   lysis	   assay.	   As	   with	   the	   lysis	   on	   unstimulated	   HUVECs,	   varying	  
concentrations	  of	  tPA	  were	  used	  to	  determine	  the	  optimal	  conditions	  but	  150ng/ml	  
was	  again	  found	  to	  be	  the	  optimal	  concentration.	  
Figure	  3.13	  shows	  the	  lysis	  time	  on	  stimulated	  HUVECs.	  There	  was	  a	  clear	  effect	  of	  
TNF-­‐α	  stimulation	  and	  an	  apparent	  dose	  response	  with	  increasing	  TNF-­‐α	  prolonging	  
the	   lysis	   time,	   however	   no	   statistical	   difference	   was	   seen	   between	   TNF-­‐α	  
concentrations	  of	  0.1nM	  and	  1.0nM.	  	  	  	  
	  	  	  
Figure	  3.13	  Lysis	  time	  on	  TNF-­‐α 	  stimulated	  HUVECs	  
HUVECs	  were	   seeded	   at	   30,000	   cells	   per	  well	   in	   a	   96	  well	   plate	   and	   incubated	   overnight.	  
Cells	  were	  stimulated	  with	  TNF-­‐α	   (0-­‐1.0nM)	  for	  5	  hours.	  Plasma	  (50µl),	  phospholipid	  8µM,	  
150ng/ml	  tPA	  and	  HEPES	  buffer	   is	  added	  to	  the	  cells	  and	  the	  reaction	  was	   initiated	  by	  the	  
addition	  of	  CaCl2.	  Absorbance	  at	  405nm	  was	  measured	  at	  2	  minute	   intervals	   and	   the	   lysis	  
time	  was	   calculated.	   TNF-­‐α	   stimulation	  prolonged	   the	   lysis	   time	   significantly	   compared	   to	  
unstimulated	  HUVECs	  (****	  p=<0.0001).	  There	  was	  no	  difference	  in	  lysis	  time	  between	  0.1	  
and	  1.0nM	  TNF-­‐α	  stimulation.	  Results	  shown	  as	  mean	  	  ±	  SD	  (n=	  4).	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To	  ensure	   that	   the	   lysis	   assay	  was	   sensitive	   to	   the	   TF	   expression	  on	  HUVECs	   after	  
TNF-­‐α	   stimulation,	  MabTFE	  (an	  inhibitory	  anti-­‐TF	  antibody)	  was	  incubated	  with	  the	  
cells	   after	   the	   initial	   stimulation	   with	   TNF-­‐α.	   The	   addition	   of	   anti-­‐TF	   antibody	  
brought	  the	  lysis	  time	  back	  to	  the	  baseline	  on	  unstimulated	  cells.	  (Figure	  3.14)	  	  
	  	  
Figure	   3.14	   Lysis	   time	   on	   TNF-­‐α 	   stimulated	  HUVECs	  with	   the	   addition	   of	   anti-­‐TF	  
antibody	  
HUVECs	  were	   seeded	   at	   30,000	   cells	   per	  well	   in	   a	   96	  well	   plate	   and	   incubated	   overnight.	  
Cells	  were	   stimulated	  with	   TNF-­‐α	   (0-­‐1.0nM)	   for	   5	  hours	   and	   then	   incubated	   for	   one	  hour	  
with	  25µg/ml	  inhibitory	  anti-­‐TF	  antibody	  (ERL).	  Addition	  of	  the	  anti-­‐TF	  antibody	  brought	  the	  
lysis	  time	  back	  to	  the	  baseline.	  Data	  shown	  as	  mean	  ±	  SD	  (n=3)	  (***	  p<	  0.001)	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3.7 Conclusions	  	  
As	  a	  result	  of	  the	  experiments	  described	  in	  this	  chapter	  an	  optimised	  CAT	  assay	  for	  
use	   on	   endothelial	   cells	   with	   both	   exogenous	   TF	   and	   TNF-­‐α	   stimulation	   was	  
developed.	  In	  addition	  a	  clot	  lysis	  assay	  both	  in	  plasma	  and	  on	  endothelial	  cells	  was	  
established.	  Both	  assays	  were	  shown	  to	  be	  sensitive	  to	  tissue	  factor	  concentration.	  	  
	  
For	   the	   CAT	   assay,	   although	   peak	   thrombin	   was	   the	   same	   in	   plasma	   and	   on	  
unstimulated	   cells	   with	   the	   same	   concentrations	   of	   exogenous	   TF,	   lower	   peak	  
thrombin	  was	  seen	  on	  TNF-­‐α	  stimulated	  cells	  compared	  to	  exogenous	  TF	  or	  plasma	  
alone.	   This	   showed	   that	   the	  TF	  expressed	  by	   the	   stimulated	   cells	  was	   sufficient	   to	  
result	   in	   thrombin	   generation.	   Other	   factors	  may	   also	   be	   important	   in	   the	   results	  
obtained	  on	  stimulated	  cells;	  there	  may	  be	  a	  limit	  to	  the	  amount	  of	  TF	  the	  cells	  can	  
express,	   the	   TF	   is	   localised	   rather	   than	   in	   solution	   and	   other	   cell	   surface	   proteins	  
such	  as	  TM	  may	  be	  affected	  by	  TNF-­‐α.	  
	  
In	   the	   lysis	   assay,	   a	   longer	   lysis	   time	  was	   seen	   in	   in	   the	   presence	   of	   unstimulated	  
HUVECs	  compared	  to	  plasma	  alone	  (Figure	  3.12).	  Interestingly	  this	  effect	  was	  more	  
marked	   at	   lower	   TF	   concentrations.	   This	   may	   be	   due	   to	   the	   fact	   that	   at	   lower	  
thrombin	   concentrations	   TAFI	   activation	   is	   thrombomodulin	   dependent	   so	   in	   the	  
presence	  of	   cells	  more	  TAFI	   is	  activated	   than	   in	  plasma	  alone	  at	   the	   same	  TF	   (and	  
therefore	   thrombin)	   concentration.	   At	   the	   higher	   TF	   (and	   therefore	   thrombin)	  
concentrations,	  TAFI	  activation	  is	  not	  as	  thrombomodulin	  dependent	  and	  therefore	  
the	  effect	  of	  the	  cells	  is	  less	  marked.	  When	  the	  lysis	  time	  on	  TNF-­‐α	  stimulated	  cells	  is	  
compared	  to	  plasma	  and	  exogenous	  TF	  on	  unstimulated	  cells,	   then	  the	  addition	  of	  
5pM	  exogenous	  TF	  to	  unstimulated	  HUVECs	  resulted	  in	  a	  similar	  lysis	  time	  to	  that	  on	  
1nM	  TNF-­‐α	  stimulated	  HUVECs	  (Figure	  3.15).	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Figure	  3.15	  Comparison	  of	  lysis	  time	  in	  plasma	  and	  on	  HUVECs	  (unstimulated	  and	  
stimulated)	  
Lysis	  was	   significantly	   longer	   on	   unstimulated	  HUVECs	  with	   5pM	   TF,	   compared	   to	   plasma	  
alone	  *	  p<0.05.	  All	  results	  shown	  as	  mean	  ±	  SD	  (plasma	  n=3,	  unstimulated	  cells	  with	  TF	  n=4,	  
TNF-­‐α	  stimulated	  cells	  n=4).	  	  	  
It	  is	  important	  to	  remember	  however,	  that	  the	  peak	  thrombin	  generated	  with	  1.0nM	  
TNF-­‐α	   was	   significantly	   lower	   than	   the	   peak	   at	   5pM	   TF	   on	   unstimulated	   cells.	  	  
Therefore	   although	   no	   difference	   in	   lysis	   time	   is	   seen	   between	   unstimulated	   and	  
stimulated	  cells,	  this	  suggests	  the	  cells	  are	  playing	  a	  role	  as	  we	  would	  expect	  the	  lysis	  
time	   to	  be	  shorter	   if	   it	  was	  dependent	  only	  on	   thrombin	  generation.	  This	   suggests	  
that	  the	   lysis	   is	  not	  solely	  dependent	  on	  thrombin,	  but	  other	  cellular	   factors	  which	  
might	  include	  thrombomodulin	  or	  other	  fibrinolytic	  modulators	  must	  contribute.	  	  	  	  
The	   assays	   were	   therefore	   shown	   to	   be	   sensitive	   to	   cellular	   influences,	   especially	  
after	  TNF-­‐α	   stimulation	  and	  were	  used	   to	  assess	   thrombin	  generation	  and	   lysis	  on	  
BOECS,	  as	  described	  in	  the	  next	  chapter.	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4 Thrombin	   generation	   and	   clot	   lysis	   assays	  
performed	  on	  blood	  outgrowth	  endothelial	  cells	  
	  
Blood	  outgrowth	  endothelial	  cells	  (BOECs)	  are	  an	  example	  of	  endothelial	  progenitor	  
cells.	  The	   isolation	  of	   these	  cells	  was	   first	  described	  by	   Ingram	  et	  al	   in	  2004	   [102].	  
Since	  then	  there	  has	  been	  a	  lot	  of	  interest	  in	  their	  use,	  both	  as	  a	  possible	  therapeutic	  
tool	   and	   for	   research	   into	   the	  endothelium	  because	   it	   allows	   growth	  of	   cells	   from	  
patients	   with	   many	   different	   diseases	   with	   the	   need	   for	   only	   a	   peripheral	   blood	  
sample.	  Study	  of	  the	  endothelium	  before	  this	  discovery	  was	  complicated,	  requiring	  
animal	  models	  or	  specimens	  obtained	  at	  surgery.	  	  
Using	  a	  modified	  method	  from	  that	  first	  described,	  which	  had	  been	  optimised	  by	  Dr	  
Koralia	   Paschalaki	   and	   Dr	   Richard	   Starke	   in	   Dr	   Anna	   Randi’s	   laboratory,	   I	   isolated	  
BOECs	  from	  healthy	  controls	  and	  CTEPH	  patients.	  This	  chapter	  will	  be	  divided	  into	  4	  
sections.	   In	   the	   first	   section	   I	  will	   describe	   the	   isolation	   of	   the	   cells,	   their	   general	  
characteristics	  and	  compare	  healthy	  control	  cells	  with	  CTEPH	  cells.	  In	  section	  2,	  I	  will	  
describe	  the	  CTEPH	  patient	  characteristics	  and	  how	  these	  affect	  the	  	  	  isolation	  of	  the	  
cells.	  The	  third	  section	  will	  be	  an	  account	  of	  characterisation	  of	  the	  cells.	  The	  fourth	  
section	  will	  comprise	  the	  functional	  assays	  performed	  on	  the	  cells	  with	  the	  CAT	  and	  
lysis	  assays.	  	  	  
4.1 Isolation	  of	  cells	  	  
BOECs	  were	  isolated	  from	  healthy	  volunteers	  or	  from	  patients	  with	  CTEPH	  attending	  
the	  pulmonary	  hypertension	  clinic	  at	  Imperial	  College	  Healthcare	  NHS	  Trust.	  All	  gave	  
informed	   consent.	   All	   healthy	   controls	   were	   non-­‐smokers	   with	   no	   major	   health	  
problems.	  Due	  to	  the	  requirement	  for	  age	  matching	  aspirin	  and	  statins	  were	  allowed	  
medications.	  
Table	  4.1	  shows	  the	  general	  characteristics	  of	  the	  groups,	  as	  well	  as	  the	  success	  rates	  
of	  the	  growth	  of	  the	  initial	  colonies	  and	  passaging	  to	  P4.	  	  Small	  colonies	  appeared	  in	  
over	  70%	  of	  samples,	  however	  not	  all	  survived	  to	  P4.	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Table	  4.1	  General	  characteristics	  of	  patients	  recruited	  and	  success	  rate	  of	  isolating	  
and	  growing	  BOECs	  
	   Healthy	  Control	   CTEPH	  
Total	  number	  recruited	   14	   17	  



















The	  mean	  age	  is	  not	  statistically	  different	  between	  the	  two	  groups.	  Considering	  the	  
age	   of	   only	   those	   that	   were	   successfully	   grown	   to	   P4	   then	   the	  mean	   age	   is	   even	  
closer,	  51.5	  year	   for	  CTEPH	  patients	  and	  49	  years	   for	  healthy	  controls.	  The	  greater	  
number	  of	  males	  in	  the	  control	  group	  may	  reflect	  difficulty	  recruiting	  appropriately	  
age	  and	  sex	  matched	  healthy	  controls.	  The	   increase	   in	  females	   in	  the	  CTEPH	  group	  
may	  represent	   the	  patient	  demographics	   reported	  by	  Kirson	  et	  al	   [258]	  although	  a	  
more	   recent	   prospective	   registry	   study	   found	   that	   the	  male:	   female	   ratio	  was	   1:1	  
[194].	  	  
The	   frequency	   of	   initial	   colony	   formation	   was	   slightly	   higher	   for	   CTEPH	   patients.	  
However,	  there	  is	  no	  difference	  between	  groups	  in	  the	  proportion	  who	  successfully	  
reached	  P4	  (the	  minimum	  passage	  at	  which	  assays	  were	  performed).	  
The	   number	   of	  mononuclear	   cells	   per	  ml	   of	   blood	   collected,	   the	   number	   of	   initial	  
colonies	  per	  107	  mononuclear	  cells	  isolated,	  the	  number	  of	  colonies	  and	  the	  time	  of	  
appearance	   of	   colonies	   were	   analysed	   (Figure	   4.1).	   No	   difference	   was	   seen	   in	   in	  
these	   parameters	   between	   patients	   and	   controls.	   Results	   were	   not	   changed	  
following	  removal	  of	  the	  outliers:	  one	  CTEPH	  patient	  and	  one	  healthy	  control	  (Figure	  
4.1).	  The	  outlying	  patient	  from	  the	  CTEPH	  group	  is	  discussed	  in	  section	  4.2.	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Figure	   4.1	   Isolation	   of	   BOECs:	   comparison	   between	   healthy	   controls	   (HC)	   and	  
CTEPH	  patients	  
BOECs	  were	  isolated	  from	  the	  mononuclear	  cell	  fraction	  of	  peripheral	  blood.	  The	  two	  groups	  
are	   compared	   with	   respect	   to:	   number	   of	   mononuclear	   cells	   collected	   (A),	   the	   day	   the	  
colonies	   first	   appeared	   (in	   days	   after	   blood	   collection)	   (B),	   the	   number	   of	   colonies	   that	  
appeared	  (C),	  number	  of	  colonies	  per	  ml	  of	  collected	  blood	  (D)	  and	  the	  number	  of	  colonies	  
per	  mononuclear	   cells	   isolated	   (E).	   There	  were	  no	   significant	   differences	  between	  healthy	  
controls	   (HC)	  and	  CTEPH	  patients.	  Combining	  both	  HC	  and	  CTEPH	  results,	  a	  weak	  negative	  
correlation	  with	  number	  of	  colonies	  isolated	  and	  age	  (r=	  -­‐0.4194,	  p<0.05)	  was	  seen	  (F).	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In	  an	  analysis	  of	  both	  groups	  combined,	  if	  the	  age	  of	  the	  recruits	  and	  the	  number	  of	  
colonies	  was	   compared	   then	  a	  negative	   correlation	   could	  be	   seen	  with	   lower	   final	  
colony	   numbers	   in	   older	   patients	   or	   controls	   (r=-­‐0.4194,	   p<0.05	   Spearman	  
correlation).	  This	  was	  analysed	  without	  the	  2	  outliers,	  if	  these	  were	  included	  then	  no	  
correlation	  was	  seen.	  	  
4.2 Patient	  characteristics	  	  
The	   patients	   were	   all	   attending	   the	   Imperial	   College	   Healthcare	   NHS	   Trust	  
pulmonary	  hypertension	  service.	  All	  the	  patients	  had	  been	  assessed	  and	  investigated	  
to	  diagnose	  CTEPH.	  The	  most	   recent	   recommendations	   for	   the	  diagnosis	  of	  CTEPH	  
[259]	  suggest	  that	  a	  V/Q	  scan	  should	  be	  performed	  in	  any	  patient	  with	  unexplained	  
PH.	  If	  this	  shows	  unmatched	  perfusion	  defects	  then	  the	  patient	  should	  be	  referred	  to	  
a	   centre	   with	   expertise	   in	   the	   medical	   and	   surgical	   management	   of	   CTEPH.	   To	  
determine	   the	   extent	   of	   the	   disease	   and	   the	   appropriate	   therapeutic	   strategy,	   CT	  
Pulmonary	   Angiogram,	   right	   heart	   catheterisation,	   coronary	   angiogram	   (if	   being	  
considered	  for	  pulmonary	  endarterectomy	  (PEA),	  Echocardiography	  and	  cardiac	  MRI	  
as	  well	  as	  functional	  assessments	  such	  as	  the	  6-­‐minute	  walk	  test	  or	  cardiopulmonary	  
exercise	  test	  should	  be	  carried	  out.	  The	  service	  at	   Imperial	   is	  one	  of	  the	  centres	  of	  
excellence	   in	   the	   UK,	   with	   experience	   in	   the	   medical	   management	   of	   PH,	   whilst	  
patients	  are	  referred	  to	  Papworth	  Hospital	  for	  PEA.	  	  
To	   obtain	   the	   patient	   characteristics	   and	   investigation	   results,	   the	   clinical	   notes,	  
letters,	   medical	   reports	   and	   discharge	   summaries	   were	   reviewed.	   The	   cardiac	  
catheter	  data	  are	  those	  obtained	  at	  the	  time	  of	  the	  diagnostic	  catheterisation;	  the	  6-­‐
minute	  walk	   and	   cardiopulmonary	   exercise	   tests	   were	   performed	   at	   the	   time	   the	  
blood	   was	   taken	   for	   the	   BOEC	   isolation	   or	   within	   the	   preceding	   6	   months.	   WHO	  
functional	   class,	   assessed	  by	   the	  doctors	  or	  nurses	   in	   the	  clinic,	   is	   from	   the	  day	  of	  
BOEC	  isolation.	  	  
A	  summary	  of	   the	  patient	  characteristics	   is	  shown	   in	  Table	  4.3.	  Full	  details	  of	  each	  
individual	   patient	   can	   be	   found	   in	   appendix	   2.	   For	   one	   patient	   (pt	   15)	   no	   cardiac	  
catheter	   data	   was	   available.	   15/17	   patients	   were	   on	   at	   least	   one	   disease-­‐specific	  
medication	   (Bosentan,	   Sildenafil	   or	  Ambrisentan)	  with	   6	   on	   dual	   or	   triple	   therapy.	  	  
All	   patients	   were	   anticoagulated	   with	   warfarin.	   5	   patients	   had	   undergone	   PEA	   of	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whom	  2	  had	  documented	  residual	  pulmonary	  hypertension.	  One	  had	  undergone	  PEA	  
2	   months	   prior	   to	   the	   recruitment;	   although	   a	   good	   response	   had	   been	   seen	   on	  
cardiopulmonary	  exercise	  test	  and	  disease	  specific	  medication	  (sildenafil)	  had	  been	  
stopped	  post	  surgery,	  it	  was	  considered	  to	  be	  too	  early	  to	  fully	  assess	  whether	  there	  
was	   any	   residual	   pulmonary	   hypertension.	   In	   12	   (70.5%)	   patients,	   there	   was	   a	  
documented	  history	  of	  DVT	  and/or	  PE,	  which	  is	  consistent	  with	  recent	  registry	  data	  
[194].	   Of	   these,	   five	   had	   had	   recurrent	   thromboses.	   With	   regard	   to	   medical	   co-­‐
morbidities,	  two	  patients	  had	  previously	  undergone	  splenectomy,	  two	  patients	  had	  
inflammatory	   bowel	   disease,	   one	   patient	   had	   a	   Ventriculo-­‐peritoneal	   shunt	   for	  
hydrocephalus	   secondary	   to	   spina	   bifida	   and	   one	   patient	   was	   receiving	   thyroxine	  
replacement	  therapy	  for	  hypothyroidism.	  Two	  patients	  were	  heterozygous	  for	  Factor	  
V	  Leiden,	  which	   is	  known	  to	  be	  associated	  with	  an	   increased	  risk	  of	  PE/DVT	  and	   in	  
some	  studies	  is	  also	  associated	  with	  CTEPH	  [195].	  
In	  all	  types	  of	  PH,	  functional	  classification	  is	  strongly	  predictive	  of	  mortality	  [260].The	  
World	  Health	  Organisation	  (WHO)	  functional	  assessment	  classification	   is	  specific	   to	  
PH	   (Table	   4.2).	   It	   was	   developed	   from	   the	   New	   York	   Heart	   Association	   functional	  
classification	   of	   heart	   failure	   to	   reflect	   the	   unique	   physiology	   of	   PH	   including	   the	  
importance	  of	  near	  syncope	  and	  syncope	  in	  the	  symptom	  complex.	  
	  
Table	  4.2	  World	  Health	  Organisation	  functional	  assessment	  classification	  
Class	   Description	  
I	   Patients	  with	  pulmonary	  hypertension	  but	  without	  resulting	  limitation	  of	  
physical	   activity.	   Ordinary	   physical	   activity	   does	   not	   cause	   undue	  
dyspnoea,	  fatigue,	  chest	  pain	  or	  near	  syncope.	  
II	   Patients	   with	   pulmonary	   hypertension	   resulting	   in	   slight	   limitation	   of	  
physical	  activity.	  They	  are	  comfortable	  at	  rest.	  Ordinary	  physical	  activity	  
causes	  undue	  dyspnoea,	  fatigue,	  chest	  pain	  or	  near	  syncope.	  
III	   Patients	  with	   pulmonary	   hypertension	   resulting	   in	  marked	   limitation	   of	  
physical	  activity.	  They	  are	  comfortable	  at	  rest.	  Less	  than	  ordinary	  activity	  
causes	  dyspnoea	  fatigue	  chest	  pain	  or	  near	  syncope.	  
IV	   Patients	   with	   pulmonary	   hypertension	   with	   inability	   to	   carry	   out	   any	  
physical	  activity	  without	  symptoms.	  These	  patients	  manifest	  signs	  of	  right	  
heart	   failure.	   Dyspnoea	   and	   or	   fatigue	   may	   even	   be	   present	   at	   rest.	  
Discomfort	  is	  increased	  by	  physical	  activity.	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The	  majority	  of	  patients	  were	   in	  the	  class	   III-­‐	   IV	  group.	   	   	  There	  were	  no	  patients	   in	  
class	   IV	  although	  one	  patient	  had	   just	   recovered	   from	  an	  episode	   in	  which	  he	  had	  
been	  class	   IV	  only	  2	  weeks	  prior	   to	   the	   sample	  being	   taken.	  Only	  one	  patient	  was	  
class	  I.	  There	  was	  a	  wide	  variation	  in	  the	  6-­‐minute	  walk	  distances	  achieved,	  from	  24	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Table	  4.3	  Summary	  of	  patient	  characteristics	  (n=17)	  	  
Therapy	   	  
ET-­‐1	  receptor	  antagonist	  (Bosentan	  or	  Ambrisentan)	   12	  
PD5E	  inhibitors	  (Sildenafil)	   8	  
Prostanoids	   1	  
Warfarin	   17	  
Pulmonary	  endarterectomy	   5	  
World	  Health	  Organisation	  classification	   	  
I-­‐II	   7	  
III-­‐IV	   10	  
6	  minute	  walk	  distance	   	  
6MW	  (m)	   300	  
(24-­‐594)	  
Cardiac	  dynamics	   	  
Mean	  pulmonary	  artery	  pressure	  (PAP)	  (mmHg)	   43	  
(32-­‐73)	  
Mean	  right	  atrial	  pressure	  (RAP)	  (mmHg)	  	   8	  
	  (4-­‐24)	  	  
Cardiac	  Index	  (CI)	  	  (L	  min-­‐1m-­‐2)	   2.27	  
(1.05-­‐4.07)	  




Associated	  medical	  conditions	   	  
PE/DVT	   12	  
Splenectomy	   2	  
VP	  shunt	   1	  
Hypothyroidism	   1	  
Inflammatory	  bowel	  disease	   2	  
Thrombophilia	   	  
Factor	  V	  Leiden	  	   2	  
All	  data	  are	  given	  as	  the	  number	  of	  patients	  (from	  the	  17	  recruited)	  except	  for	  cardiac	  
dynamic	  data	  and	  the	  6-­‐minute	  walk	  distance,	  which	  is	  given	  as	  the	  median	  and	  range.	  
	  
Normal	  ranges:	  
mPAP	  9-­‐18mmHg,	  mRAP	  3-­‐8mmHg,	  CI	  2.6-­‐4.2	  L	  min-­‐1m-­‐2,	  PVR	  20-­‐130	  dynes	  sec-­‐1	  cm-­‐5
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The	   data	   were	   analysed	   to	   determine	   any	   correlation	   between	   the	   isolation	   of	  
BOECs	  in	  CTEPH	  patients	  and	  their	  clinical	  parameters.	  	  The	  number	  of	  colonies	  per	  
mononuclear	  cells	  (x	  107)	  isolated	  compared	  to	  the	  cardiac	  catheter	  results	  from	  the	  
diagnostic	   catheter	   is	   shown	   in	   Figure	   4.2:	   no	   correlation	   was	   seen,	   including	  
following	  exclusion	  of	  the	  single	  outlier.	  However,	   it	   is	  possible	  that	  the	  findings	  at	  
the	  time	  of	  diagnosis	  do	  not	  reflect	  the	  status	  of	  the	  patients	  at	  the	  time	  of	  sampling	  




Figure	  4.2	  Isolation	  of	  BOECs	  and	  cardiac	  catheter	  results	  
The	   number	   of	   colonies/mononuclear	   cells	   x107	   was	   compared	   to	   the	   cardiac	   catheter	  
results	   at	   diagnosis.	   A	   mean	   pulmonary	   artery	   pressure	   (mmHg),	   B	   pulmonary	   vascular	  
resistance	  (dynes	  sec-­‐1cm-­‐5)	  and	  C	  cardiac	  index	  (Lmin-­‐1m-­‐2).	  No	  correlation	  was	  seen.	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The	   isolation	   of	   cells	   was	   correlated	   with	   the	   functional	   status	   of	   the	   patient	  
assessed	   by	   WHO	   classification	   and	   6-­‐minute	   walk	   distance	   (Figure	   4.3).	   A	  
correlation	  can	  be	  seen	  between	  6-­‐minute	  walk	  distance	  and	  the	  ratio	  of	  colonies	  to	  
mononuclear	  cells;	  the	  further	  the	  patient	  was	  able	  to	  walk,	  the	  higher	  the	  ratio	  of	  
colonies	  to	  mononuclear	  cells	  (r=0.5302,	  p<0.05	  Spearman	  correlation).	  The	  patient	  
who	  had	  been	  the	  outlier	  did	  have	  a	  6	  minute	  walk	  value,	  however	  it	  was	  over	  a	  year	  
old	   and	   as	   the	   patient	   also	   had	   a	   below	   knee	   amputation	   which	   may	   have	  
confounded	   the	   result,	   it	   was	   not	   included	   in	   the	   analysis.	   There	   was	   also	   a	  
significant	  difference	  between	  the	  WHO	  classes	  in	  the	  isolation	  of	  BOECs,	  with	  those	  
in	   class	   I-­‐II	   having	   a	   higher	   ratio	   of	   colonies	   to	   mononuclear	   cells	   than	   those	   in	  
classes	   III-­‐IV.	  This	  was	   true	  whether	   the	  analysis	   included	   (p<0.01)	  or	  excluded	   (p<	  




Figure	  4.3	  Isolation	  of	  BOECs	  and	  the	  functional	  status	  of	  the	  patient	  
The	  number	  of	  colonies/mononuclear	  cells	  was	  compared	  to	  the	  6-­‐minute	  walk	  distance	  (A)	  
and	   the	   WHO	   functional	   class	   (B).	   Longer	   6-­‐minute	   walk	   distances	   correlated	   with	   more	  
colonies/mononuclear	   cells	   (r=0.5302,	   p<0.05).	  A	  better	  WHO	   functional	   class	   gave	  higher	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Because	  15	  of	  the	  patients	  were	  receiving	  disease	  specific	  medication,	  including	  dual	  
therapy	   in	   many	   cases,	   it	   was	   not	   possible	   to	   analyse	   the	   data	   for	   differences	   in	  
isolation	  between	  those	  on	  Bosentan	  (or	  other	  ET-­‐1	  antagonists)	  or	  Sildenafil.	  Those	  
with	  a	  documented	  clinical	  history	  of	  VTE	  were	  compared	  to	  those	  without	  and	  no	  
difference	   could	   be	   seen	   (Figure	   4.4	   A).	   There	   was	   no	   statistically	   significant	  
difference	   in	   frequency	   of	   BOECs	   isolation	   between	   patients	   who	   had	   previously	  
undergone	  PEA	  and	  those	  who	  had	  not	  (Figure	  4.4	  B).	  The	  outlier	  is	  included	  in	  this	  
analysis	  but	  if	  she	  was	  excluded	  there	  was	  still	  no	  difference.	  
	  
	  
Figure	  4.4	  Isolation	  of	  BOECs:	  VTE	  and	  PEA	  	  
The	  number	  of	  colonies/mononuclear	  cells	  in	  patients	  +/-­‐history	  of	  VTE	  	  (A)	  and	  patients	  +/-­‐	  
PEA	  (B).	  No	  statistical	  difference	  is	  seen	  between	  the	  groups.	  
	  
Note.	  The	  outlier	  merits	  consideration	  in	  more	  detail	  at	  this	  point.	  	  This	  patient	  grew	  
45	  colonies	  in	  5	  wells	  of	  a	  6	  well	  plate.	  At	  the	  time	  of	  collection	  the	  mononuclear	  cell	  
fraction	  isolated	  was	  no	  different	  to	  other	  samples.	  The	  cells	  appeared	  at	  day	  9,	  which	  
was	  not	  statistically	  different	  from	  the	  group	  but	  was	  one	  of	  the	  earliest.	  	  This	  was	  the	  
highest	   number	   of	   colonies	   recorded	   in	   the	   research	   group	   during	   experience	   of	  
collecting	   over	   100	   samples.	   Review	  of	   the	  medical	   notes	   revealed	   that	   the	   patient	  
was	  ANCA	  positive	  with	  additional	  medical	  problems	   including	  diabetes	  and	  a	  below	  
knee	  amputation	  for	  a	  Charcot	  deformity.	  It	  is	  possible	  that	  the	  positive	  ANCA	  reflects	  
an	   underlying	   vasculitic	   process.	   Indeed	   in	   a	   study	   by	   Woywodt	   et	   al	   [261],	   the	  
number	   of	   circulating	   endothelial	   cells	   was	   found	   to	   be	   significantly	   increased	   in	  
patients	   with	   ANCA-­‐associated	   vasculitis	   compared	   to	   healthy	   controls.	   Higher	  
numbers	   were	   seen	   in	   those	   with	   active	   disease	   compared	   to	   those	   in	   clinical	  
remission.	  They	  found	  that	  86%	  of	  the	  cells	  stained	  positive	  for	  tissue	  factor	  and	  84%	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stained	   for	   necrotic	   markers	   (annexin	   and	   propidium	   iodide).	   They	   postulated	   that	  
these	  are	  endothelial	  cells	   that	  detach	  from	  the	  basement	  membrane	  as	  part	  of	   the	  
vasculitic	   process;	   possibly	   having	   undergone	   necrosis.	   Although	   these	   cells	   are	  
different	  to	  the	  BOECs	  used	  in	  the	  experiments	  in	  this	  research	  project	  (identified	  by	  
dynabeads,	  CECs	  rather	  than	  ECFCs),	   it	   is	   interesting	  to	  note	  that	   increased	  numbers	  
were	   seen	   in	   ANCA	   positive	   disease.	   It	   is	   also	   possible	   that	   damage	   to	   the	  
endothelium	  releases	  increased	  numbers	  of	  endothelial	  progenitor	  cells	  as	  part	  of	  the	  
repair	  process.	   Further	   comment	   is	   limited	  by	  how	   little	   is	   known	  about	   the	  normal	  
growth	   of	   BOECs,	   the	   normal	   range	   of	   colonies	   isolated,	   what	   might	   affect	   the	  
numbers	   e.g.	   drugs,	   exercise,	   age	   and	   how	   quickly	   they	   grow.	   This	   patient	   was	  
interesting	  but	  not	  investigated	  further.	  As	  the	  numbers	  of	  recruits	  are	  small	  the	  data	  
has	  been	  analysed	  with	  and	  without	  the	  outlying	  patient’s	  results.	  
	  
In	   conclusion,	   there	  was	  no	  significant	  difference	   in	   the	   frequency	  and	   isolation	  of	  
BOECs	   between	   healthy	   controls	   and	   patients	   with	   CTEPH.	   However,	   within	   the	  
CTEPH	  population,	  functional	  status	  measured	  by	  6-­‐minute	  walk	  distance	  and	  WHO	  
functional	  class	  was	  related	  to	  the	  isolation	  of	  BOECs,	  with	  lower	  numbers	  of	  BOECs	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4.3 Characterisation	  of	  BOECs	  
4.3.1 Morphology	  
In	   culture,	   endothelial	   cells	   exhibit	   classical	   cobblestone	  morphology.	  When	   BOEC	  
colonies	  are	  first	  seen,	  a	  small	  well	  circumscribed	  monolayer	  of	  cells	  appears	  and	  as	  
the	   colony	   increases	   in	   size	   the	   classical	   cobblestone	   appearance	   is	   seen.	  
Representative	   colony	   growth	   and	   morphology	   is	   shown	   in	   Figure	   4.5	   (healthy	  
control)	   and	   Figure	   4.6	   (CTEPH	   patient).	   Overall	   no	   difference	  was	   seen	   in	   colony	  
morphology	  between	  healthy	  controls	  and	  CTEPH	  samples.	  However	  in	  the	  first	  few	  
CTEPH	  isolates,	  it	  was	  noticed	  that	  the	  cells	  appeared	  larger	  and	  flatter	  more	  quickly	  
after	   the	   first	   passage,	   which	   is	   suggestive	   of	   senescence.	   This	   will	   be	   discussed	  
further	  in	  section	  4.3.3.	  
	  
Figure	  4.5	  Morphology	  of	  healthy	  control	  BOECs	  	  
Representative	   images	   of	   colony	   growth	   from	   a	   healthy	   control.	   Scale	   bar	   represents	  
400µm,	  except	  for	  HC	  passage	  1	  which	  represents	  100µm.	  
	  
	  






Figure	  4.6	  Morphology	  of	  CTEPH	  BOECs	  
Representative	  images	  of	  colony	  growth	  from	  a	  CTEPH	  patient.	  Scale	  bar	  represents	  400µm,	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4.3.2 Immunofluorescence	  	  
To	   confirm	   that	   the	   cells	  were	  endothelial	   cells,	   colonies	  of	   confluent	  BOECs	  were	  
stained	  with	  antibodies	  to	  detect	  VE-­‐Cadherin	  and	  VWF	  which	  are	  characteristic	  of	  
EC	   lineage.	  All	  cells	  were	  confirmed	  as	  endothelial	  cells.	  Representative	   images	  are	  
shown	  in	  Figure	  4.7	  (healthy	  control)	  and	  Figure	  4.8	  (CTEPH).	  	  
	  	  
Figure	  4.7	  Immunofluorescent	  staining	  of	  healthy	  control	  BOECS	  
Cells	  were	  seeded	  at	  100,000	  cells	  on	  to	  collagen-­‐coated	  coverslips	  and	  incubated	  overnight.	  
The	  cells	  were	  fixed	  and	  then	  stained.	  A	  shows	  VE-­‐Cadherin	  (red),	  VWF	  (green)	  and	  nucleus	  
(blue).	  B	  VE-­‐Cadherin	  (red)	  and	  nuclear	  stain	  (blue)	  C	  VWF	  (green)	  and	  nuclear	  stain	  (blue)	  
and	   D	   nuclear	   stain	   alone.	   Images	   were	   captured	   using	   an	   LSM510	   META	   confocal	  
microscope	   (Carl	   Zeiss)	   using	   a	   63x	   objective	   lens	   and	   running	   Version	   3.2	   of	   the	   LSM	  
acquisition	  software.	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Figure	  4.8	  Immunofluorescent	  staining	  of	  CTEPH	  BOECs	  
Cells	  were	  seeded	  at	  100,000	  cells	  on	  to	  collagen-­‐coated	  coverslips	  and	  incubated	  overnight.	  
The	  cells	  were	  fixed	  and	  then	  stained.	  A	  shows	  VE-­‐Cadherin	  (red),	  VWF	  (green)	  and	  nucleus	  
(blue).	  B	  VE-­‐Cadherin	  (red)	  and	  nuclear	  stain	  (blue)	  C	  VWF	  (green)	  and	  nuclear	  stain	  (blue)	  
and	   D	   nuclear	   stain	   alone.	   Images	   were	   captured	   using	   an	   LSM510	   META	   confocal	  
microscope	   (Carl	   Zeiss)	   using	   a	   63x	   objective	   lens	   and	   running	   Version	   3.2	   of	   the	   LSM	  
acquisition	  software.	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4.3.3 Senescence	  	  
During	   the	   growth	  of	   the	  BOECs,	   it	  was	  observed	   that	   some	  of	   the	  BOEC	   colonies	  
from	  CTEPH	  patients	  appeared	   to	  contain	   larger,	   flatter	  cells.	  This	  can	  be	  a	   sign	  of	  
senescence.	   The	   cells	   were	   therefore	   tested	   for	   the	   presence	   of	   β-­‐gal,	   a	   known	  
marker	  of	  senescence.	  Using	  a	  histochemical	  staining	  method,	  described	   in	  section	  
2.7,	  the	  cells	  were	  stained	  for	  β-­‐gal.	  If	  β-­‐gal	  is	  present	  then	  an	  intense	  blue	  staining	  is	  
seen	   in	   the	   cells.	   Figure	   4.9	   shows	   representative	   images	   of	   BOECs	   exhibiting	   low	  
levels	  of	   senescence	   (a	  healthy	   control	  and	  a	  CTEPH	  patient).	   It	   also	   shows	   results	  




Figure	  4.9	  Senescence	  in	  BOECs	  
BOECS	  were	  seeded	  at	  80,000	  per	  well	  in	  a	  24	  well	  plate	  and	  incubated	  overnight.	  Cells	  were	  
fixed	   and	   stained	   for	   β-­‐gal	   as	   per	   the	   manufacturer’s	   instructions	   (Biovision,	   USA).	  
Representative	   images	  are	  shown	  of	  BOECS	  with	   low	  senescence	   (A)	   (healthy	  control)	  and	  
(B)	  (CTEPH)	  and	  high	  senescence	  (C)	  and	  (D),	  both	  from	  patients	  with	  CTEPH	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Figure	  4.10	  shows	  a	  comparison	  of	  the	  rates	  of	  senescence	  between	  healthy	  controls	  
and	   CTEPH	   patients:	   no	   significant	   difference	   was	   shown;	   however	   a	   group	   of	   4	  





Figure	  4.10	  Comparison	  of	  senescence	  in	  BOECs	  from	  patients	  and	  healthy	  controls	  
BOECS	  were	  seeded	  at	  80,000	  per	  well	  in	  a	  24	  well	  plate	  and	  incubated	  overnight.	  Cells	  are	  
fixed	   and	   stained	   for	   β-­‐gal	   as	   per	   the	   manufacturer’s	   instructions	   (Biovision,	   USA).	   The	  
number	  of	  blue	  (senescent)	  and	  non-­‐blue	  cells	  was	  counted.	  	  The	  percentage	  of	  senescence	  
cells	  is	  calculated.	  A	  minimum	  of	  500	  cells	  in	  each	  sample	  was	  counted.	  	  
This	   difference	  was	   only	   noted	   as	   the	   cells	  were	   being	   grown;	   therefore	   the	   early	  
controls	  had	  not	  been	  tested.	  Therefore	  the	  senescence	  assay	  for	  4	  of	  the	  controls	  
was	  performed	  on	  cells	  that	  had	  been	  previously	  frozen.	  This	  may	  have	  affected	  the	  
results,	  as	  it	  is	  possible	  that	  senescence	  assays	  performed	  on	  frozen	  cells	  will	  lead	  to	  
slightly	  higher	  measures	  of	  senescence.	  When	  cells	  are	  frozen	  and	  thawed,	  there	  is	  
always	   loss	   of	   some	   cells	   due	   to	   cell	   death.	   There	   may	   also	   be	   a	   higher	   ratio	   of	  
senescent	   to	   non-­‐senescent	   cell	   initially	   until	   only	   those	   that	   are	   proliferating	  
survive.	   This	   may	   mean	   that	   the	   senescence	   was	   overestimated	   in	   the	   healthy	  
controls.	   It	   is	   also	   possible	   that	   the	   converse	   is	   true	  with	   the	   freeze-­‐thaw	  process	  
resulting	  in	  reduced	  survival	  of	  senescent	  cells.	  
However,	   the	  CTEPH	  samples	  which	  showed	  the	  highest	   levels	  of	  senescence	  were	  
all	   fresh	   samples.	  All	   assays	  were	  performed	  at	   P4	  or	   P5	   (depending	  on	   the	   initial	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growth	  of	   the	  colonies	  and	  whether	  an	  extra	   step	  was	   required	   in	  passaging	   them	  
before	  there	  were	  sufficient	  for	  3	  T75s).	  The	  CTEPH	  patient	  data	  was	  compared	  with	  
historical	   healthy	   control	   results	   from	   a	   colleague,	   where	   all	   assays	   had	   been	  
performed	   on	   fresh	   cells.	   There	  was	   still	   no	   statistical	   difference	   even	   though	   the	  
historical	   controls	   had	   lower	   senescent	   percentages.	   Increasing	   age	   is	   known	   to	  
cause	  an	   increase	   in	   senescence	  but	  no	   correlation	  was	   seen	  between	   senescence	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4.4 Functional	  Assays	  on	  BOECs	  
4.4.1 CAT	  assay	  
The	   CAT	   assay	   was	   performed	   on	   BOECs	   from	   both	   healthy	   controls	   and	   CTEPH	  
patients	  with	  both	  exogenous	  TF	  and	  after	  TNF-­‐α	  stimulation.	  Overall,	  no	  significant	  
difference	   in	   peak	   thrombin	   generation	   was	   shown	   between	   patient	   and	   control	  
groups	  (Figure	  4.11).	  
	  
	  
Figure	  4.11	  Peak	  thrombin	  generation	  on	  BOECS	  
BOECs	  were	   seeded	   at	   30,000	   cells	   per	  well	   and	   incubated	   overnight.	   5pM	   exogenous	   TF	  
was	  used	  to	  trigger	  thrombin	  generation	  (A)	  or	  cells	  were	  stimulated	  with	  1.0nM	  TNF-­‐α	  for	  5	  
hours	   (B).	   Thrombin	   generation	   was	   measured	   in	   real	   time	   by	   cleavage	   of	   a	   fluorogenic	  
substrate.	  The	  peak	  thrombin	  is	  shown.	  There	  was	  no	  significant	  difference	  between	  healthy	  




The	   assay	   was	   performed	   on	   all	   BOECS	   in	   both	   groups.	   However,	   some	   technical	  
problems	  were	  encountered:	  
• the	  curve	  did	  not	  return	  to	  baseline	  in	  2	  healthy	  control	  experiments	  and	  therefore	  
the	  data	  could	  not	  be	  analysed.	  	  
• in	  one	  healthy	  control	  the	  substrate	  did	  not	  dispense	  correctly	  
• in	  one	  CTEPH	  patient	  (CTEPH	  3)	  there	  were	  insufficient	  cells	  and	  therefore	  only	  lysis	  
experiments	  were	  performed.	  	  
• some	  BOECs	  did	  not	  respond	  to	  stimulation	  with	  TNF-­‐α.	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  Samples	  used	  in	  the	  analysis	  are	  tabulated	  in	  Appendix	  3.	  
	  
Examination	  of	  the	  other	  parameters	  of	  thrombin	  generation	  (ETP	  and	  lag	  time),	  as	  
well	   as	   use	   of	   other	   concentrations	   of	   TF	   (1pM)	   and	   TNF-­‐α	   (0.1nM)	   revealed	   no	  
significant	  difference	  between	  healthy	  control	  and	  CTEPH	  patients.	  	  
	  
Comparison	   of	   the	   results	   from	   experiments	   with	   exogenous	   TF	   revealed	   no	  
difference	   in	   peak	   thrombin	   generation	   between	   BOECs,	   HUVECs	   or	   plasma.	   This	  
suggests	  that	  either	  the	  cells	  have	  broadly	  the	  same	  baseline	  phenotype,	  or	  the	  cells	  
do	  not	  contribute	  to	  the	  thrombin	  generation	  in	  this	  setting.	  
For	  the	  TNF-­‐α	  stimulated	  cells,	  there	  is	  no	  statistical	  difference	  between	  the	  groups,	  
however,	  there	  appears	  to	  be	  a	  trend	  towards	  lower	  thrombin	  generation	  on	  BOECs	  
compared	  to	  on	  HUVECS,	  as	  well	  as	  possible	  higher	  thrombin	  generation	  on	  CTEPH	  
BOECs	  compared	  to	  healthy	  controls	   (Figure	  4.12).	  Larger	  numbers	  are	  required	  to	  




Figure	  4.12	  Comparison	  of	  peak	  thrombin	  on	  TNF-­‐α 	  stimulated	  cells	  between	  
groups	  
Cells	  were	  seeded	  at	  30,000	  per	  well,	  incubated	  overnight	  and	  stimulated	  with	  1.0nM	  TNF-­‐α	  
for	  5	  hours.	  Thrombin	  generation	  was	  then	  assayed	  using	  the	  same	  PPP.	  Results	  are	  shown	  
as	  mean	  ±	  SD	  (n=	  5	  for	  HUVEC,	  n=	  6	  for	  HC,	  n=	  4	  for	  CTEPH).	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4.4.2 Clot	  Lysis	  assay	  
The	  lysis	  assay	  was	  performed	  on	  all	  BOECS	  samples.	  Figure	  4.13	  shows	  the	  results	  
from	   healthy	   control	   BOECS.	   A	   dose	   response	   can	   be	   seen	   with	   increasing	   TF	  
concentration	   resulting	   in	   longer	   lysis	   time	   as	   was	   previously	   demonstrated	   on	  




Figure	  4.13	  Lysis	  time	  on	  healthy	  control	  BOECs	  
BOECs	   were	   seeded	   at	   30,000	   cells	   per	   well	   in	   a	   96	   well	   plate	   and	   incubated	   overnight.	  
Exogenous	  TF	  was	  added	  to	  the	  reaction	  (A)	  or	  cells	  were	  stimulated	  with	  TNF-­‐α	  for	  5hours	  
(B).	  Clot	  formation	  was	  triggered	  by	  the	  addition	  of	  CaCl2	  and	  absorbance	  was	  measured	  at	  
405nm	  over	   time.	  Lysis	   time	  was	  calculated	  as	  described	   in	  2.5.1.	  A	  dose	   response	  can	  be	  
seen	  with	  increasing	  TF	  concentration	  resulting	  in	  prolongation	  of	  the	  lysis	  time	  (0	  vs.	  1	  p=	  
0.007,	   0	   vs.	   5	   p=0.002,	   1	   vs.	   5	   p=0.015).	   TNF-­‐α	   also	   produced	   a	   dose	   response	   but	   only	  
1.0nM	  was	  significantly	  different	  to	  unstimulated	  cells	   (p=	  0.02).	   (*	  p<0.05,	  **	  p<0.01,	  ***	  
p<0.005)	  	  
Lysis	  results	  were	  available	  for	  all	  controls	  using	  exogenous	  TF	  (Figure	  4.13	  A).	  In	  all	  
samples	   a	   change	   in	   absorbance	   was	   seen,	   even	   on	   unstimulated	   cells	   but	   this	  
appeared	  much	  later	  than	  in	  experiments	  with	  additional	  TF.	  Using	  the	  time	  to	  the	  
midpoint	  of	  the	  increase	  in	  turbidity	  as	  a	  marker	  of	  how	  quickly	  clots	  formed,	  there	  
was	   a	   dose	   dependent	   shortening	   in	   this	   time	   with	   increasing	   concentration	   of	  
exogenous	  TF.	  In	  unstimulated	  cells	  with	  no	  exogenous	  TF	  added,	  this	  time	  was	  also	  
at	   least	   double	   the	   time	   for	   the	   lowest	   TF	   concentration,	   indicating	   that	   the	   clot	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formation	  is	  much	  slower	  in	  the	  unstimulated	  cells	  and	  may	  be	  due	  to	  much	  lower	  
concentrations	  of	  TF	  expressed	  on	  the	  cells.	  	  
On	   TNF-­‐α	   stimulated	   cells	   a	   dose	   response	  was	   also	   seen.	   	   At	   1.0nM	   there	  was	   a	  
significant	   difference	   between	   unstimulated	   and	   stimulated	   cells	   (p=	   0.02).	   2	  
samples	   did	   not	   show	   any	   difference	   in	   the	   lysis	   time	   between	   stimulated	   and	  
unstimulated	   cells.	   However,	   when	   the	   time	   to	   the	   midpoint	   of	   the	   increase	   in	  
turbidity	  is	  used	  as	  a	  surrogate	  marker	  for	  clot	  formation,	  this	  showed	  longer	  times	  
on	  unstimulated	  cells	  (15-­‐	  20	  minutes),	  compared	  to	  those	  that	  had	  been	  stimulated	  
(3-­‐6	   minutes).	   This	   suggests	   that	   the	   TNF-­‐α	   had	   resulted	   in	   an	   increase	   in	   TF	  
expression	  on	  stimulated	  cells	  but	  that	  this	  was	  not	  sufficient	  to	  affect	  the	  lysis	  time.	  
When	   the	   data	   were	   analysed	   the	   data	   following	   removal	   of	   these	   2	   samples,	   a	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On	   CTEPH	   BOECs	   all	   10	   samples	   were	   assayed	   using	   exogenous	   TF,	   but	   only	   9	  
samples	  were	  analysed	  using	  TNF-­‐α	  stimulation,	  as	  there	  were	  insufficient	  cells	  from	  
one	  sample.	  Figure	  4.14	  A	  shows	  the	  dose	  response	  with	  exogenous	  TF.	  	  
	  
Figure	  4.14	  Lysis	  time	  on	  CTEPH	  BOECs	  
Lysis	   time	   was	   calculated	   for	   exogenous	   TF	   (A)	   and	   TNF-­‐α	   stimulated	   BOECs	   (B).	   A	   dose	  
response	   can	   be	   seen	   with	   exogenous	   TF	   (0	   vs.	   1	   p	   =0.0328,	   0	   vs.	   5	   0.0004,	   1	   vs.	   5	   not	  
significant).	  On	  TNF-­‐α	  stimulated	  cells	  1.0nM	  TNF-­‐α	  prolonged	  the	  lysis	  time	  (p=0.001).	  	  
(*	  p<0.05,	  ***p<0.005)	  
	  
	  
There	  is	  one	  outlier	  at	  the	  5pM	  TF	  concentration.	  This	   is	  the	  same	  outlier	  that	  was	  
described	  in	  the	  patient	  characteristics	  in	  relation	  to	  the	  growth	  of	  the	  cells.	  The	  lysis	  
time	  for	  this	  was	  almost	  double	  that	  for	  all	  other	  patients	  and	  controls	  at	  5pM.	  The	  
lysis	  time	  at	  1pM	  TF	  was	  also	  the	  longest	  in	  the	  group	  (64.15	  minutes)	  but	  this	  was	  
not	  as	  marked	  a	  difference	  as	  at	   the	  higher	  TF	   concentration.	  Analysis	  of	   the	  data	  
without	  this	  result	  made	  no	  statistical	  difference	  to	  the	  comparison	  between	  groups.	  	  
	  
On	   the	   TNF-­‐α	   stimulated	   cells,	   a	   dose	   response	   is	   apparent	   with	   1.0nM	   TNF-­‐α	  
causing	  significant	  prolongation	  of	  the	  lysis	  time	  (Figure	  4.14	  B).	  Interestingly,	  it	  was	  
not	  possible	  to	  calculate	  a	  lysis	  time	  on	  unstimulated	  cells	  for	  4	  of	  the	  samples	  in	  this	  
group.	  In	  two	  of	  these	  samples	  there	  was	  no	  obvious	  clot	  formation,	  with	  an	  almost	  
flat	  line	  (similar	  to	  that	  seen	  in	  plasma),	  and	  in	  the	  other	  2	  although	  a	  peak	  did	  occur,	  
it	  was	  delayed	  at	  over	  50	  minutes.	  	  In	  one	  case	  it	  did	  not	  return	  to	  baseline	  and	  so	  
lysis	  time	  could	  not	  be	  calculated	  and	  in	  the	  other	  a	  single	  peak	  was	  not	  present	  (a	  
double	  peak	  was	  seen)	  which	  made	  calculation	  of	  lysis	  time	  impossible.	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The	  lysis	  time	  on	  BOECs	  from	  CTEPH	  patients	  (53.68	  ±	  6.45	  mins)	  was	  shorter	  than	  
that	   on	   healthy	   controls	   (62.36	   ±	   6.1	   mins)	   (p=	   0.02)	   after	   5pM	   TF	   (Figure	   4.15).	  	  
However,	  this	  analysis	  did	  not	  include	  the	  lysis	  time	  from	  the	  “outlier”	  as	  it	  was	  not	  
clear	  why	  the	  lysis	  was	  so	  long	  in	  this	  patient	  and	  I	  could	  not	  be	  sure	  that	  this	  result	  
is	  representative	  of	  CTEPH	  alone.	  When	  the	  data	  are	  analysed	  including	  this	  results	  
no	  difference	  is	  shown	  between	  the	  groups.	  
Following	  TNF-­‐α	  stimulation	  there	  was	  no	  statistical	  difference	  between	  the	  groups.	  
Lysis	   times	   of	   43.04	   (±	   12.88)	  minutes	   and	   37.34	   (±	   7.59)	  were	   shown	   for	   healthy	  
controls	  and	  CTEPH	  BOECs	  respectively	   (p=ns).	  There	  does	  appear	  to	  be	  a	  trend	  to	  
shorter	   lysis	   time	   on	   CTEPH	   BOECs,	   but	   the	   wider	   spread	   of	   results	   in	   normal	  






Figure	  4.15	  Comparison	  of	  lysis	  time	  on	  healthy	  control	  and	  CTEPH	  BOECs	  
Lysis	  time	  with	  5pM	  exogenous	  TF	  (A)	  and	  1.0nM	  TNF-­‐α	  stimulation	  (B)	  was	  calculated.	  Lysis	  
time	   is	   shorter	  on	  CTEPH	  BOECS	  compared	   to	  controls	   (p=	  0.02).	  There	   is	  no	  difference	   in	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To	   identify	   a	   reason	   for	   the	   differences	   seen	   in	   lysis	   time,	   the	   lysis	   time	   was	  
compared	  with	  the	  thrombin	  generation	  assays	  that	  had	  been	  performed	  in	  parallel.	  
It	   is	   known	   that	  higher	   thrombin	  generation	   leads	   to	   stronger	   clots	  and	  prolonged	  
lysis	  time	  in	  both	  purified	  plasma	  systems	  and	  on	  HUVECs	  [262].	  No	  correlation	  was	  
seen	  between	  lysis	  time	  and	  peak	  thrombin	  on	  unstimulated	  cells	  with	  exogenous	  TF	  




Figure	  4.16	  Comparison	  of	  peak	  thrombin	  generation	  and	  lysis	  time	  on	  BOECs	  
Lysis	  time	  and	  peak	  thrombin	  were	  plotted.	  No	  correlation	  was	  seen	  for	  experiments	  with	  
exogenous	  TF	  (A)	  or	  TNF-­‐α	  stimulation	  (B).	  (Circle=	  HC,	  triangle	  =CTEPH)	  
	  
	  
Although	   there	   was	   no	   significant	   difference	   between	   the	   healthy	   controls	   and	  
patient	  BOECs	  when	  the	  percentage	  of	  senescent	  cells	  was	  calculated,	   there	  was	  a	  
group	   of	   4	   patient	   samples	   that	   showed	  much	   higher	   levels	   of	   senescence.	   In	   the	  
literature,	  senescence	  has	  been	  associated	  with	  increased	  PAI-­‐1	   levels	   in	  senescent	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Initially	  with	  the	  early	  samples	   (those	  that	  had	  a	  higher	  percentage	  of	  senescence)	  
there	   appeared	   to	   be	   a	   correlation	   between	   lysis	   time	   and	   senescence.	   However	  
Figure	  4.17	  (B	  and	  C)	  shows	  that	  there	  is	  no	  correlation	  with	  use	  of	  either	  exogenous	  
TF	   or	   TNF-­‐α	   stimulation.	   Thrombin	   generation	   was	   weakly	   correlated	   with	  
senescence	  in	  experiments	  using	  exogenous	  TF	  but	  not	  after	  TNF	  stimulation:	  	  higher	  






Figure	  4.17	  Senescence	  and	  the	  functional	  assays	  
Percentage	  senescence	  was	  compared	   to	  peak	   thrombin	  measurement	  with	  exogenous	  TF	  
(A)	  and	  TNF-­‐α	  stimulation	  (B).	  A	  correlation	  was	  seen	  between	  peak	  thrombin	  generated	  on	  
unstimulated	   BOECs	   with	   exogenous	   TF	   and	   senescence	   (r=0.63,	   p=0.024)(A).	   Percentage	  
senescence	  was	  compared	  to	  lysis	  time	  with	  exogenous	  TF	  (C)	  and	  TNF-­‐α	  stimulation	  (D).	  No	  
correlation	  was	  seen.	  (Circle	  =	  Healthy	  control,	  triangle	  =	  CTEPH)	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As	   a	   further	   control,	   I	   was	   kindly	   given	   BOECs	   collected	   from	   4	   patients	   with	  
idiopathic	  pulmonary	  hypertension	  as	  part	  of	  Raymond	  Lao’s	  PhD	  project	  under	  the	  
supervision	  of	  Dr	  Wharton.	  Full	  clinical	  characteristics	  of	  these	  patients	  can	  be	  seen	  
in	   Appendix	   2	   (Section	   7.2	   Table	   7.5).	   A	   summary	   of	   the	   comparison	   between	  
healthy	  control,	  CTEPH	  and	  IPAH	  is	  shown	  in	  Table	  4.4.	  
	  
Table	  4.4	  Comparison	  of	  characteristics	  between	  Healthy	  Control,	  CTEPH	  and	  IPAH	  
patients	  
	   HC	   CTEPH	   IPAH	  
Age	  (years)	   50.64	   59.24	   48.5	  




	  F	  4	  
Mean	  pulmonary	  artery	  pressure	  (mmHg)	   N/A	   47.75	   67.75	  
Pulmonary	  vascular	  resistance	  (dynes	  sec-­‐1	  cm-­‐5)	   N/A	   848.2	   1272.75	  
6	  minute	  walk	  distance	  (m)	   N/A	   275.06	   361	  
	  
Data	  are	  shown	  as	  mean	  (except	  for	  sex).	  For	  HC	  and	  CTEPH	  the	  means	  represent	  all	  controls	  
and	  patients	  recruited,	  whereas	  the	  IPAH	  is	  only	  the	  data	  from	  the	  4	  samples	  I	  was	  given.	  	  
	  
	  
The	  mean	  age	  was	  not	  different	  between	  groups	  overall,	  or	  for	  those	  that	  grew	  past	  
P4	   in	   the	  HC	   and	   CTEPH	   group	   (49	   and	   51.5	   respectively).	   In	   both	   the	   CTEPH	   and	  
IPAH	  groups	  there	  were	  more	  females:	  IPAH	  is	  more	  common	  in	  women	  than	  men.	  
The	  mean	  pulmonary	  artery	  pressure	  and	  pulmonary	  vascular	  resistance	  was	  higher	  
in	   the	   IPAH	   group.	  With	   respect	   to	   functional	   assessments,	   the	   entire	   IPAH	   group	  
were	  in	  WHO	  class	  III	  or	  IV.	  However,	  the	  6-­‐minute	  walk	  distance	  was	  longer	  in	  the	  
IPAH	  group	   suggesting	   that	  despite	  worse	   cardiac	   catheter	   results	   this	   group	  were	  
able	  to	  walk	  further.	  One	  patient	  was	  treatment	  naïve;	  the	  other	  3	  were	  on	  at	  least	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Thrombin	   generation	  was	  measured	  with	   exogenous	   TF	   on	   the	   IPAH	  BOECs	   in	   the	  
same	  way	  as	  the	  healthy	  control	  and	  CTEPH	  BOECs.	  With	  exogenous	  TF	  no	  significant	  
difference	  was	  seen	   in	   the	  peak	   thrombin	  generated	   (see	  Figure	  4.18).	  The	  4	   IPAH	  
BOECs	   results	  were	   tightly	   clustered	  whereas	   the	   healthy	   controls	   and	   the	   CTEPH	  





Figure	  4.18	  Peak	  thrombin	  generation	  on	  BOECs	  
BOECs	  were	   seeded	   at	   30,000	   cells	   per	  well	   and	   incubated	   overnight.	   5pM	   exogenous	   TF	  
was	   used	   to	   trigger	   the	   reaction.	   Thrombin	   generation	   was	   measured	   in	   real	   time	   by	  
cleavage	  of	  a	   fluorogenic	  substrate.	  The	  peak	   thrombin	   is	   shown.	  There	  was	  no	  significant	  
difference	  between	  healthy	  controls,	  CTEPH	  or	  IPAH	  patients	  in	  peak	  thrombin	  generated.	  
	  
	  
The	  IPAH	  cells	  were	  stimulated	  with	  TNF-­‐α as	  before.	  Only	  one	  sample	  gave	  a	  true	  
peak	   with	   1.0nM	   TNF-­‐α	   (42.21nM	   thrombin).	   This	   was	   lower	   than	   the	   mean	  
thrombin	   generation	   on	   BOECs	   in	   both	   the	   healthy	   control	   (67.99nM)	   and	   CTEPH	  
(79.46nM)	  group.	  In	  2	  of	  the	  IPAH	  samples	  the	  curves	  did	  not	  return	  to	  baseline	  and	  
therefore	  the	  data	  could	  not	  be	  analysed.	  The	  third	  sample	  did	  give	  a	  peak	  thrombin	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Lysis	  was	  measured	  on	  the	  IPAH	  BOECs.	  With	  exogenous	  TF,	  no	  difference	  was	  seen	  
in	   lysis	   time	  between	   the	   groups	   at	   1pM	  TF.	  At	   5pM,	   there	  was	   a	  difference	   seen	  
between	  healthy	  control	  and	  CTEPH	  as	  described	  before,	  but	  no	  difference	  was	  seen	  
between	  the	  IPAH	  BOECs	  and	  either	  healthy	  control	  or	  CTEPH	  (Figure	  4.19).	  The	  IPAH	  
group	  has	  the	  widest	  spread	  of	  results.	  The	  sample	  that	  gave	  the	  shortest	  lysis	  time	  





Figure	  4.19	  Lysis	  time	  on	  BOECs	  with	  exogenous	  TF	  
Lysis	  time	  was	  calculated	  after	  reactions	  were	  triggered	  with	  1pM	  TF	  (A)	  and	  5pM	  TF	  (B).	  No	  
difference	  was	   seen	   in	   lysis	   times	  at	  1pM	  TF.	  At	  5pM	  TF	   the	  only	  difference	  was	  between	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No	  difference	  is	  seen	  in	  lysis	  time	  between	  the	  groups	  when	  BOECs	  were	  stimulated	  
with	   0.1nM	   TNF-­‐α.	   	   At	   1.0nM	   TNF-­‐α,	   no	   difference	   was	   seen	   between	   healthy	  
controls	   and	  CTEPH	  BOECS,	  but	   lysis	   time	  on	   IPAH	  BOECs	  was	   significantly	   shorter	  
than	  both	  healthy	  controls	  (p=	  0.024)	  and	  CTEPH	  (p=0.036).	  In	  addition	  there	  was	  no	  





Figure	  4.20	  Lysis	  time	  on	  BOECs	  with	  TNF-­‐α 	  stimulation	  
Lysis	   time	  was	   calculated	   after	   cells	  were	   stimulated	  with	   0.1nM	   (A)	   and	  1.0	   nM	   (B)	   TNF-­‐
α. No	  difference	  was	  seen	  between	  groups	  at	  0.1nM.	  At	  1.0	  nM	  lysis	  time	  was	  significantly	  






One	  patient	   in	   the	   IPAH	  group	  was	  treatment	  naïve,	  however	   this	  did	  not	  seem	  to	  
affect	   the	   lysis	   or	   thrombin	   generation	   results	   as	   the	   results	   obtained	   from	   that	  
patient’s	   cells	   gave	   results	   in	   the	  middle	  of	   the	   IPAH	  group;	   it	  was	  not	   the	  outlier	  
seen	  in	  the	  lysis	  time	  with	  exogenous	  TF.	  	  
Senescence	  in	  the	  IPAH	  cells	  was	  assessed	  and	  this	  was	  similar	  to	  the	  controls,	  with	  
low	  senescence	  (all	  less	  than	  20%).	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Shorter	   lysis	   times	  were	   observed	   on	   CTEPH	   BOECs	   compared	   to	   healthy	   controls	  
after	   triggering	   with	   5pM	   exogenous	   TF.	   After	   TNF-­‐α	   stimulation,	   no	   significant	  
difference	   was	   seen	   between	   healthy	   controls	   and	   CTEPH	   BOECs,	   however	   the	  
healthy	  control	  group	  did	  show	  a	  much	  wider	   range	  of	  values.	   If	  BOECs	   from	   IPAH	  
patients	  were	  used	  as	  a	  disease	  control,	  no	  difference	  was	  seen	  with	  exogenous	  TF.	  
Interestingly	  the	  lysis	  time	  on	  IPAH	  BOECs	  was	  significantly	  shorter	  than	  both	  healthy	  
controls	  and	  CTEPH	  BOECS	  after	  1.0nM	  TNF-­‐α	  stimulation.	  The	  small	  number	  of	  IPAH	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5 Gene	  expression	  analysis	  of	  BOEC	  for	  CTEPH	  and	  controls	  	  
Analysis	   of	   the	   results	   from	   the	   CAT	   and	   lysis	   assays	   on	   the	   BOECs	   led	   to	   the	  
unexpected	  finding	  of	  shorter	  lysis	  times	  on	  cells	  isolated	  from	  CTEPH	  patients	  after	  
addition	   of	   exogenous	   TF,	   which	   did	   not	   correlate	   with	   the	   amount	   of	   thrombin	  
produced.	   This	   implied	   that	   the	   reduction	   in	   lysis	   time	   was	   generated	   by	   some	  
constitutive	  property	  of	   the	   cells	   and	  a	  method	   to	   analyse	   the	   cells	  was	   therefore	  
required	  to	  identify	  a	  molecular	  explanation	  for	  this	  difference.	  PCR	  array	  analysis	  is	  
useful	   in	   establishing	   broad	   patterns	   of	   gene	   expression	   and	   screening	   for	  
differential	   gene	   expression.	   As	  my	   interest	   lay	  with	   the	   cells	   themselves,	   a	   panel	  
containing	   endothelial	   markers	   as	   well	   as	   markers	   related	   to	   clot	   formation	   and	  
fibrinolysis	   including	   thrombin,	   tPA,	   uPA,	   plasminogen	   and	   thrombomodulin	   was	  
chosen.	  
To	   ensure	   comparability	   and	  based	  on	   the	  manufacturer’s	   instruction	  500	  µg	  RNA	  
was	   used.	   This	   meant	   that	   3	   healthy	   controls	   and	   3	   CTEPH	   samples	   had	   to	   be	  
excluded,	  as	  lower	  levels	  of	  RNA	  were	  isolated.	  	  
The	   analysis	   software,	   available	   on	   the	  manufacturer’s	   website,	   allows	   analysis	   of	  
the	   data.	   The	   results	   of	   the	   gene	   expression	   are	   normalised	   to	   the	   expression	   of	  
housekeeping	  genes.	  Either	  automatic	  selection	  of	  the	  gene	  from	  the	  housekeeping	  
panel	  or	  manual	  selection	  can	  be	  chosen	  for	  normalisation.	  The	  choice	  of	  gene	  for	  
normalisation	  may	  have	  an	  effect	  on	  the	  fold	  changes	  seen.	  	  
The	  data	  were	  analysed	  by	  normalising	  the	  data	  to	  the	  housekeeping	  gene	  with	  the	  
most	   stable	   expression	   between	   the	   2	   groups	   being	   analysed.	   The	   software	  
measures	   and	   identifies	   the	   genes	   from	   the	   housekeeping	   panel	   with	   the	   most	  
stable	   expression.	   The	   CT	   values	   for	   the	   housekeeping	   gene(s)	   are	   geometrically	  
averaged	  and	  used	  for	  the	  ΔΔCT	  calculations.	  	  
The	   normalised	   change	   expression	   level	   (quantity	   of	   mRNA)	   is	   expressed	   as	   Δ CT	  
which	  is	  the	  difference	  in	  CT	  values	  between	  the	  gene	  and	  the	  housekeeping	  control.	  
The	  difference	  in	  normalised	  values	  between	  the	  individual	  genes	  in	  each	  group	  (i.e.	  
between	  normal	  controls	  and	  CTEPH)	  (ΔΔCT)	  is	  then	  obtained	  and	  the	  ‘fold-­‐change’	  
calculated	  (2-­‐ΔΔCT)	  by	  considering	  that	  each	  cycle	  will	  double	  the	  amount	  of	  product.	  
‘Fold	   regulation’	   represents	   the	   fold-­‐change	   in	  a	  more	  meaningful	  way	  with	  values	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greater	   than	  one	   indicating	   a	   positive	   (or	   up	   regulation)	   and	   the	   fold	   regulation	   is	  
equal	   to	   the	   fold	  change.	  Fold	  changes	   less	   than	  one	   indicates	  a	  negative	  or	  down	  
regulation	  and	  the	  fold	  regulation	   is	  the	  negative	   inverse	  of	  the	  fold-­‐change.	  The	  p	  
values	  are	  calculated	  using	  the	  student	  t	  test	  by	  the	  software.	  
	  
The	  plates	  also	  contain	  wells	  designed	   to	  assess	  PCR	   reproducibility,	   genomic	  DNA	  
contamination	  and	  RT	  efficiency,	  which	  is	  performed	  by	  the	  software.	  The	  results	  for	  
each	   individual	   sample	   reproducibility,	   RT	   efficiency	   and	   genomic	   DNA	  
contamination	  can	  be	  found	  in	  Appendix	  4.	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5.1 Healthy	  control	  compared	  to	  CTEPH	  	  
The	   PCR	   arrays	   on	   the	   RNA	   isolated	   from	   CTEPH	   BOECs	   all	   passed	   tests	   for	   PCR	  
reproducibility,	   RT	   efficiency	   and	   genomic	   DNA	   contamination.	   The	   PCR	   arrays	   on	  
healthy	   controls	   passed	   PCR	   reproducibility	   and	   RT	   efficiency.	   	   For	   the	   healthy	  
controls,	   two	  passed	  the	  Genomic	  DNA	  contamination	  criteria,	   two	  results	  showed	  
values	   greater	   than	   34	   (34.71/34.62)	   where	   greater	   than	   35	   is	   the	   cut	   off	   for	   no	  
significant	  contamination,	  the	  final	  sample	  had	  a	  value	  of	  32.18	  which	  suggests	  some	  
genomic	   DNA	   contamination.	   However	   when	   the	   data	   was	   analysed	   with	   and	  
without	  this	  array	  data	  no	  difference	  was	  seen	  and	  therefore	  it	  was	  included	  in	  the	  
results.	  	  
The	   results	   are	   shown	  with	  normalisation	   to	  RLP01,	   the	  most	   stable	  housekeeping	  
gene	  in	  these	  2	  groups.	  The	  results	  are	  shown	  in	  Table	  5.1,Table	  5.2	  and	  Figure	  5.1.	  
Figure	  5.1	  A	  shows	  a	  volcano	  plot	  of	  the	  results	  showing	  those	  results	  with	  statistical	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Table	  5.1	  Genes	  with	  increased	  expression	  in	  CTEPH	  BOECs	  compared	  to	  healthy	  
control	  BOECs	  
Increased	  expression	   Fold	  regulation	  (RLP01)	  
P	  values	  
Arachidonate	  5-­‐lipoxygenase	   	  2.04*	   0.9068	  
Endothelin	  receptor	  type	  A	   	  2.41*	   0.1749	  
Fibroblast	  Growth	  Factor	  2	   2.04	   0.0089	  
Fibronectin	  1	   2.07	   0.0334	  
Matrix	  metallopeptidase	  2	   2.09	   0.1727	  
Matrix	  metallopeptidase	  9	   	  2.31*	   0.4053	  
Tissue	  plasminogen	  activator	   2.04	   0.3627	  
Thrombomodulin	   2.41	   0.0962	  
Vascular	  cell	  adhesion	  molecule	  1	   4.57	   0.1137	  
	  
*	   This	   gene’s	   average	   threshold	   cycle	   is	   relatively	   high	   (>	   30),	  meaning	   that	   its	   relative	   expression	  
level	  is	  low,	  in	  both	  control	  and	  test	  samples,	  and	  the	  p-­‐value	  for	  the	  fold-­‐change	  is	  either	  unavailable	  
or	  relatively	  high	  (p	  >	  0.05).	  
	  
The	   normalised	   change	   in	   expression	   levels	   is	   expressed	   as	   the	  Δ CT.	   	  The	   difference	   in	   normalised	  
values	   (ΔΔCT)	   for	   a	   given	   gene	   between	   test	   and	   control	   is	   then	   obtained	   and	   the	   fold	   change	  
calculated,	   considering	   that	   each	   cycle	   will	   double	   the	   amount	   of	   product.	   This	   value	   is	   used	   to	  
calculate	   the	   fold	  regulation.	  The	  statistical	   significance	  of	   the	  difference	   is	   then	  assessed	  using	   the	  
student	   t-­‐test,	   which	   depends	   on	   the	   variability	   of	   the	   changes.	   Thus	   similar	   fold	   changes	   in	   two	  
genes	  may	  differ	  in	  their	  significance	  if	  the	  variance	  of	  the	  measurements	  is	  different.	  
	  
	  
Table	  5.2	  Genes	  with	  decreased	  expression	   in	  CTEPH	  BOECs	  compared	  to	  healthy	  
control	  BOECs	  
Decreased	  expression	   Fold	  regulation	  
(RLP01)	  
P	  values	  
Heme	  oxygenase	  1	   -­‐2.17	   0.1047	  
Interleukin	  1β	   	  -­‐2.09*	   0.1548	  
Kinase	  insert	  domain	  receptor	   -­‐2.08	   0.0057	  
	  
*	   This	   gene’s	   average	   threshold	   cycle	   is	   relatively	   high	   (>	   30),	  meaning	   that	   its	   relative	   expression	  
level	  is	  low,	  in	  both	  control	  and	  test	  samples,	  and	  the	  p-­‐value	  for	  the	  fold-­‐change	  is	  either	  unavailable	  










Figure	  5.1	  Comparison	  of	  gene	  expression	  in	  healthy	  control	  and	  CTEPH	  BOECs	  	  
	  A	  Volcano	  plot	  of	  gene	  expression.	  Results	  were	  normalised	  to	  RLP01	  (automatic	  selection).	  
The	  blue	   line	  represents	  a	  p	  value	  of	  <0.01.	  B	  Scatter	  plot	  of	  gene	  expression.	  The	  2	  outer	  
lines	   represent	   a	   2-­‐fold	   change	   in	   expression.	   Red	   circles	   show	   increased	   expression	   and	  
green	  circles	  decreased	  expression.	  	   	  
CTEPH	  v	  Normal	  Controls	  
CTEPH	  v	  Normal	  Controls	  A	  
A	  
B	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In	   the	  analysis,	  using	  a	   cut	  off	  of	  a	   two-­‐fold	   change,	  nine	  genes	   showed	   increased	  
expression	   in	  CTEPH	  BOECS,	  while	  only	  3	  genes	  showed	  decreased	  expression.	  The	  
numbers	  used	   in	   the	  analysis	  are	   small,	   so	   the	   results	  have	   to	  be	   interpreted	  with	  
caution.	   Nonetheless,	   levels	   of	   significance	   were	   reached	   for	   the	   increase	   in	  
expression	   of	   fibroblast	   growth	   factor	   2	   (p<0.01)	   and	   fibronectin	   (p<0.05),	   and	  
decreased	  in	  expression	  of	  kinase	  insert	  domain	  receptor	  (KDR)	  (p<0.01).	  KDR	  is	  the	  
VEGFR-­‐2.	   Although	   not	   significant	   statistically	   it	   is	   interesting	   to	   note	   a	   two-­‐fold	  
increase	   in	   thrombomodulin	   and	   tPA,	   both	   of	   which	   may	   affect	   fibrinolysis.	  
Endothelin	   receptor	   type	   A	   is	   also	   important	   in	   the	   pathogenesis	   of	   pulmonary	  
hypertension	  and	  is	  the	  basis	  for	  one	  of	  the	  treatments	  for	  pulmonary	  hypertension	  
so	  the	  two-­‐fold	  increase	  was	  interesting.	  VCAM-­‐1	  showed	  a	  four-­‐fold	  increase.	  MMP	  
2	  and	  9	  also	  showed	  a	  two-­‐fold	  increase	  which	  was	  interesting	  as	  MMPs	  have	  been	  




















	   138	  
5.2 Comparison	  of	  Healthy	  Control	  and	  IPAH	  
	  
The	  healthy	  control	  data	  used	  were	  the	  same	  as	  section	  1.1.	  IPAH	  data	  showed	  good	  
PCR	  reproducibility,	  RNA	  efficiency	  and	  no	  significant	  genomic	  DNA	  contamination	  
was	  seen.	  Only	  2	  IPAH	  samples	  yielded	  sufficient	  RNA	  so	  no	  statistically	  valid	  values	  
are	  available.	  Results	  were	  normalised	  by	  automatic	  selection	  from	  housekeeping	  
panel	  (RLP01).	  Results	  are	  shown	  in	  Table	  5.3,	  Table	  5.4	  and	  Figure	  5.2.	  	  
Nine	  genes	  showed	  increased	  expression	  and	  twenty	  genes	  decreased	  expression	  in	  
the	  IPAH	  BOECs	  compared	  to	  the	  healthy	  controls.	  There	  was	  a	  three-­‐fold	  increase	  in	  
tissue	   factor,	   a	   twelve-­‐fold	   increase	   in	   fibroblast	   growth	   factor	   1	   and	   a	   five-­‐fold	  
increase	   in	   tPA	   expression.	   MMP1	   and	   MMP9	   showed	   a	   five-­‐fold	   and	   two-­‐fold	  
increase	   respectively.	   Platelet	   factor	   4	   showed	   a	   two-­‐fold	   increase.	   Interleukin	   7	  
showed	  a	  forty	  one-­‐fold	  increase.	  Genes	  that	  showed	  decreased	  expression	  included	  
Endothelin	   1,	   fibroblast	   growth	   factor	   2,	   prostaglandin	   synthases,	   PAI-­‐1	   and	   VWF.	  
VCAM-­‐1	   showed	   an	   eighteen-­‐fold	   decrease.	   Many	   of	   these	   genes	   have	   been	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Table	   5.3	   Genes	   with	   increased	   expression	   in	   IPAH	   BOECs	   compared	   to	   healthy	  
control	  BOECs	  
Increased	  expression	   Fold	  regulation	  
(RLP01)	  
Chemokine	  Ligand	  5	   4.11+	  
Tissue	  factor	  	   3.73*	  
Fibroblast	  growth	  factor	  1	   12.05*	  
Interleukin	  7	   	  41.12+	  
Matrix	  metalloproteinase	  1	   5.48	  
Matrix	  metalloproteinase	  9	   	  	  2.48*	  
Platelet	  factor	  4	   	  2.13*	  
Tissue	  plasminogen	  activator	   5.58	  




+	  This	  gene’s	  average	  threshold	  cycle	   is	  relatively	  high	  (<30)	   in	  either	  the	  control	  or	  the	  test	  sample	  
and	  relatively	  low	  in	  the	  other	  sample	  (>30).	  These	  data	  mean	  that	  the	  gene’s	  expression	  is	  relatively	  
low	   in	  one	  sample	  and	   readily	  detected	   in	   the	  other	   sample	   suggesting	   that	   the	  actual	   fold	  change	  
value	  is	  at	  least	  as	  large	  as	  the	  calculated	  and	  reported	  fold	  change	  results.	  
	  
*	   This	   gene’s	   average	   threshold	   cycle	   is	   relatively	   high	   (>	   30),	  meaning	   that	   its	   relative	   expression	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Table	  5.4	  Genes	  with	  decreased	  expression	  in	  IPAH	  BOECSs	  compared	  to	  healthy	  
controls	  BOECS	  
Decreased	  expression	  
Fold	  regulation	  	  
(RLP01)	  
ADAM	  metallopeptidase	  domain	  17	   -­‐2.07	  
Arachidonate-­‐5-­‐lipoxygenase	   -­‐2.27*	  
Caspase	  3	   -­‐2.28	  
Chemokine	  ligand	  2	   -­‐2.54	  
Cadherin	  5,	  type	  2	  (vascular	  endothelium)	   -­‐2.38	  
Endothelin	  1	   -­‐2.42	  
Thrombin	  receptor	  (F2	  receptor)	   -­‐3.27	  
Fibroblast	  growth	  factor	  2	   -­‐2.02	  
Interleukin	  6	   -­‐27.77+	  
Integrin,	  beta	  1	  (CD29)	   -­‐2.58	  
Integrin,	  beta	  3	  (CD61)	   -­‐2.54	  
KIT	   -­‐4.9	  
Matrix	  metalloproteinase	  2	   -­‐7.4	  
Prostaglandin	  I2	  (prostacyclin)	  synthase	   -­‐10.26+	  
Prostaglandin-­‐endoperoxidase	  synthase	  2	  (PG	  G/H	  synthase	  and	  
cyclooxygenase)	  
-­‐6.84	  
Selectin	  E	   -­‐2.55+	  
Serpine	  peptidase	  inhibitor	  1	  (PAI	  -­‐1)	   -­‐2.45	  
Thrombospondin	  1	   -­‐3.03	  
Vascular	  cell	  adhesion	  molecule	  1	   -­‐18.59+	  
Von	  Willebrand	  factor	   -­‐8.35	  
	  
+	  This	  gene’s	  average	  threshold	  cycle	  is	  relatively	  high	  (<30)	  in	  either	  the	  control	  or	  the	  test	  sample	  
and	  relatively	  low	  in	  the	  other	  sample	  (>30).	  These	  data	  mean	  that	  the	  gene’s	  expression	  is	  relatively	  
low	  in	  one	  sample	  and	  readily	  detected	  in	  the	  other	  sample	  suggesting	  that	  the	  actual	  fold	  change	  
value	  is	  at	  least	  as	  large	  as	  the	  calculated	  and	  reported	  fold	  change	  results.	  
	  
*	  This	  gene’s	  average	  threshold	  cycle	  is	  relatively	  high	  (>	  30),	  meaning	  that	  its	  relative	  expression	  
















Figure	  5.2	  Comparison	  of	  gene	  expression	  in	  healthy	  control	  and	  IPAH	  BOECs	  
Scatter	   plot	   of	   gene	   expression.	   Results	   were	   normalised	   to	   RLP01	   (automatic	   selection).	  
Red	  circles	  show	  increased	  expression	  and	  green	  circles	  decreased	  expression.	  The	  2	  outer	  
lines	  represent	  a	  2-­‐fold	  change	  in	  expression.	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5.3 Comparison	  of	  CTEPH	  and	  IPAH	  	  
As	   only	   two	   IPAH	   samples	  were	   analysed,	   it	  was	   not	   possible	   to	   achieve	   levels	   of	  
statistical	   significance	  when	  the	  array	  data	  was	  compared	  with	   that	  obtained	   from	  
CTEPH	   arrays.	   The	   data	   in	   this	   analysis	   was	   normalised	   to	   GAPDH/ACTB	   as	   these	  
were	  the	  most	  stable	  housekeeping	  genes	  by	  automatic	  selection.	  
Analysis	  of	  the	  arrays	  showed	  thirteen	  genes	  with	   increased	  expression	  and	  fifteen	  
with	  decreased	  expression	   in	   IPAH	  BOECs	  compared	  to	  CTEPH	  BOECs.	  The	  greatest	  
relative	   change	  was	   in	   the	   interleukin	   7	   gene	   (fifty-­‐fold),	   but	   it	  was	   interesting	   to	  
observe	  an	  almost	  four-­‐fold	  increase	  in	  tPA	  in	  IPAH	  compared	  to	  CTEPH	  as	  well	  as	  a	  
three-­‐fold	  increase	  in	  urokinase.	  There	  was	  also	  a	  fourteen-­‐fold	  increase	  in	  fibroblast	  
growth	  factor	  1.	  See	  Figure	  5.3,	  Table	  5.5	  and	  Table	  5.6.	  	  
Table	  5.5	  Genes	  with	  increased	  expression	  in	  IPAH	  BOECs	  compared	  to	  CTEPH	  
BOECs	  	  
Increased	  expression	   Fold	  Change	  
(GAPDH/	  
ACTB)	  
Caspase	  1	   2.14	  
Chemokine	  ligand	  5	  	   5.32+	  
Tissue	  factor	   4.57*	  
Fas	   2.69	  
Fibroblast	  growth	  factor	  1	   14.87*	  
Heme	  oxygenase	  1	   2.05	  
Interleukin	  7	   49.55+	  
KDR	   3.09	  
Matrix	  metalloproteinase	  1	   5.78	  
Platelet/endothelial	  cell	  adhesion	  molecule	   2.06	  
Platelet	  factor	  4	  	   4.91*	  
Tissue	  plasminogen	  activator	   4.46	  
Urokinase	   3.15	  
Tumour	  necrosis	  factor	  ligand	  superfamily,	  number	  10	   3.86	  
	  
+	  This	  gene’s	  average	  threshold	  cycle	  is	  relatively	  high	  (<30)	  in	  either	  the	  control	  or	  the	  test	  sample	  
and	  relatively	  low	  in	  the	  other	  sample	  (>30).	  These	  data	  mean	  that	  the	  gene’s	  expression	  is	  relatively	  
low	  in	  one	  sample	  and	  readily	  detected	  in	  the	  other	  sample	  suggesting	  that	  the	  actual	  fold	  change	  
value	  is	  at	  least	  as	  large	  as	  the	  calculated	  and	  reported	  fold	  change	  results.	  
	  
*	  This	  gene’s	  average	  threshold	  cycle	  is	  relatively	  high	  (>	  30),	  meaning	  that	  its	  relative	  expression	  
level	  is	  low,	  in	  both	  control	  and	  test	  samples.	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Interleukin	   6	   showed	   an	   eighteen-­‐fold	   decrease.	   Prostaglandin	   I	   (prostacyclin)	  
synthase	  and	  prostaglandin	  endoperoxidase	  (PG	  G/H	  synthase)	  showed	  a	  ten	  and	  six	  
fold	   decrease	   respectively.	   Vascular	   cell	   adhesion	  molecule	   1	   (VCAM-­‐1)	   showed	   a	  
fifty	  two-­‐fold	  decrease.	  VWF	  showed	  a	  six-­‐fold	  decrease.	  
	  
Table	  5.6	  Genes	  with	  decreased	  expression	  in	  IPAH	  BOECs	  compared	  to	  CTEPH	  
BOECs	  
	  
Decreased	  expression	   Fold	  Change	  
Arachidonate	  5-­‐lipoxygenase	   -­‐2.83*	  
Chemokine	  ligand	  2	  	   -­‐2.05	  
Thrombin	  receptor	  (F2	  receptor)	   -­‐2.80	  
Fibroblast	  growth	  factor	  2	  	   -­‐2.53	  
Fibronectin	  1	   -­‐2.26	  
Interleukin	  6	   -­‐18.54+	  
Integrin	  alpha	  V	  (CD51)	   -­‐3.05	  
KIT	   -­‐2.01*	  
Matrix	  metallopeptidase	  2	  	   -­‐9.44	  
Prostaglandin	  I2	  (prostacyclin)	  synthase	   -­‐10.01+	  
Prostaglandin	  endoperoxidase	  synthase	  2	  (PG	  G/H	  synthase	  
and	  cyclooxygenase)	  
-­‐5.80	  
Selectin	  E	   -­‐2.84+	  
Thrombospondin	  1	   -­‐2.16	  
Vascular	  cell	  adhesion	  molecule	  1	   -­‐52.06+	  
Von	  Willebrand	  factor	   -­‐6.16	  	  
+	  This	  gene’s	  average	  threshold	  cycle	  is	  relatively	  high	  (<30)	  in	  either	  the	  control	  or	  the	  test	  sample	  
and	  relatively	  low	  in	  the	  other	  sample	  (>30).	  These	  data	  mean	  that	  the	  gene’s	  expression	  is	  relatively	  
low	  in	  one	  sample	  and	  readily	  detected	  in	  the	  other	  sample	  suggesting	  that	  the	  actual	  fold	  change	  
value	  is	  at	  least	  as	  large	  as	  the	  calculated	  and	  reported	  fold	  change	  results.	  
	  
*	  This	  gene’s	  average	  threshold	  cycle	  is	  relatively	  high	  (>	  30),	  meaning	  that	  its	  relative	  expression	  
level	  is	  low,	  in	  both	  control	  and	  test	  samples.	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Figure	  5.3	  Comparison	  of	  gene	  expression	  in	  CTEPH	  and	  IPAH	  BOECs	  	  
Scatter	   plot	   of	   gene	   expression.	   Results	  were	   normalised	   to	   ACTB	   and	  GAPDH	   (automatic	  
selection).	  Group	  1	  is	  the	  CTEPH	  BOECs	  and	  Group	  2	  IPAH	  BOECs.	  Red	  circles	  show	  increased	  
expression	   and	   green	   circles	   decreased	   expression.	   The	   2	   outer	   lines	   represent	   a	   2-­‐fold	  
change	  in	  expression.	  	  
	  
The	  PCR	  arrays	   therefore	   gave	   some	   interesting	   results	   that	   suggested	   there	  were	  
differences	  in	  the	  gene	  expression	  between	  healthy	  controls	  and	  CTEPH	  BOECs.	  The	  
small	  number	  of	  all	   the	  samples,	  especially	  the	   IPAH	  may	  mean	  the	  results	  are	  not	  
representative,	  however	  many	  of	  the	  genes	  showing	  differences	  in	  expression	  have	  
already	  been	  shown	  to	  play	  a	  role	  in	  the	  pathogenesis	  of	  pulmonary	  hypertension.	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5.4 Summary	  of	  results	  	  
These	  experiments	  show	  that	  it	  is	  possible	  to	  grow	  BOEC	  cells	  from	  patients	  and	  to	  
obtain	  sufficient	  numbers	  to	  perform	  experiments.	  No	  difference	  in	  the	  isolation	  of	  
BOECS	   between	   healthy	   controls	   or	   CTEPH	   patients	   was	   seen.	   Overall,	   higher	  
numbers	   of	   BOECs	   were	   isolated	   from	   younger	   subjects/individuals.	   Within	   the	  
CTEPH	   group,	   better	   patient	   status	   as	   defined	   by	   the	   6-­‐minute	  walk	   distance	   and	  
WHO	   score	   was	   positively	   correlated	   with	   higher	   number	   of	   colonies	   per	  
mononuclear	  cells	  isolated.	  
	  
The	   functional	   assays	   showed	   no	   difference	   in	   thrombin	   generation	   on	   the	   cell	  
surface	   between	   the	   healthy	   controls	   and	   CTEPH	   BOECs	   irrespective	   of	   whether	  
exogenous	   TF	   or	   TNF-­‐α	   stimulation	  was	   used.	   Contrary	   to	  my	   original	   hypothesis,	  
triggering	  with	  5pM	  exogenous	  TF	  resulted	  in	  shortened	  lysis	  times	  on	  CTEPH	  BOECS	  
compared	   to	  healthy	  controls.	  No	   significant	  difference	  was	   seen	  between	  healthy	  
controls	   and	   CTEPH	   BOECs	   after	   TNF-­‐α	   stimulation,	   however	   the	   healthy	   control	  
group	   did	   show	   a	  much	   wider	   range	   of	   values.	   Use	   of	   BOECs	   from	   IPAH	   patients	  
resulted	  in	  there	  being	  no	  difference	  with	  exogenous	  TF,	  although	  this	  comparison	  is	  
limited	  by	  the	  small	  number	  of	  available	  IPAH	  samples.	  	  Interestingly,	  lysis	  times	  on	  
IPAH	  BOECs	  were	  significantly	  shorter	  than	  both	  healthy	  controls	  and	  CTEPH	  BOECS	  
following	  1.0nM	  TNF-­‐α	  stimulation.	  
	  
The	  PCR	  array	  data	  has	  shown	  there	  to	  be	  altered	  gene	  expression	  shown	  between	  
healthy	  control	  and	  CTEPH	  patients.	  Although	  only	  a	  very	  small	  group	  was	  available	  
for	  disease	  control,	   the	   IPAH	  PCR	  arrays	  showed	  differences	  between	  both	  healthy	  
control	  and	  CTEPH	  BOECs.	  The	  genes	  to	  be	  discussed	  in	  detail	  in	  the	  final	  chapter	  are	  
thrombomodulin,	   tPA,	  endothelin	   receptor	  A,	   fibroblast	   growth	   factor,	   fibronectin,	  
matrix	  metalloproteinases,	  vascular	  cell	  adhesion	  molecule	  1	   (VCAM-­‐1),	  KDR	  (VEGF	  
receptor	  2).	  Some	  of	  these	  have	  been	  selected	  based	  on	  their	  magnitude	  of	  change	  
of	  gene	  expression,	  others	  because	  of	  their	  previous	  implication	  in	  the	  pathogenesis	  
of	  pulmonary	  hypertension.	  Although	  the	  changes	  in	  gene	  expression	  between	  IPAH	  
and	   both	   healthy	   controls	   and	   CTEPH	   BOECs	   were	   more	   marked	   than	   changes	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between	  CTEPH	  and	  healthy	  controls,	  this	  is	  likely	  to	  be	  due	  to	  the	  small	  numbers	  of	  
IPAH	  samples.	  The	  significance	  of	  these	  results	  in	  relation	  to	  what	  is	  already	  known	  
about	  the	  pathogenesis	  of	  CTEPH	  will	  be	  discussed	  together	  with	  their	  relationship	  
to	  the	  original	  hypothesis	  and	  how/what	  further	  investigation	  may	  further	  elucidate	  
the	  pathogenic	  mechanisms	  in	  the	  final	  chapter.	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6 Discussion	  	  
CTEPH	   is	   a	   very	   rare	   disease	   that	   is	   thought	   to	   develop	   after	   an	   overt	   or	   occult	  
thromboembolic	   event.	   The	   pathogenesis	   of	   the	   disease	   is	   poorly	   understood	   but	  
failure	   of	   clot	   lysis	   and	   abnormal	   vascular	   remodelling	   are	   both	   thought	   to	   have	  
important	  roles.	  	  
6.1 Background	  	  	  
Up	  to	  75%	  of	  patients	  with	  CTEPH	  have	  a	  documented	  history	  of	  acute	  PE	  prior	   to	  
development	   of	   CTEPH	   [194]	   with	   evidence	   of	   persistent	   mismatched	   perfusion	  
defects.	  A	  study	  of	  320	  PE	  patients	  by	  Miniati	  et	  al	  showed	  that	   for	   those	  patients	  
who	   survived	   a	   year	   after	   PE	   there	   was	   almost	   complete	   resolution	   on	   perfusion	  
scan,	   whereas	   the	   four	   patients	   who	   subsequently	   developed	   CTEPH	   had	   large	  
persistent	   perfusion	   defects	   on	   sequential	   scans	   [191].	   Sanchez	   et	   al	   showed	   that	  
29%	   of	   PE	   patients	   had	   persistent	   perfusion	   defects	   at	   12	   months;	   age,	   initial	  
pulmonary	   vasculature	   obstruction,	   longer	   time	   between	   symptom	   onset	   and	  
diagnosis	  and	  previous	  VTE	  were	  shown	  to	  be	  independent	  predictors	  of	  persistent	  
defects	  [264].	  Interestingly,	  those	  with	  persistent	  defects	  were	  shown	  to	  have	  higher	  
systolic	   pulmonary	   artery	   pressure	   [264].	   These	   findings	   all	   suggest	   that	   failure	   to	  
lyse	   the	   embolic	   thrombus	  may	   be	   a	   pathogenic	   stage	   in	   the	   evolution	   of	   CTEPH.	  
Sporadic	  variants	  in	  fibrinogen	  causing	  abnormalities	  of	  fibrin	  polymer	  structure	  and	  
impaired	  lysis	  have	  been	  found	  in	  CTEPH	  patients,	  which	  further	  implicates	  impaired	  
clot	   lysis	   in	   pathogenesis	   [234,	   235].	   Finally,	   in	   a	   study	   of	   haemostatic	  
polymorphisms	  in	  CTEPH	  patients,	  the	  Aα	  T312A	  fibrinogen	  allele,	  which	  is	  known	  to	  
increase	  resistance	  to	  thrombolysis,	  was	  found	  at	  an	   increased	  frequency	   in	  CTEPH	  
compared	  to	  healthy	  controls	  (OR	  1.86).	  
	  
Previous	   studies	  of	   the	  plasma	   fibrinolytic	   system	   in	  CTEPH	  patients	  have	   failed	   to	  
demonstrate	  any	  specific	  abnormality	  that	  could	  explain	  failure	  of	  lysis.	  Welsh	  et	  al	  
found	  prolonged	  euglobulin	  clot	  lysis	  times	  and	  elevated	  PAI-­‐1	  levels	  in	  patients	  with	  
primary	   pulmonary	   hypertension	   as	   well	   as	   decreased	   fibrinolytic	   activity	   in	  
secondary	   pulmonary	   hypertension	   [237].	   Raised	   PAI-­‐1	   and	   tPA	   antigen	   levels	   in	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CTEPH	   patients	   were	   found	   by	   Olman	   et	   al	   [238],	   but	   there	   was	   no	   difference	   in	  
functional	   activity	   between	   age	   matched	   healthy	   controls	   and	   CTEPH	   patients.	   A	  
further	   study	   looking	   at	   tPA	   and	   PAI-­‐1	   antigen	   levels	   released	   by	   endothelial	   cells	  
extracted	   from	   PEA	  material	   showed	   no	   difference	   between	   controls	   or	   patients.	  
Thus	   there	   is	  no	  evidence	   that	  CTEPH	  patients	  have	  any	   consistent	  abnormality	  of	  
individual	  plasma	  components	  of	  the	  fibrinolytic	  system.	  	  
	  
It	  was	  hypothesised	  that	  defective	  global	  fibrinolysis	  on	  the	  surface	  of	  the	  pulmonary	  
endothelium	   resulting	   in	   failure	   to	   resolve	   the	   embolic	   thrombus	   determined	  
progression	  from	  PE	  to	  CTEPH.	   	  
6.2 BOEC	  characteristics	  and	  relation	  to	  phenotype	  
The	  study	  of	  patient	  endothelium	  is	  complicated	  by	  the	  difficulty	  in	  accessing	  tissue	  
for	  analysis.	   I	   therefore	  used	  a	   recently	  developed	   technique	   [102]	   to	  grow	  BOECs	  
from	  healthy	   controls	   and	  CTEPH	  patients	   as	   a	   surrogate	   population	   to	   assess	   the	  
role	   of	   the	   patients’	   endothelium	   in	   the	   disease	   process.	   These	   cells	   exhibit	  
numerous	   characteristics	   of	   EC	   and	   are	   thought	   to	   be	   a	   form	   of	   endothelial	  
progenitor	   cell	   but	   the	   definition	   of	   these	   cells	   is	   still	   a	   matter	   of	   debate.	   It	   is	  
important	   to	  consider	   the	  method	  of	  extraction	  and	  growth	  of	  cells	   to	  ensure	  that	  
comparisons	   are	   made	   between	   the	   same	   cell	   types:	   	   cells	   may	   be	   identified	   as	  
endothelial	  progenitor	  cells	  using	  flow	  cytometry	  or	  cell	  culture,	  or	  as	  cells	  extracted	  
from	  tissue	  samples	  during	  surgical	  procedures	  such	  as	  lung	  transplant	  or	  PEA.	  	  
	  
The	  method	  I	  used	  to	  identify	  endothelial	  progenitor	  cells	  was	  a	  cell	  culture	  method,	  
growing	   cells	   from	   the	   peripheral	   blood	   of	   patients	   and	   controls.	   These	   late	  
outgrowth	   cells	   show	   a	   high	   proliferation	   index,	   express	   endothelial	   markers	   and	  
form	   capillary	   like	   structures	   in	   vitro.	   They	   express	   CD34,	   105	   and	   KDR	   (VEGF	  
receptor)	   and	   are	   negative	   for	   CD33,	   14	   (a	   monocyte	   marker)	   and	   45	   (a	   pan	  
leucocyte	  marker).	  These	  characteristics	  are	  consistent	  with	  these	  cells	  representing	  
an	   endothelial	   progenitor	   cell.	   	   Notably,	   Toshner	   et	   al	   found	   an	   up-­‐regulation	   of	  
endothelial	  progenitor	  cell	  markers	   in	   remodelled	  arteries	  of	  PH,	   specifically	   in	   the	  
plexiform	  lesions	  [157].	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There	   is	   currently	   great	   interest	   in	   these	   cells	   as	   both	   a	   method	   for	   studying	  
endothelial	   function	   (in	   health	   and	   disease),	   as	   well	   as	   for	   treatment	   in	   various	  
conditions,	   including	   PH.	   However,	   what	   is	   considered	   to	   represent	   “normal”	   in	  
terms	  of	  isolation	  and	  the	  factors	  affecting	  isolation	  is	  not	  yet	  fully	  understood.	  	  
	  
I	   was	   able	   to	   grow	   cells	   from	   both	   healthy	   controls	   and	   CTEPH	   patients:	   no	  
difference	  was	  seen	  in	  the	  ease	  of	  isolation	  of	  these	  cells	  between	  groups.	  There	  was	  
however	  a	  correlation	  with	  age,	  with	   increasing	  age	  resulting	   in	  fewer	  colonies	  per	  
mononuclear	   cells	   isolated.	   	  Within	   the	  CTEPH	  group	   there	  was	   a	   correlation	  with	  
functional	  status,	  with	  better	  functional	  status	  (assessed	  by	  6	  minute	  walk	  distance	  
and	  WHO	  classification)	  being	  associated	  with	  more	  colonies	  per	  mononuclear	   cell	  
isolated.	  Diller	  et	  al	  showed	  a	  similar	  correlation	  with	  functional	  status	  in	  both	  IPAH	  
and	   Eisenmenger	   syndrome	   patients	   [155].	   	   By	   contrast,	   they	   found	   decreased	  
numbers	  of	  cells	  in	  the	  patients	  compared	  to	  controls	  whereas	  I	  did	  not.	  Moreover,	  
their	   principal	   assessment	   of	   cell	   numbers	   was	   by	   flow	   cytometry.	   In	   the	  
Eisenmenger	   group	   the	   capacity	   of	   peripheral	   blood	   mononuclear	   cells	   to	   form	  
colonies	  was	  also	  reduced	  using	  the	  CFU	  or	  early	  cell	  method.	  Therefore	  although	  a	  
correlation	  of	  endothelial	  cell	  numbers	  with	  functional	  status	  was	  seen	  in	  the	  study	  
by	   Diller	   et	   al	   [155],	   different	   methods	   were	   used	   to	   identify	   EPCs	   and	   it	   is	   now	  
understood	   that	   these	   are	   not	   the	   same	   cells	   as	   the	   BOECs	   used	   in	  my	   research.	  
Rehman	  et	  al	  reported	  that	  exercise	  can	  increase	  the	  number	  of	  EPCs	  isolated	  from	  
peripheral	  blood	  [105].	  However	  this	  study	  looked	  at	  CACs	  rather	  than	  BOECs	  (ECFC).	  	  
Nonetheless,	   these	   cells	   are	   closely	   related	   and	   it	   is	   possible	   that	   similar	   effects	  
would	  be	  seen	  with	  BOECs.	  
	  
Interestingly	   I	   found	  no	  correlation	  with	  the	  cardiac	  catheter	  results,	  an	  alternative	  
measure	   of	   disease	   severity.	   I	   used	   the	   cardiac	   catheter	   results	   from	   the	   time	   of	  
diagnosis	  and	  therefore	  the	  addition	  of	  disease	  modifying	  treatment	  e.g.	  endothelin	  
type	   1	   receptor	   antagonists,	   may	   have	   subsequently	   improved	   the	   patients’	  
functional	   status	   and	   thus	   masked	   any	   relationship.	   It	   may	   also	   suggest	   that	   the	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treatment	  has	  an	  effect	  on	  the	  endothelial	  cells.	  Diller	  et	  al	  also	  found	  a	  correlation	  
with	  catheter	  results	  in	  keeping	  with	  the	  functional	  status	  [155].	  	  
BOECs	  isolated	  from	  IPAH	  patients	  have	  been	  shown	  to	  be	  more	  angiogenic	  (using	  a	  
matrigel	  assay)	  and	  resistant	  to	  apoptosis	  (caspase	  3/7	  assay)	  than	  normal	  controls	  
(unpublished	   data	   from	   a	   parallel	   project	   in	   the	   department).	   It	  would	   have	   been	  
interesting	  to	  do	  formal	  proliferation	  and	  angiogenesis	  assays	  on	  the	  CTEPH	  cells	  to	  
establish	  if	  this	  difference	  was	  also	  present	  in	  CTEPH	  patients.	  	  
6.3 Assays	  of	  thrombin	  generation	  and	  clot	  lysis	  on	  HUVECs	  	  
The	   functional	   assays,	   thrombin	   generation	   and	   lysis	   assays,	   were	   established	   in	  
plasma	  and	  then	  on	  HUVECs	  prior	  to	  using	  them	  to	  assess	  the	  function	  of	  the	  BOECs.	  
The	  thrombin	  generation	  assay	  showed	  no	  difference	  when	  exogenous	  TF	  was	  used	  
on	  HUVECs	  compared	  to	  plasma	  alone	  suggesting	  that	  the	  HUVECs	  did	  not	  affect	  the	  
thrombin	   generation	   of	   plasma	   in	   this	   assay.	   When	   the	   HUVECs	   were	   stimulated	  
with	   TNF-­‐α,	   tissue	   factor	   expression	   was	   induced	   and	   thrombin	   generation	   was	  
seen.	  Interestingly	  a	  plateau	  effect	  was	  seen	  in	  all	  thrombin	  generation	  parameters	  
at	  0.5nM	  TNF-­‐α.	  This	  might	  be	  because	  the	  HUVECs	  are	  only	  able	  to	  produce	  a	  finite	  
amount	   of	   TF	   to	   drive	   thrombin	   generation	   during	   the	   5-­‐hour	   incubation	   period.	  
However,	   TNF-­‐α	   is	   known	   to	   have	   many	   effects	   on	   endothelial	   cell	   mRNA	   and	  
protein	  expression	  that	  might	  also	  limit	  thrombin	  generation.	  It	  has	  been	  shown	  to	  
affect	  many	  different	  pathways	   including	  vascular	  remodelling	  (MMPs),	  endothelial	  
apoptosis	   (caspases),	   vascular	   inflammation	   and	   cell	   infiltration	   (MCP-­‐1,	   VCAM,	  
ICAM,	  IL6,	  IL8)	  and	  oxidative	  stress	  (NADPH	  oxidase).	  With	  regard	  to	  the	  coagulation	  
and	  fibrinolysis	  pathways,	  it	  is	  known	  that	  TNF-­‐α	  causes	  TF	  expression	  in	  vitro	  (and	  
probably	   in	   vivo)	   [265]	   but	   Nan	   et	   al	   also	   demonstrated	   that	   TNF-­‐α	   treated	   cells	  
showed	  a	  97%	  decrease	  in	  thrombomodulin	  mRNA	  after	  only	  6	  hours	  exposure	  and	  
there	   was	   a	   corresponding	   decrease	   in	   TM	   protein	   expression	   [266].	   TNF-­‐α	   also	  
causes	   a	   decrease	   in	   EPCR	  mRNA	   and	   protein	   expression.	  However	   these	   changes	  
are	  expected	  to	  increase	  the	  likelihood	  and	  quantity	  of	  thrombin	  generation	  on	  the	  
cell	  surface	  after	  exposure	  to	  TNF-­‐α	  rather	  than	  limiting	  it.	  The	  plateau	  in	  response	  is	  
therefore	  most	  likely	  to	  represent	  maximal	  TF	  expression	  and	  its	   localisation	  to	  the	  
cell	  surface.	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A	   study	   by	   Ensley	   et	   al	   on	   endothelial	   outgrowth	   cells	   showed	   the	   importance	   of	  
shear	   stress	   in	   regulating	   haemostatic	   factors.	   Increased	   TM,	   TFPI	   and	   eNOS	   gene	  
and	   protein	   expression	  was	   demonstrated	   as	  well	   as	   increased	   APC	   activity	   [267].	  
This	   demonstrates	   the	   importance	   of	   considering	   flow	   as	   well	   as	   inflammatory	  
stimulation	  when	   studying	   the	   function	   of	   endothelial	   cells	   as	   the	   effects	  may	   be	  
opposing	  eg	  TNF-­‐α	  decreases	  TM,	  yet	  shear	  stress	  increases	  TM.	  This	  is	  an	  important	  
parameter	  to	  consider	  in	  future	  studies.	  	  
	  
In	   contrast	   to	   thrombin	   generation,	   unstimulated	   HUVECs	   were	   able	   to	  modulate	  
lysis	  times,	  which	  were	  shown	  to	  be	  longer	  on	  the	  cells	  than	  in	  plasma	  alone.	  	  Clearly	  
this	   did	   not	   result	   from	   any	   difference	   in	   the	   parameters	   of	   thrombin	   generation.	  
Studies	   have	   shown	   that	   the	   addition	   of	   soluble	   TM	   prolongs	   the	   lysis	   time	   in	   a	  
plasma	   model	   through	   the	   resulting	   increased	   activation	   of	   TAFI	   [43,	   83,	   256].	  
Endothelial	  cells	  constitutively	  express	  TM	  and	  it	  is	  likely	  that	  this	  is	  responsible	  for	  
the	  prolongation	  of	  the	  lysis	  time,	  although	  release	  of	  PAI-­‐1	  from	  the	  cells	  is	  another	  
potential	  contributory	  factor.	   	   In	  future	  studies,	  this	  effect	  could	  be	  studied	  further	  
with	  the	  use	  of	  a	  blocking	  TM	  antibody.	  The	  presence	  of	  plasminogen	  receptors	  on	  
the	  cells	  may	  also	  affect	  the	  lysis	  time,	  although	  this	  would	  be	  expected	  to	  shorten	  
lysis	  time,	  as	  more	  plasminogen	  would	  be	  activated	  to	  plasmin.	  
	  
The	  effect	  of	  prolongation	  of	   lysis	  time	  by	  HUVEC	  is	  more	  marked	  at	   lower	  TF	  (and	  
therefore	   lower	   thrombin)	   concentrations.	   It	   is	   known	   that	   TAFI	   activation	   has	   2	  
distinct	  pathways:	  at	  low	  thrombin	  it	  is	  TM	  dependent,	  whereas	  at	  high	  thrombin	  it	  
is	   TM	   independent.	   Therefore	   at	   the	   lower	   TF	   concentrations	   the	   TM	   has	   a	  more	  
important	   role	   in	   inhibiting	   lysis,	   which	   is	   consistent	   with	   the	   more	   marked	  
prolongation	  of	   the	   lysis	   time	  at	  1pm	  TF	  on	  HUVECs	  compared	  to	  plasma	  than	  the	  
difference	  seen	  at	  5pM	  TF.	  	  
	  
On	   TNF-­‐α	   stimulated	   HUVECs	   a	   dose	   response	   was	   seen	   with	   increasing	   TNF-­‐α	  
resulting	   in	  a	   longer	   lysis	   time.	  TNF-­‐α	   increases	   thrombin	  generation	  and	  prolongs	  
lysis	   time,	   which	   is	   consistent	   with	   an	   effect	   mediated	   via	   TM-­‐dependent	   TAFI	  
activation,	   which	   must	   therefore	   outweigh	   any	   decrease	   in	   TM	   expression.	   No	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difference	  was	  seen	   in	   the	   lysis	   time	  between	  cells	   stimulated	  with	  0.1	  and	  1.0nM	  
TNF-­‐α,	  again	  demonstrating	  a	  plateau	  effect.	  The	  lysis	  time	  on	  stimulated	  cells	  was	  
longer	  than	  in	  plasma	  alone	  and	  similar	  to	  the	  lysis	  times	  on	  unstimulated	  cells	  with	  
exogenous	  TF.	  	  
6.4 Assays	  of	  thrombin	  generation	  and	  clot	  lysis	  on	  BOECs	  
No	  difference	   in	  peak	   thrombin	  generated	  was	   seen	  between	  BOECs	   from	  healthy	  
controls	   and	   from	  CTEPH	  patients	  with	   either	   exogenous	   TF	   or	   TNF-­‐α	   stimulation.	  
There	   did	   appear	   to	   be	   a	   trend	   towards	   lower	   thrombin	   generation	   on	   BOECs	  
compared	  to	  HUVECs	  with	  TNF-­‐α	  stimulation.	  	  
	  
Contrary	   to	   my	   original	   hypothesis	   lysis	   times	   were	   shorter	   on	   CTEPH	   BOECs	  
compared	  to	  healthy	  controls	  with	  5pM	  exogenous	  TF.	  No	  significant	  difference	  was	  
seen	   after	   TNF-­‐α	   stimulation.	   There	   are	   many	   possible	   explanations	   for	   this	  
apparently	   paradoxical	   shorter	   lysis	   time	   in	   the	   absence	   of	   any	   difference	   in	  
thrombin	  generation.	  One	  must	  first	  determine	  whether	  the	  difference	  is	  genuine	  or	  
artefactual.	  The	  numbers	  are	  only	  small	  and	  a	  small	  sample	  is	  more	  likely	  to	  deviate	  
from	  the	  true	  mean.	  The	  assay	  may	  not	  be	  the	  optimal	  method	  to	  assess	  lysis	  on	  the	  
cell	  surface,	  although	  it	  has	  been	  widely	  used	  in	  the	  literature	  to	  study	  the	  effects	  of	  
cells	   on	   clot	   structure	   and	   is	   sensitive	   to	   changes	   in	   TF	   and	   TNF-­‐α	   stimulation.	   In	  
addition,	   exogenous	   tPA	   was	   used	   rather	   than	   relying	   on	   tPA	   from	   the	   cells	   and	  
plasma	  which	  may	  therefore	  mask	  the	  actual	  cell	  phenotype.	  	  
	  
Secondly,	   it	   is	   possible	   that	   the	   patient	   cells	   express	   more	   TM	   or	   plasminogen	  
receptors	  than	  controls.	   Increased	  TM	  expression	   is	  known	  to	  have	  more	  effect	  on	  
the	   APC	   pathway	   than	   TAFI	   [83].	   It	   has	   been	   shown	   that	   higher	   levels	   of	   TM	   can	  
shorten	  the	  lysis	  time	  (through	  effect	  on	  APC	  and	  therefore	  thrombin	  generation)	  in	  
plasma	  and	  endothelial	  cell	  studies	  [83].	  However,	  if	  increased	  TM	  expression	  were	  
responsible	  for	  the	  difference	  in	  lysis	  it	  should	  also	  produce	  a	  difference	  in	  thrombin	  
generation,	  which	   is	   not	   seen.	   It	   therefore	   seems	  more	   plausible	   that	   the	   shorter	  
lysis	  time	  results	  from	  increased	  plasmin	  generation.	  Although	  an	  increase	  in	  plasmin	  
appears	  to	  be	  counter	  to	  the	  original	  hypothesis,	  it	  is	  important	  to	  note	  that	  plasmin	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has	  many	  important	  roles	  beyond	  fibrinolysis,	  some	  of	  which	  could	  play	  a	  role	  in	  the	  
pathogenesis	  of	  CTPEH.	  For	  example,	  plasmin	  assists	   in	  permitting	  endothelial	  cells	  
to	  migrate	  through	  the	  basement	  membrane	  enabling	  their	  organisation	  into	  tubular	  
structures.	  Increased	  uPA	  and	  UPAR	  have	  been	  found	  on	  late	  outgrowth	  endothelial	  
cells	  [268],	  which	  may	  suggest	  a	  role	  for	  plasmin	  in	  angiogenesis.	  Plasmin	  also	  has	  a	  
role	   in	  activating	  matrix	  metalloproteases,	  which	  are	  believed	  to	  have	  a	  role	   in	  the	  
pathogenesis	  of	  PH.	  	  Finally,	  plasmin	  also	  activates	  TGF-­‐β,	  which	  has	  been	  implicated	  
in	  the	  pathogenesis	  of	  PH	  via	  stimulation	  of	  abnormal	  proliferation	  and	  remodelling.	  
Interestingly,	  increased	  TGF-­‐β	  results	  in	  PAI-­‐1	  expression,	  which	  although	  it	  may	  act	  
to	  inhibit	  plasmin,	  has	  also	  been	  shown	  to	  have	  many	  other	  roles	  in	  disease	  including	  
scarring,	  fibrosis	  and	  inflammation	  [269].	  Thus	  the	  observed	  shortening	  of	  lysis	  times	  
may	   be	   an	   epiphenomenon	   reflecting	   increased	   plasmin	   generation,	   which	  
contributes	  to	  the	  development	  of	  CTEPH	  via	  other	  pathways.	  It	  would	  therefore	  be	  
important	   to	   measure	   plasmin	   generation	   and	   determine	   its	   effects	   on	   cell	  
behaviour	  in	  more	  detail	  in	  future	  studies.	  
	  
Thirdly,	   it	   is	   not	   known	   if	   the	   endothelial	   cells	   from	   the	   patients	   had	   been	  
“conditioned”	   by	   the	   environment	   within	   the	   patients.	   For	   example,	   a	   change	   in	  
gene	  expression	  may	  have	  been	  provoked	  by	  the	  presence	  of	  multiple	  clots,	  making	  
the	  cells	  more	  fibrinolytic	  or	  chronic	  inflammatory	  stimulation	  may	  have	  affected	  the	  
cell	   phenotype	   by,	   say,	   altering	   TM	   expression.	   	   In	   a	   study	   of	   chronic	   exposure	   of	  
pulmonary	  smooth	  muscle	  and	  endothelial	  cells	  to	  fibrin	  and	  fibrinogen,	  differential	  
regulation	   of	   intracellular	   calcium	   and	   augmentation	   of	   smooth	   muscle	   cell	  
proliferation	   was	   found	   [230].	   Thus	   the	   cells	   may	   reflect	   the	   presence	   of	   CTEPH	  
rather	  than	  representing	  the	  cell	  phenotype	  that	  led	  to	  its	  development.	  The	  ability	  
of	  induced	  changes	  to	  persist	  after	  isolation	  and	  culture	  is	  not	  known.	  	  
	  
Fourthly,	  the	  effect	  of	  drugs	  on	  these	  cells	  is	  not	  known.	  All	  but	  two	  of	  the	  patients	  
were	   receiving	   disease	   specific	   medications	   (Endothelin	   receptor	   antagonists	   or	  
PD5E	   antagonists).	   All	   the	   patients	   were	   taking	   warfarin,	   a	   vitamin	   K	   antagonist.	  
These	  drugs	  may	  have	  affected	  gene	  expression	  and/or	  protein	  levels	  to	  alter	  the	  cell	  
phenotype	   detected	   during	   these	   experiments.	   	   Alternatively,	   these	   medications	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may	  mobilise	   a	   specific	   subgroup	   of	   endothelial	   cells.	   In	   pulmonary	   hypertension,	  
warfarin	   is	   used	   as	   an	   anticoagulant	   to	   inhibit	   vitamin	   K	   epoxide	   reductase,	   the	  
enzyme	   that	   recycles	   oxidised	   vitamin	   K1.	   Vitamin	   K1	   is	   a	   vital	   cofactor	   in	   the	  
carboxylation	  of	  glutamic	  acid	   residues	  on	   factors	   II,	  VII,	   IX	  and	  X.	  Other	  vitamin	  K	  
dependent	   proteins	   include	   Matrix	   Gla	   protein	   (MGP)	   and	   growth	   arrest	   specific	  
gene	   6	   (Gas-­‐6).	   It	   has	   been	   shown	   in	   vitro	   and	   in	   animal	   models	   that	   warfarin	  
prevents	  the	  activation	  of	  MGP	  and	  Gas-­‐6	  resulting	  in	  increased	  arterial	  calcification	  
[270].	  Although	  these	  proteins	  are	  active	  in	  vascular	  smooth	  muscle	  cells	  to	  prevent	  
vascular	  calcification	  and	  smooth	  muscle	  cell	  apoptosis,	  there	  may	  be	  other	  vitamin	  
K	  dependent	  proteins	   that	  play	  a	   role	   in	   the	  pathogenesis	  of	  CTEPH.	  On	   the	  other	  
hand	  these	  cells	  have	  been	  in	  culture	  for	  approximately	  6-­‐8	  weeks	  by	  the	  time	  the	  
experiments	  are	  performed	  so	   it	   seems	  more	   likely	   that	  any	  drug	  effects	  will	  have	  
been	  “washed	  out”.	  
6.5 Comparisons	  between	  CTEPH	  and	  IPAH	  cells	  
BOECs	   from	   patients	   with	   IPAH	   were	   studied	   as	   a	   disease	   control.	   Only	   a	   small	  
number	  of	  IPAH	  patients	  were	  used	  because	  the	  cells	  were	  a	  gift	  from	  another	  group	  
performing	   experiments	   on	  BOECs.	   The	   small	   number	   of	   IPAH	   cells	  may	   therefore	  
limit	   the	   certainty	   of	   these	   conclusions.	   No	   significant	   difference	   was	   seen	   in	  
thrombin	  generation	  with	  exogenous	  TF	  between	  healthy	  control	  and	  CTEPH	  BOECs	  
(although	   there	   was	   a	   trend	   to	   lower	   peaks	   with	   IPAH).	   With	   exogenous	   TF	   no	  
difference	  in	   lysis	  time	  was	  seen	  between	  IPAH	  and	  either	  controls	  or	  CTEPH.	  With	  
TNF-­‐α	   stimulation	   at	   1.0nM,	   lysis	   times	   were	   significantly	   shorter	   on	   IPAH	   BOECs	  
compared	  to	  both	  healthy	  controls	  and	  CTEPH	  BOECs.	  	  Three	  out	  of	  four	  of	  the	  IPAH	  
patients	   were	   on	   the	   same	   medications	   as	   the	   CTEPH	   patients	   (warfarin	   plus	   a	  
disease	  specific	  medication)	  and	  therefore	  the	  effect	  seen	  with	  shorter	  lysis	  time	  on	  
stimulated	  cells	  may	  be	  a	  drug	  effect	  or	  may	  be	  intrinsic	  to	  the	  cells.	  	  
	  
To	   investigate	   this	   further	   it	   would	   be	   interesting	   to	   grow	   endothelial	   cells	   (both	  
HUVECs	  and	  BOECs)	   in	   the	  presence	  of	   the	  drugs	   (endothelin	   receptor	  antagonists	  
e.g.	  Bosentan,	  PD5E	  antagonists	  e.g.	  sildenafil	  and	  warfarin)	  and	  study	  their	  effect	  on	  
thrombin	  generation	  and	  lysis	  time	  on	  the	  cells.	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It	  would	  have	  been	  interesting	  to	  perform	  studies	  using	  the	  patients’	  own	  plasma	  in	  
parallel	   to	   the	   cell	   experiments,	   however	   as	   all	   the	   patients	   were	   anticoagulated	  
with	  warfarin	  this	  was	  not	  possible.	  Measurement	  of	  tPA,	  plasmin	  and	  PAI-­‐1	  levels	  in	  
the	  plasma	  may	  have	  added	  additional	  information	  and	  could	  have	  been	  correlated	  
with	  the	  cellular	  findings.	  
6.6 Gene	  expression	  analyses	  of	  BOECs	  
The	   analysis	   of	   the	   results	   from	   the	   CAT	   and	   lysis	   assays	   on	   the	  BOECs	   led	   to	   the	  
unexpected	   finding	   of	   shorter	   lysis	   times	   on	   cells	   from	   CTEPH	   and	   IPAH	   patients,	  
which	  showed	  no	  correlation	  with	   the	  amount	  of	   thrombin	  produced.	  This	   implied	  
that	   the	  difference	  was	  generated	  by	   some	  property	  of	   the	   cells	   and	  a	  method	   to	  
analyse	  the	  cells	  was	  therefore	  required	  to	  identify	  a	  molecular	  explanation	  for	  this	  
difference.	  PCR	  array	  analysis	  of	  the	  BOEC	  samples	  obtained	  was	  used	  as	  a	  discovery	  
cohort	   to	   establish	   if	   any	   patterns	   of	   gene	   expression	   were	   present	   which	   could	  
guide	  further	  investigational	  work.	  I	  used	  a	  standard	  measure	  of	  significance	  (using	  a	  
student	  t-­‐test)	  and	  an	  arbitrary	  minimum	  2-­‐fold	  change	  for	  the	  comparisons	  of	  gene	  
expression.	  As	  this	  was	  a	  discovery	  cohort,	  with	  multiple	  comparisons	   it	   is	  possible	  
that	   the	   changes	   seen	   may	   be	   due	   to	   chance	   alone.	   A	   confirmatory	   cohort	   will	  
therefore	   be	   required	   to	   confirm	   these	   findings.	   Nonetheless,	   it	   is	   valuable	   to	  
compare	  the	  gene	  expression	  results	   from	  healthy	  controls	  with	  those	  from	  CTEPH	  
and	   consider	   the	   plausibility	   of	   genes	   showing	   significant	   changes	   as	   candidate	  
disease-­‐causing	  genes	  in	  light	  of	  their	  known	  functions.	  	  	  
	  
In	  the	  comparison	  of	  CTEPH	  with	  healthy	  control	  BOECs,	  nine	  genes	  showed	  at	  least	  
a	   2-­‐fold	   up-­‐regulation	   and	   two	   showed	   statistically	   significant	   up-­‐regulation:	  
Fibroblast	   growth	   factor	   2	   and	   fibronectin.	  However	   the	   other	   genes	   that	   showed	  
between	  a	  2	  and	  4	  fold	  change	  were	  also	  of	   interest	  because	  many	  of	  the	  proteins	  
have	  been	  implicated	  in	  the	  pathogenesis	  of	  PH.	  Three	  genes	  were	  down-­‐regulated	  
with	  KDR	   (or	  VEGF	  receptor	  2)	   showing	  a	  statistical	   significant	  decrease.	   I	  will	  deal	  
with	   those	  genes	   showing	  a	   statistically	   significant	  difference	  as	  well	   as	   those	   that	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have	  previously	  been	  implicated	  in	  the	  pathogenesis	  of	  PH	  below	  (see	  Table	  6.1	  for	  a	  
summary	  of	  the	  genes	  showing	  altered	  expression).	  	  
	  
Table	  6.1	  Gene	  expression	  in	  CTEPH	  BOECs	  compared	  to	  healthy	  control	  BOECs	  
Increased	  expression	   Decreased	  expression	  
Arachidonate	  5-­‐lipoxygenase	   Heme	  oxygenase	  1	  
Endothelin	  receptor	  type	  A	   Interleukin	  1β	  
Fibroblast	  Growth	  Factor	  2	  *	   VEGF	  receptor	  2	  (KDR)*	  
Fibronectin	  1*	   	  
Matrix	  metallopeptidase	  2	   	  
Matrix	  metallopeptidase	  9	   	  
Tissue	  plasminogen	  activator	   	  
Thrombomodulin	   	  
Vascular	  cell	  adhesion	  molecule	  1	   	  
	  
*	  p	  ≤0.05	  for	  difference	  
	  
	  
1. Fibroblast	   growth	   factor	   2	   (or	   basic	   FGF)	   showed	   significantly	   increased	  
expression	  in	  the	  CTEPH	  BOECs	  in	  the	  PCR	  array	  compared	  to	  healthy	  control	  
BOECs.	  FGF-­‐2	  has	  been	  shown	  to	  be	  increased	  in	  both	  the	  plasma	  and	  urine	  
of	   patients	   with	   PH	   [144].	   	   It	   has	   also	   been	   demonstrated	   that	   FGF-­‐2	   is	  
markedly	   overproduced	   by	   pulmonary	   endothelial	   cells	   in	   IPAH	   and	  
contributes	  to	  the	  observed	  smooth	  muscle	  cell	  hyperplasia.	  A	  recent	  study	  
by	   Tu	   et	   al	   found	   increased	   FGF-­‐2	   expression	   in	   cultured	   pulmonary	  
endothelial	   cells	   and	   suggested	   that	   excessive	   autocrine	   release	   of	  
endothelial-­‐derived	   FGF-­‐2	   contributes	   to	   the	   abnormal	   endothelial	   cell	  
phenotype	  which	  results	   in	  enhanced	  proliferation	  and	  decreased	  apoptosis	  
[271].	   This	   effect	   is	   mediated	   via	   activation	   of	   ERK1/2.	   FGF-­‐2	   is	   also	   a	  
substrate	   for	  Neprilysin,	   a	   cell	   surface	  metallopeptidase,	  which	   cleaves	   and	  
inactivates	   vasoactive	   and	   proinflammatory	   mediators.	   In	   Neprilysin	  
knockout	  mice	  an	  exaggerated	  remodelling	  occurs	  in	  mouse	  models	  of	  PH	  in	  
response	  to	  hypoxia	  with	  an	   increase	   in	  Src	  kinase	  activity	  and	  activation	  of	  
platelet	  derived	  growth	  factor	  receptor	  [272].	  This	  study	  also	  found	  that	  FGF-­‐
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2	  (or	  endothelin	  1)	  increased	  activation	  of	  Src	  and	  PDGFR	  in	  a	  similar	  manner.	  
Therefore	   increased	   FGF-­‐2	  may	   result	   in	   increased	   Src	   and	   PDGFR	   activity,	  
which	  in	  turn	  leads	  to	  the	  abnormal	  smooth	  muscle	  cell	  phenotype	  in	  PH.	  It	  
has	   also	   been	   shown	   that	   FGF-­‐2	   may	   act	   via	   NFkB	   in	   a	   signalling	   cascade	  
involving	  PAI-­‐1	  and	  MCP-­‐1,	  resulting	   in	  FGF2-­‐induced	   inflammation	  (studied	  
in	  a	  rat	  model	  of	  PH)	  [273].	  	  
Hosokawa	  et	  al	  demonstrated	   that	   inhibition	  of	  NFkB	   led	   to	   lower	   levels	  of	  
FGF-­‐2,	  PAI-­‐1	  and	  tPA	  at	  the	  mRNA	  level	  [273].	  They	  also	  showed	  that	  FGF-­‐2	  
stimulated	   cells	   produced	  more	   PAI-­‐1	   (protein	   expression).	   PAI-­‐1	   has	   been	  
shown	   to	   have	   a	   direct	   effect	   on	   the	   proliferation	   of	   pulmonary	   artery	  
smooth	   muscle	   cells,	   but	   it	   also	   in	   may	   also	   play	   a	   role	   in	   decreasing	  
fibrinolysis	  by	  [274,	  275]	  inhibiting	  plasmin	  generation.	  Although	  an	  increase	  
in	  PAI-­‐1	  does	  not	  fit	  with	  the	  shorter	  lysis	  time	  found	  in	  this	  study,	  it	  does	  fit	  
with	   the	   finding	   that	   thrombosis	   is	  present	   in	  almost	  all	   types	  of	  PH	  and	   is	  
thought	  to	  contribute	  to	  the	  pathogenesis.	  	  The	  increase	  in	  FGF-­‐2	  mRNA	  seen	  
in	  the	  array	  was	  therefore	  consistent	  with	  previous	  findings	  in	  PH.	  
	  
2.	   An	   increase	   in	   fibronectin	   gene	   expression	   was	   seen	   in	   CTEPH	   BOECs	  
compared	   to	   healthy	   controls.	   Fibronectin	   binds	   extracellular	   matrix	  
components	  such	  as	  collagen	  and	  fibrin.	  It	  plays	  a	  major	  role	  in	  cell	  adhesion,	  
growth	   and	   migration	   and	   wound	   healing	   [276,	   277].	   Altered	   levels	   of	  
fibronectin	  or	  alterations	  in	  its	  structure	  have	  been	  suggested	  to	  play	  a	  role	  in	  
abnormal	   wound	   healing	   and	   fibrosis.	   Fibronectin	   has	   been	   found	   within	  
plexiform	   lesions	   and	   interestingly	   a	   recent	   study	   showed	   increased	  
serotonylated	  fibronectin	  in	  PH	  patients	  [278].	  Posttranslational	  modification	  
of	   fibronectin	   by	   tissue	   transglutaminase	   to	   form	   serotonylated	   fibronectin	  
stimulates	   proliferation	   and	   migration	   of	   pulmonary	   smooth	   muscle	   cells.	  
5HT	  (serotonin)	  is	  believed	  to	  play	  a	  role	  in	  the	  pathogenesis	  of	  PH	  and	  this	  is	  
thought	   to	  be	  one	  of	   the	  plausible	  mechanisms.	  The	   increase	   in	   fibronectin	  
mRNA	  is	  therefore	  consistent	  with	  current	  pathogenesis	  models	  in	  PH.	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3. Endothelin	   receptor	   A	   showed	   increased	   expression	   in	   CTEPH	   BOECs	  
compared	   to	  healthy	   controls.	   ET-­‐1	   levels	   are	   known	   to	  be	   increased	   in	  PH	  
[139,	  140,	  279]	  and	  use	  of	  endothelin	  receptor	  antagonists	   is	  central	   to	  the	  
treatment	  for	  both	  CTEPH	  and	  other	  types	  of	  PH,	  but	  the	  cause	  for	  the	  high	  
ET-­‐1	  in	  PH	  is	  not	  clear.	  Star	  et	  al	  [280]	  demonstrated	  that	  BMPR-­‐2	  knockdown	  
in	  pulmonary	  microvascular	  cells	   	  causes	  high	  ET-­‐1	   levels.	  The	  study	  did	  not	  
look	   at	   ET	   receptor	   A,	   but	   ET	   receptor	   B	   levels	   were	   not	   affected.	   This	  
increase	   in	  gene	  expression	  could	  be	  a	  contributory	  cause	  of	  the	  disease	  by	  
enhancing	   the	   response	  of	   pulmonary	   EC	   to	   lower	   levels	   of	   ET-­‐1	   but	  might	  
also	  be	   a	   consequence	  of	   the	  drug	   therapy	  with	   ET-­‐1	   receptor	   antagonists.	  
Interestingly,	   increased	  ET	   receptor	  A	  was	  detected	   immunohistochemically	  
in	  the	  myocardium	  of	  patients	  with	  right	  ventricular	  hypertrophy,	  as	  well	  as	  
increased	  ET-­‐1	  levels	  [281].	  It	  is	  important	  to	  remember	  that	  the	  small	  vessel	  
disease	   seen	   in	   CTEPH	   is	   almost	   identical	   to	   IPAH	   and	   therefore	   their	  
pathogenesis	  overlaps.	  
	  
4. Matrix	  metalloproteinase	   (MMP)	   2	   and	   9	   were	   increased	   in	   CTEPH	   BOECs.	  
MMPs	  are	  important	  in	  the	  degradation	  of	  the	  extracellular	  matrix	  including	  
collagen	   and	   fibronectin	   during	   normal	   remodelling	   and	   repair.	   They	   also	  
have	  a	  role	  in	  migration	  and	  proliferation	  of	  endothelial	  and	  smooth	  muscle	  
cells	   [282].	   Excess	   or	   inappropriate	   MMP	   secretion	   may	   contribute	   to	   the	  
pathogenesis	   of	   tissue	   destructive	   processes	   in	   a	   wide	   variety	   of	   diseases.	  
MMP	  2	  and	  9,	  produced	  by	  endothelial	  cells	  and	  fibroblasts	  [283],	  	  are	  felt	  to	  
be	   important	   in	   thrombus	   breakdown	   and	   have	   also	   been	   associated	   with	  
other	   lung	   diseases	   including	   a	   destructive	   effect	   on	   the	   basement	  
membrane	   in	   alveolar	   remodelling	   [284].	   MMP	   2	   has	   been	   found	   in	  
endothelial	   cells	   and	   to	   a	   lesser	   extent	   in	   myofibroblasts	   in	   the	   plexiform	  
lesion	  of	  PH	  [285].	   In	  experimental	  PH	  models,	  an	  imbalance	  in	  MMP/tissue	  
inhibitor	  of	  metalloproteinase	  (TIMP)	  has	  been	  shown	  and	  a	  further	  study	  of	  
tissue	   collected	   at	   the	   time	   of	   lung	   transplant	   in	   PH	   patients	   showed	  
increased	  levels	  of	  MMP	  2,	  which	  the	  authors	  hypothesised,	  might	  contribute	  
to	  abnormal	  smooth	  muscle	  cell	  proliferation	  [148].	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It	  has	  been	  shown	  that	  the	  resting	  state	  endothelial	  cells	  express	  MMP	  2	  but	  
not	   MMP	   9	   but	   that	   MMP	   9	   expression	   is	   induced	   after	   stimulation	   by	  
proangiogenic	   or	   proinflammatory	   factors.	   	   VEGF	   is	   also	   known	   to	   increase	  
MMP	   2	   expression.	   MMP	   2	   and	   MMP	   9	   are	   felt	   to	   have	   a	   critical	   role	   in	  
endothelial	   cell	   proliferation,	   migration	   and	   vascular	   ECM	   invasion	   which	  
facilitates	   endothelial	   sprouting.	   It	   has	   been	   shown	   that	   MMP-­‐9	   mobilises	  
VEGF	  which	   is	   important	   in	   the	   initiation	   of	   angiogenesis	   [282]	   	   	   In	   rodent	  
models	   of	   PH	   (using	  monocrotaline	   (MCT))	  MMP2	   and	   9	  were	   found	   to	   be	  
increased	   [286].	   The	   increased	   MMP	   2	   and	   9	   found	   using	   the	   array	   are	  
therefore	  consistent	  with	  the	  current	  understanding	  of	  PH	  pathogenesis.	  
	  
5. tPA	   gene	   expression	   was	   increased	   in	   CTEPH	   BOECs	   compared	   to	   healthy	  
controls.	   This	   may	   result	   from	   the	   presence	   of	   multiple	   thrombi	   in	   these	  
patients	  stimulating	  the	  endothelium	  to	  increase	  tPA	  expression.	  	  Raised	  tPA	  
antigen	  levels	  have	  been	  previously	  described	  in	  CTEPH	  [238]	  	  but	  these	  were	  
associated	  with	   increased	  PAI-­‐1	   levels.	  Because	  most	  antigenic	  tPA	  is	  bound	  
to	   PAI-­‐1,	   high	   tPA	   levels	   often	   reflect	   high	   PAI-­‐1	   levels	   and	   consequently	  
functional	  assays	   in	  the	  same	  study	  showed	  no	  difference	  between	  patients	  
with	  CTEPH	  and	  healthy	  controls.	  	  It	  is	  not	  possible	  to	  say	  if	  this	  is	  the	  cause	  
of	  the	  shorter	  lysis	  time	  seen	  in	  CTEPH	  (and	  IPAH)	  BOECs	  without	  looking	  at	  
the	  protein	  levels.	  Interestingly	  in	  the	  rodent	  model	  using	  MCT,	  increased	  tPA	  
mRNA	  levels	  were	  seen	  using	  microarrays	  [286].	  
	  
6. Thrombomodulin	   gene	   expression	   was	   found	   to	   be	   increased	   in	   CTEPH	  
BOECs.	  This	   is	   interesting	  because	  serum	  thrombomodulin	   levels	  have	  been	  
shown	  to	  be	  low	  in	  both	  IPAH	  and	  CTEPH	  [287,	  288].	  Raised	  plasma	  TM	  levels	  
were	   seen	   after	   PEA	   in	   CTEPH	   patients	   by	   Sakamaki	   and	   colleagues	   who	  
suggested	  that	  lower	  plasma	  TM	  levels	  pre	  PEA	  may	  be	  a	  sign	  of	  endothelial	  
cell	  dysfunction	  [288].	  However	  the	  role	  TM	  may	  have	  in	  pathogenesis	  is	  not	  
clear	  as	  higher	  soluble	  TM	  has	  been	  seen	  in	  association	  with	  scleroderma	  and	  
PH	  [289].	  The	  relationship	  between	  plasma	  (soluble)	  TM	  and	  cell	  surface	  TM	  
is	  uncertain	  and	  it	  is	  likely	  that	  the	  cell	  surface	  expression	  is	  more	  relevant	  to	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the	   results	   obtained	   here	   and	   changes	   in	   soluble	   TM	   would	   probably	   not	  
have	   been	   detected	   in	   this	   experimental	   system.	   A	   study	   by	   Edgar	   et	   al	  
looked	   at	   gene	   expression	   in	   tissue	   taken	   at	   the	   time	   of	   lung	   transplant	   in	  
IPAH	   patients	   and	   found	   expression	   of	   TM	   was	   upregulated	   [290].	   	   The	  
increased	   TM	   gene	   expression,	   if	   reflected	   in	   protein	   expression,	   could	   be	  
one	   explanation	   for	   shorter	   lysis	   times	   on	   CTEPH	   BOECs.	   However	   the	  
competing	  effects	  on	  thrombin	  and	  TAFI	  activation	  maybe	  difficult	  to	  unravel.	  
TM	  is	   important	   in	  the	  activation	  of	  TAFI,	  however	  at	  high	   levels	  of	  TM,	  the	  
activation	  of	  APC	  predominates	  and	  therefore	  lysis	  is	  not	  inhibited	  and	  would	  
proceed	  faster.	  
	  
7. VCAM-­‐1	  showed	  a	  four-­‐fold	  increase	  in	  gene	  expression	  in	  CTEPH	  BOECs.	  As	  
an	   endothelial	   cell	   adhesion	   molecule,	   increased	   levels	   may	   be	   a	   sign	   of	  
endothelial	  dysfunction,	   vascular	   injury	  or	  proliferation.	  Raised	  VCAM-­‐1	  has	  
not	   been	   shown	   in	   CTEPH,	   however	   high	   VCAM-­‐1	   is	   part	   of	   a	   pro-­‐
inflammatory	  phenotype	   seen	   in	   animal	  models	  of	   severe	  hypoxic	  PH.	  High	  
VCAM-­‐1	  levels	  have	  also	  been	  seen	  in	  systemic	  sclerosis	  associated	  PAH	  [291,	  
292]	   as	   well	   as	   Sickle	   cell	   associated	   PH	   [293].	   	   This	   result	   may	   suggest	  
endothelial	   dysfunction,	   but	   further	   investigation	   would	   be	   required	   to	  
determine	  whether	  VCAM-­‐1	  has	  a	  role	  in	  CTEPH	  pathogenesis.	  
	  
8. A	  two	  fold,	  but	  statistically	  significant,	  decrease	  in	  KDR/VEGF	  receptor	  2	  was	  
found	   in	   CTEPH	   BOECs	   compared	   to	   healthy	   controls.	   VEGF	   plays	   an	  
important	   role	   in	   angiogenesis	   and	   vasculogenesis,	   with	   VEGFR2	   being	   the	  
receptor	  through	  which	  most	  of	  the	  cellular	  responses	  to	  VEGF	  are	  mediated.	  
The	   function	   of	   VEGFR	   receptor	   1	   is	   less	   well	   defined	   but	   is	   thought	   to	  
modulate	  VEGFR2.	  The	  role	  of	  VEGF	  in	  pulmonary	  hypertension	  is	  debated	  as	  
there	   are	   conflicting	   studies	   in	   animal	   models	   [143].	   Two	   studies	   have	  
described	  raised	  VEGF	  and	  VEGFR2	   in	   the	  plexiform	   lesions	  of	  patients	  with	  
PH	   [142,	   294].	   Interestingly,	   inhibition	   of	   VEGFR	   and	   hypoxia	   has	   led	   to	   a	  
mouse	   model	   of	   PH	   [295]	   which	   postulates	   a	   role	   for	   VEGF	   in	   the	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pathogenesis	  of	  PH.	  Lower	  levels	  of	  the	  receptor	  may	  perhaps	  mean	  that	  less	  
angiogenesis	  occurs	  which	  contributes	  to	  the	  pathogenesis	  of	  PH.	  
	  
	  
Although	  many	   genes	   also	   showed	   altered	   expression	   between	   IPAH	   and	   healthy	  
control	  as	  well	  as	  between	  CTEPH	  and	  IPAH,	  as	  the	  number	  of	  IPAH	  samples	  was	  so	  
small,	  it	  is	  difficult	  to	  be	  sure	  that	  this	  is	  a	  representative	  sample.	  It	  was	  interesting	  
to	  see	  an	  increase	  in	  matrix	  metalloproteinases	  1	  and	  9,	  fibroblast	  growth	  factor	  and	  
IL-­‐7	  because	  they	  have	  been	  implicated	  in	  the	  pathogenesis	  of	  PH.	  Platelet	  factor	  4	  
also	  showed	  an	  increase,	  which	  is	  interesting	  as	  it	  is	  thought	  to	  be	  angiostatic	  [219].	  
It	  has	  also	  been	  shown	  that	  PF-­‐4	  inhibits	  TM	  mediated	  activation	  of	  TAFI	  [296],	  so	  if	  
this	   	  were	  confirmed	   it	  may	  also	  explain	   the	   faster	   lysis	   time	  seen	  on	   IPAH	  BOECS.	  
The	   decrease	   in	   prostacyclin	   synthase	   and	  prostaglandin	   synthase	   is	   interesting	   as	  
low	  levels	  of	  prostacyclin	  have	  been	  found	  in	  IPAH	  and	  this	  is	  the	  basis	  for	  treatment	  
with	   prostacyclin.	   In	   comparing	   IPAH	   and	   CTEPH,	   the	   fact	   that	   tPA	   and	   urokinase	  
were	  increased	  in	  IPAH	  BOECs	  fits	  with	  the	  faster	  lysis	  time	  seen	  in	  the	  experiments	  
on	  the	  BOECs,	  but	  whether	  the	  changes	  in	  gene	  expression	  are	  actually	  reflected	  in	  
the	  cell	  phenotype	  is	  not	  known.	  
	  
To	  investigate	  these	  findings	  further,	  direct	  PCR	  of	  the	  target	  genes	  will	  be	  required	  
to	   confirm	   the	   findings.	   Having	   completed	   the	   discovery	   cohort,	   a	   validation	   or	  
replication	  cohort	  is	  now	  required	  to	  ensure	  that	  the	  array	  data	  was	  representative	  
of	  the	  patient	  groups.	  As	  the	  largest	  difference	  in	  lysis	  time	  with	  the	  IPAH	  cells	  was	  
seen	  in	  TNF-­‐α	  stimulated	  cells	   it	  would	  be	  interesting	  to	  study	  the	  gene	  expression	  
pre	  and	  post	  TNF-­‐α	  stimulation	  to	  see	  if	  the	  cells	  from	  either	  CTEPH	  or	  IPAH	  patients	  
respond	  differently	  to	  healthy	  controls.	  
	  
Although	  gene	  expression	  may	  be	  altered,	  it	  is	  also	  important	  to	  look	  at	  the	  effect	  on	  
protein	  expression	  to	  examine	  for	  correlation	  between	  the	  gene	  findings	  and	  protein	  
expression	   or	   other	   changes	   in	   the	   proteome	   not	   detected	   by	   the	   array.	   Recent	  
studies	  comparing	   the	  proteome	  and	   transcriptome	  have	  shown	  the	  correlation	   to	  
be	  weak	  in	  nucleated	  cells.	  [297]	  In	  platelets	  the	  proteome	  has	  been	  shown	  to	  bear	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little	  resemblance	  to	  the	  transcriptome	  and	  therefore	  further	  highlights	  the	  need	  for	  
protein	  studies	  [298].	  
	  
Immunofluorescence	   would	   be	   a	   direct	   method	   to	   examine	   cell	   surface	   protein	  
expression	   of	   candidate	   genes	   such	   as	   thrombomodulin	   or	   endothelin	   receptor	   A	  
and	  could	  be	  quantitated.	  Cell	   lysates	  and	  supernatants	  were	  collected	  so	   it	  would	  
be	  possible	  to	  perform	  proteomic	  studies	   looking	  at	  both	  the	  protein	  expression	   in	  
the	  cell	  as	  well	  as	  secretion	  of	  some	  of	  the	  proteins	  into	  the	  supernatant.	  	  	  
	  	  
All	  these	  experiments	  have	  been	  performed	  with	  cells	  grown	  under	  static	  conditions.	  
It	   is	   known	   that	   shear	   stress	   alters	   gene	   expression	   and	   surface	   phenotype	   and	   it	  
may	   be	   that	   the	   differences	   in	   lysis	   I	   observed	   on	   the	   CTEPH	   BOECs	   would	   be	  
significantly	   altered	  had	   the	   cells	   been	   grown	  under	   shear	   stress;	   perhaps	   even	   in	  
keeping	  with	  the	  original	  hypothesis.	  Flow	  also	  profoundly	  influences	  fibrin	  network	  
structure	   [71]	   and	   therefore	   static	   experiments	  may	   not	   be	   representative	   of	   not	  
only	  the	  cells	  but	  also	  the	  clot	  formation.	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6.7 Conclusions	  	  
The	  assessment	  of	  a	  patient’s	  endothelium	   is	   technically	  difficult	   requiring	   invasive	  
biopsies.	   The	   use	   of	   this	   relatively	   new	   technique	   of	   culturing	   endothelial	   cells	  
(BOECs	  also	  known	  as	  ECFCs)	  from	  the	  patients’	  peripheral	  blood	  allowed	  me	  to	  look	  
at	  endothelial	  function	  in	  CTEPH.	  
	  
The	   shorter	   lysis	   time	   on	   CTEPH	   BOECs	   with	   exogenous	   TF	   was	   an	   unexpected	  
finding,	  which	   led	   on	   to	   the	   study	   of	   gene	   expression	   using	   PCR	   arrays.	  Using	   the	  
small	   number	   of	   samples	   as	   a	   discovery	   cohort,	   interesting	   changes	   in	   gene	  
expression	  were	  seen	  which	  would	  warrant	  further	  investigation	  both	  to	  confirm	  the	  
results	   and	   to	   study	   their	   role	   in	   the	   pathogenesis	   of	   CTEPH.	   Because	   the	   shorter	  
lysis	  times	  are	  inconsistent	  with	  the	  original	  hypothesis	  artefactual	  explanations	  for	  
the	   finding	   require	   consideration.	   	   Alternatively	   it	   is	   possible	   that	   the	   shorter	   lysis	  
times	   are	   an	   incidental	   side	   effect	   of	   increased	  plasmin	  which	  plays	   other	   roles	   in	  
pathogenesis.	  	  
	  
Future	   work,	   which	   has	   been	   described	   throughout	   this	   chapter,	   would	   include	   a	  
validation	  cohort	  for	  the	  PCR	  data,	  gene	  expression	  studies	  pre	  and	  post	  stimulation	  
with	  TNF-­‐α	  as	  well	  as	  proteomic	  studies	  to	  look	  at	  both	  cell	  protein	  expression	  and	  
possible	  secretion	  into	  the	  supernatant.	  It	  would	  also	  been	  interesting	  to	  look	  at	  the	  
clots	  formed	  on	  the	  cells	  by	  the	  patient	  using	  confocal	  microscopy	  to	  see	  if	  there	  is	  
any	   structural	   difference	   seen	   which	   might	   explain	   the	   shorted	   lysis	   time	   with	  
exogenous	   TF.	   Another	   interesting	   area	   for	   further	   study	   would	   be	   the	   effect	   of	  
drugs,	  especially	  the	  endothelin	  receptor	  antagonists,	  e.g.	  Bosentan,	  on	  the	  BOECS	  in	  
relation	   to	   both	   gene	   expression	   and	   the	   functional	   assays.	   In	   vivo	   these	   cells	   are	  
under	  shear	  stress	  and	  it	  would	  be	  interesting	  to	  grow	  the	  cells	  under	  shear	  and	  see	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Despite	  the	  paradoxical	  results,	  BOECs	  clearly	  offer	  a	  valuable	  non-­‐invasive	  method	  
of	   studying	   disease	   mechanisms	   in	   CTEPH	   as	   well	   as	   many	   other	   vascular	  
disorders.	  	   Further	   analysis	   of	   these	   cells	   and	   the	   preliminary	   findings	   presented	  
here	   may	   help	   to	   identify	   genes	   and	   pathways	   responsible	   for	   development	   of	  
CTEPH	   in	   a	   subgroup	   of	   patients	   with	   PE	   and	   thus	   develop	   and	   target	   future	  
therapies.	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7 Appendices	  	  	  
7.1 Appendix	  1:	  Genes	  in	  RT2	  Profiler™	  PCR	  Array	  	  
Table	  7.1	  Genes	  in	  PCR	  array	  
Position	   Symbol	   Description	  
A01	   ACE	   Angiotensin	  converting	  enzyme	  
A02	   ADAM17	   ADAM	  metallopeptidase	  domain	  17	  
A03	   AGT	   Angiotensinogen	  (serpin	  peptidase	  inhibitor,	  clade	  A,	  
member	  8)	  
A04	   AGTR1	   Angiotensin	  II	  receptor,	  type	  1	  
A05	   ALOX5	   Arachidonate	  5	  lipoxygenase	  
A06	   ANGPT1	   Angiopoietin	  1	  
A07	   ANXA5	   Annexin	  A5	  
A08	   APOE	   Apolipoprotein	  E	  
A09	   BAX	   BCL2-­‐assocated	  X	  protein	  
A10	   BCL2	   B-­‐cell	  CLL/lymphoma	  2	  
A11	   BCL2L1	   BCL2-­‐like1	  
A12	   CALCA	   Calcitonin-­‐related	  polypeptide	  alpha	  
B01	   CASP1	   Caspase	  1,	  apoptosis-­‐related	  cysteine	  peptidase	  
(interleukin	  1,	  beta,	  convertase)	  
B02	   CASP3	   Caspase	  3,	  apoptosis-­‐related	  cysteine	  peptidase	  
B03	   CAV1	   Caveolin	  1,	  caveolae	  protein,	  22kDa	  
B04	   CCL2	   Chemokine	  (C-­‐C	  motif)	  ligand	  2	  
B05	   CCL5	  	   Chemokine	  (C-­‐C	  motif)	  ligand	  5	  
B06	   CDH5	   Cadherin	  5,	  type	  2	  (vascular	  endothelium)	  
B07	   CFLAR	   CASP8	  and	  FADD-­‐like	  apoptosis	  
B08	   COL18A1	   Collagen,	  type	  XVIII,	  alpha	  1	  
B09	   CX3CL1	   Chemokine	  (C-­‐X3-­‐C	  motif)	  ligand	  1	  
B10	   EDN	  1	   Endothelin	  1	  
B11	   EDN	  2	   Endothelin	  2	  
B12	   EDNRA	   Endothelin	  receptor	  type	  A	  
C01	   ENG	   Endoglin	  
C02	   F2R	   Coagulation	  factor	  II	  (thrombin)	  receptor	  
C03	   F3	   Coaguation	  factor	  III	  (thromboplastin,	  tissue	  factor)	  
C04	   FAS	   Fas	  (TNF	  receptor	  superfamily,	  member	  6)	  
C05	   FASLG	   Fas	  ligand	  (TNF	  superfamily,	  member	  6)	  
C06	   FGF1	   Fibroblast	  growth	  factor	  1	  (acidic)	  
C07	   FGF2	   Fibroblast	  growth	  factor	  2	  (basic)	  
C08	   FLT1	   FMS-­‐related	  tyrosine	  kinase	  1	  (vascular	  endothelial	  
growth	  factor/vascular	  permeability	  factor	  receptor)	  
C09	   FN1	   Fibronectin	  
C10	   HIF1A	   Hypoxia	  inducible	  factor	  1,	  alpha	  subunit	  (basic	  helix	  
loop	  transcription	  factor)	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Position	   Symbol	   Description	  
C11	   HMOX1	   Heme	  oxygenase	  (decycling)	  1	  
C12	   ICAM1	   Intercellular	  adhesion	  molecule	  1	  
D01	   IL11	   Interleukin	  11	  
D02	   IL1B	   Interleukin	  1,	  beta	  
D03	   IL3	   Interleukin	  3	  (colony	  stimulating	  factor,	  multiple)	  
D04	   IL6	   Interleukin	  6	  (interferon,	  beta	  2)	  
D05	   IL7	   Interleukin	  7	  
D06	   ITGA5	   Integrin,	  alpha	  5	  (fibronectin	  receptor,	  alpha	  
polypeptide)	  
D07	   ITGAV	   Integrin,	  alpha	  V	  (vitronectin	  receptor,	  alpha	  
polypeptide,	  antigen	  CD51)	  
D08	  	   ITGB1	   Integrin,	  beta	  1	  (fibronectin	  receptor,	  beta	  
polypeptide,	  antigen	  CD29	  included	  MDF2,	  MSK12)	  
D09	   ITGB3	   Integrin,	  beta	  3	  (platelet	  glycoprotein	  IIIa,	  antigen	  
CD61)	  
D10	   KDR	   Kinase	  insert	  domain	  receptor	  (a	  type	  III	  receptor	  
tyrosin	  kinase)	  
D11	   KIT	   V-­‐kit	  Hardy	  Zuckerman	  4	  feline	  sarcoma	  viral	  
oncogene	  homolog	  
D12	   KLK3	   Kallikrein-­‐related	  peptidase	  3	  
E01	   MMP1	   Matrix	  metallopeptidase	  1	  (interstitial	  collagenase)	  
E02	   MMP2	   Matrix	  metallopeptidase	  2	  (gelatinase	  A,	  72kDa	  
gelatinase,	  72kDa	  type	  IV	  collagenase)	  
E03	   MMP9	   Matrix	  metallopeptidase	  9	  (gelatinase	  B,	  92kDa	  
gelatinase,	  92kDa	  type	  IV	  collagenase)	  
E04	   NOS3	   Nitric	  oxide	  synthase	  3	  (endothelial	  cell)	  
E05	   NPPB	   Natriuretic	  peptide	  B	  
E06	   NPR1	   Natriuretic	  peptide	  receptor	  A/guanylate	  cyclase	  A	  
(atrionatriuretic	  peptide	  receptor	  A)	  
E07	   OCLN	   Occludin	  
E08	   PDGFRA	   Platelet-­‐derived	  growth	  factor	  receptor,	  alpha	  
polypeptide	  
E09	   PECAM1	   Platelet/endothelial	  cell	  adhesion	  molecule	  
E10	   PF4	   Platelet	  factor	  4	  
E11	   PGF	   Placental	  growth	  factor	  
E12	   PLAT	   Plasminogen	  activator,	  tissue	  
F01	   PLAU	   Plasminogen	  activator,	  urokinase	  
F02	   PLG	   Plasminogen	  
F03	   PROCR	   Protein	  C	  receptor,	  endothelial	  
F04	   PTGIs	   Prostaglandin	  I2	  (prostacyclin)	  synthase	  
F05	   PTGS2	   Prostaglandin-­‐endoperoxidase	  synthase	  2	  
(prostaglandin	  G/H	  synthase	  and	  cyclooxygenase)	  
F06	   PTK2	   PTK2,	  protein	  tyrosine	  kinase	  2	  
F07	   SELE	   Selectin	  E	  
F08	   SELL	   Selectin	  L	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Position	   Symbol	   Description	  
F09	   SELPLG	   Selectin	  P	  ligand	  
F10	   SERPINE1	   Serpin	  peptidase	  inhibitor,	  clade	  E	  (nexin,	  plasminogen	  
activator	  inhibitor	  type	  1),	  member	  1	  
F11	   SOD1	   Superoxide	  dismutase	  1,	  soluble	  
F12	   SPHK1	   Sphingosine	  kinase	  1	  
G01	   TEK	   TEK	  tyrosine	  kinase,	  endothelial	  
G02	   TFPI	   Tissue	  factor	  pathway	  inhibitor	  (lipoprotein	  associated	  
coagulation	  inhibitor)	  
G03	   TGFB1	   Transforming	  growth	  factor,	  beta	  1	  
G04	   THBD	   Thrombomodulin	  
G05	   THBS1	   Thrombospondin	  
G06	   TIMP1	   TIMP	  metallopeptidase	  inhibitor	  1	  
G07	   TNF	   Tumour	  necrosis	  factor	  
G08	   TNFSF10	   Tumour	  necrosis	  factor	  (ligand)	  superfamily,	  member	  
10	  
G09	   TYMP	   Thymidine	  phosphorylase	  
G10	   VCAM1	   Vascular	  cell	  adhesion	  molecule	  1	  
G11	   VEGFA	   Vascular	  endothelial	  growth	  factor	  A	  
G12	   VWF	   Von	  Willebrand	  Factor	  
	  
Angiogenesis	  
ANGPT1,	  CCL2	  (MCP-­‐1),	  CCL5	  (RANTES),	  CX3CL1,	  EDN1,	  EDNRA,	  ENG	  (EVI-­‐1),	  F3,	  
FASLG	  (TNFSF6),	  FGF1,	  FGF2	  (bFGF),	  FLT1,	  FN1,	  HIF1A,	  HMOX1,	  IL1B,	  IL6,	  ITGA5,	  
ITGAV,	  ITGB1,	  ITGB3,	  KDR,	  KIT	  (CD117),	  KLK3,	  MMP2,	  MMP9,	  NOS3	  (eNOS),	  NPPB,	  
NPR1,	  PF4,	  PGF,	  PLAU	  (uPA),	  PTGS2	  (COX2),	  SERPINE1	  (PAI-­‐1),	  SPHK1,	  TEK	  (TIE2),	  
THBS1,	  TYMP,	  VEGFA.	  
	  
Vasoconstriction	  and	  Vasodilation	  
ACE,	  AGT,	  AGTR1,	  ALOX5,	  APOE,	  CALCA,	  CAV1,	   CX3CL1,	   EDN1,	   EDN2,	   EDNRA,	   F2R,	  
HMOX1,	  ICAM1,	  NOS3	  (eNOS),	  NPPB,	  NPR1,	  PTGIS,	  PTGS2	  (COX2),	  SOD1	  
	  
Inflammatory	  response	  
ACE,	   AGT,	   AGTR1,	   ALOX5,	   APOE,	   CALCA,	   CCL2	   (MCP-­‐1),	   CCL5	   (RANTES),	   CX3CL1,	  
EDNRA,	  F2R,	  F3,	  FN1,	  HIF1A,	  HMOX1,	   IL1B,	   IL6,	  NPPB,	  PTGS2	   (COX2),	  SELE,	  SPHK1,	  
TGFB1,	  THBS1,	  TNF,	  VCAM1	  
	  
Apoptosis	  
ANXA5,	  BAX,	  BCL2,	  BCL2L1	   (BCL-­‐X),	  CASP1	   (ICE),	  CASP3,	  CAV1,	  CCL2	   (MCP-­‐1),	  CCL5	  
(RANTES),	  CFLAR	  (CASPER),	  CX3CL1,	  EDN1,	  EDNRA,	  FAS	  (TNFRSF6),	  FASLG	  (TNFSF6),	  
FGF2,	  HIF1A,	  HMOX1,	  IL1B,	  IL3,	  IL6,	  IL7,	  OCLN,	  PF4,	  PTK2,	  SPHK1,	  TEK	  (TIE2),	  THBS1,	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Cell	  adhesion	  
ADAM17	   (CD156B),	   AGT,	   BCL2,	   CALCA,	   CDH5,	   COL18A1	   (Endostatin),	   CX3CL1,	   ENG	  
(EVI-­‐1),	   FGF1,	   FN1,	   ICAM1,	   IL1B,	   ITGA5,	   ITGAV,	   ITGB1,	   ITGB3,	   KDR,	   PDGFRA,	  
PECAM1,	  PLAU	  (uPA),	  PLG,	  PTK2,	  SELE,	  SELL	  (LECAM1),	  SELPLG	  (P-­‐selectin),	  SERPINE1	  
(PAI-­‐1),	  TGFB1,	  THBS1,	  TNF,	  VCAM1,	  VEGFA,	  VWF	  
	  
Coagulation	  
ANXA5,	   CAV1,	   EDN1,	   F2R,	   F3,	   FN1,	  MMP1,	   PECAM1,	   PF4,	   PLAT	   (tPA),	   PLAU	   (uPA),	  
PLG,	  PROCR,	  PTK2,	  SELL	  (LECAM1),	  SELPLG	  (P-­‐selectin),	  SERPINE1	  (PAI-­‐1),	  TEK	  (TIE2),	  
TFPI,	  THBD,	  THBS1,	  TIMP1,	  VWF	  
	  
Platelet	  activation	  
APOE,	  CX3CL1,	  F2R,	  FN1,	  IL11,	  IL6,	  ITGB3,	  NOS3	  (eNOS),	  PDGFRA,	  PECAM1,	  PF4,	  PLG,	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7.2 Appendix	  2:	  Clinical	  data	  from	  PH	  patients	  	  
Table	  7.2	  CTEPH	  patient	  characteristics:	  functional	  data	  









1	   M	   75	   III	   48	   	  
2	   F	   80	   III	   40	   	  
3	   F	   80	   III	   160	   	  
4	   M	   38	   II	   594	   	  
5	   F	   24	   II	   515	   VO2	  62%	  
6	   M	   34	   I	   489	   	  
7	   M	   65	   III	   24	   	  
8	   M	   48	   II	   420	   VO2	  75%*	  
9	   F	   65	   III	   300	   VO2	  68%	  
10	   F	   71	   II	   348	   VO260%	  
11	   M	   66	   III	   360	   	  
12	   F	   78	   III	   210	   	  
13	   M	   76	   III	   342	   	  
14	   F	   61	   II	   40	   	  
15	   F	   55	   II	   420	   VO2	  95%	  
16	   F	   49	   III	   216	   	  
17	   F	   46	   III	   150	   VO2	  76%	  
	  
The	  rows	  shaded	  grey	  were	  cells	  that	  grew	  to	  at	  least	  P4	  and	  were	  used	  in	  the	  CAT	  and	  lysis	  
assays.	  *post	  PEA	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Table	  7.3	  CTEPH	  patient	  characteristics:	  cardiac	  dynamics	  and	  echo	  data	  
	  
Patient	   Mean	  
PAP	  








(mmHg)	   Echo	  (Descriptive	  summary)	   Echo	  (RVSP	  mmHg)	  
1	   46	   1.63	   843	   21	   RA	  dilated,	  RV	  mod	  to	  severe	  impairment	  of	  
systolic	  
function	   67	  
2	   40	   1.98	   856	   6	   	   65-­‐70	  
3	   73	   2.44	   	   12	   	   118	  
4	   37	   3.1	   312	   10	   RV	  dilated,	  moderate	  systolic	  
impairment	   N/A	  
5	   66	   1.5	   1768	   6	   Severe	  PH,	  dilated	  hypertrophied	  
RV	   122-­‐127	  
6	   54	   2.69	   696	   8	   Moderate	  overall	  RV	  systolic	  
impairment	   80	  
7	   32	   3.6	   224	   11	   Good	  RV	  and	  LV	  function	   39	  
8	   41	   4.07	   600.8	   8	   RV	  dilated	  and	  hypertrophied	   88-­‐93	  
9	   39	   2.27	   684.8	   6	  




10	   52	   2.51	   968.8	   4	  
Dilated	  RA,	  





11	   43	   2.2	   344	   4	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Table	  7.3	  (cont.)	  	  




















12	   43	   2.3	   700	   6	  




13	   43	   1.13	   1240	   	  




14	   49	   1.37	   1040	   24	  





15	   	   	   	   	   RA	  and	  RV	  dilated	   30	  
16	   67	   	   1200	   4	  




17	   39	   1.05	   1245.6	   16	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Table	  7.4	  CTEPH	  patient	  characteristics:	  therapy	  and	  associated	  medical	  problems	  
Patient	   VTE	   PEA	   Disease	  
specific	  
therapy	  
Other	  medication	   Past	  Medical	  History	  






Mesalazine	  400mg	  tds,	  
Bisoprolol	  1.25mg,	  
Gliclazide	  80mg	  bd,	  







2.5mg,	  symbicort,	  	  
Inflammatory	  bowel	  
disease	  
CABG,	  recurrent	  VT,	  ICD,	  
Type	  2	  diabetes,	  
hypertension,	  
hypercholesterolaemia	  
2	   Yes2	   	   Sildenafil	  
Warfarin	  
Lansoprazole	  30mg,	  
Alendronic	  acid	  70mg	  
weekly,	  Simvastatin	  
20mg	  
R	  lung	  mass	  






Trazadone	  100mg,	  Vit	  
B12	  
	  
IVC	  filter,	  iron	  deficiency,	  
vitamin	  D	  deficiency	  





vitamin	  D	  deficiency	  
Family	  history	  of	  DVT	  
























Splenectomy	  post	  RTA	  	  
CVA,	  Type	  2	  diabetes,	  
Hypertension,	  AF	  





1	  PE	  1991,	  DVT	  1995,	  2	  PE	  2010,	  3	  PE	  1995,	  4	  PE	  2005	  and	  2007,	  5	  bilat	  axillary	  vein	  thrombosis	  
1997,	  PE	  2002,	  6	  PE/DVT	  2002	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Table	  7.4	  (cont)	  CTEPH	  patient	  characteristics:	  therapy	  and	  associated	  medical	  
problems	  
Patient	   VTE	   PEA	   Disease	  
specific	  
therapy	  
Other	  medication	   Associated	  
medical	  
conditions	  
















11	   Yes8	   Yes	   Warfarin	  
Lanzoprazole	  30mg,	  




upper	  lobe,	  mild	  
obstructive	  sleep	  
apnoea	  







Factor	  V	  Leiden	  
Measles	  
pneumonia	  	  


















Furosemide	  80mg,	  Asacol	  
400mg	  tds,	  Ramipril	  











15	   Yes11	   	   Warfarin	   	   	  







Bumetanide	  4mg	  bd,	  
Levetiracetam	  500mg	  bd,	  
Thyroxine	  100/75mcg	  alt	  
day,	  Amiloride	  5mg	  od,	  
Carbemazepine	  200mg	  bd	  










HbS	  and	  α-­‐thal	  
trait	  
7	  PE	  2008,	  8	  PE	  1995,	  9	  PE	  2004	  and	  2005,	  10	  PE	  2003,	  DVT	  2005,	  11	  PE	  2005,	  12	  PE	  and	  bilat	  
DVT	  2010	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Table	  7.5	  IPAH	  patient	  characteristics	  
	  


















Disease	  specific	  	  
therapy	  




2	   F	   67	   III	   396	   68	   1.96	   905	   Naive	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7.3 Appendix	  3:	  BOEC	  samples	  used	  for	  experiments	  	  
	  
Table	  7.6	  Samples	  used	  in	  CAT	  and	  lysis	  experiments	  	  








HC1	   ✓	   ✓	   ✓	   ✓	  
HC2	   ✓	   ✓	   ✓	   ✓	  
HC3	   X	   ✓	   ✓	   ✓	  
HC4	   ✓	   X	   ✓	   ✓	  
HC6	   ✓	   ✓	   ✓	   ✓	  
HC7	   X	   X	   ✓	   ✓	  
HC12	   ✓	   ✓	   ✓	   ✓	  
HC14	   X	   ✓	   ✓	   ✓	  
	   	   	   	    
CTEPH3	   X	   X	   ✓	   X	  
CTEPH4	   ✓	   ✓	   ✓	   ✓	  
CTEPH5	   ✓	   X	   ✓	   ✓	  
CTEPH6	   ✓	   ✓	   ✓	   ✓	  
CTEPH7	   ✓	   ✓	   ✓	   ✓	  
CTEPH8	   ✓	   ✓	   ✓	   ✓	  
CTEPH9	   ✓	   X	   ✓	   ✓	  
CTEPH14	   ✓	   X	   ✓	   ✓	  
CTEPH15	   ✓	   X	   ✓	   ✓	  
CTEPH16	   ✓	   X	   ✓	   ✓	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7.4 Appendix	  4:	  PCR	  array	  reproducibility	  and	  efficiency	  data	  	  
On	  each	  96	  well	  array	  plate,	  3	  wells	  contain	  a	  positive	  PCR	  control	   (PPC),	  3	  wells	  a	  
reverse	   transcription	   control	   (RTC)	   and	   one	   well	   assesses	   genomic	   DNA	  
contamination.	  These	  are	  used	  to	  look	  at	  the	  reproducibility	  and	  efficiency	  of	  results.	  
	  
Table	  7.7	  PCR	  reproducibility	  and	  efficiency:	  healthy	  control	  samples	  
Array	   HC1	   HC3	   HC6	   HC12	   HC14	   Average	   Std	  Dev	  
Average	  CT	  (PPC)	   19.44	   19.24	   19.22	   19.5	   18.89	   19.26	   0.24	  
Std	  Dev	  CT	  (PPC)	   0.01	   0.12	   0.19	   0.02	   0.74	   0.22	   	  
Average	  CT	  RTC	   22.45	   22.64	   22.55	   22.96	   22.55	   22.63	   	  
Std	  Dev	  CT	  (RTC)	   0.03	   0.05	   0.01	   0.46	   0.02	   0.11	   0.2	  
Delta	  CT	  	  
(AVG	  RTC-­‐AVG	  PPC)	  
3.01	   3.4	   3.33	   3.46	   3.66	   	   	  
Genomic	  DNA	   35	   35	   34.71	   34.62	   32.68	   	   	  
	  
If	   the	  Average	  PPC	  Ct	   is	  20±2	  and	  no	   two	  arrays	  have	  Average	  PPC	  CT	  which	  are	  >	  2	  away	  
from	  one	  another	  then	  the	  sample	  and	  group	  Pass.	  
If	  Delta	  CT	  (AVG	  RTC	  -­‐	  AVG	  PPC)	  <=	  5,	  RT	  Efficiency	  reports	  'Pass'	  
Genomic	  DNA	  ≥35	  is	  a	  pass	  
Table	  7.8	  PCR	  reproducibility	  and	  efficiency:	  CTEPH	  samples	  
Array	   CT	  4	   CT5	   CT	  6	   CT7	   CT8	   CT14	   CT15	   Average	   Std	  
Dev	  
Average	   CT	  
(PPC)	  
18.88	   19.42	   19.47	   18.96	   19.41	   19.14	   19.3	   19.23	  
	  
0.24	  
Std	   Dev	   CT	  
(PPC)	  
0.12	   0.01	   0.01	   0.05	   0.16	   0.32	   0.17	   0.12	   	  
Average	   CT	  
(RTC)	  
22.67	   23.05	   22.74	   21.9	   22.46	   22.61	   22.64	   22.53	  
	  
	  
Std	   Dev	   CT	  
(RTC)	  
0.02	   0.04	   0.04	   0.03	   0.01	   0.01	   0.03	   0.03	   0.35	  
Delta	   CT	  
(AVG	   RTC-­‐
AVG	  PPC)	  
3.79	   3.63	   3.27	   2.94	   3.05	   3.47	   3.35	   	   	  
Genomic	  
DNA	  
35	   35	   35	   35	   35	   35	   35	   35	   	  
	  
If	  the	  Average	  PPC	  Ct	  is	  20±2	  and	  no	  two	  arrays	  have	  Average	  PPC	  CT	  are	  >	  2	  away	  from	  one	  
another	  then	  the	  sample	  and	  group	  Pass.	  
If	  Delta	  CT	  (AVG	  RTC	  -­‐	  AVG	  PPC)	  <=	  5,	  RT	  Efficiency	  reports	  'Pass';	  	  
Genomic	  DNA	  ≥35	  is	  a	  pass	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Table	  7.9	  PCR	  reproducibility	  and	  efficiency:	  IPAH	  samples	  	  
Array	   IPAH2	   IPAH	  4	   Average	   Std	  Dev	  
Average	  CT	  (PPC)	   19.32	   19.12	   19.22	   0.14	  
Std	  Dev	  CT	  (PPC)	   0.15	   0.03	   0.9	   	  
Average	  CT	  RTC	   21.98	   22.03	   22.01	   0.04	  
Std	  Dev	  CT	  (RTC)	   0.02	   0.04	   0.03	   	  
Delta	  CT	  	  
(AVG	  RTC-­‐AVG	  PPC)	  
2.66	   2.91	   	   	  
Genomic	  DNA	   35	   35	   	   	  	  
If	   the	  Average	  PPC	  CT	   is	  20±2	  and	  no	   two	  arrays	  have	  Average	  PPC	  CT	  which	  are	  >	  2	  away	  
from	  one	  another	  then	  the	  sample	  and	  group	  Pass.	  
If	  Delta	  CT	  (AVG	  RTC	  -­‐	  AVG	  PPC)	  <=	  5,	  RT	  Efficiency	  reports	  'Pass';	  	  
Genomic	  DNA	  ≥35	  is	  a	  pass	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